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Zusammenfassung 
Im Rahmen dieser Arbeit wurde Chlorinase Wi-WelO15 von Westiella intricata UH HT-29-1 
bezüglich ihrer Anpassungsfähigkeit an nicht-natürliche Substrate sowie ihre biokatalytische 
Anwendung getestet. 
Organohalogene spielen eine wichtige Rolle als Pharmazeutika, Agrarchemikalien oder syn-
thetische Intermediate. Jedoch ist die selektive Chlorierung aliphatischer Kohlenstoffe an kom-
plexen Molekülen unter milden, nicht giftigen Bedingungen noch immer eine große Heraus-
forderung in der chemischen und enzymatischen Katalyse. 
2014 wurde eine neue Klasse aliphatischer Halogenasen entdeckt, die ein großes Potential als 
Biokatalysator für late-stage Chlorierung hat. Die Enzymklasse gehört zu einer großen Familie 
von nicht-Häm-Eisen Oxygenasen. Eine zuvor gefundene Unterklasse von aliphatischen Ha-
logenasen ist abhängig davon, dass die Substrate an ein Acyl-Carrier-Protein gebunden sind. 
Im Gegensatz dazu, können Mitglieder der neuen Halogenasen-Unterklasse freistehende Sub-
strate halogenieren. Synthetische Methoden, die von Chemikern benutzt werden um ge-
wünschte Substrate herzustellen, können als Synthese-Werkzeugkoffer verstanden werden. 
Wenn diese Klasse von Halogenasen so angepasst werden kann, dass nicht-natürliche Sub-
strate selektiv chloriert werden und die Enzyme im Labor einfach produziert und verwendet 
werden können, können sie als neue Methode zum Werkzeugkoffer hinzugefügt werden um 
Halogene zu einem späten Synthesestadium an komplexe Moleküle hinzuzufügen..  
Wi-welO15 and Hw-welO15 (von Hapalosiphon welwitschii UH IC-52-3) wurden aus der entspre-
chenden genomischen DNA amplifiziert und in ein Plasmid, welches mit hoher Kopienanzahl 
in der Zelle vorliegt, eingefügt. Durch heterologe Expression in E. coli konnten die Halogena-
sen in guten Ausbeuten von 60-80 mg/L Zellkultur hergestellt werden. Aufreinigung wurde 
durch Affinitäts-Chromatographie und wenn nötig auch Größenausschlusschromatographie 
erreicht. Kristallisation der Variante Wi-0, der Startpunkt für die gerichtete Evolution, wurde 
erreicht und die Enzymstruktur konnte gelöst werden. Um die Chlorierungsaktivität an nicht-
natürlichen Substraten zu untersuchen, wurde eine Anzahl nicht natürlicher Substrate synthe-
tisiert, die eine Keto-Funktion, anstelle des natürlich vorkommenden Isonitriles, tragen. Diese 
wurden durch die Wildtyp Enzyme unter initialen Bedingungen nicht chloriert. 
Zunächst, als keine Strukturinformationen vorhanden waren, wurde ein Enzym-Model mit 
Hilfe von SwissModel kreiert um Hw-WelO15 zufällig zu mutieren. Als die Enzymstruktur 
von Wi-0 gelöst war, wurde gerichtete Evolution mittels semi-rationaler und rationaler Muta-
genese angewendet. Innerhalb von 4 Generationen wurde die Halogenase an das ausgewählte 
Leitmolekül angepasst. Eine Anzahl an Chlorinasen wurden als Zelllysate sowie als aufgerei-
nigt Enzyme getestet und die besten Varianten zeigten 87% Produktbildung unter optimierten 
Bedingungen, während die Startvariante Wi-0 Produktbildung von <1% zeigt. Modifikationen 
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am Leitmolekül wurden teilweise akzeptiert und insgesamt wurde die regio- und diastereose-
lektive Chlorierung von fünf nicht-natürlichen Substraten, mit Chemoselektivitäten von 96-
99% ermöglicht. Weitere fünf Substrate wurden in komplexe Produktmixe transformiert. Un-
ter allen gebildeten Produkten konnte nur ein chloriertes Produkt gefunden werden. 
Wenn nicht-natürliche Substrate von Halogenasen umgesetzt werden, werden häufig vor al-
lem hydroxylierte Produkte gebildet. Eine Enzymvariante, die während der gerichteten Evo-
lution gefunden wurde, hatte eine verringerte Chemoselektivität von 68% Chlorierung und 
32% Hydroxylierung. Mit dem Ziel Biokatalysatoren zu erschaffen, die nur Hydroxylierung 
erzielen, wurden mehrere Varianten erstellt, diese hatten jedoch keine Aktivität. Stattdessen 
wurde die Monooxygenase P450BM3 verwendet um vier neue, hydroxylierte und epoxidierte 
Produkte herzustellen. 
Halogenasen, die während verschiedenen Stufen der gerichteten Evolution gefunden wurden, 
wurden bezüglich ihrer kinetischen Eigenschaften untersucht. Dabei zeigte sich, dass die beste 
Variante eine 93-fache Verbesserung im Vergleich zum niedrigsten, messbaren kcat/Km hatte. 
Die beiden Varianten mit höchster Produktbildung unterschieden sich jeweils in ihren Eigen-
schaften. Während Wi-11 mit einem kcat von 0.64 min-1die höchste Umsatzrate hat, kann Wi-12 
die Substrate besser binden mit dem niedrigsten Km von 20 µM.  
Weiterhin wurde die Stabilität der Halogenasen untersucht und stabilisierte Wi-WelO15 Vari-
anten, die von dem PROSS Server vorgeschlagen wurden, hergestellt. Zum Auslesen der Sta-
bilität wurde die Schmelztemperatur (Tm) der Enzyme bestimmt. Es zeigte sich, dass die Ha-
logenasen mit Tm von 62 °C für Hw-WelO15 und 54 °C für Wi-WelO15 schon recht stabil sind. 
Die hergestellten Varianten während des Aktivitätsscreening zeigten im Vergleich zur Start-
variante generell schon eine leichte Verbesserung in ihrer thermischen Stabilität und Kombi-
nation aus stabilitäts- sowie aktivitätsverbessernden Mutationen resultierte in der stabilsten 
Wi-WelO15 Variante Wi-5P3 mit Tm=61 °C. Inkubation der aufgereinigten Enzyme in Puffer 
bei verschiedenen Temperaturen mit anschließender SDS-PAGE Analyse zeigte, dass für die 
stabilste Variante nach 4 h bei 65 °C immer noch lösliches Enzym vorhanden war. Aktivitäts-
tests bei erhöhten Temperaturen zeigten überdies eine Restaktivität von 90% bei Reaktionen, 
die bei 45 °gemacht wurden sowie 85% Restaktivität in Anwesenheit von 5% Ethanol. 
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Abstract 
Within this thesis, the chlorinase Wi-WelO15 from Westiella intricata UH strain HT-29-1 was 
explored for its evolvability towards non-natural substrates and its biocatalytic applicability. 
Organohalogens play an important role as pharmaceuticals and agricultural chemicals or syn-
thetic intermediates. However selective aliphatic chlorination under mild and non-hazardous 
conditions at complex molecules is still a formidable challenge in chemical and enzymatic ca-
talysis.  
A new class of aliphatic halogenases, which carries a great potential as useful biocatalysts for 
late stage chlorination, was discovered in 2014. The enzyme class belongs to a big superfamily 
of non-heme iron oxygenases. A previously found subclass of aliphatic halogenases are de-
pendent on an acyl-carrier protein, in contrast to that, the new subclass is able chlorinate free-
standing substrates. Synthetic methods, available to chemists, can be imagined as a toolbox 
which is used to create molecules of interest. If this class of halogenases can be engineered to 
chlorinate selectively non-natural substrates and can be produced and used under convenient 
conditions in the lab, they can be added to the synthesis toolbox enabling late-stage chlorina-
tion at complex molecules. 
Within this thesis, Wi-welO15 and Hw-welO15 (from Hapalosiphon welwitschii UH IC-52-3) were 
amplified from genomic DNA, and inserted into a high copy plasmid, resulting in great 
amounts of 60-80 mg enzyme/L expression culture by heterologous expression in E. coli. Puri-
fication of the halogenase was achieved by immobilized metal affinity chromatography and if 
necessary, also size exclusion chromatography. Crystallization of the starting variant Wi-0 for 
directed evolution was achieved and a structure of the enzyme could be solved by molecular 
replacement. To test the evolvability of the halogenases towards non-natural substrates, a lead 
molecule was chosen that contains a ketone instead of the naturally occurring isonitrile func-
tionality, which was not converted by both halogenases, with initial reaction conditions. 
First random mutagenesis of Hw-WelO15, based on a model created by SwissModel, was pur-
sued while no structural information was available. After we solved the structure of Wi-0, di-
rected evolution via semi-rational and rational mutagenesis was applied to evolve the halo-
genase in 4 generations to accept the chosen lead molecule. A panel of chlorinases was tested 
as lysates as well as isolated enzymes. Hereby the best variants revealed up to 87% product 
formation under optimized conditions while <1% product formation was present with Wi-0. 
Modifications at the lead structure were partially accepted and in total five non-natural sub-
strates were chlorinated with >99.9% regio- and diastereoselectivity and chemoselectivities of 
up to 96-99%. In addition, transformation of a range of seven substrates were transformed into 
complex mixtures of novel products.  
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Hydroxylation by aliphatic halogenases is described, if non-native substrates are used. One 
variant found in the directed evolution already has a decreased chlorination selectivity and 
produces 32% hydroxylated side product. With the goal to increase the hydroxylation selec-
tivity, several variants were created. Because these catalysts completely lost their activity, in-
stead the monooxygenase P450BM3 was used to produce four new, oxygenated products of the 
lead structure.  
Our discovered halogenases from different states of the engineering process were character-
ized for their kinetic properties, revealing that the best variant Wi-12 has a 93-fold improve-
ment in comparison to Wi-2, which has the lowest measurable kcat/Km . The two variants with 
highest product formation each have their own kinetic profile. While Wi-11 is most active with 
a kcat of 0.64 min-1, Wi-12 has the lowest Km of 20 µM for the lead substrate.  
Furthermore, the stability of the halogenases was examined and stabilized variants proposed 
by the PROSS server created. As read out, melting temperatures were determined revealing a 
high thermal stability for the wild types with Tm of 62 °C for Hw-WelO15 and 54 °C for Wi-
WelO15. Created variants generally showed an improve in thermal stability and combination 
of stability with activity improving mutations resulted in a melting temperature of 61 °C for 
Wi-5P3. Incubation of purified enzymes in buffer at different temperatures with subsequent 
SDS-PAGE analysis showed that after incubation at 65 °C for 4 h, still soluble enzyme of the 
stabilized variants remains. Activity assays at increased temperatures or solvent ratios, 
showed a residual activity of 90% at 45 °C with Wi-5P3 and 85% residual activity in the pres-
ence of 5% ethanol. 
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1. Introduction 
1.1 Relevance of Organohalogens 
In 1968 only 24 naturally occurring organohalogens were known. Until today the number in-
creased to over 5000 and is continuously growing.[1] Nearly one-quarter of pharmaceuticals 
and agrochemicals currently used are halogenated.[2,3] Hence, these compounds are important 
in everyday life. The halogen within the molecule increases the thermal and oxidative stability, 
as well as the biological membrane permeability, resulting in a higher efficacy. These proper-
ties are inevitable for molecules used as drugs.[3–5] Likewise, many found molecules carry 
astonishing biological activities such as anticancer, antibiotic, cytotoxic, herbicidal and insec-
ticidal properties.[2,5,6] 
Even though organohalogens are found in terrestrial and marine organisms, the majority 
is found in marine sources. This can be explained by the high concentration of chloride and 
bromide in the ocean. Terrestrial halogens are mostly present in insoluble form which hinders 
the uptake by living organisms.[1–3,7]  
The diversity of identified organohalogens produced by nature ranges from chloroform to 
terpenes, complex macrocycles and peptides. The molecules are produced as secondary me-
tabolites and their contribution to growth, reproduction, and defense play a primary role for 
the survival of the organisms. Chlorometabolites (51%) and bromometabolites (45%) are dom-
inating while organoiodines (2%) and organoflourides (2%) are less common, however some 
orders of brown algae use iodination over chlorination and bromination.[2,3,8–10] Often more 
than one halogen atom is present. In figure 1, some examples of naturally occurring organo-
halogens with biogenic properties are shown. Aureomycin (1), chloramphenicol (2) and van-
comycin (3) are antibiotics, produced by bacteria.[11–13] Further examples are 12-epi-hapalindole 
E (4), an inhibitor for bacterial RNA polymerase,[14] (+)chlorolissoclimide (5), a potent cytotoxic 
labdane diterpenoid,[15] and jamaicamide A (6), a sodium channel blocker.[16] 
The importance of the halogen within medicinal compounds has been demonstrated for 
example on the dechlorinated vancomycin molecule, where the antibiotic activity decreases 
about 70%.[17] Also the human cathepsin L inhibitor has an increased binding affinity of factor 
13 in comparison to its unsubstituted derivative.[18] The increased efficacy is based on a halogen 
bond between a covalently bonded halogen atom (e.g. C-X, X=Cl, Br, I) and a nucleophile (e.g. 
Lewis base). In proteins, carbonyl groups of the amino acid backbone or polar amino acids can 
be the nucleophile, that can interact with a positively charged electrostatic region on the ex-
tension of the C-X bond which is due to the anisotropy of the charge distribution.[19] Because 
of its enhancing effect of the ligand-acceptor interaction, halogen bonds have attracted more 
attention in drug discovery within the last years.[20–22]  
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Figure 1. Examples of biogenic organohalogens. Aureomycin (1), chloramphenicol (2) and vancomycin (3) are antibiotics, pro-
duced by bacteria. 12-epi-hapalindole E (4) is an inhibitor for bacterial RNA polymerase, (+)chlorolissoclimide (5) is a potently 
cytotoxic labdane diterpenoid, and jamaicamide A (6) is a sodium channel blocker.[11–16] 
The indispensable need of biogenic organohalogens in clinical medicine can be seen on high 
selling drugs as chloramphenicol (2) and vancomycin (3). In the last years, also the number of 
preclinical anticancer lead compounds originating from marine organisms increased.[4] The 
importance of organohalogens is irrefutable but the general trend for increasing complexity is 
pushing organic synthesis to its limits. General synthetic methods for direct and selective func-
tionalization of non-activated, aliphatic C(sp3)-H bonds are especially sought-after.[23]  
Next to their potential as pharmaceuticals and agrochemicals, organohalogens also possess 
a high synthetic value for further transformations. Especially transition metal-catalyzed cross-
coupling reactions have become an indispensable tool in the synthesis of complex molecules, 
which use halogenated molecules as starting materials. Via these coupling reactions, formation 
of C-C, C-F, C-N and other C-heteroatom bonds are possible.[24–31] Methods for robust and se-
lective halogenation in the absence of directing groups are essential in today’s synthesis 
toolbox.[23,32] In the next chapter, several halogenation methods are described. 
1.2 Halogenation Methods 
If natural products are used in agrochemical or pharmaceutical industry, suitable molecules 
must be accessible in huge amounts. Often, only a few mg of secondary metabolites can be 
extracted from the natural producing hosts, typically below 0.1 % of dry bacterial weight.[33,34] 
Therefore, robust synthetic routes must be developed. Especially the introduction of halogen 
species in a regio- and stereoselective manner can be problematic. Some chemical and enzy-
matic halogenation reaction will be discussed in the following chapters. 
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1.2.1 Chemical Halogenation 
Examples of previously described halogenation reactions are shown in scheme 1.Traditional 
halogenation with elementary chlorine possess a high importance for industrial production of 
organohalogens since many years.[35,36] The reactions have to be performed under harsh condi-
tions with high reactivity of starting materials and in acidic environment. Especially with more 
complex molecules – larger or functionalized, in comparison to small hydrocarbons- this re-
sults in polyhalogenation and poor regio- and stereoselectivity.[37,38] Bromination in contrast to 
chlorination is more often regioselective for the weakest C-H bond.[39] Reagents with the halo-
gen bound to a nitrogen of a small molecule, such as succinimide or methylamines, increase 
the selectivity in the reaction.[39,40] The use of N-halide amides as halogen donor was developed 
over the years and combined for example to visible light to produce complex molecules in 
good regio- and stereoselectivity.[41,42] Another method to introduce chlorine stereoselectivly, 
is the nucleophilic ring opening of ethers which was first published with TiCl4[43] in 1986 fol-
lowed by alternative opening reagents as BCl3[44], acetyl chloride[45] and HCl[46]. This technique 
can be used in total syntheses such as (-)N-methylwelwitindolinone B.[47]  
 
Scheme 1. Examples of halogenation reactions in organic chemistry.[36,39,43,48–51] 
Asymmetric halogenation at olefins and activated carbons is possible by nucleophilic attack at 
the -position of aldehydes, carbonyls and 1,3-dicarbonyl compounds after activating the car-
bonyl compounds with an organocatalyst.[49,52–58] Another important transformation at olefins 
is the electrophilic addition that transforms one functional group into two, with formation of 
new stereocenters.[59] The olefin is hereby activated by the halogen in presence of a nucleophile 
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and both, halogen and nucleophile are added which typically results in the trans product.[60] 
One important variation of this reaction is the intramolecular cyclization reaction, in which 
unsaturated acids are turned into lactones.[50] The first iodocyclization was already described 
in 1904.[61] Until today it belongs to the synthetic useful and important processes of organic 
chemistry.[62]  
Of recent interest is also the development of fluorination reactions. The first breakthrough 
was in 2002 and since then several strategies were published.[63–65] Vicinal fluorination as well 
as vicinal chlorination methods were developed for polyhalogenation of alkanes[48,66] and 
chlorosulfolipids[67,68]. Stereoselective introduction of halogens with chiral auxiliars was shown 
by Evans in 1987.[69,70] The use of auxiliars in halogenation reactions is nowadays an established 
methodology for example in the synthesis of syn-vinylchlorohydrins[51,71,72] and the combina-
tion of halogenation with lactamization.[73] 
In recent years progress has been made in the field of halogenation. Even though many 
possible routes are known, the transformations are still highly challenging. A vast majority of 
reactions use conditions that are impractical and lack generality because the substrate scope is 
extremely limited and mechanistic understanding of the reactions is often not explored.[59] Hal-
ogenation of unactivated, aliphatic carbons is a substantial challenge for chemists.[74–78] To syn-
thesize complex molecules, the halogen atom is currently introduced quite early and the re-
maining synthesis has to be planned with proper care to not eliminate the halogen, once intro-
duced. Weires et al. and Reyes et al. have discussed these issues in the total synthesis of (-)-N-
methylwelwitindolinone B isothiocyanate.[47,79] Especially while developing new pharmaceu-
ticals it is often necessary to adjust the properties such as reactivity, permeability or ligand-
target interaction by testing different stereoisomers of a certain molecule once the core struc-
ture is synthesized. Therefore, late stage halogenation would be of advantage since the syn-
thesis of the core substance has to be performed once and selective C-H bond functionalization 
in the absence of directing groups in further steps would greatly simplify synthesis[23,32,78] and 
enable late-stage diversification of the complex molecules.[80–82] 
A different approach for halogenation is the use of enzymes which is described in detail in 
the next chapter. Additional to enzymes, which have a high complexity, high molecular weight 
and often low stability, some groups started to build synthetic mimics of the catalytic center 
of enzymes, which could be a versatile alternative to enzymes, once the catalysts are estab-
lished. So far, halogenation of several alkyl moieties was achieved with the help of a manga-
nese porphyrin catalyst.[83,84] Cyclohexane as well as toluene were halogenated by the use of 
hexacoordinated iron catalysts that mimic the active site of non-heme iron (NHI) dependent 
halogenases.[85] In both cases problems with chemoselectivity occur which results in hydrox-
ylated by-products. The challenge of higher chemoselectivity needs to be tackled by further 
catalyst engineering. 
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1.2.2 Biological Halogenation 
Biological halogenation occurs on a diverse array of organic scaffolds, from volatile hydrocar-
bons to indoles, terpenes, peptides, phenols, polyketides and nonribosomal peptides. Within 
these scaffolds, halogen atoms are incorporated on aliphatic carbons, olefinic centers and a 
wide variety of aromatic and heterocyclic rings.[77,86] 
The activity of the first halogenating enzyme was verified in 1959 when the biosynthesis of 
chlorinated metabolites, such as caldariomycin, of Caldariomyces fumago was investigated.[87] 
Nowadays four different enzyme classes, haloperoxidases, flavin dependent halogenases (Fl-
Hal), nucleophilic halogenases and non-heme iron (NHI) dependent halogenases are known. 
In table 1, characteristics are compared for the enzyme classes. 
Table 1. Comparison of four halogenase classes.[86,88] Haloperoxidases and NHI dependent halogenases can be classified again 
into two subclasses. Haloperoxidases can either have a catalytic center containing vanadate or heme. One subclass of NHI de-
pendent halogenases can only transform substrates, that are bound to an acyl carrier protein, while the other subclass acts on 
freestanding substrates. VCPO – vanadium chloroperoxidase, CPO – chloroperoxidase. 
 haloperoxidases 
flavin dep. 
halogenases 
nucleophilic 
halogenases 
NHI dep. 
halogenase 
activated 
halogen 
X+ X- X· 
accepted  
halogens 
Cl-, Br-, I- Cl-, Br- F-, Cl- Cl-, Br- 
represent-  
tatives 
VCPO CPO 
PrnA 
RebH 
FDAS 
SalL 
ACP dep. 
SyrB2 
CurA 
WelO5, 
AmbO5 
Wi-WelO15 
cofactor 
vanadate, 
H2O2 
heme, 
H2O2 
FADH2, O2  FeII/KG, O2 
substrate 
require-
ments 
electron rich arenes or enolates  
electrophilic, 
good leaving 
group, SAM 
aliphatic, unactivated 
examples 
of natural 
products 
 
  
As shown in table 1, each halogenase class requires their own cofactors and has quite different 
substrates as well as individual reaction mechanisms. In the next chapters, the halogenases 
will be described in detail. 
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1.2.2.1  Haloperoxidases 
The first halogenase was discovered in 1966 and is a heme dependent chloroperoxidase 
(CPO).[89] Later, more haloperoxidases were found that either contain heme or vanadium as 
cofactor and use halides (Cl-, Br-, I-) and hydrogen peroxide to form hypohalous acid or hypo-
halite as freely diffusible halogenating agent. Due to that, they possess a flexible substrate 
scope,[90] and the reaction, works without any regioselectivity.[91] This results in generation of 
mono-, di- and trihalogenated products.[92] It was shown that few members of this enzyme 
family show a specific reaction by binding their substrates[93–95] or performed regio- and enan-
tioselective reactions by trapping the hypohalite.[96,97] Brominations and iodinations are possi-
ble for these enzymes, too. In this case a high ratio of bromide versus chloride is important to 
achieve bromination, as could also be shown for other types of halogenases.[98–101] 
Haloperoxidases generally have a poor stability at high temperatures and high concentra-
tion of its substrate hydrogen-peroxide.[102] The enzyme stability can be enhanced by immobi-
lization as was shown several times either by adsorption on talc[103], mesoporous materials[104–
108] or amino-agarose gel[109] or covalent attachment with mesoporous silica[105,106,110,111], methac-
rylate[112], chitosan membranes[113], magnetic beads[114] or others[109,115]. But because of leaking 
from the surface or sterically hindrance by the attached surface, these methods need further 
improvement. By entrapping CPO in silica gel, doped with chitosan polysaccharide, the bio-
catalyst showed increased reusability and thermal stability.[102] Successful application has been 
demonstrated by Merck that obtains indene oxide, an intermediate in the synthesis of the HIV-
1 protease inhibitor Crixivan through biotransformation with a haloperoxidase.[116] 
1.2.2.2  Flavin dependent Halogenases 
Flavin dependent halogenases (Fl-Hal) belong to the superfamily of flavin dependent monoox-
ygenases.[117,118] The tryptophan halogenase PrnA from Pseudomonas fluorescens was discovered 
as first representative of this enzyme class in the year 2000.[119] Since then, several members 
were discovered. The most extensively studied halogenases are tryptophan halogenases which 
introduce chlorine in position 7 (PrnA, RebH), 6 (KtzR, ThalL) and position 5 (PyrH) in tryp-
tophan.[120] As in chloroperoxidases, first hypohalous acid is produced which is generated by 
the reaction of reduced flavin with molecular oxygen. However, unlike the other halogenase 
class, the hypohalous acid is not the halogenation agent. It is presumed that the hypohalous 
acid reacts with a lysine (Lys79, RebH) to form a chloramine which acts as final chlorination 
species. In comparison to the hypohalous acid it is more stable and therefore less reactive. The 
lysine is located between the flavin binding site and the binding site of the substrate which are 
about 10 Å apart, so that the chlorination occurs in a regioselective way.[121] Also known but 
less extensively studied are flavin dependent pyrrole and phenolic halogenases, that halogen-
ate either freestanding substrates or substrates tethered to a carrier protein.[120] 
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Fl-Hal have been shown to halogenate a range of synthetic as well as natural aromatic 
compounds. The exquisite regioselectivity makes them potentially useful biocatalysts.[122–125] 
However, the application of Fl-Hal in vitro has been hampered by their poor catalytic activity 
and lack of stability. These drawbacks can be overcome by directed evolution.[126,127] By for-
mation of cross-linked enzyme aggregates, regioselective bromination up to gram scale could 
be developed.[128] Also the finding of a thermostable Fl-Hal is of advantage for biocatalysis.[127] 
Furthermore it could be shown that sequential or tandem halogenation/cross-coupling is pos-
sible to transform C-H into C-C, C-N or C-O bonds.[120,129–132] Of special interest is the develop-
ment of a high-throughput screening method with fluorescent output published 2016, that 
combines enzymatic halogenating of tryptophan with bioorthogonal Pd mediated cross-cou-
pling to produce fluorescent products, which makes further enzyme engineering more fac-
ile.[133] All these recent developments prove the high biocatalytic potential of Fl-Hal. However 
only halogenation on electron rich or activated systems are possible and the reaction system 
additionally needs a NADPH-dependent reductase, that reduces FAD to FADH2 and a third 
enzyme that recycles NADP+ since NADPH as stoichiometric reagent is far too expensive.[134,135] 
1.2.2.3  Fluorinases 
Fluorinated metabolites could only be isolated from plants and bacteria so far.[136] In 2004, 
5’FDAS from Streptomyces cattleya, the first enzyme able to fluorinate substances, was identi-
fied. The fluorinase works with a nucleophilic mechanism and uses S-adenosyl methionine as 
substrate to produce 5’fluoro-5’deoxiadenosine.[137] The fluorinase can also perform chlorina-
tion, although the dechlorination is thermodynamically favored. A found homologue enzyme 
SalL is only able to chlorinate but not fluorinate.[138,139] Until now only four more fluorinases 
have been identified.[140–142] 
The nucleophilic halogenase FDAS has already proven its usefulness as biocatalyst in the 
production of [18F]fluorine-labeled molecules for positron emission tomography. Because the 
enzymatic reaction is performed in aqueous solution, it eliminates the need to secure dry 
[18F]fluoride.[143,144] Fluorinases are able to accept non-native substrates but often with a lower 
activity.[144–147] Rational design and directed evolution have already been successfully applied 
to increase the activity towards non-native substrates.[146,148] In the same study it was shown 
that the enzyme in general seem to be quite stable and good evolvable, as the fluorinase FlA1 
has a higher activity at 42 °C and variants are active even at 47 °C.[148] These recent findings 
suggest the fluorinase as great candidate for usage as biocatalyst especially since selective 
fluorination is such an important transformation and under mild conditions difficult to enable 
chemically.[148] 
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1.2.2.4  Non-Heme Iron dependent Halogenases 
The fourth family of halogenases, which was recently discovered are non-heme iron (NHI) or 
FeII and -ketoglutarate (FeII/KG) dependent halogenases. Their ability to work on unacti-
vated, aliphatic substrates makes them special since the addition of halogens in stereoselective 
manner of unactivated (sp3)-carbons is quite difficult for organic chemistry as well. The first, 
in 2005 discovered and so far best investigated member is SyrB2 from Pseudomonas syringae.[149] 
The enzyme family belongs to the mononuclear FeII/KG dependent oxygenases, one of the 
largest subfamilies of non-heme iron enzymes. NHI halogenases can be further classified 
based on their substrate. The first subclass need their substrate to be tethered to an acyl-carrier 
protein (ACP),[149–154] while the other class can transform freestanding substrates.[155–158] The hal-
ogen addition works radically while the halide can originate from salts like sodium chloride.  
Unlike the other halogenases, few investigations were conducted to test the biocatalytic 
potential of this enzyme class. Naturally these enzymes chlorinate their substrate, but in ab-
sence of chloride and with a high excess of bromide, also bromination can be performed.[98,99] 
If the substrate positioning is improper, hydroxylation instead of chlorination will occur.[159] 
Hydroxylation can furthermore be triggered with mutation in the 1st (G166D, WelO5) and 2nd 
(S189A, WelO5) sphere around the catalytic center,[160] as well as by mutation in the substrate 
binding site.[158] Also, for NHI-dependent hydroxylases to date, few engineering studies are 
published, the best studied member is TauD from Escherichia coli.[161–166] This may be based on 
their low activity. Only a turnover number of 7 is described for SyrB2.[149] The first directed 
evolution study with NHI dependent halogenases was performed in the Hoebenreich group 
within this thesis.[158] It was shown that the halogenase Wi-WelO15 from Westiella intricata can 
be engineered to accept non-native substrates. This proves the power of directed evolution to 
evolve the members of this challenging enzyme class and that activity problems can be over-
come.[158] In the next chapter, this halogenase class will be described in detail, followed by 
chapters about biocatalysis and directed evolution. 
1.3 Non-Heme Iron, α-Ketoglutarate Dependent Enzymes 
FeII/KG dependent enzymes encompass a large family of oxidative enzymes, which are wide 
spread along all kinds of organisms, as can be mentioned, humans, plants and prokaryotes. 
Variations to a common mechanism are used to hydroxylate structural proteins, regulate the 
hypoxic response, modulate histone methylation, repair alkylated DNA/RNA and synthesize 
or degrade a range of natural products. Hereby chemical transformations like halogenation, 
demethylation, desaturation, O-cyclization, ring expansion and epimerization are catalyzed. 
Substrate oxidation is coupled with reductive activation of molecular oxygen and decarboxy-
lation of KG to succinate.[162,167–177] 
In vitro reconstitution of aliphatic halogenases require halogenase, FeII and cosubstrates 
KG and Cl-. For the reaction furthermore O2 is needed. NHI dependent halogenases share 
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similarities in structure and mechanism to well-studied hydroxylases.[149,178] Mutagenesis of an 
hydroxylase enabled the chlorination of its substrate while a chlorinase could also hydroxylate 
its substrate. This reversal of activity however is not possible for all members of this enzyme 
class. Structure and mechanism of both, halogenase and hydroxylase, will be discussed in de-
tail in the next chapters. The chapter will focus on aliphatic halogenase Wi-WelO15 which is 
used within this thesis[158] and its homologue WelO5, which was characterized by the group of 
Liu.[99,155,156,160] 
1.3.1 Crystal Structure 
Structurally, the enzymes share a jelly-roll motif that defines the cupin superfamily and is 
composed of an eight-stranded antiparallel beta sandwich containing an FeII in the active cen-
ter (figure 2).[77,160] The versatility of NHI dependent enzymes is possible since the iron is coor-
dinated by only two or three protein ligands and thus has three to four sites available to coor-
dinate substrates. Hydroxylases share a facial triade consisting of His(Xm)Asp/Glu(Xn)His for 
iron binding. Crystal structures of SyrB2[149,178], CytC3[153,179] and WelO5[160] revealed that the 
facial triade in halogenases consists of His(Xm)Gly/Ala(Xn)His. The substitution of Asp/Glu by 
Ala/Gly creates an open space at the iron center for the chloride to bind (figure 2a).[149,178,180]  
Halogenase WelO5 exclusively produces the hydroxylated fischerindole if mutation 
G166D is introduced instead of the chlorinated product[160], while hydroxylase SadA halogen-
ates its substrate when mutation D157G is present.[181] However mutation of Ala to Asp in 
halogenase SyrB2[178] and Asp to Ala in hydroxylase TauD[182] failed to convert enzyme activi-
ties. Structural studies of halogenase CytC3 revealed that numerous additional interactions 
with the protein environment are critical in ensuring chlorine can bind to the iron center, 
which explains the failure in modifying the enzyme activity.[179] A nearby Arg residue located 
15-22 residues beyond His2 in the sequence provides additional stabilization to the C-1 car-
boxylate in the cases of TauD, AtsK, CAS, CarC and AlkB.[167]  
Crystallization of several enzymes revealed that the structure seems to be quite flexible. 
The loops, covering the active site of SyrB2 have higher B-factors, indicating that they have 
some degree of mobility[178]. It is assumed that once iron and chloride bind, the protein closes 
around the active site. This closure involves motions of two loops and a beta hairpin. The 
phosphopantetheine arm with substrate enters the active site through the remaining narrow 
tunnel above.[178] The structure of CurA could be solved in five different states.[183] Also, the 
structure of WelO5 was solved in an open and a closed conformation (figure 2b)[160] and 
Wi-WelO15[158] which differs only in 2 amino acids to WelO5 shows a third structural state in 
its crystallized form (figure 2c). Even though the crystal structure of some halogenases are 
oligomers, e.g. WelO5 is a monomer in solution[160] with no known subunit interaction. While 
CurA is a dimer in solution which is consistent with the dimeric architecture of PKS mod-
ules.[183]  
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Figure 2. a) Active site of halogenase WelO5, shows the octahedral coordinated iron center (green ball). b) Compares open and 
closed conformation of WelO5, shown as surfaces. While the open structure has the substrate binding tunnel quite open and it 
can be seen to the iron center, while in the closed conformation, the center is shielded. In cyan, the lid is shown which can close 
over the active site. c) Comparison of three different crystallization states of Wi-0 (PDB 6GEM)[158] and WelO5 (PDB 5IQT)[160]. The 
lid (cyan can adapt in three different conformations) 
The stability of the structure seems to depend on the enzyme. Some members are readily iso-
lable in apo form and adopt in the same overall conformation as the holo enzymes,[168] as could 
be shown by some crystal structures in apo form (AtsK,[184] P3H,[185] DAOCS,[186] CAS[187]). How-
ever there is evidence that at least in some cases, the overall structure of enzymes becomes 
more ordered when FeII and KG is added.[188,189] Apo SyrB2 has a low affinity for FeII and 
yields only ~35% incorporation while reconstitution with KG followed by FeII yields 90% in-
corporation.[149] TauD abolishes its activity in the presence of EDTA[162] while for XanA it was 
shown that activity remains in the presence of EDTA which shows that cofactor binding differs 
depending on the enzymes.[190] Since ferrous ion is required for all enzymatic activities of KG 
enzymes the addition of a reducing agent as ascorbic acid to the reaction can increase the ac-
tivity.[158,162] 
When FeII is present together with KG, the metallocenter exhibit a characteristic metal-to-
ligand charge transfer transition[191–194] resulting in a lilac color to this state of enzyme. The rate 
of chromophore formation is independent of the concentration of FeII -TauD or KG. This is 
consistent with KG binding to the protein followed by a conformational change that gives 
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rise to the absorption.[195] The lilac-colored KG-TauD complex reacts with O2 in the absence 
of added substrate to generate a transient yellow species λmax = 408 nm, which was identified 
as a tyrosyl radical on the basis of EPR studies, which is formed after KG decomposition.[196] 
Another species is observed if FeII is added to an anaerobic sample of apoprotein TauD. A 
weak and broad absorption band near 650 nm arises which is attributed to an FeIII-catecholate 
species.[182] The green color originates from the electron transfer from FeII to an ortho-quinone 
at position Tyr73 (TauD) where the oxidized side chain is derived from intracellular enzyme 
self-hydroxylation during aerobic cell growth followed by oxidation of the catechol to quinone 
state during further growth and protein purification.[195] Self-oxidation is a common problem 
reported for many related FeII/KG dependent dioxygenases leads to destruction of activ-
ity.[196–198] This was also shown for SyrB2, which only catalyzed 7 turnovers before inactiva-
tion.[149]  
1.3.2 Mechanism 
FeII/KG-dependent enzymes encompass a large family of oxidative enzymes that use varia-
tions to a common mechanism to transform a wide range of molecules.[195] The enzymes cata-
lyze a two-electron oxidation. The two reducing equivalents required for the four-electron re-
duction of oxygen are often provided by a cosubstrate. This cosubstrate include KG[167], tet-
rahydrobiopterin[199], reduced nicotinamides[200], and ascorbic acid[201]. Few enzymes oxidize 
their substrates by four electrons and thus do not require a reducing cosubstrate.[200,202,203] The 
versatility of NHI dependent enzymes is possible since the iron is coordinated by only two 
protein ligands and thus has four sites available to coordinate substrates.  
The proposed reaction mechanisms include several intermediates following the addition 
of oxygen to the FeII center.[200,204,205] Almost 30 years ago, Hanauske-Abel and Günzler pro-
posed a theoretical reaction mechanism for 4-prolyl hydroxylase.[206,207] In the last years, studies 
of several KG-dependent enzymes lead to the characterization of non-heme iron-oxo inter-
mediates providing some insight into the reaction mechanism. Important roles played the tau-
rine hydroxylase TauD[208,209] and the halogenases SyrB2[210,211] and CytC3[74,212]. 
Halogenases and hydroxylases belong to the same class of oxidoreductases, however, since 
the sequence identity of some of the enzymes is quite low, it can be assumed that not all these 
genes evolved from a common ancestor but they developed by convergent evolution.[162,172] 
Hydroxylation as well as halogenation reactions involve activation of the substrates through 
H-atom abstraction of the target C-H bond by the FeIV-oxo intermediate to yield a substrate 
radical and an FeIII-OH complex. Followed by a rebound which formally involves recombina-
tion of a coordinated radical (hydroxyl or chloride) with the substrate radical to yield the prod-
uct and a coordinatively unsaturated FeII center.[213] Alternative reactions that do not involve 
radical recombination involve for example abstraction of a second H-atom to yield desaturated 
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or cyclized products and an FeII-OH2 complex. Significant insight into the geometric and elec-
tronic structures of high-valent non-heme Fe-oxo complexes and their reactivity was obtained 
from studies of inorganic complexes[214–217] and quantum mechanism calculation[211,218–222]. 
The observation of non-heme FeIV-oxo intermediates and FeII containing product com-
plexes with almost identical spectroscopic parameters in the reactions of two distantly related 
KG dependent hydroxylases suggest that this subfamily follow a conserved mechanism for 
substrate hydroxylation.[213] Although the mechanism of O2 activation, leading to the highly-
reactive Fe(IV)=O intermediate (with spin S=2 ), are thought to be similar for all KG-depend-
ent NHI enzymes, there is notable divergence in their subsequent catalytic cycles.[223] The 
mechanisms of hydroxylase and halogenase are shown in scheme 2. Halogenation versus hy-
droxylation within the reaction will be discussed in the next chapter. 
 
Scheme 2. General accepted reaction mechanism of αKG dependent enzymes.[213] Proposed halogenase mechanism, with different 
conformation of FeIV-oxo species is shown in comparison to proposed conformation of hydroxylase.[213,222,223] 
The catalytic cycle starts formally with a binary complex, which represents the enzyme in its 
apo form (I). When KG and Cl- are inserted in the active center, the tertiary complex (II) is 
formed. The crystal structure of SyrB2 showed, that the halide binds to iron before decarbox-
ylation.[178] The substrate does not bind directly to the metal but its coordination to the KG-FeII 
enzyme complex induces the displacement of water which was shown to serve as a trigger to 
create an O2 binding site,[178,224] so that the quaternary complex (III) reacts with O2.  
Two types of intermediates have been proposed: First a Fe coordinated (su)peroxo com-
plexes (IV) with an intact O-O bond, [Fe-O2]2+/3+,which could not be detected so far. The attack 
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of the superoxide on the carbonyl carbon of KG yields a peroxohemiketal bicyclic complex 
(V). Which decomposes to eliminate CO2 and a bound succinate at an FeIV-oxo ([Fe=O]4+) com-
plex (VI), the second proposed intermediate, which could be confirmed by spectroscopic meas-
urements.[212,225–227] This FeIV-oxo complex in TauD revealed a unusual high-spin (S ¼ 2) config-
uration.[164] The large kinetic isotope effect on its decay in the presence of deuterated substrate 
identified this intermediate as the species that cleaves the C-H bond.[228,229] The hydrogen ab-
straction occurs via hydrogen atom transfer from the C-H bond of the substrate, yielding a 
FeIII-OH and a substrate radical (VII). [74,230] 
Comparable analysis of the halogenase CytC3 revealed the formation of at least two FeIV 
complexes upon reaction with O2. Both are FeIV complexes which are in a rapid equilibrium 
and are believed to be two distinct conformers.[74] The existence of these two conformers of the 
Fe site may be the key factor accounting for the divergence of the halogenase reaction from the 
hydroxylation pathway after C-H bond cleavage.[213] Recent studies[223,231,232] propose the FeIV-
oxo complex (VII) to be in a quintet state in which the oxido oxygen points away from the 
substrate (π-orientation of the oxo group, relative to the native C-H bond) as shown in scheme 
2 (halogenase pathway) and scheme 3.[223] For hydroxylases, rebound occurs with the axial 
positioned hydroxyl group while for halogenases, the hydroxyl group originating from oxy-
gen isomerizes in a equatorial formation. If the chlorine rebound occur from a equatorial or 
axial position is not completely clear yet,[222,231,232] but it was shown that in halogenases, hydrox-
ylation and halogenation do not compete. Substrate positioning directs the reaction toward 
halogenation or hydroxylation (see next chapter hydroxylation).[159] 
Efforts to purposely generate a FeIII-OH species and a taurine radical failed. Considering 
calculations, it is likely that the lack of intermediates is due to the nature of the substrate, not 
the protein environment. The lack of a stable FeIII-OH species is consistent with spectroscopic 
studies which identified an FeII intermediate following the FeIV-oxo species.[164] After the re-
bound is performed, the product is released and the iron complex can be regenerated. 
Selective hydroxylation of unactivated carbons is of interest as well as the differentiation 
between halogenation and hydroxylation and therefore recent findings of hydroxylases and 
halogenases will be compared in the following chapter. 
1.3.3 Halogenation versus Hydroxylation 
After the discussion of general mechanistic intermediates above, a closer look on the differ-
ences between hydroxylation and halogenation will be taken in this chapter. No hydroxylation 
side reaction has been detected for SyrB2 with native substrate L-Thr, indicating that Cl radical 
transfer is greatly favored,[149] while non-native substrates are preferably hydroxylated.[227] Un-
til today it remains largely unknown how the enzymes avoid potentially competing hydrox-
ylation outcomes. There are several possible explanation including positioning of the substrate 
in the active site[223] or lower potential of Cl radical versus OH radical[223], as has been proposed 
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to explain similar reactivity in model complexes.[149,233] Recent studies[223,231,232] propose the FeIV-
oxo complex to be in a quintet state in which the oxido oxygen points away from the substrate 
(π-orientation of the oxo group, relative to the native C-H bond). The presence of this interme-
diate is supported by the crystal structure of WelO5 which shows a H-bond between carbox-
ylate group of KG and Ser189.[160] 
Recent findings by QM/MM studies from Huang et al.[222] revealed the existence of three 
Cl-FeIV-oxo isomers which interconvert (scheme 3). 
 
Scheme 3. Reaction network of the selective halogenation by SyrB2 starting from the FeIV=O species. The green pathway is the 
sole pathway for halogenation of L-Thr.[222] 
Only the one pointing its oxo ligand towards the target C-H bond is active during the hydro-
gen atom abstraction. It was shown, that an isomerization of the Cl-FeIV-oxo species is possible 
with an overall energy barrier of 16 kcal/mol (scheme 3, first row). In further optimization 
steps, RC3 always isomerizes back to RC1. Also, all attempts of hydrogen abstraction from the 
substrate led back to RC1, which leads to the conclusion that RC1 is the sole reactive species 
in the C-H activation (scheme 3).[222]  
After H-abstraction, the FeIII species can undergo an isomerization which has only an en-
ergy barrier of 6 kcal/mol (scheme 3, middle).[222] The crystal structure of WelO5 also indicated 
a relocation of the oxo unit from the axial position to the equatorial plane, defined by the chlo-
ride and the KG, which would draw the oxo group further away from the substrate. This 
transition is apparently aided by a hydrogen bonding interaction with the hydroxyl group of 
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Ser189 in FeII secondary sphere. Mutation of Ser189 to Ala led to an equal portion of hydrox-
ylation and chlorination products.[160,234] 
A hydrogen bonding between Arg254(SyrB2) and the OH ligand of Cl-FeIII-OH intermedi-
ate not only prevents the OH ligand from participating in the reaction, but also facilitates the 
isomerization of the Cl-Fe-OH so that the Cl is directing towards the alkyl radical. Experi-
mental data support the importance of the Arg residue in CurA, since mutation of Arg241 and 
Arg247 mutant completely suppress activity.[183]  
Calculations by Srnec and Solomon[232] reveal that substrate orientation strongly influences 
if chlorination or hydroxylation happens. Their results are in agreement with experimental 
observations of Bollinger and Krebs.[159] Hydroxylation is thermodynamically favored, but 
chlorination intrinsically more reactive.[232] Selectivity is then determined by the orientation of 
the substrate C with respect to the HO-Fe-Cl plane. Especially non-native substrates are often 
hydroxylated rather than halogenated which supports a change in positioning with respect to 
the Fe center.[159,227,235] Positioning of the alkyl group of a substrate away from the oxo/-hydroxy 
ligand and closer to halogen ligand sacrifices H abstraction proficiency for halogen rebound 
selectivity.[227] This interesting reactivity and selectivity has been examined by theoretical 
groups, but so far most of the calculations do not reflect the experimental data.[210,211,218,220,222] 
Results within this thesis showed that also by mutations in the substrate binding site, 
chemoselectivity for transformation of non-native hapalindole derivatives can be changed 
from 98% chlorination to 68% chlorination (32% hydroxylation) by introducing mutation I84H 
(Wi-WelO15), see chapter 3.6.4.1.[158] 
The observation, that some halogenases are able to hydroxylate, if their chloride binding 
site is filled and vice versa, but other members are not able to change their transformation 
potential shows, that the mechanistic understanding of hydroxylation versus halogenation is 
far from being understood. 
1.3.4 Halogenase Wi-WelO5 
After general discussion of FeII/KG dependent halogenases and hydroxylases, a closer look 
will be taken to halogenase Wi-WelO15, which was mainly analyzed in this thesis. Wi-WelO15 
belongs to the recently discovered, new class of non-heme iron halogenases, that act on free-
standing substrates and therefore has a high potential as biocatalyst.[155] Today, five represent-
atives of this enzyme class are known, which all originate from the gene clusters of cyanobac-
terial strains subsection V (Stigonematales).[236] Whereby the classification of subsections is 
based on cyanobacteria morphology.[237] Cyanobacteria (blue green algae) occur in terrestrial 
and aquatic ecosystems. They produce a large number of bioactive substances with a diverse 
range of biological activities. The two major alkaloids biosynthesized by cyanobacteria are 
saxitoxin and hapalindoles.[238,239] The family of hapalindole natural products is a group of iso-
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prenoid-indole alkaloids, found exclusively in the subsection V cyanobacteria. Over 80 varia-
tions belong to this substrate class, which are divided in subfamilies including hapalindoles, 
welwitindolinones, fischerindoles and ambiguines. All contain either an isonitrile or isothio-
cyanate with an indole alkaloid skeleton and one or more cyclized isoprene units.[236] Interest-
ingly, some substances were isolated from cyanobacteria cultures as chlorinated and dechlo-
rinated substance.[236] Representative members of hapalindoles are shown in figure 3. 
 
Figure 3. Examples for hapalindoles, isolated from cyanobacteria strains.[236] Hapalindole-type alkaloids are a large group of in-
dole monoterpenoids with broad spectrum antimicrobial and antitumor activities.[236] 
Each substance has unique bioactivities, ranging from antitumor, anticancer, antialgal, anti-
mycotic to antituberculotic activities.[33,236,240] Gene clusters responsible for the biosynthesis of 
these natural products were identified[236,241,242] and key biosynthetic steps towards the for-
mation of hapalindoles were characterized.[243–247] Next to other genes, several oxygenase genes 
were identified and numbered O1-19 combined with abbreviation for the gene cluster.[236] Fur-
ther information about the gene clusters is given in chapter 3.1, table 3. The oxygenases of the 
five gene clusters with their host organism are given in the following.  
▪ welO1-5, Hapalosiphon welwitschii UTEX B1830,  
▪ ambO1-7 Fischerella ambigua UTEX 1903,  
▪ welO11-19 Westiella intricata UH strain HT-29-1,  
▪ welO11-17 Hapalosiphon welwitschii UH strain IC-52-3,  
▪ hpiO4-10 Fischerella sp. PCC 9339 
Since welO11-17 are present in Westiella intricata UH strain HT-29-1 and Hapalosiphon wel-
witschii UH strain IC-52-3, genes and proteins will be named Wi-welOX and Hw-welOX. Num-
bering was made based on sequence identity. Protein sequences with an identity greater than 
90% were believed to be homologous proteins and labelled with the same number.[236] WelO5 
and its homologues AmbO5, HpiO5, Wi-WelO15 and Hw-WelO15 were first suggested and 
later proven to be FeII/KG dependent halogenases, responsible for the halogenation of 
12-epi-hapalindole C and 12-epi-fischerindole U.[155] AmbO5 was shown to have an even 
broader substrate scope.[156] The in vitro halogenase activity for WelO5, AmbO5, 
Hw-WelO15[157] and Wi-WelO15[158] was shown, while no in vitro characterization was per-
formed so far for HpiO5. In figure 4, all-natural substrates that are accepted by the halogenases 
are shown. 
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Figure 4. Natural substrate scope of halogenases WelO5 and AmbO5. Substrates are sorted by their acceptance. 42, is accepted 
best, while 51 is accepted worse.[156] 
The halogenases stereo specifically replace the pro R hydrogen at the C13 of the substrates. 
Aligning the sequences, the highest difference in sequence appears in the part of the lid region 
which is assumed to be partially responsible for substrate recognition (ch. 3.1.3, figure 10).[156] 
It was shown that by creating chimeras from AmbO5 and WelO5, the substrate scope of WelO5 
could be enlarged albeit with reduced activity.[156] Enzymes performing fascinating reactions 
as the selective halogenation of unactivated sp3-carbons are considered highly interesting for 
further use in biocatalysis. However the overall activity of the best substrate is still only 75 
turnovers, which is 5-10 times greater than that of CmaB and SyrB2.[155] To overcome the limit 
of a small substrate scope and low activity, enzyme engineering can be used to change prop-
erties of enzymes. 
1.4 Biocatalysis  
“Biocatalysis is the application of enzymes and microbes in synthetic chemistry.”[248] Nature’s 
catalysts are applied for new purposes, for which enzymes have not evolved.[248] In the last 
years, scientific and technological advances have established biocatalysis as a practical and 
environmentally friendly alternative to traditional metallo- and organocatalysis in chemical 
synthesis, in laboratory and industrial scale.[248,249]  
Focusing on halogenation, even though synthetic ways for halogenation reactions are 
known today (ch. 1.2.1), chemists often struggle with problems to halogenate unactivated car-
bons. To regio- and stereoselective introduce halides, many additional synthetic steps must be 
performed and once, the halogen is introduced, attention of further reaction conditions must 
be paid to not eliminate it again.[47,79] But nature has developed a variety of elegant mechanisms 
to produce all these organohalogens, in an environmental friendly way selectively. Reducing 
the risk potential and increasing sustainability in chemistry has been an important topic in the 
last years, which will be further discussed in the next chapter. 
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1.4.1 Green Chemistry 
Starting 20 years ago, in the 1997, the concept of green chemistry was defined for the first 
time.[250] The „design of chemical products and processes to reduce or eliminate the use and 
generation of hazardous substances”[251] strives to work at the molecular level to achieve sus-
tainability.[252] Chemistry is often associated with toxicity, the first step in the lab to reduce 
personal risk is to use protective gear. However, in 1998, twelve principles were set by Paul 
Anastas and John Warner as a guiding framework for the design of new chemical products 
and processes.[253] The rules should be applied to all aspects of the process life-cycle, from the 
raw materials used to efficiency and safety of the transformation, as well as toxicity and bio-
degradability of used products and reagents. The goal is to reduce intrinsic hazards to a min-
imum and limit the risks for accidents and damage for human and environment.[252] In table 2, 
the twelve rules are overviewed. 
Table 2. Twelve principles of green chemistry. For detailed explanation see Anastas and Eghbali.[252] 
Twelve Principles of Green Chemistry 
waste prevention use of renewable feedstocks 
atom economy reduce derivatives 
less hazardous chemical synthesis catalytic reagents rather than stoichiometric reagents 
designing safer chemicals 
design for degradation: (products should break down 
into innocuous degradation products) 
safer solvents and auxiliaries real-time analysis for pollution prevention 
design for energy efficiency  
(ambient temperature and pressure) 
accident prevention 
 
The twelve principles were not meant to be twelve independent goals but rather an integrated 
cohesive system of design. Only if all principles are applied a truly sustainable process can be 
achieved.[252] Using one catalyst for various independent reactions or achieving an entire syn-
thesis in one pot, would bring chemistry to a new level, as more complex molecules could be 
made with higher material and energy efficiency.[252] 
The typical reaction conditions for enzymatic transformations is aqueous reaction media 
at ambient temperatures, using renewable enzymes as catalysts.[128] Mainly the latter named 
reagents are non-toxic, while conventional halogenation chemistry is often a noxious, environ-
mentally hazardous process that requires harsh reaction conditions involving toxic reagents 
and solvents.[254] One example is the carcinogenic solvent CCl4, which is now forbidden in 
many countries because of its toxicity.[120,255–257] However it must be taken into account that 
biocatalytic processes are sometimes run at low concentrations, producing huge amounts of 
waste-water.[258] Water as solvent and high substrate loadings can often come together with 
solubility problems. Concentrations are reduced to a low millimolar range, which yield poor 
economic performances. Therefore, it can be of advantage to use a two-phase system, with one 
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aqueous and a second either organic phase or a solid resin. In this way, the substrate loading 
can be increased, while product inhibition most likely is prevented, since the organic phase 
serves as substrate reservoir and product sink.[258] But the solvent and the high substrate con-
centration must be tolerated by the enzyme.  
Stability against temperature, solvents and a variable pH range make enzymes attractive 
as biocatalysts. While in the lab, activity assays are mostly performed at 30 °C and individually 
chosen pH, in big processes, several factors like waste heat and economic profitability must be 
considered.[259] The efficiency of some enzymes relative to analogous chemical processes has 
led to an increased use as biocatalysts in preparative and industrial applications. Furthermore, 
unlike small molecule catalysts, enzymes can be systematically optimized via directed evolu-
tion for a particular application and can be expressed in vivo to augment the biosynthetic ca-
pability of living organisms.[260] Today there are already some biocatalytic processes that out-
perform conventional processes with regard to quality and economic profitability.[259,261–263] In 
the past, an enzyme-based process was designed around the limitations of the enzyme; today, 
the enzyme can be engineered to fit the process specifications.[248] 
1.4.2 Enzyme Engineering and Directed Evolution 
Protein or enzyme engineering describes the process of altering the structure of an existing 
protein to improve its properties.[264] Even though enzymes in their natural substrate scope are 
often quite limited, successful enzyme engineering studies showed that the substrate scope of 
many enzymes can be enlarged or changed by adapting the active site to different molecule 
shapes.[158,265–267] In contrast to classical synthetic chemistry, the structures of enzymes are able 
to imprint selectivities, overwrite electronic and steric properties of compounds which makes 
them excellent starting  points for catalyst development and enable reactions that are not pos-
sible chemically.[268] Also, low stability in general, against temperature or organic solvents 
could be overcome in several studies.[249,269–272] If enzymes with low activity are used for bio-
transformation, large amounts of proteins are needed, reducing yield and hamper work-up 
because of emulsion formation.[248] Adapting enzymes by engineering, and the use of isolated 
enzymes in contrast to lysate, is often is considered more economic and practical because less 
mass is added and usually the product is easier to isolate.[248] Purified enzymes tolerate harsher 
conditions, eliminate potential diffusion limitations caused by cell membranes and are easier 
to ship around the world. Improved enzymes with a long shelf life and good activity and sta-
bility in organic solvents should help biocatalysis to spread further into industrial laborato-
ries.[248] 
Looking in the past, the use of living organisms and enzymes to transform natural products 
into new natural products is used for many decades, e.g. wine and beer fermentation, prepa-
ration of bread and cheese or natural antibiotic production.[248] Components of living cells were 
already applied for useful chemical transformations more than a century ago.[273,274]  
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Over the years, the use of natural occurring catalysts changed. An important limitation is 
the stability of biocatalysts which can cause trouble also in today’s processes. This can partially 
be overcome by immobilization of the enzyme, which also facilitates the reuse of the cata-
lyst.[248] The term directed evolution was first used in 1972, while the pH optimum of the acids 
phosphatase in baker’s yeast (Saccaromyces cerevisiae) was changed.[275] 
Since X-ray diffraction of protein crystals[276,277] became more and more established, the 
number of protein structures grows steadily, resulting in an increased number of structure 
based protein engineering. The substrate range of enzymes could be extended, which allowed 
the synthesis of unusual synthetic intermediates, fine chemicals and pharmaceuticals.[278,279] In 
the late 1990s, directed evolution of proteins became popular in several groups and Reetz[280], 
Stemmer[281] and Arnold[282] published modifications of an in vitro version of the Darwinian 
evolution. The process is based on iterative cycles of variation (amino acid changes = library 
creation), selection of variants with improved enzyme properties (library screening) and am-
plification (template chosen for next round of randomization). The process is shown in figure 
5. 
 
Figure 5. Protein or enzyme engineering describes the process of altering the structure of an existing protein to improve its prop-
erties.[264] The gene is mutated to create a library of mutations, which is heterologous expressed in E. coli. The enzymes are exam-
ined in activity assays in 96-well plates and after extraction, their performance is read out by chromatography. An improved 
variant (hit) can be used as template in the next round of mutagenesis, if this engineering circle is run through several times, the 
process is called directed evolution. 
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Previously, most directed evolution studies started with error prone PCR[283,284] or DNA shuf-
fling[281,285]. However, soon it was emphasized that focused libraries usually are favorable since 
they decrease the screening effort. Key developments, enabling the creation of focused librar-
ies, were an increasing number of protein crystal structures, bioinformatic tools, computer 
modelling and sequence analysis. Positions for mutation can be chosen from crystal structures, 
bioinformatic consensus information such as alignments or exploratory NNK-based satura-
tion. Variant creation and screening are the bottleneck of all directed evolution studies since 
all produced variants must be examined for their properties.[248,286–289]  
Randomization of several residues simultaneously with an NNK codon, which corre-
sponds to all 20 amino acids, adds up to library sizes with astronomical numbers. Large im-
provements of the enzymes’ properties usually need multiple amino-acid substitutions be-
cause this results in bigger impact to the protein structure.[248] However, substituting simulta-
neous multiple amino-acid creates exponentially more variants for testing. There are 7,183,900 
possibilities for two substitutions anywhere in a 200 amino-acid protein and 9,008,610,600 pos-
sibilities for three substitutions. Therefore, it is useful to restrict library size to smaller alpha-
bets.[248,286] A molecular understanding of proteins helps to choose positions and alphabets as 
smart as possible.[248,249] The design of the libraries can and should be supported by informatic 
tools.[290–294] Until today, an important limitation in enzyme engineering is the unknown struc-
ture-function relationship, which makes prediction difficult.[248,289] 
In the early 2000s, 1–5 mutations were typical, whereas by 2010, 30–40 amino-acid were 
not unusual.[261,295,296] Enzyme engineering is much faster than it was ten years ago, but chang-
ing 30–40 amino acids and screening tens of thousands of candidates still requires a large re-
search team. Many, if not all, engineering strategies will yield improved variants, but some 
will yield better variants and find them faster.[248] In 2005, the Reetz group described a strategy 
called CAST - combinatorial active-site saturation test.[297] Here individually chosen residues 
are grouped  into CAST randomization sites. These small libraries are tested individually. 
Found mutations can then be combined in iterative saturation mutagenesis (ISM).[298] Both 
strategies combined are a good possibility to expand the substrate scope or change the enan-
tioselectivity of a chosen enzyme.[298]  
CAST is of advantage, because simultaneously mutagenesis of several position also in-
cludes synergistic effects. Often it is assumed, that beneficial mutations are mostly additive,[299] 
but often the contributions have unexpected behavior. For example, Weinreich and co-work-
ers[300] found in the evolution of a β-lactamase that a mutation A increased the reaction rate but 
destabilized the -lactamase. The overall effect was slightly beneficial. Mutation B by itself had 
no effect because it did not affect the rate but stabilized the -lactamase. Together, mutations 
A and B were highly beneficial because the -lactamase was faster and maintained its stability. 
In the study all 120 possible paths were tested to attain an improved variant and only 18 of the 
tested paths improved resistance at each stage. Similarly, Reetz and Sanchis[301] showed that 
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only 8 out of 55 possible paths lead to an increased enantioselectivity of an epoxide hydrolase 
at each step. Both studies show the importance of cooperative effects, leading to the creation 
of smart libraries, consisting of several positions with small codons.[302] Mutating stepwise, 
while taking always the best improved variant (hit) leads possibly to a dead end. The creation 
of small but smart libraries, takes synergistic effects into account and reduces screening effort 
and oversampling.[303,304]  
At the same time, high quality libraries are needed since they require less screening ef-
fort.[305] Hence it is always necessary to check the library quality by performing Quick Quality 
Control (QQC), to make sure the expected diversity has been created.[306] Furthermore statistics 
can be taken into account. Especially since screening is the bottleneck of engineering, it can be 
considered, if perhaps one out of the best three hits will be sufficient for the users need, then 
screening can be reduced effectively.[307,308]  
Another trend that developed in the last years is to remodel the purpose of enzymes or to 
design synthetic enzymes from scratch. The rationally designed biocatalysts are made for 
transformation that were accessible only with synthetic catalysts.[287,288,309–312] 
Today, the best approach to alter properties of enzymes, is to generate libraries containing 
multiple mutation sites with reduced amino-acid alphabets and to test them simultaneously. 
The positions to be mutated are chosen structure guided and the library design should, if pos-
sible, be supported by informatic methods. At the same time new methods for high-through-
put screening are developed constantly, facilitating the screening of larger mutant librar-
ies.[248,249,286–288,293,294,303,310,313,314] Engineered enzymes can overcome problems like low activity and 
narrow substrate scopes. Stability for solvents and temperatures opens the door for industrial 
processes.[248,249,315,316] 
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2. Thesis Goal 
Goals of this thesis are to first show the evolvability of aliphatic halogenases towards non-
natural substrates and to second test the properties of the created catalyst. Ultimately creating 
a new biocatalyst for direct and asymmetric C(sp3)-H chlorination under mild and non-haz-
ardous conditions. 
To achieve the first goal, two members, Wi-WelO15 from Westiella intricata UH strain HT-
29-1 and Hw-WelO15 from Hapalosiphon welwitschii UH strain IC-52-3, of the 2014 discovered 
subclass of non-heme iron (NHI) dependent halogenases were cloned from the genomic DNA 
and heterologous expressed in E. coli. To analyze the substrate scope of the wild-type enzymes, 
commercially available, non-natural isonitriles and isothiocyanates are tested. To broaden the 
substrate scope, structure guided directed evolution is desirable, therefore, crystallization of 
the enzyme will be pursued to gain detailed insight into the active site of the enzymes. In 
parallel, random mutagenesis via error prone polymerase chain reaction (epPCR) is performed 
until an enzymatic structure will be available. The halogenases should be engineered to accept 
user defined non-natural substrates with a ketone (54) instead of the isonitrile group (53). To 
ensure the activity of the enzyme, a simplified derivative (53) of 12-epi-hapalindole C (39) will 
be synthesized (figure 6). 
 
Figure 6. 12-epi-hapalindole C (39) is a natural substrate of the family of NHI dependent halogenases. To test the activity of the 
two representatives, used in this project, a simplified derivative of the hapalindole is synthesized (53). For the directed evolution 
towards non-natural substrates, the naturally rare occurring and instable isonitrile is substituted with a ketone functionality which 
simplifies the synthesis from 6 to 3 steps. When active variants are found, the substrate scope can further be tested with variations 
of the screening substrate (54). 
In directed evolution studies, usually medium to high throughput screening is performed, 
in which several thousand created variants are tested for their chlorination activity towards 
the target molecule (in this case 54), hence more than 2 g of substrate is required. Therefore, a 
simple and robust synthesis or cheap access should be granted. Because this is not the case for 
isonitriles which also occur rarely as intermediates, the ketone was chosen as functionality in 
position C11. Together with the substitution of the chiral center in position C10, to a simplified 
achiral dimethyl-function, the chosen screening substrate (54) can be synthesized in a 3-step 
synthesis (scheme 5).  
Thesis Goal 
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The enzyme will be engineered within several generations. Screening is performed in cell 
lysate, where different reaction conditions have to be established that grant good enzyme ac-
tivity and prevent fast iron(II) oxidation. Further reaction conditions for purified enzymes 
should be analyzed as well. With increased knowledge of the enzymatic system, smarter li-
braries can be created. Kinetic analysis of selected variants with 54 will help to gain a deeper 
understanding of the catalytic system and perhaps the effect of the targeted amino acid resi-
dues. 
The second goal includes examination if the halogenase is applicable for a general use as chlo-
rination method, which includes testing a larger non-natural substrate scope, increasing the 
reaction scale to a preparative level and determination of the enzyme’s stability. 
After finding one or more active variants in the screening, the substrate scope can further 
be tested with substrates containing variation in its structure at the indole as well as terpene 
ring. These substrates will be synthesized within this project and the master thesis of 
L. Schmermund.[317] To characterize products and to test the biocatalytic applicability, the scale 
of the biocatalytic reaction should be increased from <0.5 mL and nanogram range in the 
screening to several milligram in flask.  
Because stability of the biocatalysts is an important factor for possible future applications 
and projects, the melting temperature of several variants will be measured to get an idea of 
the overall enzyme stability. Important variants – with high selectivity and product formation 
– will then be tested for their stability in the presence of solvents and their activity at elevated 
reaction temperatures. 
Next to halogenation, also the usage as hydroxylase will be examined. NHI dependent 
halogenases are close related to NHI dependent hydroxylases and in few cases, the reactivity 
can be interchanged by modifying one amino acid close to the iron center.[160,181] This amino 
acid, G166 (Wi-WelO15 numbering), will be mutated to see if a hydroxylation of the new sub-
strates is possible. Furthermore, also oxygenase P450 from Bacillus megaterium will be tested if 
hydroxylation of the screening substrate 54 is possible. Within this project, existing oxygenase 
libraries in the group will be screened and from gained knowledge of this screening, a small 
new library of P450 will be created and selective variants will be used for preparative scale 
reactions to obtain products in mg-yield to characterize the new products. 
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3. Results and Discussion 
This thesis deals with the biocatalytic halogenation of non-activated C(sp3)-H bonds with the 
help of engineered enzymes. As catalysts, halogenases Wi-WelO15 and Hw-WelO15 originat-
ing from cyanobacteria are used, which have hapalindole-type alkaloids as natural substrates. 
These indole monoterpenoid substrates are structurally fascinating molecules with interesting 
biological activities as anticancer properties of N-methylwelwitindolinone C isothiocyanate 
(55),[318,319] or anti-tuberculosis activity of ambiguines K and M, fischambiguine B (48) as well 
as hapalindoles X and A(56).[320–322] Today over 80 variations of the isonitrile- or isothiocyanate-
containing indole alkaloid skeleton with a cyclized isoprene unit are known.[236] The structural 
diversity is generated in the pattern of terpene by cyclization, chlorination, methylation, oxi-
dation/reduction and additional prenylation.[236] The numbering of hapalindoles differs from 
IUPAC nomenclature, therefore a short overview of the atom numbers in hapalindoles is given 
in figure 7 together with some of the mentioned structures.[239] 
 
Figure 7. Numbering of atoms in hapalindoles and some examples of structures.[239] 
The results and discussion of experiments are described in several subchapters. First, the bio-
synthetic pathway of hapalindoles is shortly discussed. The cloning of several genes is de-
scribed in chapter 3.1 including the halogenase welO15, which was further examined (ch. 3.2). 
To test the halogenase activity, analogues of the natural substrate were synthesized (ch. 3.3). 
The halogenase Wi-WelO15 was then engineered by directed evolution to achieve the ac-
ceptance of a non-natural hapalindole, containing a ketone (54) instead of an isonitrile func-
tionality (ch. 3.4). Different reaction conditions were tested to optimize the halogenation (ch. 
3.5). The activity of the halogenase variants were analyzed with a broader, non-natural, sub-
strate scope (ch. 3.6). Hydroxylation as side reaction was observable for some variants within 
the engineering process. To increase the hydroxylation selectivity, first rational designed var-
iants of the halogenase were created and tested, but also the oxygenase P450BM3 was analyzed 
and engineered to transform 54 (ch. 3.6.4). Biocatalytic halogenation in large scale was con-
ducted (ch. 3.7) and kinetic analysis were performed for selected enzyme substrate pairs (ch. 
3.8). Furthermore, promising variants were analyzed on their stability towards an increased 
temperature and solvents (ch. 3.9). 
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3.1 Biosynthetic Pathway of Hapalindole-type Alkaloids  
The biosynthesis of these natural products is quite interesting and at the onset of this thesis, 
different gene clusters responsible for ambiguine (amb)[236,241], welwitindolinone (wel)[236,242] and 
hapalindole (hpi)[236] biosynthesis were identified from different cyanobacteria strains. Com-
paring the gene clusters, a core set of 19 genes were identified which share greater than 92% 
sequence identity at the protein level.[236] Blast analysis of the genes proposed their function: 
oxygenases O1-19, tryptophan biosynthesis genes T1-5 and C2, isonitrile biosynthesis genes 
I1-3, isoprenoid biosynthesis genes D1-4, geranyl pyrophosphate synthase gene P2, hapalin-
dole-specific aromatic prenyltransferase gene P1, the regulatory protein-encoding genes R1 
and R2, as well as C1 and C3.[236] In figure 8 an illustration by Micallef et al.[236] of the gene 
clusters is given. 
 
Figure 8. Illustration of the hapalindole (hpi), ambiguine (amb) and welwitindolinone (wel) biosynthetic gene clusters. A) hpi gene 
cluster from Fischerella sp. ATCC 43239. B) hpi gene cluster from Fischerella sp. PCC 9339. C) amb gene cluster from Fischerella 
ambigua UTEX 1903. D) amb gene cluster from Fischerella ambigua UTEX 1903. E) wel gene cluster from Hapalosiphon welwitschii 
UTEX B1830. F) wel gene cluster from Hapalosiphon welwitschii UH strain IC-52-3. G) wel gene cluster from Westiella intricata UH 
strain HT-29-1. H) wel gene cluster from Fischerella sp. PCC 9431. I) wel gene cluster from Fischerella muscicola SAG 1427-1.[236] 
Key biosynthetic steps forming the monoterpene indole core structure were identified by bio-
chemical characterization of some of these enzymes.[155–157,236,238,241–247,323,324] Functional decorat-
ing enzymes -like the oxygenases- are still unexplored. In scheme 4 a proposed biosynthetic 
pathway is shown based on current knowledge.[155,238,241,242,247]  
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Scheme 4. Proposed biosynthetic pathway for the production of some hapalindole-type alkaloids.[155,238,241,242,247] Depending on 
literature, the cyclase genes, responsible to form the terpene ring, are either described as famC1-5[244] or ambU1-5 genes[236]. 
As shown in scheme 4, the biosynthesis starts with tryptophan which is transformed by the 
tryptophan isonitrile synthases HpiI1-3 to build cis indole-isonitrile. The isonitrile functional-
ity is characteristic for all hapalindole alkaloids. With the prenyltransferase WelP1, geranyl 
diphosphate is introduced into the molecule to add necessary carbons and to build the basis 
for cyclization.[238] Several cyclases were found in the amb, hpi and wel gene cluster, able to 
produce different hapalindoles.[244,325] Different oxygenases are proposed to do late-stage mod-
ification, mainly hydroxylation and indole oxidation. Amongst the oxygenases, an KG/FeII 
dependent enzyme was identified as halogenase WelO5, followed by characterization of hom-
ologue halogenases WelO15 and AmbO5. The enzymes were shown to halogenate hapalin-
doles 39 and 42, while 60 and 61 have not yet been tested as substrates of WelO5. Several genes 
of the wel and hpi clusters were available in the Hoebenreich group and conducted experiments 
are described in the following chapters. 
3.1.1 Recloning and Heterologous Expression of WelP1, HpI1 and HpI3 
Codon optimized genes of prenyltransferase welP1 and tryptophan isonitrile synthases hpI1 
and hpI3 were received from R. Viswanathan.[236] welP1 was already in a suitable vector (pJEx-
press) for gene expression in a construct with C-terminal His6-tag. The prenyltransferase could 
be produced by heterologous expression in E. coli. Purification via IMAC was performed by 
N. Braun. Elution with imidazole containing buffer (analogous to the protocol in chapter 
7.1.10.1) resulted in a broad signal consisting of at least two peaks, while SDS-PAGE analysis 
(figure 9) of the eluted fractions showed two main signals and further impurities in low con-
centration. The signal at 35 kDa corresponds to the mass of WelP1, showing that the used con-
ditions are suitable and enzyme production in E. coli works quite well. 
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Figure 9. SDS-PAGE analysis of IMAC purification process via Ni-NTA of WelP1. M=Marker 26610 by Thermo Fischer, L=lysate, 
P = pellet, F3-8 are fractions collected while eluting with imidazole containing buffer, C= combined, concentrated fractions. WelP1 
has a calculated mass of 34.9 kDa (Protparam[326]). The protein band marked by an arrow contains WelP1 which was confirmed 
by mass analysis with a sequence coverage of 50% corresponding to 15 peptides. Other bands are assumed to be proteins from 
the host organism E. coli BL21-DE3(Gold), however no proteins could be assigned by mass. 
If WelP1 should be further analyzed and purified, a modification of the purification protocol 
should be carried out. hpI1, hpI3 were received in an unknown plasmid, sequencing revealed 
furthermore that no his-tag was present, which would simplify the purification process. There-
fore, the genes were cloned with restriction free cloning (rf-cloning, ch. 7.1.1.3) into the pRSF-
Duet vector to create an open reading frame with N-terminal His6-tag. Since characterization 
of the oxygenases were in the main focus of this project, no heterologous expression was per-
formed with the new created plasmids. WelP1 as well as HpI1 and HpI3 were characterized 
by other groups and recently the crystal structure of AmbP1 was published.[236,245]  
3.1.2 Cloning and Heterologous Expression of Oxygenases WelO11-WelO19 
Synthetic oxidative C-H functionalizations are challenging reactions, where success highly de-
pends on the structure and presence of functional groups. Especially challenging is control of 
stereo- and enantioselective introduction of hydroxy or halogen groups in complex molecules. 
Enzymes mostly perform reactions quite selective albeit with a limited substrate scope. If the 
substrate scope can be altered, enzymes as selective biocatalysts are a great alternative to 
chemical catalysts. The gene clusters responsible for hapalindole-like alkaloid production, 
which are not dependent on polyketide synthases or non-ribosomal peptide synthetases, carry 
a great potential to contain useful biocatalysts. Since the diversity of hapalindoles is huge, a 
variety of different transformations, such as hydroxylation, oxidation, desaturation must be 
possible with these enzymes.  
In table 3 an overview of oxygenases in hpi, wel and amb clusters is given by Micallef et 
al.[236]. Until now, few is known about the oxygenases. In 2014 and following years, 
WelO5/AmbO5/Wi-WelO15/Hw-WelO15/HpiO5, were published to be members of a new 
class of halogenases. These halogenases are non-heme iron (NHI) dependent and chlorinate 
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freestanding substrates.[155–158] The enzymes in table 3 are sorted based on their sequence iden-
tity. Also, HpiO5/AmbO5 and the WelO15 enzymes are highly related with a sequence identity 
of 78-80%. 
Table 3. List of encoded oxygenase enzymes from the hpi, amb and wel biosynthetic gene clusters.[236] The halogenases HpiO5, 
AmbO5, WelO5 and WelO15 are highlighted in purple. Organisms which are abbreviated in the table: Fs=Fischerella sp., Fa= Fisch-
erella ambigua, Hw=Hapalosiphon welwitschii, Wi=Westiella intricata.[236,242] 
organism: 
 
oxygenases 
Fs  
PCC 
9339 
Fa  
UTEX 
1903 
Hw UTEX 
1803 
Hw  
IC-52-3 
 
Wi  
HT-29-1 
 
Fs  
PCC 
9431 
Rieske oxygenase  AmbO1 WelO1 WelO11 WelO11  
Rieske oxygenase  AmbO2 WelO2 WelO12 WelO12 WelO12 
Rieske oxygenase  AmbO3 WelO3 WelO13 WelO13  
Rieske oxygenase HpiO4 AmbO4 WelO4 WelO14 WelO14 WelO14 
oxidoreductase, 
KG/FeII oxygenase family 
HpiO5 AmbO5 WelO5 WelO15 WelO15 WelO15 
alkanesulfonate monooxygen-
ase 
HpiO6 AmbO6 -    
oxidoreductase, FAD depend-
ent pyridine nucleotide disul-
fide 
- AmbO7 -    
indoleamine 2,3 dioxygenase   - WelO16 WelO16 WelO16 
choline dehydrogenase-like  
flavoprotein 
  - WelO17 WelO17 WelO17 
monooxyygenase   -  WelO18  
Rieske oxygenase   -  WelO19  
 
The genomic DNA of two cyanobacterial strains Hapalosiphon welwitschii UH strain IC-52-3 
(Hw) and Westiella intricata UH strain HT-29-1 (Wi) were received from Michelle Moffit.[236] All 
oxygenases from the wel gene cluster were amplified by polymerase chain reaction (PCR) and 
cloned by a restriction free cloning method[327] into the high copy pRSF-Duet vector. By clon-
ing, a His6-tag was added to the N-terminus of all enzymes. The genes and enzymes will be 
named after their organism, combined with the cluster and numbering. For example, 
Wi-WelO15 represents the oxygenase 15 of the wel cluster occurring in Westiella intricata UH 
strain HT-29-1. 
For the restriction free cloning, primers were designed with a partial overlap of the vector 
on one side and with the gene on the other side. These primers were used to amplify the genes 
from the genomic DNA. Due to the amplification with the primers, the gene carries overlap-
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ping areas with the pRSF-Duet vector at the 3’ and 5’ end and can further be used as megapri-
mer for the amplification of the whole vector. Successful cloning was confirmed by sequencing 
and the plasmid incorporated in E. coli BL21-Gold(DE3). Cloning of oxygenases WelO11-19 of 
Westiella intricata and WelO11-WelO17 of Hapalosiphon welwitschii (except Hw-WelO14) was 
successful. In attempts to amplify Hw-welO14, only sequences of Hw-welO13 could be found, 
due to a high sequence similarity. In further attempts to clone Hw-welO14 new primers should 
be designed. Sequences of the genes are given in ch. 8.3.2 and additional information about 
cloning, mutations in the genes and silent mutations are listed in table 36 (ch. 8.3.1).  
For genes Wi-welO11-14, test expressions were performed by S. Grobe (ch. 7.1.9.3). SDS-
PAGE analysis showed that the enzymes could be produced best in LB-medium but seem to 
be mainly insoluble in the cell pellet under tested conditions. No further optimization of ex-
pression conditions, as shorter incubation times or different production temperatures, were 
tested. J. Pilgram tested the production of Hw-WelO16-WelO17 and Wi-WelO16-WelO18 (ch. 
7.1.9.5) in E. coli, which was successful, but purification attempts indicated that the enzymes 
seem to be very instable since precipitation after purification was noticed already overnight. 
In contrast to that, the halogenase Hw-WelO15 and Wi-WelO15 were overexpressed in E. coli 
BL21-Gold(DE3), purified in high yields (~60 mg/L) and seemed to be quite stable (ch. 7.1.9.1). 
3.1.3 Characterization of Aliphatic Halogenases Wi-WelO15 and Hw-WelO15 
If the nucleotide sequence of Wi-WelO15 is analyzed with the nucleotide blast tool of the Na-
tional Center for Biotechnology Information (NCBI)[328], 13 sequences are found with a se-
quence identity >80%. The highest identity exists with welO5 (99% similarity and identity), a 
gene from Hapalosiphon welwitschii UTEX B 1830 which was published in 2014 as aliphatic hal-
ogenase, dependent on FeII, alpha-ketoglutarate (KG) and O2 which belongs to a new class of 
halogenases that works on freestanding substrates.[242] Therefore it can be assumed, that the 
halogenases Wi-WelO15 and Hw-WelO15 also belong to the class of non-heme iron (NHI) de-
pendent halogenases. This new halogenase class is of special interest since they perform 
chemo-, regio- and stereoselective C-Cl bond formation under mild and non-hazardous con-
ditions, which is still a formidable challenge in chemical[57,84,329–332] and enzymatic cataly-
sis,[101,120,148,333–336] especially by direct functionalization of unactivated C(sp3)-H bonds.[78,81,337,338] 
Therefore, the two halogenases Wi-WelO15 and Hw-WelO15 enzymes should be explored 
for their biocatalytic potential within this thesis. The project was started by amplifying Wi-
WelO15 and Hw-WelO15 from their respective genomic DNA. Identical primers were used, 
resulting in two mutations V6I and D284N in Wi-WelO15 which therefore is not the wild type 
but a starting variant, in the following named Wi-0. Figure 10 shows an amino acid alignment 
of all those FeII/KG dependent halogenases that so far have been cloned and recombinantly 
expressed. The two mutations introduced in Wi-0 are highlighted with blue boxes. The two 
 Results and Discussion  
 
31 
amino acids that differ between Wi-WelO15 and WelO5 are highlighted with red boxes. The 
green box highlights the area in which all enzymes differ most. After the crystal structure was 
solved it became clear that this area is a helical lid which closes over the active site and is 
partially responsible for substrate recognition.[156] 
 
Figure 10. Alignment of cloned and recombinantly expressed FeII/KG dependent halogenases which are able to chlorinate free-
standing substrates. N-terminal His6-tag and linker are not shown for clarity. Wi-0 is a variant of Wi-WelO15 from Westiella 
intricata HT-29-1, containing mutations V6I and D284N from primer design (blue boxes) and represents the starting point of this 
directed evolution study. Hw-WelO15 from Hapalosiphon welwitschii IC-52-3.[236] WelO5 from Hapalosiphon welwitschii UTEX 
B1830[242] and AmbO5 from Fischerella ambigua UTEX 1903.[241] Red boxes highlight naturally occurring differences between Wi-0 
and WelO5. The green box highlights the α-helices forming an active site lid. 
The alignment shows that the amino acid sequences share a high identity with most differ-
ences in the part of the helical lid. AmbO5 has with 77% the lowest sequence identity to WelO5 
and comparing the substrate scope, AmbO5 chlorinates more hapalindole alkaloids then 
WelO5.[156] Comparison of sequences reveal 99% identity and similarity between Wi-WelO15 
and WelO5 and 94% identity and 97% similarity between Hw-WelO15 and WelO5.[339] In the 
following chapter, the expression and purification (ch. 3.2) as well as the activity of the halo-
genases Wi-0 and Hw-WelO15 (ch. 3.3 ff) will be analyzed. 
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3.2 Halogenase Production and Purification 
Hw-WelO15 and Wi-0 (Wi-WelO15 V6I/D284N, mutations originate from primer design) were 
produced with N-terminal His6-tag in E. coli BL21-Gold(DE3). In the beginning, different ex-
pression conditions were tested including TB and LB medium as well as IPTG concentrations 
in the range of 20 µM to 1 mM. The following conditions worked best and were further used 
throughout this thesis: 0.5 L LB-medium containing 50 µg/mL kanamycin and 50 µM FeCl3 in 
2 L baffled flask. The medium was inoculated with 5 mL preculture and let grown at 37 °C 
until an OD600 reached 0.4, gene expression was induced by adding IPTG to a final concentra-
tion of 20 µM and the temperature was reduced to 22°C. After further shaking for 16 h the cells 
were harvested by centrifugation, the pellet was resuspended in buffer containing 50 mM 
HEPES, 10 mM NaCl, 10% glycerol with pH 7.4 and stored at -20°C until further usage. 
In figure 11, an SDS-PAGE analysis of lysates, containing Hw-WelO15, Wi-0 and Wi-
WelO15 V6I, is shown. Since the C-terminus points into the active site (see ch. 3.2.1.2 and figure 
19) it could be possible that a mutation in this region effects folding or activity. Cells were 
normalized to OD600 before lysis. Cleared lysate was applied to the SDS-polyacrylamide gel to 
compare the levels of soluble halogenase, which can be seen in the band at around 34.5 kDa, 
marked by an arrow. Lane 3 shows Wi-WelO15 V6I, where mutation D284N from Wi-0 was 
reversed to the wild-type sequence, to see if it has an effect on the expression level.  
 
Figure 11. SDS-PAGE analysis of OD600 normalized E. coli BL21-Gold(DE3) cells induced with IPTG after lysis with lysozyme.  
1) Hw-WelO15 2) Wi-0 and 3) Wi-WelO15 V6I. The halogenases have a calculated molecular weight of 34.4 kDa (Hw-WelO15) and 
34.5 kDa (Wi-WelO15), the band corresponding to the halogenase, is marked by an arrow. 
Expression levels of Hw-WelO15, Wi-0 and Wi-WelO15 V6I are comparable. Because of the 
His6-tag, simple one step immobilization metal ion chromatography (IMAC) purification was 
possible. Therefore, the cells were lysed by sonication and insoluble cell debris removed by 
centrifugation. An Äkta purification system with Ni-NTA column in combination with a Tris 
buffer was used. As can be seen in figure 12 the elution profile of both WelO15 enzymes did 
not show a Gaussian distribution as expected but a very strong tailing. This also persisted 
while washing with buffer containing 0.5 M imidazole.  
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Figure 12. Elution profile of affinity chromatography of Wi-0 and Hw-WelO15. To load the enzyme to the nickel resin buffer, 
buffer Tris A (50 mM Tris, pH=7.4, 500 mM NaCl, 0.1% Tween-20, 20 mM imidazole, 10 mM β-mercaptoethanol) was used. After 
washing unbound enzymes from the column, elution was performed by a gradient increasing the concentration of buffer Tris B 
(50 mM Tris, pH=7.4, 500 mM NaCl, 250 mM imidazole, 10 mM β-ME). The purification process is described in ch. 7.1.10.1. 
From the elution profile, it appears that the enzyme binds strongly to the column material, 
which leads to the observed strong tailing. It could be possible that polar surface residues in-
teract with the Ni-ions or that the enzyme is quite flexible and the iron binding site containing 
two histidines, in the active center, interacts with the column material. The ability of this en-
zyme class to bind nickel was shown for oxygenase TauD and halogenase WelO5 as both en-
zymes are inhibited by divalent ions Co2+ and Ni2+.[155,340] However, this strong interaction with 
the resin resulted in pure enzyme solution, as can be seen from the SDS-PAGE analysis in 
figure 13. 
Batch purification with the same resin was tested by M. Biermeier but the yield decreased 
dramatically, therefore this purification approach was omitted.[341] The exchange from Nickel 
resin to Talon, a cobalt based resin, was tested and lead to a low binding under similar buffer 
conditions. The enzyme was detected by SDS-PAGE analysis to be in the flow-through frac-
tion.  
In another approach to minimize tailing, the Ni-NTA column was run with phosphate 
buffer pH 6 (100 mM potassium phosphates, 500 mM NaCl, 20 mM imidazole to 250 mM im-
idazole). Less tailing was observed, however the enzyme eluted at higher imidazole concen-
tration in a broad peak. While concentrating the enzyme, precipitation could be observed, 
therefore it was concluded that this buffer is not suitable for storage of the halogenase. Dialysis 
into another buffer was tried but activity assays showed a lower turnover than halogenase, 
purified with Tris buffer. In figure 13, the samples are shown, taken at different steps during 
the purification process.  
Sample I (lane 2, figure 13a) represents the cell culture when IPTG is added. After 16 h 
growth time, the cells were harvested (H). After applying the lysate to the column, unbound 
samples are washed from the column (W). For elution, the concentration of imidazole was 
raised to 250 mM by a linear gradient and 5 mL fractions are collected (1-5).  
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Figure 13. a) SDS-PAGE analysis of IMAC purification of Wi-0, the protein band of Wi-0 is marked by an arrow. The shown 
samples were taken at I =induction with IPTG, H=harvest, W=wash fraction of IMAC, 1-5 = elution fractions. Marker (M) 26610, 
Thermo Fisher. b) Purified halogenases, concentration determined via Bradford Assay. Lane 1: Hw-WelO15, lane 2 Wi-0, each line 
contains 3.3 µg protein. 
Figure 13b) shows 3.3 µg isolated Hw-WelO15 (lane 1) and Wi-0 (lane 2), after concentration 
determination with Bradford Assay. Protein production followed by IMAC purification 
yielded a reproducible yield of 60-65 mg/L of bacteria culture. In comparison to published 
yields of 25 mg/L,[155] the yield could be increased by a factor of 2.5. Since a different vector 
and E. coli strain in combination with changed cell growth conditions as well as purification 
procedures were used, no conclusion can be drawn if one factor or several changes in the pro-
tocol lead the increased yield. 
For crystallographic experiments, size exclusion chromatography (SEC) was performed af-
terwards using a Superdex26/60 column. Therefore, the enzyme was concentrated to 1 mL and 
applied to the column via a loop. It could be seen that the enzyme did not precipitate at con-
centrations up to 1.7 mM (60 mg/mL) in the presence of 10% glycerol, while the absence of 
glycerol in the purification buffers causes precipitation at lower enzyme concentrations. With 
isocratic elution by HEPES 2 buffer (50 mM HEPES, 10 mM NaCl, 10% glycerol, 0.5 mM DTT, 
pH 7.4), the enzyme eluted at 227 mL as can be seen in figure 14.  
Samples were taken from the main peak that were analyzed by SDS-PAGE (figure 14a). To 
exclude, that the small band at about 25 kDa is an impurity, both bands (A and B, figure 14b) 
were analyzed by tryptic digestion, followed by mass analysis. Both showed the highest frag-
ment coverage with Wi-0, which leads to the assumption that the smaller band is a fragment 
of the enzyme that cannot be separated with this chromatography step or originates from SDS-
PAGE sample preparation. To see if it results from sample preparation for SDS-PAGE analysis, 
a native PAGE could be run, where no boiling with SDS for linearization is necessary. 
After purification by chromatography, which include a dialysis step against EDTA con-
taining buffer to remove metal ions (FeIII or NiII), the enzyme solution is colorless. When KG 
and iron are added, the color of the solution turns lilac, as can be seen in figure 14c. 
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Figure 14. a) Wi-0 elution profile from size exclusion chromatography (SEC). SEC was performed with an isocratic flow of 
1.5 mL/min and 50 mM HEPES, pH 7.4, 10 mM NaCl, 10% glycerol, 0.5 mM DTT. b) SDS-PAGE gel of fractions that eluted in the 
main peak with a maximum at 227 mL. Gel bands A and B were cut and analyzed by tryptic digestion, followed by mass analysis. 
Both bands are from Wi-0. c) Freshly prepared reagent solutions for crystallization are shown, for color comparison. Iron sulfate 
was dissolved in N2 purged buffer and has a greenish color, while the 1 mM Wi-0 solution containing iron and KG has a lilac 
color. The metal free enzyme solution is colorless. 
The color is based on a charge transfer complex that is formed between KG and FeII inside of 
the enzyme, as it is also described for TauD.[191,192,224] This behavior could only be observed for 
Wi-0, but not for Hw-WelO15 so far. The color intensity however is quite weak, as for TauD an 
extinction coefficient of only ε530 = 140 M-1 cm-1 was determined.[342] In figure 14c a 1 mM en-
zyme solution with iron and KG is shown in comparison to an iron-free sample. Storage of 
the lilac enzyme solution overnight lead to color change. The yellowish color of the solution 
indicate that FeII is oxidized to FeIII by oxygen from air. 
For some non heme iron dependent hydroxylases, for example TfdA (Trp113)[163], AlkB 
homologue hABH3 (Leu177)[343] and TauD (Tyr73, Trp 128, Trp240, Trp248)[163,196,344] it was 
shown that the enzyme performs self-hydroxylation in the absence of a substrate. For the NHI 
dependent halogenase SyrB2 this was also supposed because of an overall low turnover num-
ber of 7 when chlorinating its natural substrate L-Thr-S-SyrB1.[149,198,345] All cofactors, KG, 
NaCl, FeII/III and O2 are present in the growth media, therefore, it also could be possible that a 
long expression time results in self-hydroxylation which might inactivate the enzyme. To rule 
this out, samples with purified enzyme were submitted to the mass department to analyze the 
denatured mass. In figure 15, the received mass spectra (time of flight combined with electro 
spray ionization in positive ion mode (TOF-ESI+)) of Wi-0 are shown, the ones of Hw-WelO15 
can be found in the attachment (ch. 8.3.3).  
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Figure 15. Mass spectrum of the isolated, denatured Wi-0. The denatured enzyme was measured via HPLC-TOF-ESI+ by the mass 
department of the Philipps-University Marburg. The theoretical mass of Wi-0 is 34451 Da, calculated with Expasy Protparam.[326] 
Further peaks correspond to adducts with ions or solvents (+78 = 2K+, +100 = 2K+,1Na+,  
With mass analysis no autooxidation could be detected for enzymes after heterologous expres-
sion and purification under standard conditions (ch. 7.1.9.1, ch. 7.1.10.1). But no information 
is available if this autoxidation happens during biotransformation.  
Enzyme production and purification worked reliably with good yields and excellent pu-
rity. For the goal to do directed evolution, it is necessary to know as much about the enzyme 
as possible. Therefore, experiments regarding structural information and stability were con-
ducted. On the one hand, this includes circular dichroism to examine melting temperatures of 
the halogenase, with which information about the effect of different buffers and presence of 
its cofactors should be examined. On the other hand, crystallization experiments were made 
to solve the structure of the enzyme, which was unknown at that time. 
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3.2.1 Structural Analysis of Halogenases Wi-0 and Hw-WelO15 
3.2.1.1 Circular Dichroism 
For further stability and folding information, circular dichroism (CD) measurements were per-
formed. Folding of both enzymes were measured in HEPES and KPi buffer to check if the 
folding is influenced by the buffer but no remarkable differences could be seen. It was observ-
able that iron phosphate precipitated when FeSO4 was added to the enzyme solution in KPi, 
therefore the enzyme was only used in HEPES afterwards. 
 
Figure 16. CD measurements of Wi-0 and Hw-WelO15. a) 5 µM enzyme solution was measured in buffer which was diluted 1-10 
with H2O to reduce background by high salt concentrations (final concentration: 5 mM HEPES, 1 mM NaCl, pH 7.4),. b) To see 
the unfolding a concentration of 25 µM enzyme in 5 mM HEPES, 1 mM NaCl,pH 7.4 was needed.  
From the obtained data it could be seen, that quite high differences in folding were measured 
for the two enzymes, even though they are thought to have a quite similar structure based on 
a high sequence identity of 98%. From the later published crystal structure of WelO5 it could 
be seen, that WelO5 has 28% helical structures and 24% beta sheet,[160] which differs from both 
obtained data sets. The folding was determined by triplicate measurements. But within differ-
ent enzyme concentrations, folding changes of up to 10% for one motive could be observed. 
High errors in the range of 6-10% often occur and can be lead back to errors in concentration 
determination.[346,347]  
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Measurement of melting curves showed that the melting temperature of Hw-WelO15 with 
61.4 °C is about 8 °C higher than that of Wi-0 with 53.7 °C. Five-time measurement of a sample 
gave a standard deviation of only 0.3 °C. It can be assumed that the results from melting tem-
peratures are more reliable since these values are independent from enzyme concentration or 
environmental influences since the measurement observes the change in millidegree at one 
fixed wavelength. Further results to melting curves and CD measurement can be found in 
chapter 3.9.1.  
3.2.1.2 Crystallization 
For enzyme engineers, it is less effective to engineer a system without knowing the structure. 
In cooperation with the MarXTal, the crystallography department of the Philipps-University, 
a crystallization screening was performed. Commercially available 96-well crystallization 
screening plates from Quiagen were used to test different crystallization conditions. Therefore, 
Wi-0 was isolated by affinity and size exclusion chromatography. In total ten 96-well plates 
were pipetted (all given in table 29, chapter 7.1.14) and with each well, two crystallization 
conditions can be screened. A 1 mM solution of Wi-0 in 50 mM HEPES, 10 mM NaCl, 10% 
glycerol and 0.5 mM DTT was used for crystallization. As cofactors, one sample contained 
additionally 2 mM KG, while the second sample contained 2 mM KG and 1 mM FeSO4 ∙  
7 H2O. Already after three days some crystals were formed in the set-up with iron (figure 17a). 
The measurement at the synchrotron in Grenoble was done by Dr. V. Srinivasan. The obtained 
data set resulted in a resolution of about 3.5 Å. Refinement and repetition of screening condi-
tions, pipetted by hand, could not reproduce crystal growth. However, in the same plate but 
conditions without iron, more crystals with hexagonal shape grew within several months (fig-
ure 17b). Even though they had a diffraction of around 2 Å, the structure could not be solved 
because the molecules were twinned within the crystals. A third kind of crystals grew (figure 
17c), which did not diffract in measurements at the synchrotron. 
 
Figure 17. Crystals of Wi-0. a) The enzyme crystallized aerobically within 3 days. A stock solution of 32.5 mg/mL Wi-0, 2 mM KG 
and 1 mM FeSO4 was mixed 1-1 with reservoir buffer (0.2 M KOAc, 2.2 M AmSO4). b) The aerobic growth of these crystals took 
about 3 months. A stock solution of 32.5 mg/mL Wi-0, 2 mM KG was mixed 1-1 with reservoir buffer (0.1 M Tris pH 8.5, 2.4 M 
AmSO4). c) The aerobic growth of these crystals took about 10 months. A stock solution of 32.5 mg/mL Wi-0, 2 mM KG was 
mixed 1-1 with reservoir buffer (0.1 M Bicine, 1.6 M AmSO4).  
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The structure of the first crystals (figure 17a) could be solved with a resolution of 3.46 Å, based 
on molecular replacement using the structure of WelO5[160] which was published while crystals 
of Wi-0 where measured at the synchrotron.  
To reproduce crystal growth, a new enzyme stock was prepared (new purification without 
previous freezing) and four plates were prepared, three that resulted in crystals last time and 
one, which contains a variety of different divalent metal ions (table 29, chapter 7.1.14). These 
plates were pipetted and incubated aerobically and anaerobically. After about 6 months, few 
crystals grew as shown in figure 17c. Some crystals were soaked with a 1 mM solution of 
hapalindole Q in EtOH, but all tested crystals did not diffract. Interestingly all conditions that 
resulted in crystal growth had ammonium sulfate as salt present, which suggests its im-
portance for the enzyme. 
Also, Hw-WelO15 was tried for crystallization. Therefore, it was purified by affinity and 
size exclusion chromatography and three crystallization screening plates, which resulted in 
crystals for Wi-0, were pipetted by the crystallization department, however, no crystal grew 
within 2 years. 
The solved structure of Wi-0 (PDB 6GEM) shows the typical jelly-fold with iron center 
which is bound to His164 and His259. In figure 18 the structure of Wi-0 is shown in comparison 
to the 3 known states of WelO5. 
 
Figure 18. Crystal structure of Wi-0 (Wi-WelO15 V6I/D284N) in comparison to different crystallization states of WelO5.[158,160,348] 
The α-helical lid, which can close over the active site, is in shown in cyan. 
The structure of Wi-0 contains the cofactor KG, however, no electron density could be de-
tected, where the chloride is supposed to be sitting. In comparison to the published WelO5 
structures, the -helical lid is shifted. Liu and coworkers solved WelO5 in two conformations, 
an open and a closed form.[160] Wi-0 shows a third conformation, which was also observed by 
Schofield and coworkers who solved the structure of WelO5 with nickel as metal center in-
stead of iron (PDB 5J4R).[348] Their structure is without chloride, too. This indicates that the 
chloride might be responsible for the different conformation. Since the metal center is different 
in the two structures (PDB 6GEM and 5J4R), no clear assumption can be drawn. WelO5 struc-
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tures of Mitchell et al. were soaked with 12-epi-fischerindole U before measuring and the struc-
ture with substrate could successfully be solved. Interestingly, the substrate was detected to 
be sitting in the enzyme with either open or closed conformation (figure 18, PDB 5IQS and 
5IQT chain).[160]  
The two halogenases Wi-WelO15 and WelO5 share an identity of 99% and only differ in 2 
amino acids S230F and E133G (Wi-WelO15 numbering). During amplification of Wi-WelO15, 
two more mutations were introduced namely V6I and D284N resulting in the variant Wi-0. 
The positions of these four mutations in comparison to WelO5 could have an effect on struc-
ture and the activity. In figure 19, these positions are highlighted.  
 
Figure 19. Highlight of amino acids differences between Wi-0 (left, shown in grey) and WelO5 (middle, shown in purple). The 
structures of both halogenases were aligned (right). Amino acid differences are shown as linkers and are named with one letter 
code and position. Mutation at position V6 is not visible since the N-terminus (highlighted on the right) was not dissolved. How-
ever, it is assumed that this position has the same effect as the N-terminal His6-tag. The α-helical lid, which can close over the 
active site is in shown in cyan. 
The three amino acids S230, E133 and D284N (Wi-0) in comparison to F230, G133 and N284 
(WelO5) are located on the enzyme surface and have no detectable effect on the enzyme con-
formation in the crystal. The fourth amino acid V6, is not solved in the crystal structure but it 
can be assumed that it has a similar effect as the His6-tag which is also connected to the N-
terminus of the enzyme. The effect of mutation D284N was further tested in activity assays 
(ch. 3.3) and it was seen that no activity influencing effect is present. 
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3.3 Syntheses of Hapalindole Derivatives and Biotransformation  
Natural substrates of these aliphatic halogenases are hapalindole-like alkaloids. For WelO5, 
different natural alkaloids were tested and so far, 12-epi-fischerindole U (42) and 
12-epi-hapalindole C (39) are converted best (figure 20), with a preference for 42.[155,156]  
Extraction of natural products from their host organisms often require several month of 
culturing the organism and generally result in a low yield with below 0.1% of dry bacterial 
weight.[33,34] Even though S. Doehring could show, that a simplified cultivation of cyanobacte-
ria is possible without artificial light cycles and aeration with CO2, the growth is slow and it 
took several month to increase cell mass.[349] It was not tested if the natural products were pro-
duced but even if, few milligrams yield are expected, therefore access to these compounds via 
extraction is hardly possible.  
The synthesis for some hapalindoles requires seven or more steps.[350–353] So far, no synthesis 
routes to 12-epi-fischerindole U isonitrile (42) or 12-epi-hapalindole C (39) were published. To 
have a close derivative of the natural products, which can be synthesized in a simpler way, in 
a first step the stereocenter at C12 was simplified to a dimethylated, non-chiral group. The 
simplified isonitrile analogue 53 (figure 20) is available via 6-step synthesis and an overall 
yield of about 4%.  
 
Figure 20. Natural substrates 12-epi-fischerindole U (42) and 12-epi-hapalindole C (39) were both shown to be chlorinated by NHI 
dependent halogenases.[155–157] Starting from 39, the molecule was simplified stepwise, first by replacing the vinyl group by a 
methyl group (53) and further by replacing the isonitrile with a ketone (54). 
53 was used as reference to test if the enzyme is active and if the activity is in the same order 
of magnitude as the one of close homolog WelO5. In a second step, the halogenase should be 
adapted to non-natural substrates. Instead of the rare isonitrile function, ketone 54 (figure 20) 
was chosen as target molecule to screen enzyme libraries in the directed evolution of the en-
zyme. The ketone occurs more common within natural and synthetic compounds and is more 
stable in comparison to the isonitrile. The synthesis of 53 and 54 is shown in scheme 5.  
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Scheme 5. Synthesis of simplified hapalindole C derivative 53. TsER = ene-reductase from Thermus scotoductus SA01, CDMT = 
2-chloro-4,6-dimethoxy-1,3,5-triazine. DMAP = N,N-dimethylaminopyridin, NMM =N-methylmorpholin. 
Both molecules, 53 and 54 crystallized upon freezing at -20 °C in EtOH. 53 was stored as 
50 mM stock and 54 had to be stored as saturated solution. The crystal structures of the mole-
cules confirmed the stereocenters, assigned by NMR in the first place.  
 
Figure 21. Crystal structures of isonitrile 53 and ketone 54.  
Comparing the molecule structures (figure 21 and figure 83, chapter 8.3.6.2), it is important to 
notice that the carbonyl group and the isonitrile group point in different directions, based on 
the different hybridization of C-11. Also, the terpene ring has a changed position. 
Both substrates, 53 and 54 were tested in biotransformation to see if the reaction conditions 
are suitable for library screening. Results were furthermore compared with published values 
for Hw-WelO15 and WelO5 with 12-epi-fischerindole U (42) and 12-epi-hapalindole C (39).[157] 
The biotransformations were performed in 202 µL in 2.2 mL 96 deep-well-plates (dw-plates). 
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A HEPES buffer was used as solvent including sodium chloride, -ketoglutarate, iron ammo-
nium sulfate and ascorbic acid (ch. 7.2.5). The buffer was flushed with nitrogen gas prior to 
the reaction to remove oxygen and to prevent fast oxidation of FeII, which is needed inside the 
active site of the enzyme. Both halogenases Hw-WelO15 and Wi-0 were tested with 53 and 54 
as purified enzymes (table 4 and table 5) and as lysates (table 5). The enzyme or lysed cell 
pellet was prepared in a volume of 100 µL and either added to a 2.2 mL squared dw-plate or 
a 2 mL reaction tube. A 2x reaction buffer containing the cofactors were prepared freshly and 
added to the plate. Finally, 2 µL substrate were added from a 50 mM stock solution in EtOH 
to the reaction. The reaction was incubated at 30 °C. To stop the reaction, it was extracted with 
ethyl acetate. The organic phase was transferred into glass plates or plastic vials for HPLC 
measurements and placed at room temperature in a clean fume-hood overnight to evaporate 
all ethyl acetate. Remaining dry samples were dissolved in 100 µL acetonitrile and analyzed 
via HPLC with UV detection at 280 nm. The results are shown in table 4 and table 5. 
Table 4: Turnover frequency (TOF) of halogenases.  
formed products isonitrile 43* isonitrile 4* ketone 53a** ketone 54a** 
enzyme TOF (min-1) TOF (min-1) TOF (min-1) TOF (min-1) 
WelO5 1.8 0.7 na na 
Wi-0 na na 0.4 <1 
Hw-WelO15 1.9 1.8 1.8 <1 
*Biotransformation performed by Zhu et al.[157]: 100 µL scale with 20 µM enzyme, 10 mM NaCl, 50 mM HEPES, pH 7.4, 0.5 mM 
(NH4)2Fe(SO4)2, 0.5 mM DTT, 0.5 mM substrate. TOF determined after 2 min. **Reactions performed within this thesis: 202 µL 
scale with 10 µM enzyme, 10 mM NaCl, 50 mM HEPES, pH 7.4, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM DTT, 0.5 mM  53 or 54. TOF 
determined after 20 min. na= not available 
12-epi-fischerindole U (42) as well as 12-epi-hapalindole C (39) were both tested with 
Hw-WelO15 and WelO5 by Zhu et al.[157] and activities were reported as observed velocity kobs, 
which actually represents the turnover frequency (TOF). In their transformations, Hw-WelO15 
showed the same turnover for both substrates in 20 min. The TOF was determined after 2 min 
and Hw-WelO15 achieved 1.8 and 1.9 min-1 for 42 and 39, respectively. WelO5 had the same 
turnover for 42 (kobs=1.8 min-1), but less than half for 39 (kobs=0.73 min-1). In a biotransformation 
with Hw-WelO15 and 53 with slightly different reaction conditions (10 µM enzyme instead of 
20 µM and 200 µL reaction volume instead of 100 µL, 20 min reaction time instead of 2 min), 
a TOF of 1.8 was achieved, showing that the missing methyl group does not influence the 
acceptance of the substrate. Wi-0 also shows a lower kobs (0.4 min-1) than Hw-WelO15 and as 
seen by WelO5 (0.7 min-1), therefore the question arises whether the two mutations have an 
influence on the activity or the difference is based on the error in measurement. Since the re-
action time to determine kobs differed between WelO5 and Wi-0, it is also possible that the 
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reaction velocity slows down after the first two minutes, based on a fast oxidation of the FeII 
located in the active center. 
After the reaction conditions were optimized to 100 mM NaCl and 2.5 mM ascorbic acid, 
the conversion increased. Ascorbic acid can work as recycling system for iron, if FeII is oxidized 
to FeIII.[354,355] Under these optimized conditions (ch. 7.2.5.2), both purified enzymes showed 
about the same conversion in 8 h (table 5). The values obtained for transformation in lysate 
however suggest, that the acceptance of 53 by Hw-WelO15 is better than that of Wi-0 (table 5).  
Table 5: Biotransformation of Hw-WelO15 and Wi-0 as well as Wi-WelO15 V6I with 53 and 54. Final reaction conditions: 202 µL 
volume in 2.2 mL 96 dw-plates sealed with a plastic lid, 50 mM HEPES, 100 mM NaCl, 2.5 mM ascorbic acid, 0.5 mM 
(NH4)2Fe(SO4)2, 0.5 mM substrate, 8 h, 30 °C, 200 rpm (Infors HT shaker). Either lysed cell pellet normalized to OD600=5.0 and 
2.5 mM KG or 10 µM purified halogenase with 5 mM KG were used. 
substrate isonitrile 53 ketone 54 
enzymes 
conv.[a] 
cell lysate 
conv.[a] 
purified enzyme 
conv.[a] 
cell lysate 
conv.[a] 
purified enzyme 
Hw-WelO15 56 91 11 11 
Wi-0 35 93 <1 <1 
Wi-WelO15 V6I 34 nt nt nt 
[a] relative conversion (% HPLC), nt= not tested 
Wi-0 showed a similar conversion of 53 as Hw-WelO15 as isolated enzyme but produced less 
chlorinated product in cell lysate. Both enzymes have a lower conversion in cell lysate than in 
its isolated form. It seemed that the isonitrile is instable in cell lysate because low signals 
(<20 mV) were detected by HPLC measurements. The same concentration of 53 in assays with 
purified enzymes or incubated in buffer resulted in signals between 150 and 200 mV. 
To exclude an insufficient extraction, also the aqueous phase was measured but there, tail-
ing peaks with signals below 10 mV were detected. At last, the organic phase was evaluated. 
Furthermore, mutation D284N of Wi-0 was reversed to D284 and tested in a lysate-based bio-
transformation. It could be shown that the mutation D284N has no activity influencing prop-
erty. 
In contrast to isonitrile 53, ketone 54 is hardly converted by Wi-0. Hw-WelO15 achieved 
11% conversion under optimized reaction conditions (100 mM NaCl and 2.5 mM ascorbic 
acid). Under initial conditions, also a low product formation of <1% was obtained for 
Hw-WelO15. With increasing activity, a hydroxylated side-product (54b) was detected with a 
chemoselectivity of 70% for 54a and 30% 54b. To increase the low conversion of 54, the halo-
genases were engineered, which will be described in the next chapter. 
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3.4 Engineering of Halogenase WelO15 
In an enzyme engineering process, different approaches are possible. Hereby the amount of 
information that is known about the enzyme and the screening method is a critical point. The 
time effort for screening must be balanced with the library size. However, the library size is 
also dependent on the probability to find an improved variant (hit). The dependency of screen-
ing effort versus information intensity was illustrates by Behrens et al.[356] and several repre-
sentative methods are given depending on the amount of available information. 
 
Figure 22. Overview of approaches for protein engineering methods. When only few information is available, methods like error 
prone PCR (epPCR) with a high screening effort have to be chosen. If more information is available, combined approaches like 
CASTing (combinatorial active-site saturation testing) or iterative saturation mutagenesis (ISM) can be performed. Rational de-
sign with distinct point mutations can only be applied if the information intensity is high.[356] 
When the project was started, error prone polymerase chain reaction (epPCR) was chosen as 
mutation strategy (ch. 3.4.1) because no enzyme structure was available. At the same time, 
crystallization trials of Wi-0 were pursued. M. Biermeier furthermore analyzed Hw-WelO15 
with Hydrogen-Deuterium exchange (HDX) analysis with the goal to identify residues that 
interact with the substrate.[341] HDX analysis did not yield information about the substrate 
binding, however two parts of the enzyme were identified that showed a high flexibility. These 
were the N-terminus as well as the lid area (amino acids 210-240).  
In 2016, the structure of WelO5 was published,[160] based on the structure, also the structure 
of Wi-0 could be solved by molecular replacement. Therefore, random mutagenesis was 
stopped which did not lead to any success at that point and combined approaches with CAST-
ing/ISM as well as rational design were used instead (ch. 3.4.2). 
3.4.1 Random Mutagenesis 
3.4.1.1 Creation of a Hw-WelO15 Model with SwissModel 
If no structure of the target enzyme is known, random mutagenesis has to be performed which 
includes a high screening effort.[248] To minimize this effort, not the whole gene was planned 
to be mutated but a user defined, by modeling chosen, region should be mutated. To avoid 
mutation of the vector during epPCR the mutated gene parts were incorporated into the wt 
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DNA after the mutagenesis. Since rf-cloning worked well for cloning of the genes, this attempt 
was also chosen to combine the mutated gene and the vector.  
The only sequence information about this enzyme class was the iron binding site which is 
a shared characteristic with two histidines (His164 and His259) in the active site in non-heme iron 
oxygenases/halogenases. To get some ideas about the structure, models were built with Swiss-
Model.[357–361] Therefore, the sequence of Hw-WelO15 was used and templates were chosen 
from the proposals given by the webpage. Three models were built. The templates were cho-
sen by: 1) Highest overall coverage (0.82), (putative uncharacterized protein PDB 3W21). 2) 
Highest coverage with a non-heme iron dependent halogenase which is SyrB2 (coverage of 
0.75, PDB 2FCU). 3) Highest coverage with an enzyme that has KG and Fe2+ as ligands Phyt-
anoyl-CoA dioxygenase (coverage of 0.78, PDB 2AX1).  
From the build models it could be seen, that each of the active site of the three models with 
the two histidines, responsible for coordination of the iron was built correctly. A substrate and 
KG were drawn in ChemDraw 3D, im-
ported to PyMol, and by hand positioned into 
the enzyme pockets. The area within 5 Å was 
marked and the residues listed with Pymol. 
All these interaction positions were marked 
in the amino acid sequence and chosen as ac-
tive site region (aa 120 – 290 shown in purple 
in figure 23).  
Since for SyrB2 and CurA, two non-heme 
iron dependent halogenases, a lid mechanism 
is known, it was hypothesized that also 
WelO15 possibly works with a lid mecha-
nism.[178,183] Therefore a second region was 
chosen (aa 60-140, shown in turquois, figure 
23), that seem to form a lid, close to the active 
site. In figure 23 the model with substrate (gray) and iron (orange) is shown.  
Figure 23. Model of Hw-WelO15 build with SwissModel based 
on template PDB 2FCU. In the active site the substrate is shown 
as grey sticks as well as the two histidines His164 and His259 with 
bound Fe (orange). In turquois, the assumed lid area is shown 
while the assumed active site is shown in purple. 
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Figure 24. Amino acid alignment non-heme iron halogenases. In blue, the assumed lid region is highlighted and in orange the 
assumed active site region is marked. Primers that were used for error prone PCR mutagenesis are shown in red, these limit the 
mutation regions. Amino acids in a range of 5 Å to the substrate are marked with a black bar above.  
Generally, the sequences have a quite high identity, except in the range of 213 and 235, where 
Hw-WelO15 and AmbO5 have several different amino acids. Based on the model, this area 
would be positioned in the active site. Several studies showed the extraction of quite different 
hapalindole-like alkaloids which support the hypothesis that the active site has to have a dif-
ferent shape to accept different substrates.[236,239] 
After the crystal structure was solved, a new 
model of Hw-WelO15 was made based on the 
structure of WelO5 and compared to the previ-
ously used model. While the two histidines with 
iron and the substrate were positioned quite cor-
rectly, the lid area was assumed incorrect. The lid 
was thought to be positioned in the range of amino 
acids 90-110 (shown in turquois, figure 25, right 
side). Alignment of the two structures followed by 
analysis with MatchMaker by Chimera 1.11.2, 
gives a RMSD of 1.269 Å between 74 pruned atom 
pairs, while across all 253 atom pairs it is 9.418 Å. 
The alignment and the 74 pruned atoms are shown 
Figure 25. Alignment of Hw-WelO15 model, based on 
template 2FCU made with SwissModel (grey) and the 
structure of WelO5 UTEX (5IQT, purple). 12-epi-fisch-
erindole U (42) and 54 are shown as greys sticks. The ac-
tive site with iron (orange) and chloride (green) are 
shown with the two histidines shown as grey sticks. 
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in figure 84. Interestingly, the area containing most amino acid substitutions within this en-
zyme class (aa 213-235) forms the -helical lid (shown in turquois, figure 25, on the left side). 
It was also shown that a chimera enzyme based on WelO5 combined with the lid area of 
AmbO5 broadens the substrate scope of the naturally more limited WelO5 to the one of 
AmbO5, proving that the lid is important for substrate recognition. Mutation of the loop region 
and the active site was performed individually and resulted in a variation of mutants. Indi-
vidual error prone PCR conditions had to be developed for each library which is  described in 
the next chapter. 
3.4.1.2 Random Mutagenesis via Error Prone PCR and Screening 
For error prone polymerase chain reaction (epPCR) it is important that well-chosen PCR con-
ditions are used, since user defined amounts of mutations per gene are created. An average of 
2-5 mutations per gene was set as goal. Based on the protocol, published in Current Protocols 
in Molecular Biology[362] two different conditions were calculated for active site and lid. For 
the only 297 base pair long gene part of the lid region, 15 rounds of amplification should be 
performed in the PCR, while for the 482 base pair long part of the active site only 8 amplifica-
tion steps should be used based on the protocol.  
Eight polymerase chain reactions in 50 µL scale were prepared. To see the amplification 
product, it was necessary to apply 25 µL PCR product in an agarose gel, because only few 
amplification rounds were performed. Mutation of the lid region worked without any further 
optimization and yielded 560 ng DNA. 
For the gene part containing the assumed active site, standard conditions were not appli-
cable, therefore the reaction was optimized, so that the Taq polymerase was only added after 
the hot start and 13 amplification rounds were used instead of 8. To produce sufficient DNA 
10x50 µL PCRs were prepared. 1032 ng mutated gene could be purified by purification kit. Via 
rf-cloning the mutated gene parts were incorporated into the vector.  
To prove the success of the random manner and the distribution of mutations within the 
gene, six clones of both mutation studies were sequenced. Sequencing revealed that 50% var-
iants of the lid area and 66% variants of the active site contain mutations without having any 
frameshifts or stop codon. In figure 26 all positions of mutated amino acids which were found 
in the sequenced clones are shown in blue (found mutations are listed in table 39).  
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Figure 26. Positions that were mutated within the error prone PCR are highlighted within the model of Hw-WelO15 and the 
crystal structure of Wi-0. The mutated amino acids are shown as sticks in blue. The assumed lid reagion is shown in turquois and 
the active site region in purple. Iron is shown as orange ball.The mutations are distributed over the enzyme but just in those areas 
that should be muated. 
As can be seen in figure 26, the sequenced variants carry mutations distributed in the enzyme 
parts that were desired, however 50% and 34% had either a frameshift or an early stop codon 
and are likely to be inactive. In total 1100 variants of the lid-library and 650 variants of the 
active site-library were analyzed in lysate-based biotransformation with substrate 54 as shown 
in scheme 6, but no product formation could be detected. 
 
Scheme 6. Reaction performed with libraries created by epPCR. The reaction was performed in 202 µL volume with 50 mM 
HEPES, 10 mM NaCl, 0.5 mM DTT, 0.5 mM (NH4)2Fe(SO4)2, 1 mM substrate, 24 h, 30 °C, 200 rpm (Infors HT shaker). 
The plates were pooled, so that the cells from four plates were suspended, combined and pel-
leted again. Then, the cells were lysed, and the reaction performed. However, no product for-
mation could be detected by HPLC. After the first library screening of epPCR-variants, the 
crystal structures of WelO5 was published[160] and simultaneously the one of Wi-0 solved, so 
that the engineering could be pursued in a more rational manner. 
3.4.2 Structure Guided Directed Evolution of Wi-WelO15 
After the crystal structure of WelO5 (99% identity) was published[160] the previously not solv-
able data set of Wi-0 (Wi-WelO15 V6I/D284N) could be  solved by molecular replacement and 
a structure guided directed evolution strategy could be started. Wi-0 was used as starting 
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point. The ketone 54 was docked into the enzyme with Yasara by Henrik Müller.[363] In figure 
27, both structures are shown. Figure 27a) shows the structure of Wi-0 with docked 54. Wi-0 
crystallized in an open conformation, while 27b) shows the closed structure of WelO5 with 
soaked, natural substrate 12-epi-fischerindole U (42). Docking of 12-epi-hapalindole C re-
vealed, that it is positioned in the same way as 42 (figure 81, ch. 8.3.6.1). 
 
Figure 27. a) shows the structure of Wi-0 with docked 54. Wi-0 crystallized in an open conformation, while b) shows the closed 
structure of WelO5 with natural substrate 12-epi-fischerindole U (42). 
For docking of 54 and Wi-0 the receptor was prepared using the standard settings of Dock 
Prep tool from UCSF Chimera, Version 1.11.2. This program deletes the solvent, fixes incom-
plete side chains and adds hydrogens and charges to the protein and the bound ligands. In the 
prepared receptor-file, KG had a charge of -2 and the Fe-ion a charge of +2. The results were 
visually analyzed using Chimeras ViewDock-tool. Of 25 outputs, the indole pointed 18 times 
in the direction of the iron, which should not result in any chlorination. Only 3 poses (11, 16, 
22, figure 82, ch. 8.3.6.2) had C13-H(R) pointed in direction of the active site, however in poses 
11 and 22, the indole flipped so that the conformation differs from the crystal structure of the 
small molecule. Pose 16 (figure 27a) was therefore chosen as the most probable binding mode. 
Since all hapalindole-like alkaloids contain either isonitrile or isothiocyanate it can be sug-
gested that these residues play a major role in native substrate recognition.[160] By replacing it 
with a carbonyl function, the H-bond acceptor feature was kept, even though the docking re-
sults showed that the orientation of the carbonyl group points in the opposite direction. Crys-
tallization of 53 and 54 also revealed that the isonitrile and the carbonyl group each are posi-
tioned in different indole half-sides (figure 83, ch. 8.3.6.2).  
Amino acids pointing towards the six-membered ring, as for example V81, A82, I84, A88, 
V90 were interesting to be mutated, since the substrate was modified in this part. State of the 
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art directed evolution strategies suggest preparing small but smart libraries, proposing to mu-
tate several positions at the same time.[303] The bottle neck of directed evolution is the screening 
effort which means that enzyme libraries cannot be created in any size, since the time effort 
necessary for screening is technically not possible. For example, screening two positions with 
an NNK codon, two times 20 possible codons, leads to 400 possible variants with three or four 
different positions, even 8000 and 160000 possible variants are suggested to be screened, if 
aiming for 95% coverage, which is barely possible in HPLC screenings. Therefore, the number 
of variants has to be limited which is described as smart libraries. Reduction of screening is 
especially possible if libraries of high quality are prepared.[302,303,364] High quality means in this 
case that incorporation of the desired codons actually worked and no template is left. The 
combined effects of enzyme dynamic, flexibility, allosteric effects, electrostatic preorganiza-
tion make prediction of mutational effects difficult. Instead of saturation of positions, infor-
mation from previous screenings or rational thinking are considered and, reduced codons are 
incorporated which leads to a reduced number of possible variants. In this way, synergistic 
effects of the amino acids are considered, and possible dead ends in single-step mutagenesis 
are avoided.  
For this enzyme class however only one engineering study was made, which involves the 
creation of AmbO5/WelO5 chimeras to enlarge the substrate scope of WelO5. The lid area of 
WelO5 was substituted by the lid of AmbO5 which lead to the acceptance of more hapalindoles 
albeit with reduced activity in comparison to AmbO5.[156] No structure guided engineering was 
performed for this enzyme class before and no non-natural substrates were tested. To start the 
structure guided directed evolution, first several positions should be saturated to gain initial 
information about this system. In a second generation of variants, the collected information 
will be used to prepare smart libraries that allow cooperative effects.[297] The preparation in-
clude appropriate statistical analysis to prevent oversampling by reducing the screening effort 
to the probability to find one out of the three best variants.[307,308,365,366] The results will be de-
scribed in the next chapter.  
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3.4.2.1 Creation and Screening of 1st Generation Libraries 
To individually check the effect of amino acid positions, eight libraries with an NNK satura-
tion were created. Positions N74, F77, A82, I84, V90, F169 were chosen because of their close 
contact to the substrate, while M221 and M225 are assumed to be anchoring residues respon-
sible to close the lid over the active site. Furthermore, a library with reduced codons of A82 
and I84 were created. Mutation was per-
formed via QuikChange PCR.[367,368] In 
contrast to the original method, primers 
were designed that only partially over-
lap. This prevents primer-dimer for-
mation and yields better success in site-
directed mutagenesis.[369] To check the 
quality of the mutation, quick quality 
control (QQC) was performed.[306]  
Generally, created libraries yielded a 
quite bad degeneracy. Therefore, the 
plasmid mix, resulting from the first mu-
tation round was used for the next PCR 
as template because it was assumed, that primers that did not bind to the template DNA might 
bind better to the mutated DNA. This procedure increased the degeneracy even though no 
desired distribution of bases could be achieved. For M221, no sufficient degeneracy could be 
achieved, therefore no further attempts were pursued. The chromatograms resulting from se-
quencing of single site libraries are shown in figure 85, ch. 8.4.1.1. If large libraries are being 
created, the number of screening variants is reduced to have a 95% to find one out of the three 
best hits. In the case of these first libraries however much information should be collected 
about the system therefore a larger number of colonies were analyzed, also based on the un-
satisfied degeneracy. Since 145 colonies would be a 99% chance to pick all variants, two plates 
(190 colonies) for each NNK library were screened.  
The following selected amino acids were chosen to be incorporated. For A82: D, Q, E, H, 
N, I, F A, L, M, S, T, V. For I84: D, Q, E, H, N, I, S, T. To achieve this tailor-made set of amino 
acids with minimal redundancy, the DC_Analyzer[370] was used, resulting in codons AWC, 
DYG, SAM for position A82 and SAM, ANC for position I84. To create this mutation a combi-
nation of 8 pairs of primer had to be bought and was introduced individually in 8 different 
PCR reactions, so in total 8 libraries were created. Initial difficulties in mutagenic PCR oc-
curred. Impurity in the sequenced chromatograms after the primer binding site indicated that 
a frameshift happened. This problem could be overcome by decreasing the betaine concentra-
tion to maximal 0.5 M combined with an increased annealing time (previously 30 s, improved 
Figure 28. Wi-0 with docked 2. Positions, chosen for mutagenesis are 
highlighted in blue. The lid is shown in cyan. 
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60 s). With a second round of PCR on the mutated product from the first mutation, the degen-
eracy could be improved, however no optimal incorporation of the degenerated codons was 
possible (figure 86, ch.8.4.1.1). Often small amounts of template DNA remained as well as 
small amounts of impurities in the background sequence. For library A82TTC/I84ANC high 
amounts of impurities were present, but the incorporation of the mutations could not be opti-
mized further and out of practical reasons, the screening was performed to see, if despite the 
presence of impurities also active variants were created. To cover all variants despite imperfect 
libraries, the number of colonies was calculated to cover >99% of all produced variants, if a 
perfect library would be present. 760 colonies were screened for a library consisting of 104 
variants. In figure 86 the chromatograms from sequenced libraries are shown. To receive li-
braries with better degeneration, it might be beneficial to buy primer with a higher purity. It 
was shown that depending on the primer supplier and the purity there can be significant dif-
ferences in library quality.[371] 
To screen the library, E. coli BL21-Gold(DE3) was transformed with the plasmid mix and 
plates on LB-agar plates. Single colonies were picked into 2.2 mL dw-plates and grown over 
night as preculture and finally transferred into expression medium. After heterologous ex-
pression overnight (ch. 7.1.9.2), the cells could be harvested, and the pellets used for activity 
assays (ch. 7.2.3.2). Therefore, the cells were lysed and all needed cofactors as well as the sub-
strate were added to the reaction. After 24 h the reaction was stopped by extracting with ethyl 
acetate. The organic phase was dried, resolved in acetonitrile and analyzed via HPLC screen-
ing.  
Within the screening two new peaks appeared in HPLC/UV-Vis measurements that later 
were further analyzed since no references were available. After scaling the reaction to prepar-
ative scale, the products could be assigned to one chlorinated (54a) and one hydroxylated (54b) 
product. Hydroxylation as side reaction is known for this enzyme class to happen if non-nat-
ural substrates are converted.[159] The reaction conditions are described in figure 29a. While 
screening the first libraries, several variants were found that produced only the chlorinated 
product 54a or chlorinated 54a and hydroxylated 54b products (figure 29c). The best enzymes 
(>1.5% prod. form.) from the first screening were sequenced, whereby some of the enzymes 
were found twice or three times. No variant was found that solely produced the hydroxylated 
product. In single site libraries, beneficial mutations A82L (Wi-1, formation of 4% 54a), N74R 
(Wi-2, formation of 3.5% 54a) and V90P (Wi-3, formation of 0.4% 54a) were found. In the two-
site library also A82V was found. Double mutants contain L, M, V and I in position 82 in com-
bination with S, T or wild-type amino acid I. In summary, unpolar amino acids in position A82 
as single variant or in combination with polar amino acids in position I84 chlorinate 54. In 
figure 29b representative chromatograms are shown.  
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Figure 29. a) Reaction conditions of the screening are shown. The reaction was performed in a volume of 200 µL. b) HPLC chro-
matogram of reaction with variants Wi-1(Wi-WelO15 V6I/A82L/D284N) and Wi-4 (Wi-WelO15 V6I/A82V/I84H/D284N) and 54. c) 
Product formation with variants found in the screening. All variants are based on Wi-0 (Wi-WelO15 V6I/D284N). The averaged 
results from quadruple measurements in a hit plate. Variants that carry position I84H produce next to the chlorinated (54a) also 
a hydroxylated product (54b) with a chemoselectivity of about 70% for 54a.  
All variants producing 54b contain I84H in combination with unpolar amino acids (V, L, T, I) 
in position A82. The variant with the highest activity, Wi-4, is Wi-WelO15 V6I/A82V/ 
I84H/D284N and has a chemoselectivity of 68% for 54a. That only small changes in the amino 
acid sequence of the active site can switch the chemistry was also shown, when two quite 
homologue enzymes SnoN and SnoK (38% sequence identity) were characterized and SnoK 
catalyzes a carbocyclization and SnoN an epimerization reaction.[372]  
N74R in contrast to the remaining found variants sits in the outer rim of the enzyme struc-
ture. This leads to the suggestion, it interacts with the indole part of the substrate. Information 
gained within these first libraries, was then used to create small and smarter libraries, one with 
three positions and one with five positions mutated at the same time. 
3.4.2.2 Creation and Screening of 2nd Generation Libraries 
Based on these first results, two libraries of A82L/V90NNK as well as A82L/F77NNK were 
created however the activity background of the template variant was so high, that only one 
variant showed clear increased activity which was Wi-WelO15 V6I/A82L/V90P/D284N (Wi-5) 
with 5.5% product formation, which is the most active variant from the first-generation librar-
ies.  
Considering the results in comparison to the docking results, it is not surprising, that bigger, 
unpolar amino acids in position 82 fill the gap that is present if no isonitrile functionality is 
present in the substrate. Since the carbonyl group points in the opposite direction, no polar 
residue is necessary in this position but the proline in V90P could perform some interaction 
with the carbonyl group. Reciprocal interaction of C=O – C=O have attracted attention recently 
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and are described to appear in proteins mainly in polyproline helices.[373] Also in a study it was 
shown that 15% of prolines performing H-bonds.[374] In all further screenings only Pro was 
found as substitution for V90 for ketone substrates, which indicates a strong positive effect on 
the acceptance for this kind of substrates. 
After collecting initial information, two multi-site libraries were designed and created to 
find variants with higher chlorination activity.  
In the first library of the 2nd generation, position A88 should be saturated combined with 
V90P and three amino acids in position I84 (I,S,T). In the first generation, the chosen mutations 
I84S and I84T as well as V90P had an activity increasing effect. The created library showed low 
conversion of 54, the only active variant is Wi-WelO15 V6I/A88V/V90P/D284N (Wi-6) with 
1.5% product formation and 0.5 mM 54.  
In the second library, five positions around the substrate were chosen which were mutated 
simultaneously, so that also synergistic effects are considered during the screening. Positions 
that should be mutated are V81, A82, I84, A88 and V90. Since these positions are quite close to 
each other on the DNA sequence, a primer design was chosen, in which only three positions 
are incorporated in one primer. The design is visualized in figure 30.  
 
Figure 30. Primer design for QuikChange PCR to create the five-site library. Forward primer in the same length but other codons 
was also used for the three-site library in combination with the cloning reverse primer. 
N74R which was also found as single variant was not included in this library because of primer 
design reasons. The effect of that mutation was further analyzed in the third generation of 
variants.  
The five-residue library was planned as smart library. For all five positions only 3-5 amino 
acids should be introduced including the wild-type amino acid and a screening effort of max-
imum of 12 plates should be needed. Finally, for each position, two reduced codons were cho-
sen except for position I84, where only one was needed (table 6).   
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Table 6. Overview of chosen residues and amino acids to be incorporated. Codons that have to be incorporated into the primers. 
B=C,G,T; M=A,C; Y=C,T; W=T,A; R=A,G 
position amino acids nucleotide codon 
V81 V, L, T, N, F BTT, AMC 
A82 A, L, M, V GYG, AWG 
I84 I, S, T ABC 
A88 A, N, S, V GYG, ARC 
V90 V, P, M, Q RTG, CMG 
 
Giving a theoretical library size of 960 variants without redundancy. To achieve a 95% chance 
to find one out of the best three hits, 1008 clones have to be tested. This corresponds to a se-
quence space of 65%.[307] 
To make sure, that amplification of the whole gene and mutation of all five positions works 
with this strategy, first a PCR with only two primers was performed, giving slight degenera-
tions in all desired positions. Based on this result, further mutation with all primers in the 
same PCR were performed, based on the first plasmid pool (plasmid pool 1), until a complete 
absence of wild–type gene was seen. Plasmid pool 2 and 3 were achieved with different PCR 
conditions, both based on plasmid pool 1. Quick quality control revealed absence of thymine 
in the 1st base of position 81 in pool indicating that Phe will be missing in the library. Similarly, 
a very low presence of adenine and guanine in the 2nd base of A88 was observed. Therefore, a 
fourth round of PCR was set on plasmid pool 2 with primers especially encoding V81BTT and 
A88ARC (primer 77 and 79), creating plasmid pool 4 (figure 87). Colonies for screening were 
picked from pools 2-4 in equal parts. In total 1080 colonies were picked. The screening was 
performed with 0.5 mM substrate concentration. The active hits were measured in triplicate 
and the best ones sequenced.  
Three variants were found with an increased formation of 54a. Based on Wi-0 following 
mutations were beneficial: V81T/A82M/A88V/V90P (Wi-7: 7% form. of 54a), V81T/A82V/I84T 
/A88V/V90P (4% form. of 54a), V81T/A82M/I84T/A88V/V90P (4% form. of 54a) in comparison 
to 6% formation of 54a by Wi-1. In the next step, the effect of N74R on the best variants found 
so far as well as scaffold sampling between Wi-WelO15 and Hw-WelO15 was tested. 
3.4.2.3 Scaffold Sampling and Fine Tuning with N74R: 3rd Generation 
Next, 2nd generation hits were rationally fine-tuned by adding mutation N74R (figure 31), a 
residue on the outer rim of the active site. Due to the position in the sequence and numerical 
reasons, the residue was not included into the multi-site library but found hits rational com-
bined. In total, the mutation N74R was added to seven hit-variants. Often it is assumed, that 
beneficial mutations are mostly additive[299] however in this case, only one variants shows in-
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creased formation of 54a with the combination of those mutations while all others show de-
creased activity. In figure 31, the two variants are in direct comparison. The reactions were 
performed in triplicate and 0.5 mM 54. 
 
Figure 31. Comparison of variants carrying N74R and without. All variants carry additional mutations V6I and N284D. Lysate-
based biotransformation with cells from 0.8 mL cell culture. Final reaction conditions: 200 µL volume in 2.2 mL 96 dw-plates 
sealed with a plastic lid, 50 mM HEPES, 10 mM NaCl, 2.5 mM KG, 0.5 mM DTT, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM 54, 8 h, 30 °C, 
200 rpm (Infors HT shaker). 
As can be seen in figure 31, V81T/A82M/A88V/V90P (Wi-7), combined with N74R to 
N74R/V81T/A82M/A88V/V90P (Wi-8) leads to an increase of product formation and results in 
the best variant that was found so far, with a product formation of 14% in a lysate based reac-
tion. In all other created variants, the addition of N74R decreased the product formation which 
shows that this position has an important synergistic effect on the substrate positioning which 
cannot generally be mutated to N74R to achieve an increase in chlorination activity. 
The strategy of scaffold sampling[315,375] examines the transfer of mutations within homolo-
gous protein structures. Generally, it could be assumed that a found mutation that has an ac-
tivity increasing effect on one enzyme could have the same positive effect on a close homo-
logue which is structurally quite similar. If this would be applicable, especially directed evo-
lution studies could be shorten dramatically because knowledge gained within one enzyme 
can be transferred to a whole class. However it was found that this is not so easy and even 
though in some cases it works, for other homologues it does not.[315,375]  
Building chimera enzymes by transfer of the lid-amino acids from AmbO5 to WelO5 en-
larges the substrate scope of WelO5 to more natural hapalindole-like alkaloids albeit with re-
duced activity.[156] Therefore it would be interesting to see the individual effect of transferring 
single amino acids to another member of the same enzyme class. The scaffold sampling strat-
egy was used inspired by two facts: Despite the high sequence identity of 95%, Wi-0 produces 
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<1% while Hw-WelO15 forms 11% 54a. The two halogenases mainly differ in the -helical ac-
tive site lid which was shown to control the native substrate scope.[156] The lid residues L221 
and I225 of Hw-WelO15, which point towards the substrate,[160] were transferred to Wi-0 and 
Wi-5, substituting M221 and M225. The new created variants are named Wi-9: 
V6I/M221L/M225I/D284N and Wi-10: V6I/A82L/V90P/M221L/M225I/D284N. Additionally it 
should be tested if the activity improving residues A82L/V90P have a beneficial influence on 
Hw-WelO15. During mutagenesis of Hw-WelO15, Hw-1 (A82L) and Hw-2 (A82L/V90P) were 
created. 
The mutants were heterologous expressed and while harvesting, OD600 normalized. Cell 
pellets of an OD600=5 were lysed and the soluble halogenase content of cleared lysate was com-
pared by SDS-PAGE analysis (figure 32). 
 
Figure 32. SDS-PAGE analysis of OD600 normalized E. coli BL21-Gold(DE3), induced with IPTG and growth for 16 h at 22 °C. After 
lysis with lysozyme, insoluble cell debris was removed by centrifugation and cleared lysate was applied to a gel (12% separation 
gel, 5% stacking gel). The applied volume represents 4.4% of the enzyme mix present in the assay 1) pRSF-Duet 2) Hw-WelO15 3) 
Hw-1 4) Hw-2 5) Wi-0 6) Wi-5 7) Wi-9 8) Wi-10. 
As can be seen in figure 32, the transfer variants Hw-1 (lane 3), Hw-2 (lane 4) and Wi-9 (lane 7) 
show reduced expression levels. Biotransformations were made with variants and their tem-
plate variants Hw-WelO15, Wi-0 and Wi-5.  
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Table 7. Biotransformation of halogenase variants with 53 and 54. Final reaction conditions: 200 µL volume in 2.2 mL 96 dw-plates 
sealed with a plastic lid, 50 mM HEPES, 100 mM NaCl, either lysed cell pellet normalized to OD600=5.0 and 2.5 mM KG or 10 µM 
purified halogenase with 5 mM KG. 2.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM substrate, 8 h, 30 °C, 200 rpm (Infors 
HT shaker). 
enzymes 
53 54 54a 54 54a 
conv.[a] 
pur. enzyme 
conv.[a] 
cell lysate 
chemo- 
select. 
conv.[a] 
pur. enzyme 
chemo- 
select. 
Wi-0 93 <1 nd <1 nd 
Wi-9 93 1 nd 2 nd 
Wi-1 67 32 98 28 96 
Wi-5 27 59 98 70 97 
Wi-10 60 30 95 18 93 
Hw-WelO15 91 11 70 11 73 
A82L nt 18 86 nt nt 
A82L/V90P nt 3 nd nt nt 
nt = not tested, nd = not determined, pur. = purified 
Hw-WelO15 and Wi-0 convert 53 with 91-93%, therefore, no difference in activity is expected 
for Wi-9. Indeed, biotransformation with selected variants show, that the transfer of L221 and 
I221 to Wi-0 result in no activity change for 53. However, a decrease in conversion is expected 
for Wi-10 since the mutations A82L/V90P (Wi-5) decrease the ability to chlorinate 53. Compar-
ing Wi-5 and Wi-10 however, it is noticeable, that the conversion for Wi-10 is twice as high as 
for Wi-5 which shows that the mutation M221L/M225I increases the chlorination activity 53. 
53 was only tested with purified enzymes. Due to their low expression level, no purification 
of Hw-WelO15 variants was performed, therefore only results with 54 are available. 
For non-natural ketone 54, it could be expected, that the introduction of L221 and I221 to 
Wi-variants increases the formation of 54a, since Hw-WelO15 wild type already produces 54a 
which is not the case for Wi-0. However, Wi-9 does not show a higher conversion then Wi-0 
and Wi-10 shows a great loss in activity in comparison to Wi-5.  
Mutation of A82L and A82L/V90P in Wi-WelO15 enables the chlorination of 54. Since the 
sequence identity is quite high (95%) and especially the active site, except the -helical lid, is 
identical (figure 10) it was expected that the two positions could be transferred and would lead 
to an increased formation of 54a within Hw-WelO15. This is the case for Hw-WelO15 A82L. A 
higher conversion as well as chemoselectivity was achieved. Hw-WelO15 A82L/V90P how-
ever, only produces 3% 54a, which can be explained by a low concentration of soluble halo-
genase in the lysate (figure 32).  
Summarizing it can be said that scaffold sampling within these two halogenases albeit their 
high sequence identity in the above chosen positions cannot be performed. Mutants show low 
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expression level and even though Hw-WelO15 A82L has a higher formation of 54a in compar-
ison to its wild-type enzyme, the formation is still lower than with Wi-1. Hence, the engineer-
ing strategy based on residue transfer was abandoned. 
3.4.2.4 4th Generation: Library for Active Site Entrance 
As Wi-8, containing N74R, is the best variant found so far, it was surprising that incorporation 
of N74R to all other variants resulted in a lower activity. Therefore, it can be assumed that N74 
is an important position, but R is not the right amino acid to combine for some variants. To 
incorporate the outer rim of the active site 
more (amino acids shown in purple in figure 
33), two more libraries were created based 
on the best variants found so far: Wi-5 and 
Wi-8. Wi-5 should be mutated in four posi-
tions: N74, S93, S103 and A175 while Wi-8 
which already includes N74R was only mu-
tated in S93, S103 and A175. In both libraries 
positions 93,103 and 175 were mutated with 
the same codons incorporating amino acids 
N, H, D, A, S, V, L. Hereby 343 variants are 
created in the library based on Wi-8. The li-
brary design of Wi-5 consists of additional 
N74 N, S, Q, R, which corresponds to 864 
combinations. Thereby first mutations in po-
sitions N74 were incorporated and in a second PCR the three remaining positions were mu-
tated. Because N74R/A82L/V90P showed a decreased activity to A82L/V90P, also 32 colonies 
of the small library of N74(N, S, Q, R)/A82L/V90P were tested which opens the possibility to 
gain more information about position N74. However, no hits were found for N74 
NSQR/A82L/V90P.  
Mutation was enabled by QuikChange (position N74) and megaprimer PCR (93,103, 175). 
After two rounds of PCR, satisfying degeneration was reached (figure 88) and the library based 
on Wi-8 was screened. Four plates were tested, with 368 colonies which correspond to a 95% 
chance to find one out of the three best hits. In the created libraries several variants with com-
parable conversion to the template were found however, no variants had a big increase in 
activity. Therefore, only eight plates for the second library based on Wi-5 were produced, cor-
responding to a sequence space coverage of 56%.  
Under optimized reaction conditions (ch. 7.2.5), the template variants showed a conversion 
of 40% and 55% formation of 54a, Wi-5 and Wi-8, respectively. Therefore, variants that had a 
Figure 33. Active site of Wi-0 with amino acids (shown as sticks) 
that are chosen for mutagenesis. Amino acids shown in blue have 
been mutated in first- and second-generation libraries. Amino ac-
ids shown in purple are chosen to be mutated in the fourth gen-
eration. 
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product formation of >30% based on Wi-5 and >40% based on Wi-8 were measured in tripli-
cates (figure 89, ch. 8.4.1.3). From 48 analyzed variants, 14 variants were found that produce 
more 54a than the template variants (table 8). Only mutated positions are given with the tem-
plate variant. Amino acids that still contain the template amino acids are shown in grey, mu-
tated residues are shown in black. 
Mutating N74 alone based on Wi-5 gave no new hits. However, in the library, variants 
could be found containing N74Q, N74R and N74N. While S103 was found to be only wild-type 
amino acid S or substituted by A, positions S93 and A175 showed more variety in their se-
quence.  
Table 8. Variants that have a higher formation of 54a in comparison to their template variants. For position N74, Q, R, S and N 
were introduced while for position S93, S103 and A175 amino acids N, H, D, A, S, V, L were possible. Amino acids shown in black 
are mutated in comparison to the wild type. Amino acids shown in grey are still the template, without mutation in this position. 
N74Q/A82L/V90P N74R/A82L/V90P Wi-5 Wi-8 
S93 
S 
D 
H 
 
S103 
A 
A 
S 
 
A175 
A 
H 
A 
S93 
D 
A 
S 
H 
S103 
S 
A 
A 
A 
A175 
A 
N 
N 
N 
S93 
D 
L 
S 
 
S103 
S 
S 
S 
 
A175 
A 
N 
N 
 
S93 
D 
N 
D 
L 
S103 
S 
A 
A 
A 
A175 
A 
S 
A 
A 
 
In summary, the activity improvement in this variant generation is 40% from Wi-5 to Wi-12 
from 43% to 60% product formation and 17% from Wi-8 to Wi-11, from 47% to 55% respec-
tively.  
Of all variants with improved activity, 13 Wi-0 variants as well as two Hw-WelO15 variants 
were chosen to test with further hapalindole-like ketones (ch. 3.6). In the next chapter, different 
conditions while handling the halogenase during heterologous expression and biotransfor-
mation are compared.  
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3.5 Handling the Halogenase and Optimization of Protocols 
The halogenase Wi-0 was engineered from no detectable product formation to 87% formation 
of 54a. However not only the enzyme was adapted to the new substrate, but also different 
ways of heterologous expression and reaction conditions were tested and optimized. Since the 
synthesis of isonitrile derivative 53 was tedious and combined with low yields and further-
more the compound seems to be quite instable in reactions. Combined with almost full con-
version by Hw-WelO15 and Wi-0 under tested conditions, it was not the appropriate substrate 
for reaction optimization. In the beginning of this project, ketone 54 was not chlorinated by 
both halogenases. Several conditions were tested however no product formation could be de-
tected. Therefore, the chlorinase was engineered before reaction conditions for the halogena-
tion were optimized. Screening and initial biotransformations were performed, using condi-
tions based on published data for WelO5.[155] After finding several variants that chlorinate 54, 
heterologous expression was analyzed again (ch. 3.5.1) with product formation as read out, as 
well as several ways of biotransformation. The addition of several cofactors and additives 
were further analyzed in 3.5.3 and 3.5.4. The final reaction conditions are described in chapter 
3.5.5Influence of Additives in Lysate Transformations. 
3.5.1 Temperature of Heterologous Expression 
Two different conditions of heterologous expression were tested in 96 dw-plates including hit 
variants from library generations 1-3. One plate was inoculated in the morning and incubated 
at 30 °C for 7 h, while the other plate was inoculated in the afternoon and incubated for 2 h at 
37 °C followed by further incubation at 22 °C for 15 h (standard protocol so far). Both plates 
were harvested each and frozen at -80 °C. To test the activity of the enzymes, a biotransfor-
mation with 54 was started. The results are shown in figure 34. 
 
Figure 34. Comparison of formation of 54a after heterologous expression at 30 °C or 22 °C. Final reaction conditions: 200 µL vol-
ume in 2.2 mL 96 dw-plates sealed with a plastic lid, 50 mM HEPES, 10 mM NaCl, 2.5 mM KG, 0.5 mM DTT, 0.5 mM 
(NH4)2Fe(SO4)2, 0.5 mM substrate, 8 h, 30 °C, 200 rpm (Infors HT shaker). 
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The results show that formation of 54a after enzyme production at 30 °C is significantly lower. 
Wi-8 and Wi-5 produce less than 25% product than after enzyme production at 22 °C. To test 
if a shorter time during heterologous expression at 30 °C works better, another 96 dw-plate 
was prepared and incubated at 30 °C. Here, two variants were tested, Wi-1 and Wi-4. Wi-4 
produced the hydroxylated side product 54b. The cell culture was taken out after 4, 5, 6, 7 and 
24 h. The samples were centrifuged, the supernatant discarded, and the cell pellet frozen. All 
pellets were thawed, lysed and a biotransformation with 54 conducted. The analysis showed 
that the highest product formation is present in the range of 5 h (Wi-1) to 7 h (Wi-4), while a 
longer expression time resulted in lower product formation (figure 35).  
 
Figure 35. Formation of 54a dependent on the time of heterologous expression at 30 °C. The reaction was performed in 200 µL 
volume, 50 mM HEPES, 10 mM NaCl, 2.5 mM KG, 0.5 mM DTT, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM 54, 8 h, 30 °C, 200 rpm (Infors 
HT shaker). 
While the formation of 54a with Wi-4 after 7 h growth is slightly better than the results after 
expression at 22 °C (figure 34), Wi-1 shows only 3% formation of 54a within this experiment, 
while 6% could be achieved after growth at 22 °C. Therefore, the standard conditions for het-
erologous expression with incubation for 2 h at 37 °C and subsequent reduction of the temper-
ature to 22 °C with a further incubation of around 15 h is performed.  
3.5.2 Whole Cell Biotransformation 
The easiest and fastest way to perform biotransformations would be to add the substrate dur-
ing cell growth and heterologous expression. This procedure was tested using Wi-1 as catalyst. 
The experiments were conducted in triplicates in LB and in TB medium containing 50 µg/mL 
kan, 20 µM IPTG and 50 µM FeCl3.  
Two plates were analyzed in parallel, one was inoculated with 1/100 and the other with 
1/10 preculture/medium, respectively. After 2h or 4h growth time, substrate and KG were 
added to a final concentration of 1 mM and 2.5 mM, respectively and the plates incubated at 
30 °C, 200 rpm (Infors HT shaker) for 4 h or overnight. None of the tested conditions showed 
product formation, which suggests that the substrate may not pass the cell membrane and 
lysis of the cells is essential for chlorination activity. 
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3.5.3 Influence of Additives in Lysate Transformations 
Biotransformations in cell lysate were generally prepared by lysis of the cells with 100 µL lysis 
buffer (50 mM HEPES, 10 mM NaCl, pH 7.4, 1 mg/mL lysozyme). The pellet was resuspended 
by vortexing and the cells lysed by incubation of the plates at 37 °C for 30 min. A 2x reaction 
buffer containing all reaction components was freshly immediately prior to addition. The re-
action was started by adding 2 µL of substrate solution (stock solutions in EtOH: 25, 50 and 
100 mM, final EtOH conc. 1%). 
To test different reducing agents as well as the influence of the substrate concentration, a 
cell pellet of Wi-1 from a heterologous expression in a 2 L flask was thawed, diluted to 47.5 mL 
and 0.5 mL cell suspension was aliquoted in each well of a 2.2 mL- 96 dw-plate. Substrate con-
centrations of 0.25, 0.5 and 1 mM were used in combination of DTT, ascorbic acid and without 
a reducing agent. After different reaction times the reaction was stopped by extraction and 
analyzed by HPLC/UV-Vis. The results sorted by reducing agent and substrate concentration 
are shown in figure 36. For better comparison the formation of 54a is presented, instead of 
conversion (%HPLC). 
 
Figure 36. Comparison of formation of 54a in dependence of different substrate concentrations (0.25 mM black, 0.5 mM red, 1 mM 
blue) and different reducing agents (without left, ascorbic acid middle, DTT right). Formation of 54a was determined from dupli-
cate measurements and is given in µmol to directly compare the different substrate concentrations.  
The error in these lysate measurements is quite high in the range of 0.002 µmol which corre-
sponds to 30% of the values. Which explains fluctuation within the time dependent product 
formation. The reason for the high error is probably based on the reaction set-up. After indi-
vidual reaction times, the reactions are stopped and extracted by ethyl acetate. Then the or-
ganic phase was transferred into HPLC vials and the solvent evaporated. The remaining dry 
sample were dissolved in acetonitrile and measured via HPLC. 
Despite the fluctuation it can be seen that a higher substrate concentration results in a 
higher turnover. With presence of 0.25 mM 54, a lower formation of 54a was detected while 
the difference between 0.5 mM and 1 mM is not clearly visible. From this experiment it can be 
concluded that no substrate inhibition occurs within the range of 0.25-1 mM. However, since 
the turnover with the 0.25 mM 54 is the lowest, it could be possible that a product inhibition 
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takes place. In the beginning, screening was performed with 1 mM 54, however since substrate 
availability is a limiting factor, it was reduced to 0.5 mM later.  
It is important to notice that half of the transformation occurs within the first hour and in 
the remaining 23 h less than 50% conversion happens. Furthermore, the addition of reducing 
agent increases the conversion slightly. After 24 h, the reactions with DTT did have a slightly 
better product formation than ascorbic acid. Therefore, in the beginning, while screening the 
variant libraries, DTT was used. After a certain time, the reducing agents were tested again, 
with purified enzymes and a new package of ascorbic acid, which resulted in a higher product 
formation then DTT. 
3.5.4 Influence of Additives in Transformations with Purified Enzymes 
The influence of various additives and reaction conditions were tested with purified enzymes. 
Different concentrations of cofactors KG and FeII in combination with various enzyme con-
centrations. Furthermore, several approaches were tested to increase the stability of FeII in so-
lution by addition of different reducing agents, catalase to destroy potentially formed hydro-
gen peroxide[376–379] and glycerol to stabilize the protein. In addition, the effect of storage con-
ditions was tested: Freezing at -80 °C or storage at 4 °C overnight, as well as IMAC purification 
with a phosphate buffer at pH 6 in comparison to Tris buffer at pH 7.4 was compared as well. 
After first experiments in cell lysate, the concentration of cofactors in comparison to the 
enzyme concentration was analyzed, therefore purified Wi-1 was used. Also, the reducing 
agents were tested again. Therefore, enzyme concentrations of 50 µM and 100 µM were used 
with 2.5 eq (NH4)2Fe(SO4)2 and 12.5 or 25 eq KG based on 0.5 mM 54. In figure 37, the for-
mation of 54a under the different reaction conditions is compared. As in previous reactions 
the addition of a reducing agent results in the highest product formation. 
 
Figure 37. Formation of 54a dependent on different reducing agents (0.5 mM). The reaction was performed in a 2.2 mL 96-dw 
plate with 300 µL reaction volume. Different cofactor concentrations were used as given above. A concentration of 0.5 mM 54 was 
used with a final concentration of 1% EtOH. The reaction was incubated for 4 h at 30 °C at 200 rpm (Infors HT shaker) and stopped 
by extraction with ethyl acetate. 
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Interestingly, a higher enzyme concentration produces less product. It is possible that a higher 
excess of KG and Fe2+ is needed to achieve the same turnover number as with the lower en-
zyme concentration. To confirm this, the reaction was repeated with doubled concentrations 
of KG and (NH4)2Fe(SO4)2. However, a low catalyst concentration generally is desirable, 
therefore the reaction conditions were further optimized using lower enzyme concentrations. 
In the following experiment 0.5 mM DTT was used and conversions of 60% could be achieved 
with 100 µM enzyme and 5 mM KG and 0.5 mM (NH4)2Fe(SO4)2 which supports the assump-
tion that the excess of Fe2+ and KG has to be quite high. For better comparison, in figure 38 
the turnover number (TON) is compared which is independent of the enzyme concentration. 
 
Figure 38. Turnover number of 54 to 54a dependent on different cofactor concentrations and different concentrations of Wi-1. The 
reaction was performed in a 2.2 mL 96-dw plate with 200 µL reaction volume. Different cofactor concentrations were used as 
given above. A concentration of 0.5 mM 54 was used with a final concentration of 0.5% EtOH. The reaction was incubated for 24 h 
at 30 °C at 200 rpm (Infors HT shaker) and stopped by extraction with ethyl acetate. 
Comparing the turnover numbers, again, the lowest enzyme concentration achieves the high-
est turnover number. This could be based on the excess of KG since 20 µM enzyme with 
0.25 mM (NH4)2Fe(SO4)2 and 0.5 mM (NH4)2Fe(SO4)2 with a constant KG concentration 
achieve similar turnover, while a constant (NH4)2Fe(SO4)2 concentration with different KG 
concentrations achieve different results, with higher turnover in the presence of higher KG 
concentration. Based on these results, for purified enzymes 5 mM KG and 0.5 mM 
(NH4)2Fe(SO4)2 and only 10 µM enzyme are used. 
In the group of Schofield, catalase is added to assays with NHI hydroxylases.[376] In the 
literature, stabilizing effects of catalase towards hydroxylases were described.[376–379] NHI en-
zymes are described to decouple electron consumption from product formation, especially 
when non-natural substrates are used.[379] Catalases reduces H2O2 to O2 and H2O. The addition 
of catalase reduced a high background[377] and increases enzyme activity[378]. Since the catalytic 
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mechanism of NHI hydroxylases and halogenases is related, it would also be possible that 
KG, H2O and O2 are converted to CO2, succinate and H2O2 within this reaction. However, the 
inhibition of catalase by DTT and ascorbic acid are literature known.[380–382] Therefore these 
reducing agents were both tested again. In contrast to previous experiments, a new batch of 
ascorbic acid was purchased and opened. Figure 39 shows the results of comparison between 
reactions with and without catalase as well as with DTT in comparison to the new batch ascor-
bic acid in a time course of 1 h.  
 
Figure 39. The reaction was performed in 2.0 mL reaction tubes with 0.2 mL volume in 50 mM HEPES, 10 mM NaCl and 10 µM 
Wi-5. Final reaction conditions contained 5 mM KG, 0.5 mM ascorbic acid or DTT, 0.5 mM (NH4)2Fe(SO4)2, 0.6 mg/mL catalase 
and 0.5 mM 54. 
Comparing DTT and the new batch of ascorbic acid, the latter one shows a clear activity im-
proving effect. While <10 % 54a is produced with DTT within 60 min, >20 % are produced in 
the presence of ascorbic acid. Wi-5 and Wi-8 the best variants found within the first three var-
iant generations were again tested within 8 h reaction time.  
Figure 40 shows that the product formation within the first minutes is fastest, more than 
50% of the conversion happens within the first then minutes but an increase in product con-
centration can still be detected after 8 h. 
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Figure 40. Formation of 54a. The reactions were performed in 2.0 mL reaction tubes with 0.2 mL volume in 50 mM HEPES, 10 mM 
NaCl and 10 µM Wi-5 or Wi-8. Final reaction conditions contained 5 mM KG, 0.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2 and 
0.5 mM 54. 
During purification of the halogenase variants it was observed that the presence of 10% glyc-
erol in HEPES buffer is necessary otherwise, the enzyme precipitates. Using glycerol is re-
quired to achieve  enzyme concentrations up to 1.5 mM (50 mg/mL) without problems. To see 
if the additive and freezing of the enzyme also influences the activity, some reactions were 
performed with Wi-5.  
While IMAC purification, a strong tailing can be observed. An increase of imidazole has 
no influence and a resin exchange to talon is not possible, because of a low binding affinity, a 
purification attempt was made at pH 6. Because Tris is not suitable to buffer a pH range of 6.0, 
phosphate buffer was used during this purification. The elution profile changed slightly, less 
tailing was present, but the peak broadened (figure 67, ch. 8.3.3). After eluting the enzyme 
from the IMAC resin, the enzyme is concentrated with the help of centrifugal filters. Then the 
enzyme solution is dialyzed against HEPES buffer (50 mM HEPES, 10 mM NaCl, 10% glycerol, 
pH 7.4). Therefore, the effect of purification at pH=6 and the presence of glycerol within the 
reaction was tested. Furthermore, within purification, the enzyme dialyses overnight. For 
longer storage, the enzyme is flash frozen in N2(l) and stored at -80 °C. It was tested if a differ-
ence is observable between freezing in N2 (l) followed by thawing on ice and storage overnight 
at 4 °C. The reactions were performed with Wi-5 that was stored overnight in the fridge (4°C) 
or flash frozen in N2 after purification and stored overnight at -80 °C in HEPES buffer pH 7.4 
and with addition of 10% glycerol or without.  
0
5
10
15
20
25
30
35
40
45
0 1 2 3 4 5 6 7 8
fo
rm
a
ti
o
n
 o
f 
5
4
a
(%
H
P
L
C
)
time (h)
Wi-5 Wi-8
 Results and Discussion  
 
69 
 
Figure 41. Formation of 54a. The reactions were performed in 2.0 mL reaction tubes with 0.2 mL volume in 50 mM HEPES, 10 mM 
NaCl and Wi-5. Final reaction conditions contained 5 mM KG, 0.5 mM DTT, 0.5 mM (NH4)2Fe(SO4)2 and 0.5 mM 54. The tubes 
were incubated at 30 °C, 500 rpm in an Eppendorf Thermoshaker for 5 h. The reaction was stopped by extraction with ethyl 
acetate. 
Figure 41 shows the formation of 54a under tested conditions. It can clearly be seen, that puri-
fication at pH 6 with phosphate buffer results in a much lower activity then the purification 
with Tris buffer, even though the enzyme was dialyzed in both cases to HEPES buffer and all 
assays were performed in a HEPES buffer at pH 7.4. FeII/III-ions precipitate in the presence of 
phosphate as iron phosphate salts. However, through dialysis, phosphate should have been 
removed except it binds to the enzyme. Interestingly, the addition of glycerol to the enzyme 
that was purified at low pH leads to an increase in product formation, while the addition to 
the enzyme that was purified at pH 7.4 results in a decreased product formation. No difference 
can be observed between storage overnight at 4 °C or freezing and thawing which is important 
because it shows that the enzyme is not destabilized by the freezing and thawing process. It 
can be assumed that storage overnight during purification and the freezing and thawing pro-
cess in general can be overcome without any activity loss. In this experiment, again, two en-
zyme concentrations were compared and in the presence of 5 mM KG, 0.5 mM 
(NH4)2Fe(SO4)2 and 0.5 mM DTT, 10 µM enzyme achieves almost comparable product concen-
trations as 20 µM enzyme. Therefore 10 µM enzyme was used as standard concentration. 
  
0
2
4
6
8
10
12
14
16
+
1
0
%
g
ly
c
e
ro
l
+
1
0
%
g
ly
c
e
ro
l
+
1
0
%
g
ly
c
e
ro
l
+
1
0
%
g
ly
c
e
ro
l
+
1
0
%
g
ly
c
e
ro
l
+
1
0
%
g
ly
c
e
ro
l
+
1
0
%
g
ly
c
e
ro
l
+
1
0
%
g
ly
c
e
ro
l
-80°C 4°C -80°C 4°C -80°C 4°C -80°C 4°C
20 µM enzyme 40 µM enzyme 10 µM enzyme 20 µM enzyme
purified with KPi pH6 purified with HEPES pH7.4
fo
rm
a
ti
o
n
 o
f 
5
4
a
(%
H
P
L
C
)
 Results and Discussion  
 
70 
3.5.5 Final Reaction Conditions 
In the previous chapter, several conditions were tested and conditions that resulted in the 
highest turnover were HEPES buffer pH 7.4, 10 µM enzyme with 5 mM KG, 0.5 mM 
(NH4)2Fe(SO4)2, 0.5 mM ascorbic acid with reaction times of 8 h or longer. Some further reac-
tion conditions were analyzed by N. Huwa within the scope of his master thesis.[383] Several 
buffer systems including (MOPS, HEPES and Bis-Tris), pH (6.8, 7.2, 7.6, 8.0), NaCl concentra-
tions (10, 50, 100, 250, 500 mM), ascorbic acid (0.5 and 2.5 mM) with different variants and -
damascone as substrate were tested.[383] The results show that an increase of NaCl in the reac-
tion from 10 to 100 mM results an increased product formation. Furthermore, an increase of 
ascorbic acid from 0.5 to 2.5 mM is beneficial. In table 9, product formation under different 
reaction conditions are compared. Even though the reaction with DTT was stopped after 5 h, 
it can be compared to the reaction that were run for 8 h, under the new and improved reaction 
conditions, because it is assumed that the enzyme was inactive after 5 h anyway, based on 
information described in the previous chapters. 
Table 9. Formation of 54a under different reaction conditions. For all reactions, a final volume of 200 µL in a 2.2 mL 96-dw plate 
was used. All reactions contained 10 µm halogenase, 50 mM HEPES buffer, 5 mM KG, 0.5 mM (NH4)2Fe(SO4)2 0.5 mM 54, 1% 
EtOH and were stopped by extraction with ethyl acetate. 
 formation of 54a (%HPLC) 
 
10 mM NaCl, 
0.5 mM DTT, 
5 h* 
10 mM NaCl, 
0.5 mM asc. acid, 
8 h** 
100 mM NaCl, 
2.5 mM asc. acid, 
8h*** 
Wi-0 nc nc <1 
Wi-1 4 11 27 
Wi-2 2 3 9 
Wi-5 13 37 68 
Wi-7 6 12 23 
Wi-8 18 44 74 
Wi-10 2 8 17 
Hw-WelO15 <1 1 11 
  
As table 9 shows, the use of 0.5 mM ascorbic acid instead of 0.5 mM DTT triples the formation 
of 54a from 13 to 37% (Wi-5). Another doubling is achieved if sodium chloride and ascorbic 
acid concentrations are increased. The quality of reducing agents is quite important since the 
performance of DTT and ascorbic acid was tested in the beginning and no difference could be 
observed, only after a fresh bottle of ascorbic acid was used, a significant improvement in 
product formation was detectable. 
Important to notice is also that with first reaction conditions no activity of Wi-0 and hardly 
detectable product formation of Hw-WelO15 was observable. Under final reaction conditions, 
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Wi-0, still produces low amounts <1% of 54a while the formation of 54a with Hw-WelO15 in-
creased to 11%. This shows the difficulty of assigning a correct substrate scope for variants 
having minimal activity. These results underline the importance of properly analyzed reaction 
conditions. After finding a number of active variants, proper exploration of reaction conditions 
became possible and product formation was significantly improved, finally allowing for sub-
strate scope exploration. 
  
 Results and Discussion  
 
72 
3.6 Substrate Scope 
In the beginning of the project, an hapalindole C derivative (53) was synthesized to test the 
chlorination activity. Furthermore, another compound was synthesized, as target substrate for 
the directed evolution study, which contained a ketone instead of the isonitrile (54) (chapter 
3.3). In parallel to the synthesis of 53 and 54 several commercially available isonitrile and 
isothiocyanate substrates were tested with Hw-WelO15 and Wi-0 (chapter 3.6.1). Since 54 was 
neither chlorinated nor hydroxylated by the two enzymes under our starting reaction condi-
tions, mutagenesis of the halogenases were performed, looking for variants that chlorinate 54 
(chapter 3.4). Wi-0 was chosen to be evolved, since it crystallized despite the late discovered 
higher activity of Hw-WelO15. After a number of variants was found that chlorinate 54, several 
modified hapalindole-like ketones were tested with a panel of chlorinases. A number of sub-
strates were chlorinated (ch. 3.6.2.1), and others were transformed into complex mixtures of 
products (ch. 3.6.2.2). Interestingly, one variant, Wi-4 is able to produce the chlorinated 54a 
and the hydroxylated (54b) product (68% chemoselectivity for 54a). Also, Hw-WelO15 has a 
low chemoselectivity of 70% towards chlorination of 54. To obtain pure hydroxylation prod-
ucts, of 54, hydroxylation with well-established oxygenase P450BM3 was pursued (ch. 3.6.4). 
Finally, also biotransformations with hapalindole-like isonitriles were performed (ch. 3.6.5).  
3.6.1 Biotransformation with Wi-0 and Hw-WelO15 and Small Molecule Isoni-
triles 
If cultures of cyanobacteria are analyzed for their secondary metabolites, all found chlorinated 
hapalindole-like alkaloids contain an isonitrile or isothiocyanate moiety in beta and trans-po-
sition to the chlorine within the six-membered ring. This suggests that the isonitrile group 
plays a major role in native substrate recognition. Biotransformation with purified 
Hw-WelO15 and Wi-0 were made with commercially available small molecules containing an 
isonitrile and isothiocyanate to test their ability to chlorinate non-natural compounds. The 
substrates are shown in figure 42. 
 
Figure 42. Tested isonitrile and isothiocyanate containing molecules. 
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When the reactions were performed, no positive control for the enzyme activity was available, 
because the synthesis of 53 was not finished yet. Therefore, the enzyme was used in a concen-
tration of 0.1 mM in combination with 1 mM substrate in expectation that even a low activity 
would have been observed. Different reaction conditions were tested including different re-
ducing agents (DTT, ascorbic acid or no additive). Also, different reaction times (3 h, 7 h 24 h) 
were used. Unfortunately, no conversion could be detected by GC-FID. Chromatograms of the 
starting material can be found in chapter 8.6.1.12. As a second strategy, a decoy molecule was 
used, which helps filling the active site, in case the enzyme needs allosteric activation or the 
lid of the enzyme only closes after recognition of a certain interaction.[384]  Since the indole 
moiety was missing in the commercial compounds, all assays were repeated with addition of 
indole. Product formation could not be observed.  
To find an explanation, these substrates were docked with the help of SwissDock[385] into 
the published crystal structure of WelO5 (PDB 5IQT) by H. Mueller. Since isonitrile groups are 
not applicable for the CHARMM force field, all isonitrile groups were substituted by nitrile 
groups. To check if this approach is working, first the nitriles of 12-epi-fischerindole U and 
12-epi-hapalindole C, were docked into the active site. The crystal structure of WelO5 with 
soaked 12-epi-fischerindole U was used as reference. Both docked molecules were placed by 
the program as expected, confirming proper docking setup, with the terpene ring covering the 
soaked molecule, therefore it can be assumed that the results of the docking study are reliable 
for this system (figure 81, ch. 8.3.6.1). 
Docking of the small molecule substrates 68-75 revealed that they predominantly bind to 
the binding site of the cofactor KG. Only for adamantane-nitrile as substitute for 68 and 
1,1,3,3 tetramethylbutyl nitrile (based on 69)  the docking showed a possible binding inside 
the substrate binding site, so that a conversion with the enzyme might be possible. In figure 
43 the docking results of the two nitriles are shown. 
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Figure 43. Results of docking with SwissDock.[385] a) The tested adamantane nitrile (turquois) was docked into WelO5 and is 
overlaid with the soaked 12-epi-fischerindole U (gray). b) shows the docking results of 1,1,3,3 tetramethylbutyl nitrile (substrate 
shown in light blue and purple for two possible binding sites) and is overlaid with the soaked 12-epi-fischerindole U (gray). The 
iron is shown as orange ball and the chloride is shown as green ball. KG is shown as grey sticks. 
But also for 1,1,3,3 tetramethylbutyl nitrile, a binding inside the KG binding site was also 
observable (possible binding mode shown in purple, figure 43), which would inhibit the ac-
tivity of the enzyme since KG is a necessary cofactor for the reaction.  
Later, it could be seen that a concentration of 100 µM enzyme has a low or even no activity 
in biotransformation if the cofactors are not available in greater excess (for details see chapter 
3.5.4, especially figure 38). Therefore, it is likely that the inactivity of the enzyme under used 
conditions (50 mM HEPES, 10 mM NaCl, pH 7.4, 2 mM KG, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM 
reducing agent and 1 mM substrate) was the reason why no product was formed and not the 
structure of the substrates or unfavorable binding. Under optimized reaction conditions (chap-
ter 7.2.5), the transformation is probable, as it was shown that Hw-WelO15 produces hardly 
54a with initial reaction conditions, while optimized reaction conditions lead to a product for-
mation of 11%. Parallel to this work on large compounds, H. Mueller and N. Huwa could show 
that a complementary set of Wi-0 variants is needed to accept smaller molecules.[383,386] 
3.6.2 Biotransformation with WelO15 variants and Hapalindole-like Ketones 
After finding a number of variants that chlorinate 54, more hapalindole-like ketones were syn-
thesized. These substrates were first synthesized by L. Schmermund (76-78, 81-83, 85) in the 
scope of his master thesis[317] and later resynthesized within this thesis. The synthesis of all 
compounds (figure 44) is based on the coupling of diversified indoles with different six-mem-
bered rings. Synthesis of 79 and 80 were performed by the group of R. Viswanathan. To syn-
thesize 81 and 82, the unsaturated ring was coupled, to first achieve 84 and 85 followed by a 
reduction with engineered ene-reductase TsER variants. Coupling of the reduced C=C bond 
rings (e.g R-dihydrocarvone, to form 87) resulted in a mix of products, lowering the overall 
yield. 
Under first reaction conditions (50 mM HEPES, 10 mM NaCl, 5 mM KG, 0.5 mM DTT, 
0.5 mM (NH4)2Fe(SO4)2, 10 µM enzyme), substrates 54 and 76-78 with modification at the in-
dole moiety were chlorinated. 79 was transformed by Wi-2 to two new products, one chlorin-
ated and one that could not be identified so far. Substrates 80-87 were not converted. After 
changing the reaction buffer, also 80-83 were accepted however no chemoselectivity is 
achieved. 84-87 have not been tested under optimized conditions. An overview of all tested 
ketones is shown in figure 44 and detailed analysis is given in the next paragraphs. 
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Figure 44. Tested hapalindole-like ketones and substrate scope of Wi-WelO15 variants. Best product formation (% HPLC) is given 
for 8 h, 30 °C in 200 µL 50 mM HEPES, 100 mM NaCl, pH 7.4 with 0.5 mM substrate with either [a] 2 mol% (10 µM) purified 
enzyme or [b] cell lysate (prior to lysis normalized to OD600 = 5.0). [c] total formation of all products. [d] no transformation with 
initial reaction conditions of 50 mM HEPES, 10 mM NaCl, pH 7.4 with 0.5 mM.  
The results regarding substrate scope are divided into substrates with modification at the in-
dole moiety 76-78 which are predominantly chlorinated. Modification at the terpene ring in 
81-83 which mainly show complex mixtures of products. Mass analysis revealed only few  
chlorinated products. For first analyses 10 Wi-WelO15 and three Hw-WelO15 variants were 
selected and normalized to a cell density of OD600=5.0. Therefore, heterologous expression was 
performed in a 2 L flask with 0.5 L culture as described in ch. 7.1.9.1. and aliquoted into a 
2.2 mL 96-dw plate. The selected variants are shown in table 10. Well performing variants were 
isolated by purification and later analyses were performed with purified enzymes. 
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Table 10. Variants chosen for analysis with abbreviation and all mutations.  
name WelO15 variants 
Wi-0* Wi-WelO15 V6I/D284N 
Wi-1* Wi-WelO15 V6I/A82L/D284N 
Wi-2* Wi-WelO15 V6I/N74R/D284N 
Wi-3** Wi-WelO15 V6I/V90P/D284N 
Wi-4* Wi-WelO15 V6I/A82V/I84H/D284N 
Wi-5* Wi-WelO15 V6I/A82L/V90P/D284N 
Wi-6** Wi-WelO15 V6I/A88V/V90P/D284N 
Wi-7* Wi-WelO15 V6I/V81T/A82M/A88V/V90P/D284N 
Wi-8* Wi-WelO15 V6I/N74R/V81T/A82M/A88V/V90P/D284N 
Wi-9* Wi-WelO15 V6I/M221L/M225I/D284N 
Wi-10* Wi-WelO15 V6I/A82L/V90P/M221L/M225I/D284N 
Wi-11* Wi-WelO15 V6I/N74R/V81T/A82M/A88V/V90P/S93L/S103A/D284N 
Wi-12* Wi-WelO15 V6I/N74R/A82L/V90P/S93D/D284N 
Wi-13*** Wi-WelO15 V6I/N74R/A82L/V90P/S93H/S103A/A175N/D284N 
Wi-5P3*** 
Wi-WelO15 
V6I/A82L/V90P/S103A/Q123R/F230K/Q236N/S239W/S268R/Q282D/D284N 
Hw-1** Hw-WelO15 A82L 
Hw-2** Hw-WelO15 A82L/V90P 
*enzymes analyzed as lysate and purified catalyst, **enzymes analyzed only in cell lysate, *** enzymes analyzed only as purified 
catalyst 
The expression level of the genes was analyzed by SDS-PAGE (figure 91). It can be seen that 
especially Hw variants as well as Wi-9 show a lower soluble enzyme concentration in lysate, 
which could be explained by a lower expression level or low solubility. SDS-PAGE analysis of 
the whole cells (ch. 8.5.1, figure 90) shows, that the halogenase expression level is lower as 
well.  
3.6.2.1 Modification at the Indole Moiety 
The substrate scope was first tested with hapalindole-like ketones containing modifications at 
the indole moiety. The indole derivatives were coupled to the terpene ring 64 with similar 
yields as indole. In lysate-based biotransformations it was tested if methyl groups in position 
5 or 6 or a methoxy group in position 5 have an influence on the acceptance of the chlorinase. 
The reaction procedure is described in ch. 7.2.5.1 and results are given in table 11. 
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Table 11: Total conversion of 54 and 76-78 and chemoselectivity obtained in lysate-based biotransformation with normalized cell 
mass. Final reaction conditions: 200 µL volume in 2.2 mL 96 dw-plates sealed with a plastic lid, 50 mM HEPES, 100 mM NaCl, 
2.5 mM KG, 2.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM substrate, 8 h, 30 °C, 200 rpm (Infors HT shaker). Area of 
starting material, chlorinated product and hydroxylated product (identified by LC-MS) were included. If relative conversion was 
below 5% no selectivity was determined. Highest product formation is highlighted in red. 
 enzymes 
54 54a 76 76a 77 77a 78 78a 
conv.[a] 
chemo- 
select. 
conv. [a] 
chemo- 
select. 
conv. [a] 
chemo- 
select. 
conv. [a] 
chemo- 
select. 
  Wi-0  <1 nd <1 nd <1 nd <1 nd 
  Wi-1 32 98 7 99 11 98 15 96 
  Wi-2 28 94 2 nd 4 nd 2 nd 
  Wi-3 3 nd 1 nd 1 nd 1 nd 
  Wi-4 43 68 34 80 36 82 23 75 
  Wi-5 59 98 33 99 48 98 42 97 
  Wi-6 22 81 17 90 18 92 2 nd 
  Wi-7 52 93 12 96 30 93 14 98 
  Wi-8 62 96 27 98 54 96 50 98 
  Wi-9 1 nd 2 nd 1 nd <1 nd 
  Wi-10 30 95 18 96 45 96 30 96 
  Wi-11 69 96 25 97 44 96 38 91 
  Wi-12 63 92 14 47 10 72 18 94 
Hw-WelO15 11 70 48 94 33 93 31 90 
   Hw-1 18 86 12 87 27 92 8 85 
   Hw-2 3 nd 2 nd 5 95 2 nd 
[a] relative conversion (% HPLC), nd= not determined. 
As shown in table 11, the chlorinated products can be produced with conversions of 33-69% 
and chemoselectivities of 96-99% by Wi-WelO15 variants. Wi-0 hardly (<1%) transforms the 
ketones 54, 76-78, whereas Hw-WelO15 produces moderate amounts of chlorinated ketones 
54a, 76a-78a, with 76 being the best substrate obtaining 45% 76a. This indicates a change in 
substrate selectivity, since 76 is the substrate accepted worst by Wi-WelO15 variants. The 4th 
generation variant Wi-11 has the highest product formation for 54a while modified substrates 
are converted best by variants found earlier in the evolution process which might be explained 
by an adaption to the screening substrate, not allowing larger residues within the structure.  
NHI dependent halogenases are known to produce hydroxylated side products, especially 
if the substrate is modified from the natural substrate.[159] Therefore it was gratifying to see that 
modification in the indole moiety did not change the chemoselectivity towards hydroxylation 
for most variants. Hw-WelO15 as well as Wi-4 however have a drastically reduced chemose-
lectivity for 54 with 68-70% selectivity for chlorination. Hydroxylation of 54 will be closer an-
alyzed in chapter 3.6.4.  
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After preparative scale reaction (ch. 3.7), chlorinated products were analyzed by mass 
(ESI+) and NMR (1H, 13C and NOESY). Products were found to be chlorinated on C13 with R-
configuration, showing identical absolute stereochemistry as related 12-epi-hapalindole E. 
Based on this information, selected variants were purified, and the transformation repeated 
with purified enzyme (ch. 7.2.5.2). The results are shown in table 12. 
Table 12: Total conversion of substrates 54 and 76-78 and chemoselectivity obtained in biotransformation with purified enzymes. 
Final reaction conditions: 200 µL volume in 2.2 mL 96 dw-plates, 50 mM HEPES, 100 mM NaCl, 5 mM KG, 2.5 mM ascorbic acid, 
0.5 mM (NH4)2Fe(SO4)2, 0.5 mM substrate, 8 h reaction time, 30 °C, 200 rpm (Infors HT shaker). Area of starting material, chlorin-
ated product and hydroxylated product (identified by LC-MS) were included. Selectivities for chlorinated products are given. If 
relative conversion was below 5% no selectivity was determined. Highest product formation is highlighted in red. Variant Wi-5 
and Wi-5P3 are highlighted in orange to compare conversion of the template variant and a thermostabilized variant with 6 °C 
increased melting temperature based on 7 further mutations on the enzyme surface. 
 enzymes  
54 54a 76 76a 77 77a 78 78a 
conv.[a] 
chemo- 
select. 
conv.[a] 
chemo- 
select. 
conv.[a] 
chemo- 
select. 
conv.[a] 
chemo- 
select. 
Wi-0 <1 nd <1 nd <1 nd <1 <1 
  Wi-1 28 96 2 nd 5 97 4 nd 
  Wi-2  9 95 <1 nd <1 nd <1 <1 
  Wi-4  3 nd 3 nd 7 80 3 nd 
  Wi-5 70 97 14 98 42 96 13 98 
  Wi-7 25 92 1 nd 8 91 2 nd 
  Wi-8 80 93 5 98 31 94 17 99 
  Wi-9 2 nd 2 nd 1 nd <1 nd 
  Wi-10 18 93 5 94 23 92 5 95 
  Wi-11 90 96 8 98 41 94 26 99 
  Wi-12 91 96 9 98 21 93 16 98 
  Wi-13 69 96 6 99 26 96 21 98 
  Wi-5P3[b] 76 96 11 96 45 94 16 98 
Hw-WelO15 11 73 33 91 28 95 9 78 
[a] relative conversion (% HPLC), nd= not determined  
[b] Wi-WelO15 V6I/A82L/V90P/S103A/Q123R/F230K/Q236N/S239W/S268R/Q282D/D284N. This variant was created as stabilized 
variant, described in chapter 3.9.1. 
SDS-PAGE analysis revealed that comparable amounts of halogenase are present in reactions 
that are performed in cell lysate or with purified enzymes(ch. 8.5.2), therefore the results can 
directly be compared. 
The lead substrate 54 is chlorinated best under conditions with isolated enzymes (Wi-11 
purified: 86% versus lysate: 66%). The highest product formation for each compound is high-
lighted in red (table 12). The best variants Wi-5, Wi-8, Wi-11 and Wi-12 show higher 54a for-
mation in isolated form then in cell lysate. While formation of 76a-78a with the same enzymes 
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worked better in cell lysate, indicating that the dependency of the reaction environment is 
dependent on the substrate, not the variant. 
Introduction of a methyl group decreases product formation with purified enzymes to 14 
and 26% for 76a and 78a, respectively. When cell lysate was used instead, product formation 
for 76a and 78a was twice as high (33% and 52%). Introducing the H-bond acceptor OMe at C5 
the drop in product formation in comparison to 76a (14%) could be recovered, giving 40% 77a 
with purified enzymes and 52% with lysates.  
Variant Wi-4 with a medium conversion and decreased chemoselectivity in cell lysate lost 
its activity almost completely. While Hw-WelO15 produces all chlorinated products in lysate 
and as isolated catalyst with decreased chemoselectivity. 
Wi-5P3 (highlighted in orange) was produced as stabilized variant (see chapter 3.9) based 
on Wi-5 and contains 7 further mutations on the enzyme surface which increased its melting 
temperature from 55 °C to 61 °C. The chlorinase has compared to Wi-5 a higher conversion 
(except for 76) but also a slight decrease in chemoselectivity. This indicates that a stabilization 
of the enzyme might result in a slight increase in activity. 
In summary, the chlorinase panel allows late-stage chlorination and access to 54a, 76a-78a 
with regio- and diastereoselectivities >99.9%. Product formation differences between reactions 
with purified enzymes and cell lysate indicate that complex stabilizing effects must happen 
within the reaction which cannot easily be explained. Kinetic analysis was performed with 
selected variants to gain information about the binding affinity and reaction velocity (ch. 3.8).  
3.6.2.2 Modification in the Terpene Ring 
Substrates 79 and 80 were send by R. Viswanathan as mix of epimers. The molecules are bigger 
than the screening substrate 54, with an additional carbon and hydroxy group in position C12. 
The compound is an intermediate in the synthesis of 12-epi-hapalindole C. 79 and 80 were 
separated by preparative HPLC and tested individually even though no absolute assignment 
of the stereo conformation could be performed. 
Under initial reaction conditions only 79 was converted into two new products, 79c and 
79d. Using optimized reaction conditions, more products were formed starting from 79. Also 
80 was converted into several new products. Products of transformations with 79 and 80 could 
only be characterized with LC-MS due to a lack of further substrate. HPLC chromatograms of 
selected variants with 79 and 80 are shown in figure 45. A complete overview of selectivities 
with all variants is given in table 41, ch. 8.5.5.  
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Figure 45. HPLC chromatograms of 79 and 80 after biotransformation with selected halogenase variants. Peaks that were not 
present in control reactions are highlighted with arrows. Final reaction conditions: 200 µL volume in 2.2 mL 96 dw-plates, 10 µM 
enzyme, 50 mM HEPES, 100 mM NaCl, 5 mM KG, 2.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM substrate, 8 h reaction 
time, 30 °C, 200 rpm (Infors HT shaker). 
While 79 is transformed best by Hw-WelO15 and Wi-1, Wi-2 and Wi-12 have the highest con-
version for 80. LC-MS analysis revealed 79a and 79b to be hydroxylated products ([M+H]+ m/z 
= 328). It was first assumed that 79c is a hydroxylated product, however repeated LC-MS meas-
urements assigned a mass of [M+H]+ m/z = 266. The mass fit to a degradation product if acet-
aldehyde (89) is eliminated in −position to the carbonyl group as shown in scheme 7. 
 
Scheme 7. Possible radical elimination of acetaldehyde as degradation process from 79. 
However, the product of this elimination process (84) is in the scope of synthesized ketones 
and does not fit to the retention time in the HPLC measurement. For proper analysis and struc-
ture elucidation, more product is needed for NMR analysis. Remaining products were identi-
fied with the following masses: [M+H]+ m/z(79d) = 266, m/z(79e) = 310, m/z(79f) = 266. 80 is 
also transformed into several new products with the following masses: [M+H]+ m/z(80a) = 266, 
m/z(80b) = 268 and 310, m/z(80c) = 346.  
In this way 80c could be identified as chlorinated product and the typical isotopic peak 
could be observed. To elucidate at which position in the molecule, the halogenation did take 
place, NMR measurements are necessary. From the educt mass of 311 g/mol, products 79e and 
80b show a mass that fit to desaturation, also masses 79f and 80a could be desaturated prod-
ucts from products 79c and 80b. What kind of transformation occurred from 79 to 79d, with a 
mass difference of -46 g/mol is not known until now. Further, no assumptions can be made 
where these modifications happen. NHI enzymes are known to catalyse a broad spectrum of 
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different reactions. Hereby reactions like halogenation, demethylation, desaturation, O-cy-
clization, ring expansion and epimerization are catalyzed therefore it is hard to predict what 
happened, without further characterization of the products.[162,167–177]  
Small structural changes in the terpene ring of 81-83 proved to be as challenging for the 
enzymatic chlorination. Elimination of a methyl group at C12 (81) or sp2 hybridization (83) in 
comparison to 54, abolished detectable chlorination, proving that C12 position requires a qua-
ternary carbon center for corrected substrate positioning prior to chlorination. Nevertheless, 
substrates 81-83 are transformed with moderate activity into several new products. All three 
compounds are converted best with variant Wi-12, a complete overview of conversion and 
selectivities is given in table 42, ch. 8.5.5. HPLC chromatograms are shown in figure 46. 
 
Figure 46. HPLC chromatograms of 81-83 after biotransformation with halogenase variants. 
Preparative scale reactions (chapter 3.7) were performed with all three substrates however the 
resulting yields from 81 and 83 were not sufficient for NMR analysis (ch. 3.7.2). LC-MS analysis 
assigned different transformation to the products. Starting with 81 (267 g/mol), product 81a 
with a retention time of 2.2 min has a mass of [M+H]+ m/z = 146, 81b and 81d are hydroxylated 
[M+H]+ m/z = 284, while 81c has a mass of [M+H]+ m/z = 254, which fits to a demethylated 
product.  
Products of transformation with 83 (267 g/mol) are desaturated ([M+H]+ m/z(83c,d,e)=266) 
and either methylated or hydroxylated combined with subsequent desaturation ([M+H]+ 
m/z(83b)=282). 83a has, as 81a, both with identical retention times a mass of [M+H]+ m/z=146. 
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Since 81 and 83 differ in their terpene rings, it leads to the assumption that it might be an indole 
with modifications. The mass would fit to structure 90 shown in figure 47. 
Transformation of 82 (227 g/mol) showed two new products in HPLC analysis (figure 46). 
LC-MS measurements revealed a mass difference of +32 (82a) and -2 (82b), in comparison to 
the starting material (227 g/mol), which could fit to a dihydroxylated and one desaturated 
product. Preparative scale reactions (ch. 3.7.2) yielded sufficient product for NMR analysis. 
However, 82b showed a double set of signals and could, because of a high complexity, not be 
solved. With help of X. Xie from the NMR department at the Philipps-University Marburg, an 
assumed structure of 82a was determined, however still a doubled set for indole signals was 
present. In figure 47, possible structures for products 81a/83a (shown as 90) and 82a are shown. 
 
Figure 47. Possible structures for product 81a and 83a (structure 90) and 82a. 
If a ring opening took place and the structure 82a shown in figure 47 indeed is the product, it 
could support a possible formation of 90 because it is a first prove that position C10 is hydrox-
ylated or transformed by the enzyme at all. To have certainty about the structure, the mole-
cules have to be purified further and analyzed by NMR and crystallization. It would also be 
interesting to crystallize educt molecules 81-83 to gain information about the stereochemistry 
of the starting materials and possible interactions with the enzyme. 
Substrates 79-83 were transformed into a variety of products which could not clearly be 
assigned but only one chlorinated product (80c) could be detected. Different kind of transfor-
mations occur which cannot be generalized. Masses were found that fit to demethylation, hy-
droxylation, desaturation and even two transformations could have happened as a dihydrox-
ylation or hydroxylation followed by desaturation can be assumed from mass analysis. Inter-
estingly, monohydroxylation was found quite rarely (only 79a,b and 81b,d) which is the mod-
ification reported to happen if non-natural substrates are converted by FeII/KG dependent 
halogenases.[159,387] 
In contrast to that, substrates 54 as well as 76-78 were mainly chlorinated with hydroxyla-
tion as side reaction, however the lowest chemoselectivity for chlorination is 68% for Wi-4. An 
approach to further shift the chemoselectivity towards hydroxylation of 54 described in chap-
ter 3.6.4.  
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Substrates 84-87 were only tested under non-optimized conditions and did not show any 
product formation. It could be assumed, that no modification of sp2-hybridized carbons is pos-
sible within this enzyme class. 87 has the needed sp3-configuration. Even though it has oppos-
ing stereocenters compared to 81, a transformation with Wi-1 is probable, based on results 
shown in chapter 3.6.3, however the starting material is already a mix of three isomers because 
R-dihydrocarvone was coupled to carvone. If this molecule should be analyzed, a new synthe-
sis should be performed, first coupling R-carvone to indole followed by a reduction by the 
ene-reductase TsER.  
3.6.3 Hapalindole-like Nitrile, Isothiocyanate and Isonitriles 
Next to hapalindole-ketones also a nitrile, isothiocyanate and isonitriles with different stereo-
information were available. While synthesizing 53, 67 is received as major side product (chap-
ter 3.3). Also, amine 65 is an intermediate in the synthesis of 53 and 67. Hapalindole Q (91) is 
a natural product however with changed stereocenters and isothiocyanate group instead of 
the isonitrile which was synthesized by the group of R. Viswanathan. After finding a number 
of variants that transform hapalindole-like ketones, the panel of chlorinases was also tested 
with compounds shown in figure 48. 
 
Figure 48. Hapalindole-like nitrile, isothiocyanate and isonitriles. 
53 as close derivative to the naturally occurring 12-epi-hapaldindole C is chlorinated by the 
wild-type enzymes and also with the engineered Wi-WelO15 variants, however, with reduced 
efficiency (table 13). Variants Wi-1 and Wi-2 with one mutation in the active site still have 
moderate activity of 67-73% conversion while an increased number of mutations in the active 
site results in conversions below 30%. Only Wi-10, which has the same mutations in the active 
site as Wi-5 (A82L/V90P) showed again a higher formation with an increase in 53a formation 
from 27% to 60%, revealing that for chlorination of 53 the two mutations M221L/M225I seem 
to be beneficial.  
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Table 13. Relative conversion of substrates 53, 67, 91 obtained in biotransformation with purified enzymes. Final reaction condi-
tions: 200 µL volume in 2.2 mL 96 dw-plates, 50 mM HEPES, 100 mM NaCl, 5 mM KG, 2.5 mM ascorbic acid, 0.5 mM 
(NH4)2Fe(SO4)2, 0.5 mM substrate, 8 h reaction time, 30 °C, 200 rpm (Infors HT shaker).  
relative conversion (%HPLC) 
 53 67* 91 
Hw-WelO15 91 4 nc 
Wi-0 93 nc nc 
Wi-1 67 88 
86 
(6% 91a, 2% 91b 77% 91c) 
Wi-2 73 nc nc 
Wi-4 3 nc nc 
Wi-5 27 71 nc 
Wi-7 15 5 nc 
Wi-8 19 6 nc 
Wi-9 93 nc nc 
Wi-10 60 57 nc 
Wi-11 20 20 nc 
Wi-12 26 55 nc 
* aqueous phase measured after reaction. nc = no conversion,  
Change of the stereocenter at C11, results in complete activity loss of product formation with 
Wi-0. Mutation of A82L in Wi-1, enables the conversion and chlorinated 67 best of all tested 
variants which supports the assumption that the position A82 is important for interaction with 
the isonitrile group. Wi-10 and Wi-12 also contain mutation A82L and have a moderate con-
version whereas variants with V81T/A82M/A88V instead have a low product formation of 
≤6%. After introduction of mutations S93L/S103A the formation of 67a however increases to 
20% (Wi-11).  
Hapalindole Q is only accepted by Wi-1, which shows again the high versatility of Wi-1 for 
other stereo conformations. The main product 91c is chlorinated (77% selectivity), while two 
side products 91a and 91b are hydroxylated.  
Amine 65 is a mix of two epimers which could not be separated by flash column chroma-
tography, therefore the mix was tested. No transformation could be observed by any variants 
under initial reaction conditions. Analysis of the educt and the reactions had to be performed 
in the presence of TFA, otherwise no distinct peaks could be identified but a broad signal. It 
could be possible that from a formed product, HCl or H2O would eliminate in the presence of 
TFA. However, LC-MS analyses of all biotransformations were performed in the presence of 
TFA without observable decrease in product. More probable is the low activity based on the 
reaction conditions. The biotransformation should be repeated under optimized conditions. 
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In summary, the created chlorinase panel is able to transform a large scope of non-natural 
hapalindole-like compounds. Ketones 54 and 76-78 with modification at the indole moiety are 
chlorinated with excellent chemoselectivity of 96-99%. Achieving such a high selectivity is ex-
ceptional because non-natural substrates for FeII/KG dependent halogenases are dominantly 
reported to be hydroxylated.[159,387] Isonitrile 67 and hapalindole Q (91) are chlorinated solely 
by one variant, Wi-1, revealing important information about further engineering processes 
with different stereo centers and perhaps leading to chlorination with different regio- or ste-
reochemistry. To further examine this, the stereochemistry of the two products have to be an-
alyzed. Modifications at the terpene moiety, present in substrates 79-83, led to a loss of selec-
tivity and abolished chlorination. Interestingly, albeit their low activity, Hw-WelO15 wild type 
and Wi-WelO15 variants carrying I84H start shifting chemoselectivity of substrates that are 
mainly chlorinated towards 30% hydroxylation of 54, an indication that chemoselectivity can 
also be controlled solely by substrate binding site mutations. The hydroxylation of 54 is ana-
lyzed closer in chapter 3.6.4 
3.6.4 Hydroxylation of Screening Substrate 54 
3.6.4.1 Hydroxylation with Wi-WelO15 Variants 
FeII dependent halogenases are known to produce hydroxylated (side) products for non-native 
substrates.[159] This ability is based on their close relationship with FeII dependent oxygenases. 
The difference is based on the active site, where the iron is coordinated to a His-Asp-His motif 
in the hydroxylases while in halogenases instead of an Asp, a small amino acid like Ala or Gly 
is incorporated whereby the binding of a chloride ion is enabled. It was shown that halogenase 
WelO5 G166D exclusively hydroxylates 12-epi-fischerindole U,[160] while hydroxylase SadA 
D157G halogenates its substrate.[181] Unfortunately, it is not as easy to interchange this residue 
to decide whether halogenation or hydroxylation should happen. Since mutation of Ala to Asp 
in halogenase SyrB2[178] and Asp to Ala in hydroxylase TauD[182] failed to convert enzyme ac-
tivities. So far it is not exactly known but it is assumed that positioning of the substrate within 
the active site is very important.  
In the screening process a number of variants were identified, carrying mutation I84H in 
combination with a bigger, unpolar amino acid in position A82 (L, V, I, T) that shifted their 
chemoselectivity from 98% chlorination to 32% hydroxylation. The highest formation of 54b 
was observed with variant Wi-WelO15 V6I/A82V/I84H/D284N (Wi-4). Also, Hw-WelO15 
shows a chemoselectivity of around 30% towards hydroxylation. 
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Scheme 8. Transformation of 54 with Wi-4. Final reaction conditions: 200 µL volume in 2.2 mL 96 dw-plates sealed with a plastic 
lid, 50 mM HEPES, 100 mM NaCl, 2.5 mM KG, 2.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM substrate, 8 h, 30 °C, 
200 rpm (Infors HT shaker). 
Under tested conditions, Wi-4 seems to be only active in cell lysate. In an attempt to completely 
reverse chemoselectivity, mutation G166D was introduced into Wi-0, Wi-1 and Wi-4. Expres-
sion levels of all Wi-variants producing 54b as well as G166D variants were analyzed and 
transformation with 54 performed. 
 
Figure 49. SDS-PAGE analysis of Wi-WelO15 variant lysates, capable of hydroxylation. Recombinant expression was performed 
in 100 mL baffled flask as described in ch. 7.1.9.1. Cells were normalized to an optical density of 5.0. Reactions were performed in 
2 mL reaction tubes as described in ch. 7.2.5.1. Lanes: 1= Wi-WelO15 V6I/A82L/G166D/D284N, M=Marker 26616 Thermo Fisher, 
2= Wi-WelO15 V6I/G166D/D284N, 3= Wi-WelO15 V6I/A82V/I84H/G166D/D284N, 4= Wi-WelO15 V6I/A82I/I84H/D284N, 5= Wi-
WelO15 V6I/A82L/I84H/D284N, 6= Wi-WelO15 V6I/A82T/I84H/D284N 7= Wi-4. Shown HPLC traces were measured with Agela 
Durashell C-18 column (150 mm x 4.6 mm, 5 µm particle size + 10 mm precolumn), 71-29 ACN-H2O, 1mL/min. * Impurities from 
lysate. 
While all G166D variants show comparable expression levels and solubility, decreased halo-
genase concentration was observed in lanes 5 and 6. Although chlorination was completely 
suppressed for G166D variants as expected, hydroxylation of 54 was equally affected and 
dropped below 1% (figure 49). In further studies, isonitrile 53 was tested with G166D variants 
and was not converted anymore, too. WelO5 G166D was described to hydroxylate 12-epi-fisch-
erindole U but no information is available if 12-epi-hapalindole C is transformed by the variant. 
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Since formation for 54b remain low but hydroxylation is also an important handle for fur-
ther functionalization, the enzyme class of cytochrome P450 was analyzed on its ability to hy-
droxylate 54. P450BM3 is one P450 representative of Bacillus megaterium this enzyme is often 
used in research projects since it is well studied and already carries a reductase domain, so 
that only cofactors must be added to enable the reaction. 
3.6.4.2 Hydroxylation with P450BM3 
Cytochrome P450 enzymes (P450s) are highly versatile monooxygenases that can be found 
throughout all domains of life and are believed to have been present in the last universal com-
mon ancestor.[388] These enzymes catalyze a range of physiological functions and accept a di-
versity of substrates.[388] Mechanistically, molecular oxygen is used as oxidant. While one oxy-
gen atom is incorporated into the substrate, the other oxygen is reduced to water. A prosthetic 
heme group, bound to a cysteine, is the place where the oxidation process occurs. The catalytic 
mechanism is shown in scheme 9. 
 
Scheme 9. Catalytic cycle of P450s modified by Krest et al.[389] and Whitehouse et al.[390]. 
The active iron center is present in its low-spin ferric form in the resting state of the enzyme 
(I). When the substrate is bound, the iron state changes to high-spin electron configuration and 
is subsequently reduced, using a nicotinamide cofactor, to its ferrous state (III). Molecular ox-
ygen binds to the iron (IV) and undergoes reductive scission. The iron is again reduced (V) 
and after taking up two protons, the oxygen-oxygen bond is cleaved (VI). After releasing one 
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oxygen atom as water, the green ferryl-oxo intermediate (VII) compound I remains with the 
oxidized FeIV center.[391] Compound II is formed, when a hydrogen is transferred from the sub-
strate, which then transfers it hydroxyl group to the substrate radical in a rebound mechanism. 
The ferric iron state is regenerated (IX) when the product dissociates and the place is taken 
again by water, returning the enzyme to its resting state (I).[389,390] It is also possible that the 
enzyme undergoes one of three shunt pathways which produces water, hydrogen peroxide or 
superoxide anion, using cofactor but no substrate transformation, which is also called leakage 
or uncoupling.[389,390] 
P450s have been classified by their electron shuttling mechanism.[392] In the reduction step 
(II to III) a minority of P450s undergo a direct reduction by NADH (Class IX) [393,394] while others 
catalyze isomerization reactions (Class X)[395–397] or act as peroxygenase with a direct oxygena-
tion of the heme without requirement of any redox partner.[398–400] The majority however rely 
on one or more auxiliary redox partners.[392] In some cases, the P450 and reductase domain are 
assembled on a single polypeptide chain (class VII and VIII) with CYP 102 being the best char-
acterized family of enzymes. One member is the cytochrome P450BM3 (CYP102A1), originating 
from Bacillus megaterium which was isolated first by Miura and Fulco.[401] The biocatalyst hy-
droxylates long-chain fatty acids at subterminal positions.[402] It contains the required diflavin 
NADPH-P450 reductase and is therefore self-sufficient.[403] P450BM3 has a size of 119 kDa[404], is 
soluble, easily recombinant expressed in Escherichia coli, and highly active, with turnover rates 
in the thousands per minute for fatty acids.[405,406] 
As preparation for the hydroxylation of hapalindole-like ketone 54 with P450BM3, the crystal 
structure of 54 (CCDC 1839575)[158] and P450BM3 (PDB 1BU7)[407] was used for docking with 
SwissDock.[385] To enable binding of 54 in the active site, the enzyme pocket was enlarged in 
silico by mutating the following residues to Gly: V26, F87, A264, T268, A328, P329, E435, L439. 
In the next step, the poses received within the docking were opened together with an aligned 
wild-type structure to visualize where amino acids of the active site clash with the docked 
ligands. Visualization was made possible with Discovery Studio and 2D view of the binding 
modes. L75 as well as F87 were clashing in all poses. F87 is an important residue, for example 
in determining the regioselectivity of fatty acid hydroxylation.[408] In table 14, all promising 
poses are analyzed and in figure 50 two examples of possible binding modes are shown. 
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Table 14. Results from docking of P450BM3 with 54 by SwissDock. The active site was enlarged before docking by mutating residues 
to glycine. Docking poses were analyzed with Chimera and Discovery Studio Visualizer. 
close to heme favorable interactions clashing amino acids 
indole K69 A264 L437 L75, F87, A328 
indole + C15 A74 A328 A264 L75, F87, L437 
terpene ring L437 A264 L75, F87, A328 T268 
indole A328 A264 I263, V78 L437 L75, F87, T268 
C12 A264 A328 A74 L71 K69 L75, F87, L437 
terpene ring  L75, F87, L437 
 
Figure 50. 2D view of docked 54 into the active site of P450BM3. The active site was enlarged before docking by mutating residues 
to glycine. Resulting poses from docking were overlaid with the wild type to find clashing residues. Analysis was performed with 
2D viewer of Discovery Studio Visualizer. Both poses show clashes with different residues. All poses are analyzed within table 
14. 
In table 14 and figure 50 it can be seen, that especially F87 and L75 are clashing with the sub-
strate. Via the carbonyl group or indole N-H, hydrogen bonds can be formed with amino acids 
in the active site. Clashing amino acids are shown as well as amino acids that can form favor-
able interactions with the enzyme. Of the found binding modes, no preference can be derived, 
if preferential the terpene ring or the indole will be hydroxylated. 
The groups of Hoebenreich, Reetz and Meggers already have performed a number of en-
zyme engineering studies with P450BM3.[307,409–415] Existing libraries of P450BM3 variants were 
checked if mutations were made in the identified positions, which should be mutated to enable 
binding of 54. A test reaction with the wild-type enzyme and four variants, showed product 
formation for all five biocatalysts and proved that the reaction principally works. While in 
HPLC measurements of the wild-type reaction only one new peak appeared, two new signals 
with a shoulder each appeared in the reaction with P450BM3 R47Y/T49F/V78L, which suggest 
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the formation of four new products 54e and 54f (figure 97). After these positive results, in total, 
10 plates of variants were selected and screened with 54. Since the screening is the time limit-
ing step, and 960 samples had to be analyzed, a short and isocratic method was used, in which 
the double peaks were not separated. In the reaction a NADP+, GDH recycling system was 
used to produce NADPH. Furthermore 5 mM EDTA, 5% glycerol was present to destabilize 
the cell walls (EDTA) and to stabilize the enzyme (glycerol). Biotransformations were per-
formed in 400 µL volume and a final concentration of 1 mM 54. After 24 h the reaction was 
stopped by extraction  and after transferring the organic phase to glass plates and drying the 
solvent, remaining dry samples were dissolved with acetonitrile and analyzed by HPLC. In 
table 15 an overview of found hit is given.  
Table 15. Total conversion and selectivity of variants found to be active in the P450 library, screened with substrate 54. The reaction 
was performed in 2.2 mL 96-dw-plates with 400 µL final reaction volume. The cell pellet from heterologous expression was sus-
pended in 196 µL lysis buffer (0.1 M KPi pH 7.4 containing 1 mg/mL lysozyme). After incubation for 30 min at 37 °C, 200 rpm 
(Infors HT shaker), 200 µL 2x reaction buffer (0.1 M KPi pH 7.4, 0.5 mM NADP+, 0.5 M glucose, 10% glycerol, 10 mM EDTA, 
2 U/mL GDH) and 4 µL 54a (0.1 M in EtOH) was added and the plates incubated for 24 h at  30 °C, 200 rpm (Infors HT shaker). 
P450BM3 variants 
total conv. 
(%HPLC) 
selectivity 
54b 
selectivity 
54e 
selectivity 
54f 
R47G/F87G 84 1 28 71 
R47E/F87G 78 1 29 69 
L181E/F87G 78 3 38 60 
L181T/F87G 91 4 60 36 
F87A/M185N/L188G 93 3 32 64 
 
In the screening, the wild-type enzyme shows less than 1% total conversion and product 54b, 
with hydroxy in position C13, was hardly formed. Instead the same the two double peaks were 
identified as in reactions with P450BM3 R47Y/T49F/V78L. Interestingly, variant L181T/F87G was 
the only variant producing 54e with a selectivity >50%.  
From collected information, it could be seen, that F87G or F87A was present in all variants 
and furthermore especially position R47 as well as L181, M185 and L188 were promising po-
sitions to be combined in a library. Therefore, five plasmids containing the P450BM3 gene with 
mutations  R47G/F87G, R47V/F87G, R47H/F87G, R47E/F87G, R47V/F87G, were mixed in an 
equivalent stoichiometric ratio and used as template for a library including positions L181, 
M185 and L188. Mutagenesis should be performed via QuikChange PCR with all three posi-
tions coded on both, reverse and forward, primers. The library was planned with 675 possible 
variants and the following substituents L181 A, Q, E, L, K, M, P, T, V; M185 N, S, M; L188 G, 
A, V, L, N. Even though several PCR conditions were tested, it was not possible to achieve a 
good degeneration. While 1-2 bases of the triplets were mutated quite well, the third position, 
had mostly still its wild-type codon (ch. 8.5.6, figure 98). Therefore, the library was screened 
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as it was, with only the following amino acids: L181 Q, L, P; M185 I, M; L188 M, I, L, V. Two 
plates were screened, and some variants were found that had a good total conversion, how-
ever, no improvement in selectivity could be observed and two more new products were pro-
duced. The four products 54c-54f, produced by P450BM3 variants are shown in scheme 10.  
 
Scheme 10. Products formed by P450BM3 variants. 
The variants with highest conversion were assayed again in triplicates (figure 51) and the se-
quence of active variants was analyzed. However, for two variants, the sequencing terminated 
early and gave incomplete results. 
 
Figure 51. Total conversion of 54 and selectivities of P450BM3 variants. *sequencing failed, ** sequencing incomplete. The reaction 
was performed in 2.2 mL 96-dw-plates with 400 µL final reaction volume. The cell pellet from heterologous expression was sus-
pended in 196 µL lysis buffer (0.1 M KPi pH 7.4 containing 1 mg/mL lysozyme). After incubation for 30 min at 37 °C, 200 rpm 
(Infors HT shaker), 200 µL 2x reaction buffer (0.1 M KPi pH 7.4, 0.5 mM NADP+, 0.5 M glucose, 10% glycerol, 10 mM EDTA, 
2 U/mL GDH) and 4 µL 54a (0.05 M in EtOH) was added and the plates incubated for 24 h at  30 °C, 200 rpm (Infors HT shaker). 
Based on analysis of created and sequenced variants compared to the quick quality control, 
most mutations that were introduced should have not been present. The problems in creation 
of the library were first thought to be based on primers, because another project had similar 
problems, that single nucleotides are not degenerated while neighboring nucleotides are. Se-
quencing of the found variants, however, suggest that there might be some problems in the 
sequencing of the library mix and that the plasmid variety was bigger than first assumed. 
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Three variants: R47H/F87G/L181A, R47E/F87G/L181V/M185S/L188G and R47V/F87G/L181T/ 
L188N were chosen based on their selectivity and total conversion. for biotransformations in 
preparative scale. 
For reactions in mg-scale, first two hits found within the plates of the Reetz group were 
used, however, the product formation was not satisfying with total conversions <25%. Then 
the library was created to look for improved variants and three variants were chosen for fur-
ther scale-up reactions. The results are summarized in table 16. 
Table 16. Preparative reactions with P450 BM3 variants. 
 
subst. 
(mg) 
vol. (mL) 
conv. 
(%HPLC) 
sel. 
54c 
sel. 
54d 
sel. 
54e 
sel. 
54f 
yield[d] 
R47G/F87G[a] 
28 mg 
100 mL 
23% na na 65% 35% 
54c 0.9% 
2 mg 
54d 3.5% 
8 mg 
54e 3.5% 
7.6 mg 
54f 3.5% 
7.5 mg 
F87G/L181T[a] 
28 mg 
100 mL 
18% na na 33% 67% 
R47H/F87G/L181A[b] 
46 mg 
2x80 mL 
60% 14 72 7 7 
R47V/F87G/L181T/L188N[b] 
23 mg 
82 mL 
83% 16 66 14 4 
R47E/F87G/L181V/M185S/L188G[b] 
27 mg 
96 mL 
65% 11 41 16 32 
R47E/F87G/L181V/M185S/L188G[c] 
27 mg 
96 mL 
9% na na 46% 54% 
R47V/F87G/L181T/L188N[c] 
23 mg 
82 mL 
14% na na 67% 33% 
[a] protocol 1, 21 h [b] protocol 2, 20 h [c] protocol 3, 2.5 h (ch. 7.3.2) [d] after preparative HPLC purification, for economic reasons 
the reaction mixtures were combined before purification. na not available 
Additionally, to different variants, also the reaction conditions were adapted to a higher buffer 
concentration (100 mM previously to 200 mM potassium phosphate). Also, the glucose con-
centration was increased from 100 mM to 250 mM. EDTA was left out and the oxygenase con-
centration was determined by absorption measurement. During the second reaction, samples 
were taken after 2.5 h and 5 h to see the time resolved product formation. Since the HPLC 
samples had to dry before measurement, the results could only be seen the next day. Within 
the first 5 h mainly product 54e and 54f were produced but after 20 h product 54d was present 
as main product. NMR analysis proved that both functionalities that were introduced individ-
ually into 54e – hydroxylation at C14- and 54f – epoxidation at C16 and C17- are both present 
in 54d. This led to the conclusion that both products can act as substrate again and are two 
times oxidized if the enzyme is still active, which was presumably not the case in the screening. 
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Product 54c with two hydroxy groups in position C14 and C17 was produced with all variants 
in quite low amounts of 11-16%. However, it is also possible that the epoxide 54d is hydrolyzed 
to produce 54c. 
From the amino acids found to be clashing in the docking only F87G was finally present in 
active variants. Even though it already could be seen the wild type also can convert 54 with 
low activity. L75 which also seemed to be quite hindering was not present in screened libraries 
and it would further be interesting to analyze which effect it has on the reaction.  
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3.7 Preparative Scale Reactions with Halogenase Wi-WelO15 
Preparative scale reactions are performed for different reasons. On the one hand, new pro-
duced products have to be characterized. Screening generally is performed in small volumes 
of 0.2-0.4 mL and low substrate concentrations of 0.5-1 mM. Depending on the conversion, 
after extraction often there is not even sufficient sample remaining for mass analysis. There-
fore, reaction conditions have to be changed to gain sufficient material for full characterization 
with mass and NMR analysis. Next to chemical characterization, it is also interesting to ana-
lyze the bioactivity of products, therefore several mg are needed, too. On the other hand, also 
the properties of biocatalysts should be tested. After finding an enzyme, that performs the 
desired transformation in small scale, it must be tested if the catalyst is robust and if the scale 
can be increased since catalyst in applications will never be used in ng-scale as it is in the 
screening. The following chapters describe the optimization of conditions and testing of sev-
eral halogenase variants within mg-scale. 
3.7.1 Characterization of Chlorinated Products 
None of the chlorinated hapalindole-like substrates have been described in the literature so 
far, therefore all products had to be fully characterized. Synthesis as well as preparative chlo-
rination and characterization of both 53 and 53a was made by L. Schmermund.[317] To chlorin-
ate 53, purified Hw-WelO15 was used. All further reactions were made with variants of Wi-
WelO15.  
The difficulty in the reactions with this enzyme family is based on the dependency on O2 
but at the same time the instability of FeII in presence of O2 which often lead to a fast termina-
tion of the reaction. Furthermore, the substrates have a quite low solubility in water as well as 
partially in EtOH (53 and 76 have a solubility of <100 mM in EtOH) and a tolerance of the 
enzymes against solvents is not present so far (ch. 3.9).  
The reactions were made with cleared lysate. Cell pellets gained from heterologous expres-
sion were lysed by sonication and insoluble cell components were subsequently removed by 
centrifugation. The halogenase concentration cannot be determined from lysate except estima-
tion by SDS-PAGE analysis which includes a high error.[383] Therefore the enzyme concentra-
tion in the reactions were estimated based on a value of around 60-80 mg enzyme/L of cell 
culture. Based on a reproducible yield of around 60-65 mg enzyme /L of cell culture after 
IMAC for all purified variants. 
Because the product formation was quite low in the beginning under initial reaction con-
ditions, increased substrate loading of 1.5 mM was used to decrease the needed reaction vol-
umes. This however did not increase the turnover but only yielded lower conversion. Within 
the project, the reaction conditions were improved for small scale reactions, which included 
an increase of NaCl from 10 to 100 mM and substitution of 0.5 mM DTT to 2.5 mM ascorbic 
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acid. Optimization for scale-up reactions were performed in analogy to the screening, includ-
ing an increase of NaCl, ascorbic acid, KG and (NH4)2Fe(SO4)2, as well as a decrease in sub-
strate loading in comparison to first preparative reactions. All cofactors were finally used in 
doubled concentration compared to small scale. Since several conditions were tested, reactions 
shown in table 14 cannot easily be compared. A reaction volume of 50 mL was set as standard 
in combination with a 0.5 mL flat bottom flask, closed with a gas permeable foil, and incuba-
tion at 100 rpm and 30 °C in an Ecotron Infors shaker. If a 2x reaction buffer is prepared, the 
solution turns dark purple shortly after all components KG, ascorbic acid and (NH4)2Fe(SO4)2 
in 50 mM HEPES, 100 mM NaCl (N2 flushed) were mixed. The enzyme, reconstituted with 
KG and FeSO4, has a weak lilac colour (ch. 3.2, figure 14c), addition of the enzyme to the 
solution, does not change its colour probably based on its low concentration. Figure 52 shows 
the fast colour change in a preparative reaction performed with purified Wi-1 and 67.  
 
Figure 52. Preparative scale reaction with purified Wi-1 and 67. The change of color from dark purple to dark yellowish can be 
observed within 2.5 h. After that, no further change of color happens. 
No further color change could be observed after 2.5 h. Time dependent measurement of a re-
action performed with Wi-5 lysate and 78 shows that the reaction runs up to 5 h, this however 
can individually be dependent on the variant and substrate. With the optimized and stand-
ardized reaction conditions, reproducible results as well as conversions matching the small-
scale reactions could be achieved, even though the final conditions have an increased catalyst 
to substrate loading compared to small scale reactions. 
Table 17 gives an overview of all performed scale-up reactions to chlorinate hapalindole-
like ketones with different reaction conditions. The reactions were not yet repeated with opti-
mized reaction conditions.  
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Table 17. Reactions with halogenase variants to chlorinate hapalindole-like ketones. Reaction conditions for scale-up reactions 
were optimized during the synthesis of chlorinated product. Individual reaction conditions and analysis of products are given in 
chapter 7.3.1. Conditions that worked best and are recommended to use are: 20-30 µM enzyme*, 50 mM HEPES, 100 mM NaCl, 
pH 7.4, 10 mM KG, 5 mM ascorbic acid, 1 mM (NH4)2Fe(SO4)2 and a substrate concentration of 0.75-1.5 mM, depending on 
solubility of substrate. *estimation of a chlorinase concentration of 60-80 mg/L expression culture, based on the fact that all vari-
ants reliably yield 60-65 mg/L after IMAC. 
product variant 
scale 
(mL) 
catalyst 
(mg) 
substrate 
loading[a] 
(mg/L) 
conv. 
(%HPLC) 
yield[d] 
53a Hw-WelO15 34 24[b] 440 80%[e] 48% 8.0 mg 
54a Wi-5 142 48-64[c] 423 20%[f] 13% 8.5 mg 
54a  
& 
54b 
Wi-4 
Wi-4 
Wi-4 
80 
3x50 
4x50 
45-60[c] 
135-180[c] 
180-240[c] 
211 
141 
141 
7% (71% 54a) [h] 
35% (66% 54a)[h] 
65% (77% 54a)[h] 
42% 
(71% 54a) 
20 mg 54a 
8.0 mg 
54b 
76a 
Wi-5 
Wi-5 
120 
120 
28[b] 
96-128[c] 
375 
275 
2%[e] 
42%[h] 
1.2% 
25% 
0.7 mg 
8.1 mg 
77a Wi-5 129 48-64[c] 470 13%[f] 7% 4.5 mg 
78a Wi-5 158 60-80[c] 440 14%[g] 10% 7.0 mg 
67a Wi-1 50 35[b] 220 86%[h] <1%  
[a] 0.5 - 1.5 mM, [b] purified enzyme, [c] cleared lysate, [d] after preparative HPLC purification, [e] 50 mM HEPES, 10 mM NaCl, 
5 mM KG, 0.5 mM DTT, 0.5 mM (NH4)2Fe(SO4)2, experiment performed by L. Schmermund[317] [f] 50 mM HEPES, 10 mM NaCl, 
2.5 mM KG, 0.5 mM DTT, 0.5 mM (NH4)2Fe(SO4)2, experiment performed by L. Schmermund[317] [g] 50 mM HEPES, 50 mM 
NaCl, 2.5 mM ascorbic acid, [h] 50 mM HEPES, 100 mM NaCl, 10 mM KG, 5 mM ascorbic acid, 1 mM (NH4)2Fe(SO4)2 
From table 17 it can be seen, that conversions as well as yields were quite low when initial 
reaction conditions were used, both however could be increased for hapalindole-like ketones 
by using optimized reaction conditions. The yields, giving amounts of isolated product, how-
ever are still quite low in comparison to the conversion which is calculated from HPLC meas-
urements without purification. Purification of products includes extraction with ethyl acetate. 
With lysate components as well as reaction cofactors, no phase separation is achieved after 
extraction. Separation of aqueous phase, organic phase and precipitated components was only 
achieved by centrifugation at 9000 rpm (40 min, Eppendorf 5810 R, rotor F-34-6-38). After 
transferring the organic phase to a new flask, ethyl acetate is removed under reduced pressure 
and the remaining sample dissolved in acetonitrile and filtered before applying it to prepara-
tive HPLC. All this results in a loss of 30-47% product (table 17), comparing conversion and 
yield. 67a could not be isolated at all after the reaction. Even though extraction with ethyl 
acetate in small scale was possible, after purification with preparative HPLC, less than 1 mg 
compound was left over. Signals in analytical and preparative HPLC were quite low, indicat-
ing that the concentration of educt and product were low in the solution. For a repeated reac-
tion, either a different solvent for extraction should be used or a solid phase extraction from 
the aqueous phase could also be tried instead.  
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3.7.2 Characterization of Unselective Reactions 
After the reaction conditions were optimized, to 50 mL volume in a 0.5 L flat bottom flask with 
50 mM HEPES, 100 mM NaCl, 10 mM KG, 5 mM ascorbic acid and 1 mM (NH4)2Fe(SO4)2, 
also products of other transformations should be analyzed. Within the scope of the reactions, 
also the differences between lysate and purified enzyme as well as different substrate loadings 
were tested. In table 18, an overview of the reactions is given. 
Table 18. Overview of mg-scale reactions. Reactions were performed in a total volume of 50 mL in a 0.5 L flat bottom flask with 
50 mM HEPES, 100 mM NaCl, 10 mM KG, 5 mM ascorbic acid, 1 mM (NH4)2Fe(SO4)2. Enzyme concentration was about 30 µM 
with an estimation of a chlorinase concentration of 60-80 mg/L expression culture, based on the fact that all variants reliably yield 
60-65 mg/L after IMAC. 
variant substrate 
scale 
(mL) 
substrate 
 loading 
(mM) 
amount of 
catalyst  
conv. 
(%HPLC) 
yield[c] 
Wi-5 
82 
50 0.75 51[a] 
58% 
(sel. 50% 82a) 
10% 82a 
(5 mg) 
 
10% 82b 
(5 mg) 
Wi-5 2x50 0.75 90-120[b] 
43% 
(sel. 53% 82a) 
Wi-5 2x50 0.75 90-120[b] 
66% 
(sel. 64% 82a) 
Wi-12 50 0.75 45-60[b] 
55% 
(sel. 46% 82a) 
Wi-5 
81 
1x50 0.75 45-60[b] 11% 
<1 mg for individual products Wi-12 3x50 0.75 135-180 [b] 28% 
Wi-12 2x50 0.50 90-120[b] 37% 
Wi-12 83 2x50 0.50 90-120[b] 19% <1 mg for individual products 
[a] purified enzyme, [b] cleared lysate, [c] reactions were combined before preparative HPLC purification 
The reactions show that under optimized conditions, Wi-5 has a comparable activity in cell 
lysate or as purified enzyme and Wi-5 as well as Wi-12 reach a higher conversion in the mg-
scale reactions in comparison to the small-scale reactions with purified enzymes. This activity 
is important because it shows that the enzymes can tolerate higher reaction volumes, which is 
necessary if it should have an application. Also, the 4th generation variants were tested in these 
reactions and show that they can be used in mg-scale reactions. Another important aspect is 
substrate loading. Within small scale optimization, it could be seen, that Wi-1 has a higher 
turnover with higher substrate loading (figure 36, ch. 3.5.3). Wi-4 in mg-scale seems to not 
tolerate the increase from 0.5 to 0.75 mM (table 17) whereas Wi-12 seem to work similar under 
both conditions with substrate 81 (table 18). Even though the conversion is lower, the esti-
mated TON is 6 with 0.5 mM and 7 with 0.75 mM substrate. To analyze products from trans-
formations with 81 and 83, the activity and selectivity have to be increased combined with an 
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improved purification process. HPLC chromatograms showing reactions 81 and 83 after ex-
traction are given in figure 95 and figure 96 in ch. 8.5.4.  
3.8 Kinetic Analysis  
Within the engineering process of halogenase Wi-WelO15, it was possible to increase the prod-
uct formation of Wi-0 (<1%) up to 87% with Wi-12. To get an idea about the kinetic properties, 
the variants were analyzed with 54. Wi-0 was also tested with 53, however it must be noted 
that Wi-0 is not the wild-type enzyme but variant Wi-WelO15 V6I/D284N and 53 is a non-
natural hapalindole C derivative. No information was available how fast the wild type chlo-
rinates its natural substrates. Still, Wi-0 and 53 give a clue what characteristic lead to a high 
product formation of 93%. In table 19, enzyme substrate pairs and their kinetic parameters are 
listed. 
Table 19. Overview of kinetic parameters of different Wi-WelO15 variants with different substrates. Final reaction conditions: 
200 µL volume in 2.0 mL reaction tube, 50 mM HEPES, 10 mM NaCl, 5 mM KG, 0.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2. 
Different substrate concentrations and reaction times were used as described in chapter 7.2.6. 
variant substrate 
prod. 
form.[a] 
Km 
(µM) 
Ki 
(µM) 
kcat 
(min-1) 
kcat/Km 
(min-1 mM-1) 
Wi-0 53 93 22 - 1.60 71.5 
Wi-1 54 27 158 - 0.12 0.7 
Wi-2 54 9 99 2190 0.02 0.2 
Wi-5 54 68 82 1106 0.43 5.3 
Wi-7 54 23 64 - 0.06 0.9 
Wi-8 54 74 158 - 0.42 2.6 
Wi-11 54 86 68 - 0.64 9.4 
Wi-12 54 87 20 - 0.37 18.5 
Wi-5 76 14 43 - 0.24 5.6 
Wi-5 77 40 127 - 0.18 1.4 
Wi-5 78 13 85 - 0.11 1.3 
[a] product formation calculated from relative conversion (%HPLC) based on areas of educt, hydroxylated and chlorinated prod-
ucts. 
The effect of active site mutations on binding and turnover were analyzed by measurement of 
kinetics (table 19). Through directed evolution of the halogenase, catalytic rate and efficiency 
could be increased for chlorination of 54 and 4th generation variants have a 93-fold higher ef-
ficiency than Wi-2. From the best two variants, Wi-11 is the fastest one, but a 3.4-fold higher 
Km compared to Wi-12 reduces the catalytic efficiency. Wi-12 has a 2-fold lower kcat than Wi-11, 
but the low Km of 20 µM makes it the most efficient variant for transformation of 54. In general, 
the kcat is quite low with values <1 min-1, while an analysis of several thousand enzyme re-
vealed an average enzyme to catalyze around 600 turnover per minute.[416] The kinetic data 
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reveals that the Wi-WelO15 variants are as efficient as the oxygenase TauD[161,342] and the engi-
neered flavin dependent halogenases PrnA[417] and RebH[418] with non-natural substrates. The 
engineered fluorinase fah2114 shows a 20-fold higher kcat/KM for conversion of 5’ClDA into 
SAM while the kcat/Km for the conversion of SAM into 5’-FDA still is 2.5.[148]  
Important to notice is that just as shown for flavin dependent halogenases and fluorinases 
also FeII dependent halogenases can be improved in their kinetic parameters. Which could be 
the key fact for using these enzymes as biocatalyst. If the reaction system of FeII and enzyme 
together with further reactants is not stable for a long time, the reaction velocity has to be 
increased in combination with a stabilization of the enzyme under used reaction conditions. 
In late stage functionalization, to create valuable and complex molecules, catalytic efficiency 
and turnover numbers are less important than in the synthesis of building blocks, where a 
high catalytic efficiency is needed.[419] 
It might also be interesting to analyze these kinetic parameters about binding and turnover 
frequency if a template for further mutation rounds is selected. If the activity for 54 should 
further be increased, Wi-12 can be used, because it binds the substrate best. While a lose bind-
ing but higher velocity (Wi-11) might be beneficial if the enzyme should be adapted for other 
substrates. To analyze the catalytic properties, the total turnover number or total turno-
ver/time is even more important. Since kinetics only describe the initial velocity, but if a fast 
catalyst is inactive after minutes, for reactions a slower catalyst that has a higher longtime 
stability might be more preferably. Therefore, the product formation which is measured in the 
screening to compare the variants is also a good indicator for the activity of the variants. In 
this study, variants that show highest product formation within 8 h also had the best kcat/Km. 
To increase the efficiency and applicability of the reaction, the enzyme should further be 
evolved to higher turnovers but also adapted to higher substrate loadings which now limit to 
a total turnover to 50. Because enzymatic reactions are often performed in water and the sub-
strate solubility therein often is a limiting step, the enzyme can be adapted to two phase sys-
tems with an organic solvent as substrate reservoir. Analysis of temperature and solvent sta-
bility is described in the next chapter. 
  
 Results and Discussion  
 
100 
3.9 Temperature and Solvent Stability of WelO15 
The stability of biocatalysts is an important factor for their usage in synthetic applications. A 
high activity combined with long shelf-life and good stability against solvents could help to 
spread biocatalysis further into industrial applications.[248] 
The term protein stability is nowadays often used with different meanings, most frequently 
the reversible unfolding is meant, which is a measure of thermodynamic stability and can be 
represented by the melting temperature. Furthermore, kinetic stability can be determined 
which describes how long the protein remains active before it irreversible denatures.[420] This 
is represented by the half-life of denaturation or the optimum operating temperature, the tem-
perature at which the activity of the enzyme is reduced by half following incubation for a 
specific amount of time.[420] In table 20 a summary is given, described by Polizzi et al.[420], about 
various stability parameters. 
Table 20. Definitions of various stability parameters by Polizzi et al.[420] 
measure symbol type of stability definition 
free energy of  
unfolding 
ΔGu thermodynamic 
change in Gibbs free energy going from the 
folded to unfolded state 
melting temperature Tm thermodynamic 
the temperature at which half of the protein 
is in the unfolded state 
unfolding equilibrium 
constant 
Ku thermodynamic 
the concentration of unfolded species di-
vided by the concentration of folded spe-
cies 
half concentration C1/2 thermodynamic 
the concentration of denaturant needed to 
unfold half of the protein 
observed deactivation 
rate constant 
kd kinetic 
time required for residual activity to be re-
duced to half 
half-life T1/2 kinetic 
temperature of incubation to reduce resid-
ual activity by half during a defined time 
period 
temperature of half-in-
activation 
T50 kinetic 
temperature of incubation to reduce resid-
ual activity by half during a defined time 
period 
optimum temperature Topt kinetic temperature leading to the highest activity 
total turnover number TTN kinetic 
modes of product produced over the life-
time of the catalyst 
 
Next to the thermal stability, which deals with the stability at elevated temperatures also the 
chemical stability is an important characteristic, which describes the stability in presence of 
organic solvents, salts or extreme pH ranges.[420] 
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Two decades ago few mutagenesis strategies were available to target stability. To increase 
the stability of enzymes, chemical modifications, lyophilization and additives as well as im-
mobilization was used, but the improvements were moderate and often insufficient for most 
chemical transformations.[248] Nowadays, protein engineering is applied to increase the stabil-
ity against temperature or reaction conditions, several successful engineering studies could be 
made[421] by phylogenetic analysis[422,423] or rational, structure based or computer design[424–427]. 
In the next chapters, the temperature and solvent stability of halogenase Wi-WelO15 is exam-
ined and the use of the PROSS Sever within this enzyme class. 
3.9.1 Temperature Stability 
One of the online available web applications, to predict solubility or stability increasing muta-
tions, is PROSS[428] (Protein Repair One-Stop Shop). In this application, problems like aggrega-
tion, short half-life and low melting temperatures are alleviated to increase the enzyme solu-
bility.[428] PROSS works with the fact that heterologous expression of proteins and their mu-
tants often results in misfolding and aggregation. Large changes in stability will require large 
free energy changes in the folding–unfolding equilibrium A molecular-level understanding of 
proteins enables the estimation of the strength of various interactions (ion pairs on the surface 
or entropic contributions of adding a proline residue), so that the needed changes to reach the 
goal can better be planned. Rarely, free energy-based measures are used to plan protein-engi-
neering strategies today but converting case studies into engineering principles requires a 
quantitative approach. The design of variants with more favorable native-state energy results 
in higher yields of soluble and function protein obtained by heterologous overexpression.[248,428] 
PROSS aligns sequences of occurring homologues and scans the allowed sequence space. 
Frequently observed amino acids often increases stability (consensus effect) but instead of se-
lecting these amino acids, the application foremost eliminates mutations that are rare or never 
seen. By applying Rosetta computational mutation scanning[429], allowed mutations are mod-
elled against the background of the wild-type structure and the energy difference between 
wild type and single-point mutant is calculated.[428] 
For the class of NHI dependent halogenases, only 5 halogenases are known and in total 12 
sequences with an identity >77% (compared to Wi-WelO15, 20.07.2018) are available in the 
NCBI data base. This is a low number of homologous and a quite high identity which could 
negatively influence the outcome, because tools that work with the consensus effect mostly 
work best if many sequences are available.  
If the closed structure of WelO5 with soaked substrate (PDB 5IQT, chain B) is uploaded to 
the server, seven different designs are given as outcome. Within the designs the number of 
mutations increases, with 20 mutations as maximum. Figure 53 shows the structure of WelO5 
and all amino acids that are chosen by the PROSS server are highlighted in blue. No chosen 
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amino acid is located within the active site, but all are on the surface of the enzyme, most on 
loops. 
 
Figure 53. WelO5 (5IQT chain B) with highlighted amino acids that were chosen by the PROSS server to be mutated.[428] 1) S103A; 
2) S103A/Q123R/F230K; 3) S103A/Q123R/F230K/Q236N/S239W/S268R/Q282D; 4) S37K/S103A/Q123R/F230K/Q236N/S239W/ 
S268R/Q282D; 5) S37K/S93D/S103A/S117N/Q123R/A175M/S207D/F230K/N235Q/Q236N/S239W/S268R/Q282D; 6) N18H/S37K/ 
S93D/S103A/S117N/Q123R/A175M/T195S/S207D/Q220D/F230K/N235Q/Q236N/S239W/S268R/Q282D 7) N18H/T20S/S37K /K68S/ 
S93D/S103A/T112E/S117N/Q123R/L171N/A175M/T195S/S207D/Q220D/F230K/N235Q/Q236N/S239W/S268R/Q282D 
The easiest way to test the mentioned mutants would be ordering them by gene synthesis. Out 
of cost reasons, this was not possible therefore the first three mutants were created by muta-
genic PCR on template Wi-0. The following variants result: Wi-P1: Wi-WelO15 V6I/S103A/ 
D284N, Wi-P2: Wi-WelO15 V6I/S103A/Q123R/S230K/D284N, Wi-P3: Wi-WelO15 V6I/S103A/ 
Q123R/S230K/Q236N/S239W/S268R/Q282D/D284N. All variants could successfully be heter-
ologous expressed and purified, followed by determining the melting temperature (Tm) by 
circular dichroism measurement. Also selected variants found during the engineering process 
were analyzed (table 21). First, the folding of the halogenase was measured and secondary 
structural elements determined but no meaningful information could be collected. High dif-
ferences within the values lead to the assumption that this method is not applicable to deter-
mine the folding (table 38). This might be based on a high flexibility within the structure which 
can be seen from many different crystallization states within the FeII/KG dependent enzymes. 
In some cases there were evidences showing that the overall structure of enzymes becomes 
more ordered when FeII and KG is added,[188,189] for WelO15 halogenases, no difference be-
tween apo and holo enzyme could be observed in the melting temperature. However, it was 
never determined, if the apo enzyme has cofactors incorporated, therefore it is just assumed 
to be the apo form after dialysis against EDTA. ICP-MS studies would be a possibility to meas-
ure remaining Fe content in the enzyme solution. To test if the stability increasing mutations 
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can be combined with activity increasing mutations, another variant was created combining 
PROSS variant 3 with A82L/V90P (Wi-5P3). 
Tm of the variants were determined as well different conditions were tested to see the en-
vironmental influence on the enzyme. A triplicate measurement of the same variant resulted 
in an error of 0.3 °C. The Tm are given in table 21 and belonging curves can be found in ch. 
8.3.5.2, figure 70 - figure 75. 
Table 21. Tm of halogenase variants. The melting was observed with CD measurement. 25 µM enzyme solution in 5 mM HEPES, 
1 mM NaCl, were analyzed in the range of 20-80 °C with: λ=220 nm, data pitch 1 °C, a temperature slope of 2 °C/min, a response 
of 2 s and a bandwidth of 10 nm. The inflection point gives the melting temperature Tm. 
enzyme apo (°C) 
+1eq KG 
(°C) 
+1eq KG 
+1eq (NH4)2Fe(SO4)2 (°C) 
Hw-WelO15 62.0 62.2 61.4 
Wi-0 54.4 54.9 53.7 
Wi-2 51.1 nd 51.7 
Wi-5 55.3 54.1 55.6 
Wi-12 55.0 nd 55.8 
Wi-8 53.3 52.8 52.4 
Wi-11 55.1 nd 54.4 
Wi-9 55.8 nd 55.9 
Wi-10 56.4 nd 56.9 
Wi-2[a] 56.1 (high noise) 
Wi-9[b] 56.7 
Wi-9[c] 53.8 
Wi-9[d] no melting observed 
Wi-P1 56.1 nd 55.6 
Wi-P2 56.0 nd 56.2 
Wi-P3 59.8 nd 59.7 
Wi-5P3 61.3 nd 61.0 
nd = not determined; [a] 5mM KG + 0.5 mM (NH4)2Fe(SO4)2; [b] 1 eq KG + 1eq NiCl2 [c] 5 mM KG+ 1eq NiCl2 [d] 5 mM KG+ 
0.5 mM NiCl2 
The melting temperature of Hw-WelO15 is about 8 °C higher than Wi-0 with around 54 °C but 
also this Tm is already quite stable. Variant Wi-9 was interesting to analyze because it is a 
scaffold sampling variant with L221/I225 transferred from Hw-WelO15 to Wi-0, substituting 
M221/M225. Since the difference in melting temperatures between Wi-0 and Hw-WelO15 is 
already quite high, it would be interesting to know which substitutions cause the thermal sta-
bilization. By transferring the two above mentioned residues, the melting temperature could 
be increased by 1.4 °C. Interestingly, most of the variants, which were created to have an in-
creased activity to chlorinate 54 also have an increased melting temperature.  
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The PROSS variants show an increased stability against thermal unfolding. The mutation 
of S103 to Ala into Wi-0 increases the Tm by ~2 °C, while additional incorporation of 
Q123R/F230K did not change the stability (Wi-P2). However further mutation of four amino 
acids to gain (Wi-P3), results in a melting temperature of 59.8 °C, which is an increase of about 
5.5 °C in comparison to Wi-0. The turnover of purified PROSS variants 1-3 are comparable 
with Wi-0 for isonitrile 53, showing that no activity loss is caused by the mutations. The com-
bination of stabilizing mutations of Wi-P3 with mutations A82L/V90P (Wi-5) created the vari-
ant Wi-5P3 which is able to chlorinate ketone 54. The chimera enzyme that combines stability 
improvement and conversion of non-natural substrates shows an even increased stabilized 
structure with a melting temp of 61.3 °C and slightly increased activity to produce 54a (70% 
Wi-5 to 76% Wi-5P3, table 12).  
Even though, the melting temperature is a measure for stability and a good way to compare 
enzymes, the temperature is increased quite rapidly (2 °C/min). To analyze the stability at con-
stant temperatures for different times, Wi-0 as well as Wi-P1, Wi-P2, Wi-P3 and Wi-5P3 were 
diluted to 50 µM and incubated at different temperatures (30, 35, 40, 45 °C) for several hours 
(1 h, 2 h, 3 h and 4 h). Then the samples were centrifuged to remove precipitated enzyme and 
the remaining soluble enzyme was compared by SDS-PAGE analysis. After 1 h at 45 °C, an 
oligomerization of the wild type enzyme can be seen by the appearance of protein bands in 
the gel in the range above 70 kDa. After 3 h, few soluble proteins are left at 45 °C and the oli-
gomerization is visible in the 40 °C sample. After 4 h, also the 40 °C sample contains almost no 
soluble protein anymore. PROSS variants 1 and 2 show already an increased stability since the 
oligomerization bands are less visible and no loss of soluble enzyme up to 40 °C and 4 h is 
detected. Figure 54 shows two gels of Wi-0 and Wi-P3, all other gels can be seen in chapter 
8.3.5.3. 
 
Figure 54. SDS-PAGE analysis of soluble fraction of Wi-0 (left) and Wi-P3 (right) after incubation at different temperatures. 
For Wi-P3 and Wi-5P3 no oligomerization or decrease in soluble enzyme concentration is ob-
served up to 45 °C within the analyzed time. Therefore Wi-P3 samples were further incubated 
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in the range of 50-65 °C. Even though an oligomerization starts already after 1 h, after 4 h at 
60-65 °C, some monomeric and oligomeric enzyme is still soluble (figure 54).  
To see the effect of elevated reaction temperatures on the product formation, biotransfor-
mations were performed with the best variants Wi-5, Wi-8, Wi-11, Wi-12 as well as the stabi-
lized Wi-5P3. The reactions were incubated at different temperatures between 30 °C and 45 °C 
for 5 h. In figure 55, the enzymes are compared. The residual activity in comparison to the 
same variant at 30 °C (standard temperature) is given. 
 
Figure 55. Temperature dependent formation of 54a, normalized to the 30°C value and given as residual activity. Reaction condi-
tions used: 10 µM enzyme, 100 mM NaCl, 50 mM HEPES, 5 mM KG, 2.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM 54, 
5 h reaction.  
It can be seen that the activity of all tested variants decreases with increased temperature ex-
cept Wi-5P3 that shows a higher formation of 54a at 35 °C. However, the residual activity at 
temperatures up to 45 °C is >50% which shows, that the overall stability and activity at in-
creased temperatures is quite good. Wi-5P3 even has a residual activity of 90% at a reaction 
temperature of 45 °C which is a great value compared to Wi-5 with less than 60% residual 
activity at 45 °C. Interestingly variants Wi-12 which is based on template Wi-5, and Wi-11 
which is based on template Wi-8, each have a higher residual activity in comparison to their 
template variants. Often it is believed that by introducing mutations into enzymes, the stability 
decreases, here the opposite seems to be the case. It is likely that under given screening condi-
tions a generally improved variant also has a higher stability and is active for a longer time. 
The results from the PROSS server are promising and further analysis of other proposed mu-
tations, not tested so far, should be followed.  
It is questionable, if increased temperatures for this reaction are applicable because of the 
decreased solubility of O2 in water. The O2 concentration in water at 30 °C, 1 bar and 1.7 salin-
ity (salt content of the used buffer is 17 g/L) is 234 µM which shows, that for complete substrate 
conversion (500 µM), oxygen has to diffuse into the buffer from the air. With increased tem-
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peratures up to 45 °C, the solubility further decreases to 186 µM and with increased salt con-
tent, the solubility also decreases as well.[430,431] However, heat purification of the enzyme 
would be of special because it simplifies purification. It could be seen, that incubation of puri-
fied Wi-P3 at 65 °C for 4 h leads partially to oligomerization but still monomeric, soluble en-
zyme is left. Heat purification of other enzymes was already achieved after incubation for 
90 min at 70 °C,[432] which is only 5 °C difference from tested conditions. Therefore, further 
analysis should be performed if an incubation at 70 °C is already applicable. Furthermore, it 
should be tested if the oligomerized enzyme still has activity. 
In some cases, enzymes that have a higher temperature stability also have an increased 
solvent stability. Because of the low substrate solubility, it would be beneficial to add solvents 
to the reaction, therefore the same variants that were tested on their temperature stability also 
were checked on their solvent stability. 
3.9.2 Solvent Stability 
Next to thermal stability also chemical stability is a very important factor since low solubility 
of substrates often is a limiting factor in the reactions. By increasing the solvent concentration 
also an increased substrate loading would be made possible. In a first test with not optimized 
reaction conditions, the influence of 5% and 10% EtOH, acetone and acetonitrile was tested on 
variants Wi-5 and Wi-8 as shown in figure 56. 
 
Figure 56. Formation of 54a in presence of different solvents and concentrations, normalized to 0.5% EtOH and given as residual 
activity. Reaction conditions used: 10 µM enzyme, 10 mM NaCl, 50 mM HEPES, 5 mM KG, 0.5 mM ascorbic acid, 0.5 mM 
(NH4)2Fe(SO4)2, 5 h reaction. Substrate added from 100 mM stock to solvent. 
All tested solvents in concentrations of 5% or 10% decrease the formation of 54a in comparison 
to 0.5% EtOH. It can be seen that the presence of acetonitrile results for all variants in the 
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lowest product formation while Wi-5 seem to tolerate acetone and EtOH equally in both con-
centrations, Wi-8 has the best formation of 54a in presence of EtOH. After the reaction condi-
tions were optimized and the last library screening was completed, again Wi-5, Wi-8, Wi-11, 
Wi-12 as well as the stabilized Wi-5P3 were tested with different EtOH and acetone concentra-
tions in comparison to 1% EtOH (standard). 
 
Figure 57. Formation of 54a in presence of different solvents and concentrations, normalized to 1% EtOH and given as residual 
activity. Reaction conditions used: 10 µM enzyme, 100 mM NaCl, 50 mM HEPES, 5 mM KG, 2.5 mM ascorbic acid, 0.5 mM 
(NH4)2Fe(SO4)2, 5 h reaction. Substrate added from 50 mM stock to solvent. 
As in the assays with increased temperature, it seems that the variants from the 4th generation 
library (Wi-11, Wi-12) have higher tolerance against an increased solvent concentration in com-
parison to their template variants Wi-5 and Wi-8. Under optimized conditions, Wi-5 as well as 
Wi-8 seem to be equally stable against EtOH as well as acetone. While 5% EtOH results in a 
higher 54a formation for Wi-11 and Wi-12 as well as Wi-5P3 in comparison to 5% acetone. 
Wi-5P3 was also tested with acetonitrile but confirms the result of the first experiment, that 
acetonitrile decreases product formation most. However, it seems that acetone instead of eth-
anol with 1% could be better or comparable, if the substrates have no sufficient solubility in 
ethanol. A residual activity of 85% with ethanol for Wi-5P3 and Wi-12 are already promising 
values that should further be tested in preparative scale reactions, especially if the reactions 
are performed with purified enzyme. If cell lysate should be used, further testing of different 
solvents with cleared lysate in bigger scale should be analyzed since denaturing E. coli en-
zymes based on an increased solvent level could have an impact on the reaction.  
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4. Summary and Conclusion  
Direct and selective C-(sp3)-H chlorination is still a remaining challenge and an area of great 
interest in catalytic research. Until now, no selective transformation is known to chlorinate 
complex molecules under mild conditions. Therefore, enzymatic halogenation is an interesting 
alternative to synthetic methods and the discovery of a new class of aliphatic halogenases that 
is independent of acyl carrier proteins and which act on non-activated C-(sp3)-H bonds, 
opened the possibility to evolve this enzyme class towards a chlorination tool that can be 
added to today’s synthesis toolbox. 
Within this thesis, the halogenases Wi-WelO15 from Westiella intricata HT-29-1 and 
Hw-WelO15 Hapalosiphon welwitschii IC-52-3 belonging to the class of FeII/KG dependent hal-
ogenases, were analyzed on their evolvability towards new substrates and their potential for 
biocatalysis. The genes were successfully cloned into a high copy vector with restriction-free 
cloning.[327] Efficient expression and purification protocols for the halogenase were established 
within this work. The optimized enzyme production yields around 60-65 mg purified enzyme 
per liter of cell culture which is three times the yield of the published protocol.[155] Simple pro-
duction with high yields are the basis to use these biocatalysts in synthesis. 
Based on primer design, the halogenase Wi-0 (Wi-WelO15 V6I/D284N) contained two surface 
mutations. While V6I is assumed to have a low impact on the activity, as the linker and His6-
tag should have, D284N was reversed and compared to Wi-0 in biotransformations. It could 
be shown that this mutation has no influence on the activity. To test the activity of the halo-
genase, a simplified derivative of 12-epi-hapalindole C (53) was synthesized which was chlo-
rinated by both Wi-0 and Hw-WelO15 with turnover frequencies (TOF) that are comparable to 
literature known values with 12-epi-hapalindole C (39) and Hw-WelO15 as well as WelO5, a 
homologue that differs only in 2 amino acids to Wi-WelO15.[157] The TOF of Wi-0 is slower than 
the one of Hw-WelO15 which confirms a lower product formation in cell lysate of Wi-0 in com-
parison to Hw-WelO15. Analysis of the experiments however indicated a low stability of the 
isonitrile in cell lysate because low intensities of the substrate could be detected, in organic as 
well as aqueous phase after extraction. Purified, both enzymes achieved the same product for-
mation within 8 h under optimized reaction conditions. The initially used reaction conditions 
yield comparable results to published results, optimized reaction conditions even improved 
the enzyme activity. Even though the enzymes have a high sequence similarity of 97%, a dif-
ference in TOF was observed, showing that the present differences in the structure influence 
the chlorination. 
For the directed evolution process, a lead substrate was chosen that contains a ketone function 
instead of the naturally rare occurring isonitrile group. Synthesis of ketone 54 could be 
achieved in gram scale, in 3 steps and 32% yield, while isonitrile 53 needed 6 steps and could 
only be obtained with a yield of 4%. The substrate scope of the template halogenases Wi-0 and 
Summary and Conclusion 
 
 
109 
Hw-WelO15 was tested with 54 as well as with eight non-natural, commercially available isoni-
trile and isothiocyanate small molecules. No substrate conversion was detected. After analyz-
ing the reaction conditions with a positive control, it is known that the non-natural small mol-
ecule isonitrile and isothiocyanates were screened under conditions at which the enzyme is 
likely to be inactive. Therefore, the substrates should be further tested under optimized con-
ditions. 
Since no structural information about the halogenases was available in the beginning of the 
project, random mutagenesis of Hw-WelO15 was performed by error prone PCR. Therefore, 
enzyme models were created with SwissModel, based on crystal structures of enzymes with a 
high amino acid sequence identity. Error prone PCR generally worked successfully for 
Hw-WelO15 although some variants are likely to be inactive due to frame shift mutations or 
early stop codons. 1750 colonies were screened with reaction conditions that should have 
yielded active halogenase, but no active variant towards 54 could be found until the halogen-
ase structure of WelO5[160] was available. Within epPCR, few mutations are introduced within 
a large part of the gene, therefore the probability of finding an active variant is low and struc-
ture guided semi-rational mutagenesis should always be preferable.  
In the meantime, crystallization of both halogenases was pursued and the structure of Wi-0 
could successfully be solved with 
molecular replacement based on 
the structure of WelO5[160] in coop-
eration with the crystallization de-
partment of the Philipps-Univer-
sity Marburg. Structure guided di-
rected evolution of Wi-0 was per-
formed, following the engineering 
workflow shown in figure 58.  
Halogenase Wi-0 was engi-
neered from <1% product for-
mation to 69% formation of 54a in 
cell lysate and even 87% with puri-
fied enzymes. This also included 
optimization of reaction conditions 
which was made after finding the 
first variants producing 54a. The 
engineering included four genera-
tions of improvement with several 
semi-rational libraries and two rational design strategies. While single site libraries from 1st 
Figure 58. Workflow of directed evolution of halogenase Wi-WelO15 for selec-
tive chlorination of 54. Within four engineering steps, the halogenase active site 
was adapted to the ketone substrate. The screening effort is given in brackets. 
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generation yielded active variants for A82NNK, N74NNK and V90NNK, in two-site libraries 
several active variants were identified, with the best variant Wi-1 containing mutation A82L 
in the active site. That one mutation already leads to an improvement of product formation in 
the range of 27% shows that few changes within the active site already have a high impact on 
substrate binding. 
In the second generation, variants Wi-1 and Wi-3 from the first libraries were used as tem-
plates, furthermore a 5-site library based on Wi-0 was created. The best variant of the second 
generation was Wi-5 with mutations A82L/V90P in the active site. Even though variants re-
sulting from a scaffold sampling strategy showed lower product formation than their template 
variants, the fine tuning of Wi-7 by adding N74R, resulting in Wi-8, the variant with highest 
product formation within the first three generations. 
After screening variants from generation 1-3, a selection of variants was first used to test a 
number of non-natural substrates in cell lysate and several variants were further purified and 
analyzed as isolated catalysts. The two best variants, Wi-5 and Wi-8 were used as templates 
for the 4th generation and together with Wi-11 and Wi-12, they constitute a panel of promising 
chlorinases with highest product formation for ketone 54. Formation of the chlorinated ketone 
(54a) 54, was not detectable with the template variant Wi-0 but engineering resulted in hit 
variant that show 87% product formation and a chemoselectivity of 96% as well as >99% dia- 
and regioselectivity. The possibility to find halogenase variants, able to chlorinate new, non-
natural substrates proves the ability to evolve this enzyme class towards new substrate classes.  
Within the project it was observed that the activity of the enzyme decreases quite fast with 
time and that most of the conversion happens within the first minutes. After finding several 
variants that produce 54a and gathering knowledge about the system, several reaction condi-
tions were tested. Exchanging 0.5 mM DTT with 2.5 mM ascorbic acid as well as increasing the 
NaCl concentration from 10 to 100 mM doubled to quadrupled the formation of 54a for several 
variants (ch. 3.5 and results in ch. 3.5.5). Also, Hw-WelO15 wild type which had under initial 
reaction conditions a product formation <1%, produced up to 8% 54a under optimized reaction 
conditions. The increase in ascorbic acid concentration resulted in an elongated time in which 
product formation could be observed. This underlines the problem of fast FeII oxidation. Even 
though the reaction time was elongated, and product formation is still observable after 8 h, 
most of the product is formed within the first minutes. To overcome this problem, a balance 
has to be found between availability of O2, present for the reaction but without an excess of 
the oxidant, to prevent oxidation of FeII to FeIII, which abolishes the enzyme activity. 
Under initial reaction conditions, substrates containing modifications within the indole 
moiety were chlorinated with low activity. Conversion could be improved by optimizing the 
reaction conditions. All tested hapalindole-like ketones with modifications in position 5 and 6 
in the indole ring (76-78) were chlorinated, showing that this part of the substrate might have 
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a less important influence on substrate binding. Wi-11 and 12 show the highest formation of 
54a in isolated form, while modified substrates were converted better in cell lysate. 76a and 
77a are produced best by Wi-5 and 78a by Wi-11 (ch. 3.6.2.1).  
Modification of the terpene ring lead to a complete loss of activity within initial reaction 
conditions. Already the removal of a methyl group at position C12 ketone 81 in comparison to 
54 shows that the quaternary center in position C12 is important for the substrate binding. 
After using optimized reaction conditions, these substrates were also transformed best by Wi-5 
and Wi-12, however, few to no chlorination could be observed. Instead complex mixtures of 
products were formed, which could not completely be analyzed. LC-MS measurements sug-
gest mono- or dihydroxylation, desaturation or two modifications combined. After prepara-
tive HPLC purification, NMR analysis of two new products were performed, however the 
fractions revealed to contain more than one compound and no clear structure elucidation 
could be performed so far. The NMR of 82a suggests that the terpene ring might be opened 
between positions C10 and C11 and a terminal carboxylate could have been formed (ch. 
3.6.2.2). To further analyze this, more experiments need to be performed and purification of 
the single products need to be achieved followed by structure analysis by NMR, IR and crys-
tallization.  
These results highlight the importance of the reaction conditions for these enzymes. The 
substrate scope under optimized reaction conditions is much broader than initially thought. 
Since also the size and steric demand of naturally found hapalindole alkaloids varies within 
the different compounds. Fischerindole 42 as well as hapalindole 39 are both chlorinated by 
WelO5, which shows that the enzyme can accept a variety of different molecule shapes and 
the binding mode is far from being understood.  
Further hapalindole-like alkaloids with isonitrile and isothiocyanate groups in position 
C11 but changed stereo conformation in comparison to 12-epi-hapalindole C were converted 
only (91) or best (67) by Wi-1 which shows the importance of position A82 (ch. 3.6.3). Consid-
ering only active site mutations, A82L is also the best single mutation variant that converts 54. 
It would be very interesting to have a crystal structure of this variant, co-crystallized with the 
different substrates to explain the versatility of it, in comparison to the template variant Wi-0 
which has a quite narrow substrate scope.  
The conversion of all tested non-natural substrates, under optimized reaction conditions, 
shows that this enzyme class can be adapted towards new substrates and that the activity can 
be engineered by directed evolution as well as reaction conditions.  
To analyze all new products, preparative scale reactions in mg-scale were performed. Initially, 
these reactions were tedious with low conversions and even lower yields. After optimizing the 
reaction conditions, the conversion and yield increased and several mg of the products could 
be isolated and analyzed. Unfortunately, still great amounts of catalyst need to be used. For a 
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50 mL reaction, a substrate to catalyst ratio of 25 : 1 are used, which correspond to 11 mg sub-
strate (0.75 mM, 281 g/mol) and 45 mg catalyst (0.03 mM, MW 34450 g/mol). Therefore, the ef-
ficiency of the catalyst should be improved for further applications. Still the enzyme displays 
a great possibility to chlorinate unactivated C(sp3)-H which might be not accessible chemically. 
No information about kinetic properties of Wi-WelO15 with the natural substrate 
12-epi-hapalindole C is available, published information of WelO5 are turnover frequencies 
within the first two minutes. Wi-0 in combination with non-natural isonitrile 53 achieves the 
highest catalytic efficiency of 71.5 min-1mM-1. Chlorination of ketone 54 is not possible with the 
template variant Wi-0. Through directed evolution of the enzyme, selective chlorination was 
enabled, and kinetic properties of the enzymes could be altered. The enzyme efficiency was 
improved 93-fold from the lowest measurable kcat/Km of 0.2 (Wi-2) to 18.5 min-1mM-1 (Wi-12). 
Further analysis of Wi-5 with 76-78 revealed that even though 77 is the substrate accepted best, 
the kcat/Km for 76 is higher. All kinetic analysis was performed under non-optimized reaction 
conditions (10 mM NaCl, 0.5 mM ascorbic acid) and will likely improve, using 100 mM NaCl 
and 2.5 mM ascorbic acid. In comparison to an average enzyme (kcat of 600 min-1)[416], the en-
zymes are still quite slow but within this thesis it was shown for the first time, that it is possible 
to evolve this enzyme class towards non-natural substrates and that kinetic properties can be 
improved. With these results, the class of enzyme displays a possibility for a selective chlorin-
ation and can be further evolved for further user defined needs. 
When enzymes are evolved, stability can be important for two reasons, first, mutations intro-
duced to alter activity, often reduce the enzyme stability which is not desired by the enzyme 
engineer, therefore the enzyme needs a high starting stability. The other option is, that the 
enzyme is engineered towards a higher stability. Higher stability can simplify the purification 
process if heat purification is enabled but also, it can increase the reaction rate at higher tem-
peratures. If solvent stability is present, reactions in biphasic systems are preferred because 
these often result in higher conversions if the solubility of the substrates is low in water-based 
buffer.  
To gain information about the stability of the halogenases, the melting temperature of sev-
eral hit variants was determined by circular dichroism measurements. Wi-0 has an 8 °C lower 
melting temperature as Hw-WelO15 (54 °C and 62 °C) but both already display a medium to 
good stability. Interestingly, the stability of Wi-0 variants did not decrease but mainly the melt-
ing temperature increased slightly, which suggests that the stability of the enzyme is a limiting 
factor in the screening assay and is optimized or kept constant within the new-found hits. To 
further improve the stability of Wi-0, the structure of WelO5 was examined by the PROSS 
server[428] and several proposed variants were created. All variants had an increased melting 
temperature in comparison to Wi-0 with a maximal Tm of 61 °C for Wi-5P3, which is based on 
Wi-5 in combination with mutations proposed for PROSS variant 3. Activity assays reveal that 
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Wi-5P3 is also able to chlorinate non-natural hapalindole-like ketones and has the highest tol-
erance against solvents and temperature increase within tested variants. A residual activity of 
90% in assays performed at 45 °C and 85% residual activity in the presence of 5% ethanol could 
be observed. High temperatures during the reaction might be impractical because of a low O2 
saturation at increased temperatures but long-time storage and heat purification of the halo-
genase would simplify the handling and isolation process of the enzyme.  
Incubation of stabilized variants in buffer at different temperatures with subsequent SDS-
PAGE analysis showed that after incubation of Wi-P3 at 65 °C for 4 h, still soluble enzyme is 
left, some in monomeric and some in oligomeric form, while Wi-0 already completely precip-
itates if incubated at 45 °C for 3 h. Other enzymes such as the used thermostable ene-reductase 
TsER and glucose dehydrogenase BsGDH, could be isolated by heat purification by incubation 
for 90 min at 70 °C. The stabilized variant Wi-P3 might already be suitable for purification by 
heat. However, no activity assay was performed with the incubated enzymes to see if oli-
gomerization results in activity loss. It can be assumed that the low turnover number and a 
fast loss of activity is solely based on FeII oxidation. All in all, these results are promising for 
easy handling the halogenase within the lab as well as for further projects that will work on 
increasing the solvent and temperature stability of the halogenase. 
In conclusion, Wi-WelO15 was evolved for mild, late-stage chlorination in water using NaCl 
as halogen source. This work demonstrates the power of directed evolution to improve cata-
lytic efficiency for non-native substrate for the challenging class of FeII/KG dependent chlo-
rinases. It was possible to exchange the isonitrile, present in natural substrates, to a common 
carbonyl group. Variants of the enzyme class are now able to functionalize non-activated, ali-
phatic C(sp3)-H bonds in the presence of more electron-rich functional groups of non-natural 
substrates. 
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5. Outlook 
Chlorination of non-activated C(sp3)-H bonds is a remaining challenge in today’s synthesis 
toolbox. Within this thesis it could be shown that a new class of halogenases is able to perform 
this transformation and that the limited substrate scope of the chlorinases can be evolved to 
new non-natural substrates.  
While substitution of the isonitrile group to a ketone as well as modification of the indole 
ring is tolerated by the enzyme variants and chlorination is performed, modifications at the 
terpene ring are only conditionally tolerated. For these substrates, complex mixtures of several 
products are formed. For these substrates, existing libraries should be screened again, or mu-
tagenesis performed to adapt the shape of the active site to the specific substrate, since the 
panel of tested chlorinases was chosen based on their chlorination activity for 54. Screening of 
the 1st and 2nd generation libraries, created within this thesis could already contain suitable 
variants to increase selectivity. 
Within the screening it was found, that mutation I84H, introduced in several variants as for 
example Wi-WelO15 V6I/A82V/D284N, reduces the chemoselectivity from 98% chlorination 
54a to 68%, with 54b as hydroxylated side product. Also, Hw-WelO15 wild type which in con-
trast to Wi-WelO15 is able to produce around 8% 54a has a decreased chlorination selectivity 
of 70%. This is a first indication that chemoselectivity can be controlled solely by substrate 
binding site mutations in Wi-WelO15, without modifying the 1st or 2nd ligand sphere of the 
active site FeII complex. 
Motivated by the hydroxylation of the screening substrate, libraries of P450BM3 were 
screened with ketone 54. Some hits were found which produced 2 new products. With the 
collected information, a new library was created with the goal to achieve a higher selectivity. 
While screening with 54, in total 4 new products (54c-f) were formed. Preparative scale reac-
tions followed by NMR analysis revealed the products to be dihydroxylated (54c), epoxidized 
and hydroxylated (54d), hydroxylated (54e) and epoxidized (54f). While the halogenase hy-
droxylated 54 in position C13 R-selective (54b), P450BM3 hydroxylates position C14, R-selective 
(54e). 54d is produced from 54e and 54f, if the enzyme is still active, so the formation of it can 
be suppressed or triggered depending on different reaction conditions. Unfortunately, no en-
zyme with selectivity for either 54e or 54f could be found within the screened libraries.  
No halogenase of P450BM3 variants could be found that selectively produces only one hy-
droxylated product. However, it could be seen that with several variants, different positions 
of the substrate are accessible. Further engineering needs to be performed to increase chemo- 
or regioselectivity.  
The restriction-free cloning method was further successfully used to clone oxygenase genes 
welO11-welO19 from Westiella intricata HT-29-1 and welO11-welO17 Hapalosiphon welwitschii IC-
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52-3 into the pRSF-Duet vector. Except Hw-welO14 which could not be isolated with primers 
9 and 14 (table 26). Amplification of a gene was observable, sequencing revealed this gene 
however to be welO13. The fast and simple cloning of 18 genes by rf-cloning shows the power 
of ligase free cloning techniques, where low costs and time effort are needed. Initial protein 
production tests of oxygenases Wi-WelO11-14 as well as Hw-WelO16-17 and Wi-WelO18 
showed the production but indicate a low solubility (WelO11-14) and low stability WelO16-
18, under used, non-optimized conditions. Optimization of protocols for heterologous expres-
sion of the latter oxygenases were not performed, since the focus was laid on halogenases 
Wi-WelO15 and Hw-WelO15. Performed experiments however suggest that the enzyme pro-
duction is possible. The same applies to HpiI1, HpiI3 and WelP1. The enzymes seem to be 
accessible by heterologous expression in E. coli. Protocols for production and purification of 
the enzymes need further improvement and assays need to confirm their activity and in case 
of the oxygenase also the natural function needs to be explored. Since selective oxidation re-
actions are highly interesting reactions, too, further characterization of the enzymes may lead 
to interesting new biocatalysts. 
A fast loss of activity within the first minutes could be observed. To overcome this problem, it 
could be examined if an engineering towards higher FeII affinity can be achieved. Different 
members of the non-heme iron enzyme family show that the iron is not bound equally well. 
The iron binding can for example be tested by addition of EDTA to the reaction. If the enzyme 
binds the metal ion tightly, higher EDTA concentration should be tolerated in the reaction in 
contrast to a loose binding affinity. A tightly bound FeII within the active site should prevent 
the oxidation. Another possibility to avoid iron oxidation, would be to run the reaction anaer-
obically and to flush the system with oxygen containing air, so that all oxygen is directly con-
sumed and the reaction in total stays anaerobically. The anaerobic reaction set-up will proba-
bly be easier in large scale, for example run in a fermenter with oxygen sensor, but within a 
screening in 96 dw-format and small volumes as 0.2 mM this is almost impossible. 
The substrates used within this project have a low solubility. If the substrate is added to 
the aqueous reaction mixture, local precipitation can be observed if the final concentration of 
substrate is 1 mM or higher. Even though the precipitated substrate in the tested concentration 
range up to 2 mM for 54 dissolves by mixing, the solubility problem will be present at higher 
substrate loadings that are needed to run efficient catalytic systems. To overcome a precipita-
tion and aggregation of the molecules, it would be beneficial to run the reaction in a biphasic 
system. With some initial experiments, the solvent stability of some halogenase variants was 
tested and found to be quite promising. Residual activity for the best variants Wi-12 and 
Wi-5P3 were found to be >80% in the presence of 5% EtOH. A preparative reaction should be 
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performed with 5% EtOH to see if the presence of EtOH has a beneficial effect on the transfor-
mation. Starting with these variants, further engineering can be performed to create variants 
that tolerate a higher solvent ratio. Especially the tolerance against water non-miscible solvents 
and their use in biphasic systems is of advantage because extraction of the products is much 
easier. Especially Wi-P3 and Wi-5P3 also possess a high tolerance against increased tempera-
tures and tolerate incubation at temperatures up to 65 °C for several hours. In further studies, 
remaining PROSS variants should be created and analyzed on their temperature and solvent 
stability. Heat purification of the catalysts and a long shelf life simplify the use. Furthermore, 
the stabilized variants should be used as template for further directed evolution studies. 
It is for sure that variants of this chlorinase are a great addition to the synthesis toolbox 
and halogenation of unactivated positions, that are not accessible so far, neither enzymatically 
nor chemically, can be addressed with these halogenases. More engineering will further in-
crease the substrate scope and simplify the handling of the promising catalyst. 
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6. Material 
6.1 Organisms and Genes 
In table 22 all used vectors and plasmids are listed 
Table 22. Used vectors and plasmids. 
organism and vectors resistance cassette origin 
E. coli BL21-Gold(DE3) tetracycline Novagen 
E. coli DH5α  Novagen 
pET22 ampicillin Novagen 
pRSF-Duet kanamycin Novagen 
 
In table 23 all cloned genes with corresponding vector and tag as well as original organism are 
listed. 
Table 23. Cloned genes with vector and organism. gDNA of Westiella intricata UH HT-29-1 and Hapalosiphon welwitschii IC 52 were 
received as gift of Michelle Moffit.[238] 
gene organism 
vector  
(antibiotic resistance) 
tag origin 
tsER 
C25D/I67T 
Thermus scotoductus SA-01 pet22 (amp) - 
Hoebenreich 
group[315] 
welP1 Westiella intricata UH HT-29-1 pJ-Express (kan) C-His6 R. Viswanathan[238] 
hpI1 Fischerella sp. ATCC 43239 pRSF-Duet (kan) N-His6 Plasmids received of 
R. Viswanathan, 
cloned in pRSF dur-
ing this research pro-
ject 
hpI3 Fischerella sp. ATCC 43239 pRSF-Duet (kan) N-His6 
welO11-18 Westiella intricata UH HT-29-1 pRSF-Duet (kan) N-His6 Cloned during this 
research project welO11-16 Hapalosiphon welwitschii IC 52 pRSF-Duet (kan) N-His6 
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6.2 Media and Buffer 
In this chapter all used media, antibiotics and buffers are listed. All buffers, used for chroma-
tographic purification and antibiotics were sterile filtered (VWR, polyether sulfone 0.45 µm) 
before usage. Water was used in micropure grade (conductivity 0.055 µS/cm MicroPure sys-
tem of TKA) as solvent if not stated otherwise. The composition of used media and buffers are 
listed in table 24.  
Table 24. Composition of different media and buffers. The pH was adjusted if a value is given. 
media composition 
LB-medium 5 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract., pH 7.0 
LB-agar 15 g agar in 1 L LB-medium. 
TB-medium 
900 mL (12 g/L tryptone, 24 g/L yeast extract, 4 mL/L glycerol) add 100 mL 
10xphosphate buffer (125 g/L K2HPO4 3·H2O, 23 g/L KH2PO4). 
SOC Medium 
20 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, pH 7.0 before use, add 10 mL 
1 M MgCl2 and 20 mL 1 M glucose 
1 M KPi 160 g K2HPO4 3·H2O und 40.6 g KH2PO4 in 1 L H2O, pH=7.4. 
KPi buffer 100 mM potassium phosphate, pH=7.4 (1-9 diluted from 1 M KPi) 
Tris A 
50 mM Tris, 500 mM NaCl, 0.1% Tween-20, 20 mM imidazole, 10 mM β-ME, 
pH=7.4 
Tris B 50 mM Tris, 500 mM NaCl, 250 mM imidazole, 10 mM β-ME, pH=7.4 
HEPES 1 50 mM HEPES, 10 mM EDTA, 10 mM NaCl, 10% glycerol, pH 7.4 
HEPES 2 50 mM HEPES, 10 mM NaCl, 10% glycerol, pH 7.4 
HEPES 3 50 mM HEPES, 10 mM NaCl, pH 7.4 
HEPES 4 50 mM HEPES, 100 mM NaCl, pH 7.4 
reaction buffer 
50 mM HEPES, pH 7.4, 100 mM NaCl, 5 mM KG, 2.5 mM ascorbic acid,  
0.5 mM (NH4)2Fe(SO4)2 
lysis buffer 1 mg/mL lysozyme in 50 mM HEPES, 100 mM NaCl, pH 7.4 
TAE buffer 40 mM tris acetate, 1 mM EDTA, pH=8.0 
10x SDS-PAGE 
buffer 
10 g SDS, 144 g glycine, 30 g Tris in 1 L H2O, pH adjusted to 8.3 with HCl 
SDS-PAGE stain 
0.25 (w/v) Coomassie Blue R250, 5% (v/v) acetic acid, 50% (v/v) ethanol filled up 
with H2O 
4x SDS-PAGE 
sample buffer 
250 mM Tris-HCl (pH 6.8), 8% (w/v) SDS, 0.2% (w/v) bromo-phenol blue, 40% 
(v/v) glycerol, 20% (v/v) β-ME. 
trace metal 
mix[433] 
675.8 mg FeCl3 ∙ 6H2O (50 mM), 111.0 mg CaCl2 (20 mM), 84.5 mg MnSO4 ∙ H2O 
(10 mM), 143.8 mg ZnSO4 ∙ 7 H2O (10 mM), 23.8 mg CoCl2 (2 mM), 17.1 mg CuCl2 
(2 mM), 23.77 mg NiCl2 ∙ 6 H2O (2 mM), 24.19 mg Na2MoO4 ∙ 2 H2O (2 mM), 
6.18 mg H3BO3 (2 mM), 312.5 µL conc. HCl, ad. 50 mL 
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In table 25 all reagents necessary for heterologous expression are listed. 
Table 25: All additives necessary for heterologous expression with stock solution concentration as well as working concentration 
and solvents. All stock solutions were filtered sterile (VWR, polyether sulfone 0.45 µm). 
media additive  stock solution  
working  
concentration  
solvent  origin  
kan50  50 mg/ml*  50 μg/ml  H2O  AppliChem 
amp50  100 mg/ml*  100 μg/ml  H2O AppliChem 
IPTG  100 mM  
10 μM (TsER) 
20 µM (Halogenase) 
H2O AppliChem 
tet  10 mg/ml  10 μg/ml  EtOH  AppliChem 
FeCl3 50 mM 50 µM H2O  
trace metal mix** 1000x 1x H2O  
*antibiotics were used as salts and counterion weight included, **composition in table 24. 
6.3 Primer 
In table 26 all used primers are listed with their sequence. The primers are subdivided by their 
use in sequencing, cloning or mutagenesis. 
Table 26: All used primers are shown in this table. Lower case bases interact with the vector, upper case bases interact with the 
gene. Bases that are highlighted red are mutations and green highlighted bases are silent mutations 
 Primer for Sequencing  
1 pRSF_rev gtgtgaccgtgtgcttc 
2 T7minus1 aatacgactcactataggg 
3 T7T ctagttattgctcagcgg 
4 BM3-2 cgagaacattcgctatc 
5 BM3-3 ttaattgtaacggcgtc 
6 BM3-4 atacccggcgtgtgaaatg 
7 P450BM3 seq primer gtattccttcacctagcac 
 Primer for Cloning  
8 WelO11+12_fw cagccaggatccgaattcgagctcgATGGTTAGCTATATTGAAAAGAGCG 
9 WelO13+14_fw CAGCCAGGATCCGAATTCGAGCTCGatggttagctatattgaaaacgacc 
10 WelO15_Halogenase_fw cagccaggatccgaattcgagctcgATGTCCAATAACACCATCTCTAC 
11 Wi-WelO15_pRSF_rv CAGCGGTGGCAGCAGCCTAGGTTAATcaactccagtaataaatcttat 
12 WelO16_fw cagccaggatccgaattcgagctcgATGTTCTCACAATTAAAGCAACCAG 
13 WelO17_fw cagccaggatccgaattcgagctcgATGACTACTGCACACTACGATTTAATC 
14 WelO18_fw cagccaggatccgaattcgagctcgATGCGTAAGTTCTACTATTATTCAACC 
15 WelO19_fw cagccaggatccgaattcgagctcgATGGTTAATGTTGAAAAGAGCGTAG 
16 Hw-WelO11_rv cagcggtggcagcagcctaggttaaTCATGGTATCGAAGATTGGTTTATC 
17 Wi-WelO11_rv cagcggtggcagcagcctaggttaaTTACTGTGCTTTAGCAACCCAAC 
18 WelO12_rv cagcggtggcagcagcctaggttaaTTACTGTGCCTTATTAACCCAAC 
19 WelO13_rv cagcggtggcagcagcctaggttaaTTATTTGTTTGACTGTGCCTTATTAAC 
20 WelO14_rv cagcggtggcagcagcctaggttaaTTACTGTGCTTTATTAACCCAACTTTG 
21 WelO15_Amb05_rv cagcggtggcagcagcctaggttaaTCAACTCCAGTAATAAATCTTATCACG 
22 WelO16_rv cagcggtggcagcagcctaggttaaTCAAGAAATTAAATGTGCGGTTGTC 
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23 WelO17_rv 
cagcggtggcagcagcctaggttaaTTAA-
GCCATACGTCCAATTAAATG 
24 WelO18_rv 
cagcggtggcagcagcctaggttaaCTAAGTTGTTTTACTT-
GTAGACTGTG 
25 WelO19_rv cagcggtggcagcagcctaggttaaTTACTGTGCCTTATCAACCCAAT 
26 Hw-WelO15_frameshiftrepair_fw  GTAATAAGATTTATTACTGGAGTTAATTAACCTAGG 
27 Hw-WelO15_frameshiftrepair_rv CCAGTAATAAATCTTATTACGCTCTTTAGAG 
28 WelO11_IC_rep_f GTTCAATAAATGGGCAACTTATTGTTGG 
29 WelO11_IC_rep_rv GTTGCCCATTTATTGAACATAATTAAAACTTGC 
30 HpI1_pRSF_f cagccaggatccgaattcgagctcgATGATCAGCGAGAAAATCCTGC 
31 HpI1_pRSF_rv cagcggtggcagcagcctaggttaaTTATGACTTGTTGtCGAAGGTGAC 
32 HpI3_pRSF_f cagccaggatccgaattcgagctcgATGATGGTTAGCACGAGCGTAG 
33 HpI3_pRSF_rv cagcggtggcagcagcctaggTTAATTACAGAATGTGCACACGCTGC 
 primer for mutagenesis  
34 WelO15_epPCR_1_f GCGATACTATGGAGCAAGTAGCC 
35 WelO15_epPCR_2_f CTTTCTGAATTGCCAGTAGAAATTCCC 
36 WelO15_epPCR_3_rv TAGGTTTGCCCTTCTGGTCC 
37 Wi-WelO15_A82_NNK_f CAAAGTGNNKCAAATATATGGTCATGCAATTGTCG 
38 Wi-WelO15_A82_NNK_r GCATGACCATATATTTGMNNCACTTTAGTACCAAATTC 
39 Wi-WelO15_I84_NNK_f GTGGCTCAANNKTATGGTCATGCAATTGTCGG 
40 Wi-WelO15_I84_NNK_r GGCATGACCATAMNNTTGAGCCACTTTGGTACC 
41 Wi-WelO15_A82SAM_I84SAM_f CCAAAGTGSAMCAASAMTATGGTCATGCAATTGTCG 
42 Wi-WelO15_A82SAM_I84SAM_r GGCATGACCATAKTSTTGKTSCACTTTAGTACCAAATTC 
43 Wi-WelO15_A82SAM_I84ANC_f CCAAAGTGSAMCAAANCTATGGTCATGCAATTGTCG 
44 Wi-WelO15_A82SAM_I84ANC_r GGCATGACCATAGNTTTGKTSCACTTTAGTACCAAATTC 
45 Wi-WelO15_A82DYG_I84SAM_f CCAAAGTGDYGCAASAMTATGGTCATGCAATTGTCG 
46 Wi-WelO15_A82DYG_I84SAM_r GGCATGACCATAKTSTTGCRHCACTTTAGTACCAAATTC 
47 Wi-WelO15_A82DYG_I84ANC_f CCAAAGTGDYGCAAANCTATGGTCATGCAATTGTCG 
48 Wi-WelO15_A82DYG_I84ANC_r GGCATGACCATAGNTTTGCRHCACTTTAGTACCAAATTC 
49 Wi-WelO15_A82AWC_I84SAM_f CCAAAGTGAWCCAASAMTATGGTCATGCAATTGTCG 
50 Wi-WelO15_A82AWC_I84SAM_r GGCATGACCATAKTSTTGGWTCACTTTAGTACCAAATTC 
51 Wi-WelO15_A82AWC_I84ANC_f CCAAAGTGAWCCAAANCTATGGTCATGCAATTGTCG 
52 Wi-WelO15_A82AWC_I84ANC_r GGCATGACCATAGNTTTGGWTCACTTTAGTACCAAATTC 
53 Wi-WelO15_A82TTC_I84SAM_f CCAAAGTGTTCCAASAMTATGGTCATGCAATTGTCG 
54 Wi-WelO15_A82TTC_I84SAM_r GGCATGACCATAKTSTTGGAACACTTTAGTACCAAATTC 
55 Wi-WelO15_A82TTC_I84ANC_f CCAAAGTGTTCCAAANCTATGGTCATGCAATTGTCG 
56 Wi-WelO15_A82TTC_I84ANC_r GGCATGACCATAGNTTTGGAACACTTTAGTACCAAATTC 
57 Wi-WelO15_A82F_f CAAAGTGTTCCAAATATATGGTCATGCAATTGTCG 
58 Wi-WelO15_A82F_r GCATGACCATATATTTGGAACACTTTAGTACCAAATTC 
59 Wi-WelO15_F77NNK_f GAAGAANNKGGTACCAAAGTG 
60 Wi-WelO15_F77NNK_r GGTACCMNNTTCTTCATTCTTATTAAG 
61 Wi-WelO15_V90NNK_f GCCATTNNKGGTCAATCACCC 
62 Wi-WelO15_V90NNK_r GATTGACCMNNAATGGCATGACC 
63 Wi-WelO15_N74NNK_f CTTAATAAGNNKGAAGAATTTGGTACCAAAG 
64 Wi-WelO15_N74NNK_rv CAAATTCTTCATTCTTMNNAAGAATTGATTTCATAC 
65 Wi-WelO15_F169NNK_f GGCAATGANNKCCTGTTAATGCCTGC 
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66 Wi-WelO15_F169NNK_rv GCATTAACAGGMNNTCATTGCCAACATGG 
67 Wi-WelO15_M221NNK_f GCAAATATGCTCAANNKCAGGAATATATGGATG 
68 Wi-WelO15_M221NNK_rv ATTCCTGCATTTGAGMNNATTTGCTTGC 
69 Wi-WelO15_M225NNK_f CAGGAATATNNKGATGATGTAGAGTCCAAG 
70 Wi-WelO15_M225NNK_rv CTCTACATCATCMNNATATTCCTGCATTTG 
71 Wi-WelO15_N74NNK_2_f 
CAATTCTTAATAAGNNKGAAGAGTTTGGTAC-
CAAAGTGGCTC 
72 Wi-WelO15_N74NNK_2_rv 
GTACCAAACTCTTCMNNCTTATTAAGAATTGAT-
TTCATACCACCGTC 
73 Wi-WelO15_F169NNK_2_f GGCAATGATNNKCTGTTAATGCCTGCGG 
74 Wi-WelO15_F169NNK_2_rv GGCATTAACAGMNNATCATTGCCAACATGGAC 
75 Wi-WelO15_I84ABC_A88ARC_V90RTG_f 
CAAABCTATGGTCATARCATTRT-
GGGTCAATCACCCGATCTCAAAGACTAC 
76 Wi-WelO15_V91BTT_A82GYG_I84ABC_r 
ATGACCATAGVTTTGCRCAAVTTTGGTAC-
CAAATTCTTCATTCTTATTAAG 
77 Wi-WelO15_I84ABC_A88GYG_V90RTG_f 
CAAABCTATGGTCATGYGATTRT-
GGGTCAATCACCCGATCTCAAAGACTAC 
78 Wi-WelO15_I84ABC_A88ARC_V90CMG_f 
CAAABC-
TATGGTCATARCATTCMGGGTCAATCACCC 
GATCTCAAAGACTAC 
79 Wi-WelO15_I84ABC_A88GYG_V90CMG_f 
CAAABCTATGGTCATGYGAT-
TCMGGGTCAATCACCCGATCTCAAAGACTAC 
80 Wi-WelO15_V91BTT_A82AWG_I84ABC_r 
ATGACCATAGVTTTGCWTAAVTTTGGTAC-
CAAATTCTTCATTCTTATTAAG 
81 Wi-WelO15_V91AMC_A82AWG_I84ABC_
r 
ATGACCATAGVTTTGCWTGKTTTTGGTAC-
CAAATTCTTCATTCTTATTAAG 
82 Wi-WelO15_V91AMC_A82GYG_I84ABC_r 
ATGACCATAGVTTTGCRCGKTTTTGGTAC-
CAAATTCTTCATTCTTATTAAG 
83 Wi-WelO15_N74R_rv 
GGTACCAAACTCTTCCCGCTTATTAAGAATTGAT-
TTCATACC 
84 Wi-WelO15_I84A88V90P_fw 
CAAABCTATGGTCATNN-
KATTCCGGGTCAATCACCCGATCTCAAAGACTAC 
85 Wi-WelO15_G166D_fw 
GCGAAATCGCAGTCCATGTTGATAATGAT-
TTCCTGTTAATGCC 
86 Wi-WelO15_G166D_rv 
GGCATTAACAG-
GAAATCATTATCAACATGGACTGCGATTTCGC 
87 WelO15_V90P_fw 
CAAATATATGGTCATGCAATTCCGGGTCAATCACC
C 
88 WelO15_A82L_rv 
ATGACCATATATTTGCAACACTTTGGTAC-
CAAATTCTTCATTC 
89 Wi-WelO15_M221L_M225I_rv 
GGACTCTACATCATCTATATATTCCTGTAATTGAG-
CATATTTGC 
90 Wi-WelO15_N74ARC_fw CTTAATAAGARCGAAGAATTTGGTACCAAAG 
91 Wi-WelO15_N74CRG_rv CAAATTCTTCCYGCTTATTAAGAATTGATTTCATAC 
92 Wi-WelO15_S103VAC_fw CTTTGCTTCTVACGCAATCTTCCGGCAGG 
93 Wi-WelO15_S103KYG_fw CTTTGCTTCTKYGGCAATCTTCCGGCAGG 
94 Wi-WelO15_S93VAC_fw GGTCAAVACCCCGATCTCAAAGACTACTTTGC 
95 Wi-WelO15_S93KYG_fw GGTCAAKYGCCCGATCTCAAAGACTACTTTGC 
96 Wi-WelO15_A175KYG_rv CAGATGGTTCRMCGCAGGCATTAACAGG 
97 Wi-WelO15_A175VAC_rv CAGATGGTTGTBCGCAGGCATTAACAGG 
98 Wi-WelO15_S103A_fw CTTTGCTTCTGCGGCAATCTTCCGGCAGG 
99 Wi-WelO15_Q123R_fw GATTTTGAGGAACGTGTAGAGTCAATATTTCAC 
100 Wi-WelO15_S230K_rv GACTTAATCTTTTTCTCTACATCATCC 
 Material  
 
122 
101 Wi-WelO15_S230K-Q236N-S239W_fw 
GATGATGTAGAGAAAAAGAT-
TAAGTCTAACAACTCTCAGTGGGTAGCTTATGC 
102 Wi-WelO15_S268R_rv CAATGGTTCGCCGTGGACGATTACCAATTA C 
103 Wi-WelO15_Q282D_rv 
CAGTAATAAATCTTATTACGATCTTTAGA-
GAAGGCTAAAAATCC 
104 Wi-WelO15_284D_rv CAGTAATAAATCTTATCACGCTGTTTA GAGAAGG 
105 P450BM3-L181-M185-L188-1_fw 
GTCCGTGCAVHGGATGAAGCAAR-
CAACAAGGBCCAGCGAGCAAATCCAG 
106 P450BM3-L181-M185-L188-2_fw 
GTCCGTGCAVHGGATGAAGCAARCAACAAGAAC-
CAGCGAGCAAATCCAG 
107 P450BM3-L181-M185-L188-3_fw 
GTCCGTGCAVHGGATGAAGCAARCAACAAGCTG-
CAGCGAGCAAATCCAG 
108 P450BM3-L181-M185-L188-4_rv 
GCTCGCTGCAGCTTGTTCATTGCTTCATCCDBTG-
CACGGACCATACTTG 
109 P450BM3-L181-M185-L188-5_rv 
GCTCGCTGGTTCTTGTTCATTGCTTCATCCDBTG-
CACGGACCATACTTG 
110 P450BM3-L181-M185-L188-6_rv 
GCTCGCTGGVCCTTGTTCATTGCTTCATCCDBTG-
CACGGACCATACTTG 
6.4 Programs and Online Tools 
The following programs and online tools have been used: 
Adobe Illustrator CC2015 
ApE v2.0.47 
BioEdit Version 7.2.5 
ChemOffice 2015: ChemDraw Professional 15.1 and Chem3D 15.1 
Chimera Version 1.11, 05.07.2016 
Discover Studio Visualizer v17.2.0.16349 
Expasy ProtParam (https://web.expasy.org/protparam/) 
Expasy Translate Tool (https://web.expasy.org/translate/) 
IDT Oligo Analyzer 3.1 (https://eu.idtdna.com/calc/analyzer) 
Mestrenova Version 9.0.1-13254 
Microsoft Office: Excel and Word 2010, Excel and Word 365 
Origin Version 8.5 Pro 
PROSS Server (http://pross.weizmann.ac.il/bin/steps) 
PyMol Version 0.99rc6, 2006 
SnapGeneViewer 3.2.1 
SwissDock (http://www.swissdock.ch/) 
SwissModel (https://swissmodel.expasy.org/) 
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6.5 Devices 
Shaker for cell cultures: 
• Infors HT Multitron shaker, 50 mm shaker throw, Modular equipped with angled 
holder for 96 dw-plates or for flasks 
• Infors Ecotron shaker, 25 mm shaker throw 
Liquid handling systems 
• Mettler Toledo, Liquidator96 (96-channel pipette. Preparation of glycerol stocks and 
inoculation of cell cultures 
• Tecan liquid handling system capable of pipetting water or organic solvents in 8- and 
96- channels, for high throughput screening. Extraction of reactions and transfer of or-
ganic phase to 96-well glass plates 
Sonicator: Bandelin Sonoplus HD 2070 with SGH 213G and TT13, 5x10cycles, 40% power 
Centrifuges 
• Thermo Sorvall RC 6 Plus, F21-8x50 at 16000 rpm, separate cell lysate components 
• Thermo Sorvall RC 6 Plus, F10s-6x500y at 5000 rpm, harvest cells after heterologous 
expression in flasks 
• Eppendorf 5810R at 4000 rpm, able to cool to 4 °C 
UV-Vis Photometer: JASCO V650, (equipped with water bath Julabo, PAC-743 Peltier cell 
changer, temperature controller) 
FPLC: Amersham Bioscience Äkta (Monitor UPC900 and pump P920, column: column body 
and material for Ni-NTA and Talon purification, GE Healthcare Hiload 26/60 Superdex) 
GC: Agilent 7890B and 7820A GC-FID,  
HPLC: Shimadzu Prominence LC-2030C capable for high throughput screening 
LC-MS: Agilent 1200 HPLC coupled with Agilent 6120 Quadrupole MS system  
Preparative HPLC: Gilson HPLC equipped with Macherey-Nagel Nucleodur C18 HTec 
250/16, 5µm 
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6.6 Chemicals 
All chemicals were purchased in the highest available purity. In table 27, some selected chem-
icals for biotransformation and synthesis are listed, all others can be found in the cataster of 
the Hoebenreich group. 
Table 27. List of selected chemicals used for synthesis and  
chemical producer purity 
-ketoglutarate disodium dihydrate Alfa Aesar 99% 
(NH4)2Fe(SO4)2 · 6H2O Bernd Kraft reinst 
L(+) ascorbic acid AppliChem BioChemica 
Dithioreithol Carl Roth ≥99% 
Lysozym AppliChem BioChemica 
NADP+ sodium AppliChem BioChemica 
Glucose Dehydrogenase self prepared  
HEPES Carl Roth ≥99.5% 
NaCl ChemSolute ≥99% 
dipotassiumhydrogenphosphate  
trihydrate 
Merck  
potassiumdihydrogenphosphate ChemSolute ≥99.5% 
LHMDS 1M in THF Sigma Aldrich  
MeI Alfa Aesar 99% stabilized with copper 
(S)-Carvone Sigma Aldrich ≥96% 
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7. Methods 
In this chapter, all methods are described. The chapter is subdivided in biological experiments 
(ch. 7.1), biotransformation (ch. 7.2), preparative scale biotransformation (ch. 7.3), chemical 
synthesis (ch. 7.4) and analytical methods (ch. 7.5). 
7.1 Biological Experiments 
Polymerase chain reactions (PCR) were performed in a Mastercycler Gradient of Eppendorf. 
Genes were sequenced using primer T7-1 and pRSF_rv (table 26) by GATC. For all experi-
ments, water of micro pure grade (conductivity 0.055 µS/cm MicroPure system of TKA) was 
used. To purify plasmid DNA, GeneElute Plasmid Miniprep kit (PLN350) purchased from 
Sigma Aldrich was used. To purify smaller fragments as genes or PCR products, GeneElute 
PCR purification kit (NA1020) purchased from Sigma Aldrich was used. 
7.1.1 Cloning with Polymerase Chain Reaction 
7.1.1.1 Polymerase Chain Reaction[434] 
Polymerase chain reaction describes the in vitro amplification of DNA with the help of puri-
fied DNA polymerase. Its discovery in 1968 was a milestone in establishing molecular biology 
research. All cloning and most mutagenic methods base on polymerase chain reaction.  
7.1.1.2 Amplification of Genes 
Amplification of genes was performed by mixing 80-100 ng template (2 µL genomic DNA, 
50 ng/µL) with 1 U KOD-polymerase (Novagen), 1xKOD-buffer, 1.5 mM MgSO4, 0.3 µM pri-
mer (forward and reverse), 0.2 mM dNTPs in a total volume of 50 µL. Hotstart PCR was per-
formed by initial denaturation at 95 °C for 3 min, followed by 30 cycles of 95 °C for 25 s, 53 °C 
for 30 s and 72 °C for 90 s and final extension at 72 °C for 10 min. 
Before usage in restriction-free cloning, the PCR product was purified by GeneElute PCR pu-
rification kit purchased from Sigma Aldrich (NA1020) following the given instructions except 
final elution with 35 µL H2O instead of elution buffer. DNA concentration was measured by 
absorption (Eppendorf Biophotometer). A yield of 55-170 ng/µL was obtained. 
7.1.1.3 Restriction-Free Cloning[327] 
Restriction-free cloning (rf-cloning) was performed by using 100 ng gene (purified PCR prod-
uct), 20 ng vector (pRSF-Duet), 1x HF buffer, 1 µL Phusion polymerase (self-produced without 
determination of U/µL), 0.2 mM dNTPs in a total volume of 50 µL. The PCR reaction was 
started by initial heating to 98 °C for 30 s, followed by 18 cycles of 98 °C for 25s and 72 °C for 
5.5 min. A final elongation time of 10 min was used. The PCR mix was digested with DpnI, 
dialyzed (ch. 7.1.4) and 50 µL electro competent E. coli BL21-Gold(DE3) cells were transformed 
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with 2 µL DNA and plated on LB-agar. To confirm the insertion of the gene, colony PCR was 
performed. In  
table 36 all cloned genes with errors and silent mutations are given.  
7.1.1.4 Colony PCR 
For colony PCR, some cell material (taken off with 10 µL pipette tip) was suspended in 20 µL 
H2O. 5 µL of the cell suspension were mixed with 0.2 mM dNTPs, 1x reaction buffer (Thermo-
Pol or HF buffer), 2.5 U polymerase Taq or Phusion Polymerase, 0.3 µM primer flanking the 
inserted gene (reverse and forward), 1.5 mM MgSO4 and water to a total volume of 50 µL. PCR 
was performed with an initial denaturation at 95 °C for 3 min, followed by 25 cycles of 95 °C 
for 25 s, 53 °C for 30 s and 72 °C for 90 s. A final elongation time of 10 min at 72 °C was used. 
The PCR was analyzed by agarose gel electrophoresis (1% agar in TAE buffer, stained with 
3 µL/100 mL midori green). If the gel confirmed gene incorporation, LB medium was inocu-
lated with the remaining water-cell mixture and grown overnight. The preculture was used 
for plasmid preparation according to the manufacturer’s instruction (GeneElute Plasmid Min-
iprep kit, Sigma Aldrich PLN350), using 70 µL H2O for final elution and send for sequencing. 
7.1.2 Mutagenesis with Polymerase Chain Reaction  
Primers were created with SnapGene Viewer. Degeneration and tailor-made mixture of co-
dons were designed using DC_Analyzer[370] and purchased in desalted quality from Sigma 
Aldrich. Quick Quality Control (QQC)[306] was performed to assess obtained degeneracy after 
PCR and transformation. If the degeneracy was not satisfying in the first attempt, a second 
round of PCR was performed using the plasmid pool resulting from the first PCR as template 
for the second PCR. For all experiments with Wi-WelO15, template Wi-welO15 V6I/D284N 
(Wi-0) was used, containing two mutations from cloning. 
7.1.2.1 QuikChange[369] 
For QuikChange PCR, two mutagenesis primer are designed which have a partially overlap-
ping part. In the PCR, the whole plasmid is amplified, and the mutation introduced through 
the primer. The overlapping part can recombine homologue and E. coli BL21-Gold(DE3) are 
transformed with the plasmid (still with nicks). E. coli enzymes ligate the plasmid after trans-
formation. 
7.1.2.2 Repair of Frame Shift Mutation in Hw-WelO15 
The reaction was performed by mixing 0.5 ng/µL plasmid DNA, with 1 U KOD Hot-start pol-
ymerase, 1xKOD-buffer, 2 mM MgSO4, 0.3 µM primer 26 and 27, 0.2 mM dNTPs in a total vol-
ume of 25 µL. The reaction was initialized by a 2 min heating at 95 °C, followed by 25 cycles 
of 95 °C for 20 s, 56 °C for 10 s and 70 °C for 5.50 min followed by a final elongation at 70 °C 
for 10 min. The PCR mixture was digested with DpnI by adding 1 µL of DpnI (20 U) into the 
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PCR mix. The mixture was incubated at 37 °C for 2 h, dialyzed against H2O for 30 min at rt. 
2 µL were transformed with 50 µL of electrocompetent cells and plated on LB-agar. 
7.1.2.3 Error Prone PCR[284,362,435,436] 
The mutation was performed by two PCR steps. In the first PCR, the gene was mutated by 
error prone PCR (epPCR). The PCR product was digested with DpnI to remove the template 
gene, followed by PCR purification (Sigma Aldrich kit). In a second PCR, the mutated gene 
was used as megaprimer to amplify the remaining plasmid. The PCR conditions were adapted 
depending on the number of mutations that should be incorporated which is dependent on 
the length of the DNA strain. Therefore, different conditions were chosen for the two parts. In 
the following, mutation of both parts is described. 
Error Prone PCR: Mutation of the Lid Region  
This part of the gene is 297 bp long. To achieve an average of 2-3 mutations per gene, 15 rounds 
of amplification will be performed. To get sufficient DNA for further steps, in total 8 reactions 
were prepared as master mix and divided in 50 µL per vial. 20 pg/µL template DNA(pRSF-
Duet containing Hw-WelO15 (1 µL with 1 ng/µL) was mixed with 1x Thermopol buffer (NEB), 
2 µM primer 34 (20 µM) and 2 µM primer 36 (20 µM), 0.5 mM MnCl2 (25mM stock solution, 
self-prepared) and 7 mM MgSO4 (25 mM stock solution, Novagen). 1 µL 10 mM dNTPs was 
added, for a final concentration of 0.2 mM dATP and dGTP. To reach a final concentration of 
1 mM dCTP and dTTP, 1.6 µL of a 25 mM solution of each dCTP and dTTP (Carl Roth) was 
added. 18.3 µL H2O and 0.05 U/µL Taq polymerase were added to reach the final volume of 
50 µL. The reaction was performed by initial denaturation at 95 °C for 30 s followed by 15 
cycles of 95 °C for 15 s, 57°C for 30 s and 68 °C for 25 s. A final elongation of 10 min at 68 °C 
was used. 
To check if amplification occurred, an agarose gel (ch. 7.1.3) was run. Because of the low 
DNA concentration, 25 µL DNA sample were applied in one gel pocket. The template DNA 
was digested by adding 2 µL DpnI (NEB, 20 U/µL) to 375 µL PCR product, coming from 8 PCR 
and incubated for 2.5 h at 37°C. After that purification of the DNA fragment was performed 
(PCR purification kit from Sigma Aldrich). Elution with 35 µL H2O yielded a DNA concentra-
tion of 16 ng/µL. The mutated gene was used in the following step as megaprimer.  
Megaprimer PCR was prepared by mixing 1x HF buffer (NEB), 0.2 mM dNTPs each, either 
0.5 mM betaine or 10% DMSO, 30 ng megaprimer (16 ng/µL), 1 ng/µL plasmid pRSF-Duet con-
taining Hw-WelO15, 0.5 mM MgSO4, 1 µL Phusion Polymerase and 8.1 µL H2O to a final vol-
ume of 25 µL. Hotstart PCR was performed by initial denaturation at 98 °C for 30 s, followed 
by 25 cycles of 98°C for 25 s and 72 °C for 10 min. The reaction was finished by a final elonga-
tion of 10 min at 72 °C. The product was digested by DpnI, dialyzed and 50 µL E. coli BL21-
Gold(DE3) were transformed with 3 µL DNA. After electroporation, cells were diluted with 
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1 mL LB-medium. After incubation for 1 h at 37°C, 300 µL medium with cells were plated on 
a big agar plate. 
Error Prone PCR: Mutation of the Active Site Region 
This part of the gene is 483 bp long. Originally only 2-3 bases should be mutated. Therefore 
only 8 amplification steps should have been used. Since no results were obtained by this trial, 
the amplification steps were increased to 13 which increases also the number of theoretical 
mutations. To get sufficient DNA for further steps, in total 10 reactions were prepared as mas-
ter mix and divided in 50 µL per vial. 
20 pg/µL template DNA (1 µL with 1 ng/µL) was mixed with 1x Thermopol buffer (NEB) 
and 2 µM primer 35 and 21 (table 26) (20 µM stock solution). 0.5 mM MnCl2 (25 mM stock 
solution, self-prepared) and 7 mM MgSO4 (25 mM stock solution from Novagen). 1 µL of a 
10 mM dNTPs solution was added, for a final concentration of 0.2 mM dATP and dGTP. To 
reach a final concentration of 1 mM dCTP and dTTP, 1.6 µL of a 25 mM solution of each dCTP 
and dTTP (Carl Roth) were added. 18.3 µL H2O were added and the initial denaturation was 
performed without polymerase for 2 min at 95 °C. Then 0.05 U/µL Taq polymerase (5 U/µL) 
was added and the reaction performed with 13 cycles of 95 °C for 20 s followed by 30 s at 53°C 
and 3 min at 68 °C. A final elongation of 10 min at 68 °C was used. 
10x50 µL PCR product were combined and purified via PCR purification kit from Sigma 
Aldrich and eluted in the last purification step with 30 µl H2O. The sample was digested by 
adding 4 µL CutSmart buffer (10x, NEB), 0.25 µL DpnI (20U/µL) and 5 µL H2O. After diges-
tion, it was purified again via purification kit, resulting in 33 µL with 31 ng/µL. The mutated 
gene was further used as megaprimer to amplify the complete plasmid. 
Megaprimer PCR was prepared by mixing 1x HF buffer (NEB), 0.2 mM dNTPs each, either 
0.5 mM betaine or 10% DMSO, 31 ng megaprimer (31 ng/µL), 1 ng/µL plasmid DNA, 0.5 mM 
MgSO4, 1 µL Phusion Polymerase and 8.75 µL H2O to a final volume of 25 µL. Hotstart PCR 
was performed by initial denaturation at 98 °C for 2 min, followed by 25 cycles of 98°C for 30 s 
and 72 °C for 12 min. The reaction was finished by a final elongation of 10 min at 72 °C. The 
product was digested by DpnI, dialyzed and 50 µL E. coli BL21-Gold(DE3) competent cells 
transformed with 3 µL. After electroporation, cells were diluted with 1 mL LB-medium. After 
incubation for 1 h at 37°C, 300 µL medium with cells were plated on a big agar plate. For fur-
ther steps, the sample with betaine was used. 
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7.1.2.4 Structure Guided Mutagenesis 
In the following the PCR conditions for each library are given. Codons in italic represent DNA 
bases, while single letter codes represent amino acids e.g. V90NNK (DNA bases) and V90P 
(amino acid). Sequencing results from quick quality control are shown in chapter 0. 
For all PCRs a standard protocol was used, 95 °C, 2 min initial denaturation followed by 
25 cycles 95 °C, 30 s; annealing time and temperature were individually chosen and are de-
scribed in the following paragraphs, 9 min 70°C and a final elongation of 10 min at 70°C. 
7.1.2.5 1st Generation: Hot Spot Identification 
N74NNK: Primers 71 and 72 were used. An annealing time of 60 s was used in combination 
with Tannealing=63.3 °C and 0.5 M betaine. A second PCR round was performed using the result-
ing plasmid pool of the first PCR as template. Here an annealing time of 60 s was used in 
combination of Tannealing=63.3 °C and 0.25 M betaine. 
F77NNK: Primers 59 and 60 were used. The best degeneration gave 1 M betaine with Tanneal-
ing=47.8 °C and an annealing time of 45 s. 
A82NNK: Primers 37 and 38 were used. The first PCR was performed with 0.5 M betaine and 
58.9 °C annealing temperature, 30 s annealing time. A second round of PCR was performed 
using the resulting plasmid pool of the first PCR. 0.25 M betaine with an annealing tempera-
ture of 58.9 °C (A82NNK-1) and 1 M betaine with an annealing temperature 60.5 °C (A82NNK-
2) gave best results. Colonies from both libraries were screened. 
I84NNK: Primers 39 and 40 were used. The first PCR was performed with 0.5 M betaine, 
63.7 °C annealing temperature and 30 s annealing time. Since the degeneracy was not satisfy-
ing, a second round of PCR was performed using the resulting plasmid pool of the first PCR. 
The best results gave 0.25 M betaine in combination with Tannealing=62.2 °C. 
V90NNK: Primers 61 and 62 were used. The best degeneration gave 0.5 M betaine with Tanneal-
ing=54 °C and an annealing time of 45 s was used. 
F169NNK: Primers 73 and 74 and an annealing time of 45 s were used. The best degeneration 
gave 0.5 M betaine with Tannealing=63.3 °. 
M221NNK: Primers 67 and 68 with an annealing time of 45 s were used. Betaine concentration 
of 0.5 M were combined with 55.1 °C in a first PCR and in a second PCR a temperature range 
of 53.2-55.0 °C was tested with 0.25-1.0 M betaine. However, no degeneration could be 
achieved. If this library should be created, new primer should be designed.  
M225NNK: Primers 69 and 70 and an annealing time of 45 s were used. The best degeneration 
gave 0.5 M betaine with Tannealing=53.5 °. A second round of PCR was performed using the re-
sulting plasmid pool of the first PCR. Here 0.5 M betaine, 55.1 °C annealing temperature and 
45 s annealing time were used. 
A82_/I84_: The following selected amino acids were chosen to be incorporated. For A82: D, Q, 
E, H, N, I, F A, L, M, S, T, V. For I84: D, Q, E, H, N, I, S, T. To achieve this tailor-made set of 
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amino acids with minimal redundancy, the DC_Analyzer[370] was used, resulting in codons 
AWC, DYG, SAM for position A82 and SAM, ANC for position I84. Mixing all primers and 
performing a single PCR resulted in poor degeneracy, leading to 8 separately optimized 
libraries as given below. Using an annealing time of 30 s, annealing temperature of 62.2 °C and 
0.5 M betaine. A second round of PCR was prepared with individually chosen parameters. 
A82AWC/ I84SAM: Primers 49 and 50 were used. In the second PCR round, the annealing time 
was elongated to 60 s and an annealing temperature of 62.2 °C used. 
A82AWC/I84ANC Primers 51 and 52 were used. In the second PCR round, a betaine concen-
tration of 1 M and an annealing temperature of 61.5 °C was used. 
A82DYG/I84SAM: Primers 45 and 46 were used. In the second PCR round, the annealing time 
was elongated to 60 s and an annealing temperature of 62.2 °C used. 
A82DYG/I84ANC: Primers 47 and 48 were used. In the second PCR round, an annealing tem-
perature of 61.5 °C and 0.25 M betaine were used. 
A82SAM/I84SAM: Primers 41 and 42 were used. In the second PCR round, the annealing time 
was elongated to 60 s and an annealing temperature of 62.2 °C used. 
A82SAM/I84ANC: With primers 43 and 44 the degeneration of I84ANC worked bad. Therefore, 
the plasmid pool from A82DYG/I84ANC was used as template where I84ANC was incorpo-
rated quite good. Based on this template, primer 29 and 30 were used for amplification in 
combination with 0.5 M betaine and annealing temperature of 62.1°C and an annealing time 
of 30 s. 
A82F: Since the degeneration of A82F/I84ANC and A82F/I84SAM worked badly, A82F was 
created as single variant and the libraries were based on this template. For the creation of A82F, 
primers 57 and 58 were used with 0.5 M betaine, Tannealing=61°C and an annealing time of 30 s 
was used. 
A82F/I84ANC: As template Wi-welO15 V6I/A82F/D284N in combination with primers 55 and 
56 were used. A betaine concentration of 0.5 M, an annealing time of 30 s and an annealing 
temperature of 63.7 °C was used. 
A82F/I84SAM: As template Wi-welO15 V6I/A82F/D284N in combination with primers 53 and 
54 were used. A betaine concentration of 0.5 M, an annealing time of 30 s and an annealing 
temperature of 63.7 °C was used.  
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7.1.2.6 2nd Generation: Multi-Site Libraries 
A82L/V90NNK: As template Wi-welO15 V6I/A82L/D284N in combination with primer 61 and 
62 were used. 0.5 M betaine was used with an annealing temperature of 56 °C and 30 s anneal-
ing time. 
I84ABC/A88NNK/V90P: Mutagenesis with primers 21 and 84 was performed by Henrik Mül-
ler.[386]  
5-Residue-Site Library 
To mutate positions V81, A82, I84, A88 and V90 at the same time, a QuikChange PCR strategy 
was chosen (figure 30). To incorporate all designed amino acids alphabets, 8 primers had to be 
bought. Amplification was tested by using only one set of primers, giving slight degenerations 
in desired positions (plasmid pool 1). Based on this template, a second and third round of PCR 
was set with the combination of all 8 primers, so that a complete absence of wild–type template 
was ensured. QQC revealed absence of thymine in the 1st base of position 81 in pool indicating 
that Phe will be missing in the library. Similarly, a very low presence of adenine and guanine 
in the 2nd base of A88 was observed. Therefore, a fourth round of PCR was set on plasmid pool 
2 with primers especially encoding these missed bases, creating plasmid pool 4. Degeneration 
of all plasmid pools can be seen in figure 87. 
Standard PCR conditions were used with the following changes: either Wi-welO15 V6I/D284N 
in pRSF-Duet (PCR 1) or plasmid pools resulting from previous PCRs (PCR 2-4) were used as 
template, primers 75+76 were used for PCR 1, primers 75-82 for PCR 2 and 3 and primers 78+80 
for PCR 4, betaine PCR1: 0.5 M, PCR 2+3: 0.6 M, PCR4: 0.8 M. Annealing time was 45 s and 
individually optimized annealing temperatures were PCR1: 57.3 °C, PCR 2+3: 53.0 °C PCR4: 
51.6 °C. 100 µL E. coli DH5α competent cells were transformed with 2 µL PCR products and 
1 mL plated on agar plates prior to QQC. E. coli BL21-Gold(DE3) competent cells were trans-
formed with plasmid pools 2, 3 and 4 by mixing 1 µL DNA with 100 µL electro competent 
cells. After electro shock, the cell suspension was mixed with 2 mL prewarmed SOC medium. 
150 µL cell suspension was plated on freshly prepared LB-kan50 agar plate (15 g agar/L LB 
medium). Colonies for screening were picked from pools 2-4 in equal parts. 
7.1.2.7 3rd Generation: Addition of N74R and Scaffold Sampling 
N74R by Megaprimer PCR 
To incorporate the N74R mutation, a PCR was prepared using the standard protocol and pri-
mer 10 and 83. Hotstart PCR was performed by initial denaturation at 95 °C for 2 min, followed 
by production of the megaprimer within 10 cycles of 95 °C for 30 s, 64.2 °C for 20 s and 68 °C 
for 15 s, followed by amplification of the whole plasmid by further 25 cycles of 95°C for 30 s 
and 68 °C for 6.5 min. The reaction was finished by a final elongation of 10 min at 68 °C.  
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M221L/M225I by Megaprimer PCR 
The mutations M221L/M225I were introduced in Wi-0 and Wi-5 using primer 10 and 89. 
Megaprimer PCR was using the standard protocol with 0.5 M betain. Hotstart PCR was per-
formed by initial denaturation at 95 °C for 2 min, followed by production of the megaprimer 
within 11 cycles of 95 °C for 30 s, 60.0 °C for 30 s and 68 °C for 45 s, followed by amplification 
of the whole plasmid by further 25 cycles of 95 °C for 30 s and 68 °C for 5.5 min. The reaction 
was finished by a final elongation of 10 min at 68 °C.  
A82L/V90P by QuikChange PCR 
These mutations were introduced into Hw-WelO15. PCR was performed by mixing 0.2 ng/µL 
plasmid DNA (pRSF-Duet with Hw-welo15), 0.3 µM each primers 87 and 88, 1x KOD buffer, 
0.2 mM dNTPs each, 0.5 M betaine, 1.5 mM MgSO4, 1 U KOD Polymerase and 18 µL H2O to a 
total volume of 50 µL. Hotstart PCR was performed by initial denaturation at 95 °C for 2 min, 
followed by 25 cycles of 95 °C for 30 s, 62°C for 45 s and 68 °C for 5.5 min. The reaction was 
finished by a final elongation of 10 min at 68 °C. Successful incorporation of mutation was 
checked by sequencing. Hereby single mutants A82L, V90P and double mutant A82L/V90P 
were identified. 
7.1.2.8 4th Generation: Multi-Site Libraries on Wi-5 and Wi-8 
N74(NSQR)/S93(NHDASVL)/S103(NHDASVL)/A175(NHDASVL) on template 
Wi-WelO15 V6I/A82L/V90P/D284N (Wi-5) 
First the degeneration in position N74 was introduced by QuikChange PCR following stand-
ard protocol using primers 90 and 91 and 0.3 M betaine. The reaction was performed by incu-
bation at 95 °C for 2 min, followed by 30 cycles of 95 °C for 30 s, 56.1 °C for 30 s and 68 °C for 
6.5 min. The reaction was finished by a final elongation of 10 min at 68 °C. The product was 
digested by DpnI, dialyzed and transformed with E. coli BL21-Gold(DE3) cells. Successful 
incorporation of mutation was checked by QQC. Since degeneration was not satisfying, the 
same reaction was performed again but as template, the plasmid pool was used that was re-
ceived in the first PCR. Positions S93, S103, A175 were mutated by megaprimer PCR. The PCR 
consisted of 10 ng templateWi-WelO15 V6I/N74(NSQR)/A82L/V90P/D284N, 0.3 µM reverse 
primer (primer 96 and 97, 0.15 µM each) and 0.3 µM forward primer (primer 92-95, 0.075 µM 
each), 1x KOD buffer, 0.3 M betaine, 1.5 mM MgSO4, 0.2 mM dNTPs each and 1 U KOD hot 
start polymerase in a final volume of 50 µL. The mix was incubated for 2 min at 95 °C followed 
by 10 cycles of 95 °C for 30 s, 64.3 °C for 30 s and 68 °C for 30 s to produce the megaprimer. 
Followed by 25 cycles of 95 °C for 30 s and 68 °C for 6.5 min. The reaction was finished with a 
final elongation step for 10 min at 68 °C. The mix was digested with DpnI, dialyzed against 
H2O and transformed into E. coli BL21-Gold(DE3) cells. Since degeneration was not satisfying, 
the same reaction was performed again but as template, the obtained plasmid pool from this 
PCR was used. 
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S93(NHDASVL)/S103(NHDASVL)/A175(NHDASVL) on template Wi-WelO15 
N74R/V81T/A82M/A88V/V90P (Wi-8) 
Positions S93, S103, A175 were mutated by megaprimer PCR using the standard protocol with 
0.3 µM reverse primer 96 and 97 (0.15 µM, each) and 0.3 µM forward primer (primer 92-95, 
0.075 µM each), 0.3 M betaine. The mix was incubated for 2 min at 95 °C followed by 10 cycles 
of 95 °C for 30 s, 64.3 °C for 30 s and 68 °C for 30 s to produce the megaprimer. Followed by 25 
cycles of 95 °C for 30 s and 68 °C for 6.5 min. The reaction was finished with a final elongation 
step for 10 min at 68 °C. QQC revealed bad degeneracy, so the PCR was repeated using the 
plasmid pool from the first mutagenesis PCR as template for the second round.  
7.1.2.9 Single Mutants 
G116D Mutants by Megaprimer PCR 
To incorporate mutation G166D, the PCR was prepared by mixing 1x KOD buffer, 0.2 mM 
dNTPs each, 0.5 M betaine, 0.3 µM primers 10 and 86, 0.2 ng/µL plasmid DNA, 1.5 mM 
MgSO4, 1 U KOD Polymerase and 18 µL H2O. Hotstart PCR was performed by initial denatur-
ation at 95 °C for 2 min, followed by production of the megaprimer within 11 cycles of 95 °C 
for 30 s, 64.2 °C for 20 s and 68 °C for 30 s, and amplification of the whole plasmid by further 
25 cycles of 95°C for 30 s and 68 °C for 5.5 min. The reaction was finished by a final elongation 
of 10 min at 68 °C. The product was digested by DpnI, dialyzed and 50 µL E. coli BL21-
Gold(DE3) competent cells transformed with 2 µL digested PCR product 
284D by Megaprimer PCR 
The PCR was prepared by mixing 1x KOD buffer, 0.2 mM dNTPs each, 0.5 M betaine, 0.3 µM 
primers 10 and 104, 0.2 ng/µL plasmid DNA, 1.5 mM MgSO4, 1 U KOD Polymerase and 18 µL 
H2O. Hotstart PCR was performed by initial denaturation at 95 °C for 2 min, followed by pro-
duction of the megaprimer within 11 cycles of 95 °C for 30 s, 57.0 °C for 30 s and 68 °C for 60 s, 
followed by amplification of the whole plasmid by further 25 cycles of 95°C for 30 s and 68 °C 
for 6.5 min. The reaction was finished by a final elongation of 10 min at 68 °C. The product 
was digested by DpnI, dialyzed and 50 µL E. coli BL21-Gold(DE3) competent cells transformed 
with 2 µL digested PCR product. 
S103A by Megaprimer PCR 
The PCR was prepared by mixing 1x KOD buffer, 0.2 mM dNTPs each, 0.5 M betaine, 0.3 µM 
primers 21 and 98, 0.2 ng/µL plasmid DNA, 1.5 mM MgSO4, 1 U KOD Polymerase and 18 µL 
H2O. Hotstart PCR was performed by initial denaturation at 95 °C for 2 min, followed by pro-
duction of the megaprimer within 11 cycles of 95 °C for 30 s, 66.0 °C for 30 s and 68 °C for 45 s, 
followed by amplification of the whole plasmid by further 25 cycles of 95°C for 30 s and 68 °C 
for 6.5 min. The reaction was finished by a final elongation of 10 min at 68 °C. The product 
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was digested by DpnI, dialyzed and 50 µL E. coli BL21-Gold(DE3) competent cells transformed 
with 2 µL digested PCR product. 
S103A/Q123R/S230K by Megaprimer PCR 
The PCR was prepared by mixing 1x KOD buffer, 0.2 mM dNTPs each, 0.5 M betaine, 0.3 µM 
primers 99 and 100, 0.2 ng/µL plasmid DNA, 1.5 mM MgSO4, 1 U KOD Polymerase and 18 µL 
H2O. Hotstart PCR was performed by initial denaturation at 95 °C for 2 min, followed by pro-
duction of the megaprimer within 11 cycles of 95 °C for 30 s, 55.0 °C for 30 s and 68 °C for 30 s, 
followed by amplification of the whole plasmid by further 25 cycles of 95°C for 30 s and 68 °C 
for 6.5 min. The reaction was finished by a final elongation of 10 min at 68 °C. The product 
was digested by DpnI, dialyzed and transformed into E. coli BL21-Gold(DE3) cells. 
S103A/Q123R/S230K/Q236N/S239W/S268R/Q282D by Megaprimer PCR 
The PCR was prepared by mixing 1x KOD buffer, 0.2 mM dNTPs each, 0.5 M betaine, 0.3 µM 
primer 101, 0.15 µM primers 102 and 0.15 µM 103, 0.2 ng/µL plasmid DNA, 1.5 mM MgSO4, 
1 U KOD Polymerase and 18 µL H2O. Hotstart PCR was performed by initial denaturation at 
95 °C for 2 min, followed by production of the megaprimer within 11 cycles of 95 °C for 30 s, 
61.0 °C for 30 s and 68 °C for 15 s, followed by amplification of the whole plasmid by further 
25 cycles of 95°C for 30 s and 68 °C for 6.5 min. The reaction was finished by a final elongation 
of 10 min at 68 °C. The product was digested by DpnI, dialyzed and 50 µL E. coli BL21-
Gold(DE3) competent cells transformed with 2 µL digested PCR product. 
7.1.2.10 Mutagenesis of P450BM3 
The PCR was prepared by mixing 1x KOD buffer, 0.2 mM dNTPs each, 0.3 M betaine, 0.1 µM 
primers 105-110, 0.2 ng/µL plasmid DNA, 1.5 mM MgSO4, 1 U KOD Polymerase and 18 µL 
H2O. Hotstart PCR was performed by initial denaturation at 95 °C for 2 min, followed by 25 
cycles of 95°C for 30 s, 68.0 °C for 30 s and 68 °C for 11 min. The reaction was finished by a 
final elongation of 10 min at 68 °C. The product was digested by DpnI, dialyzed and 50 µL 
E. coli BL21-Gold(DE3) competent cells transformed with 2 µL digested PCR product. The 
three variants used for bigger scale reactions were sequenced with primers 2 and 4-6 to cover 
the whole gene. When sequencing variant P450BM3 R47V/F87G/L181T/L188N, the sequence in 
the range between 1640-1720 bp was missing (between primer 2 and 3), therefore another se-
quencing primer 7 was created and used to sequence this part of the gene. It was confirmed, 
that the gene is complete and without any mutations in comparison to its wild type. 
7.1.3 Agarose Gel Electrophoresis 
DNA fragments were separated by agarose gel electrophoresis. For the set-up, 1% agarose in 
tris acetate EDTA (TAE) buffer were heated up in the microwave until all agarose was solved. 
After cooling to about 60 °C, 3 µL/100 mL midori green was added which interacts with the 
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DNA and acts as dye. The agarose was poured into the form together with a comb to prepare 
pockets for the DNA sample.  
The DNA samples were mixed with 6x DNA sample buffer (NEB), an appropriate amount 
of DNA (at least ~20 ng) were loaded to the gel. As size standard, a DNA ladder was added to 
one pocket of the gel. A voltage of 120 V was applied until the run is finished. Progress of 
separation was checked under UV light. 
7.1.4 DpnI Digestion and Dialysis 
To remove template DNA, a DpnI digestion was performed. DpnI from NEB (20U/µL) was 
used by preparation of a master mix, due to high DpnI concentration. To check performance 
of DpnI and avoid high background during mutagenesis, DpnI controls were always per-
formed (one sample without polymerase in PCR). A master mix was prepared for digestion 
by mixing 5 µL CutSmart buffer, 0.75 µL H2O and 0.25 µL DpnI per sample. 5.75 µL of the 
master mix was added to each probe and incubated for at least 2 h at 37 °C. For the following 
electroporation the DNA must be desalted. Therefore, dialysis membranes with a pore size of 
0.05 µm type VMWP (Merck Millipore) were used. H2O was added into a petri dish and the 
membrane placed on top. The complete DNA sample was put on the membrane and dialyzed 
for 30 min at room temperature without lid. The DNA was taken into a new cup and electro-
poration performed. 
7.1.5 Electrotransformation 
By transformation, DNA such as plasmids can be inserted into cells. Since E. coli has no natural 
competence, the membrane has to be made permeable. Hereby electro transformation was 
used. For that it is necessary to use cells that are desalted (ch. 7.1.6). 
The transformation was performed by thawing a 50 µL aliquot of competent cells on ice 
and mixing it with 4 µl of the digested, library PCR product or 1 µL plasmid DNA (~100 ng). 
The mixture was transferred into a precooled electroporation cuvette with 2 mm gap (Peqlab). 
Then a MicroPulser electroporator (Bio-Rad) was used with the setting Ec2. The voltage dura-
tion is measured with an optimal value of about 5.8 ms. Afterwards 1 mL LB media was added, 
the cell suspension was put into 1.5 mL reaction tubes and the closed tube was incubated in a 
thermomixer at 700 rpm and 37 °C for one hour. Then the cells were centrifuged (1 min, 
10000 rpm, Eppendorf centrifuge 5418) and resuspended in 100 µl LB-medium. The suspen-
sion was plated on LB-agar-antibiotic plates and incubated overnight at 37 °C. For long time 
storage, the plates were kept at 4 °C. 
To reuse electro cuvettes, the cuvettes were washed immediately after usage with water 
and 70% EtOH twice. Before reuse, the cuvettes were stored overnight in water. After drying 
the cuvettes in a heating oven (70°C), they were incubated with 0.1 M H2SO4 for 10 min, the 
cuvettes were washed again with water and 70% EtOH twice. After drying at 70°C, they were 
closed and stored in a box until further use. 
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7.1.6 Preparation of Electrocompetent Cells[437] 
5 mL LB preculture of E. coli BL21-Gold(DE3) with 10 µM tetracycline were inoculated from a 
glycerol stock and incubated overnight at 37 °C, 200 rpm (Infors HT shaker). A 2 L baffled 
flask with 300 mL LB-Media was inoculated with 3 mL preculture and 10 µM tetracycline. The 
flask was incubated in the shaker with 200 rpm, 37 °C. When OD600 reached 0.4-0.6, the flask 
was cooled on ice for 30 min. Then the cell suspension was transferred into precooled 50 mL 
reaction tubes and centrifuged at 3500 rpm, 4 °C for 8 min. The supernatant was discarded, 
the pellets washed and resuspended in several steps, using 45, 25, 2 and 0.5 mL chilled 10 % 
glycerol. After every resuspension step, the cells were pelleted at 4 °C and 3500 rpm for 8 min. 
Finally, all cells were pooled together, centrifuged and resuspended in 1.7 mL 10% glycerol. 
The cells were aliquoted in 50 µL, shock frozen in liquid nitrogen and kept frozen at -80 °C 
until further usage. 
7.1.7 Plasmid Preparation 
The isolation of plasmids was performed using the plasmid preparation kit of Sigma Aldrich. 
Either a 5 mL culture is prepared and at least incubated for 8 h at 37 °C and the cells pelleted, 
or to control the quality of libraries, the colonies, grown on an agar plate were resuspended in 
water and pelleted. The pellets were prepared as described in the manual. Before eluting, the 
column was additionally dried at room temperature for 5 min and incubated for 2 min with 
the eluent (H2O), before centrifuging. The plasmid DNA from preculture is being eluted with 
70 µL water for pRSF-Duet vector, while the DNA prepared from plate only was eluted with 
35 µL. The procedure is checked by measuring concentration and absorption coefficients. A 
biophotometer of Eppendorf is used with cuvettes which are applicable in the UV range 
(Brand). A dilution of 70 µL solvent with 5 µL sample was prepared for concentration deter-
mination. First a blank measurement was performed for each cuvette with the 70 µL solvent 
before adding DNA and measuring concentration. 
7.1.8 Cultivation of Precultures and Preparation of Glycerol Stocks 
Precultures, used for inoculation of heterologous expression, starting material for plasmid 
preparation etc. were prepared in test tubes. 5 mL LB medium with antibiotics were filled in a 
tube and either a colony from plate or some cell material from a glycerol stock was scratched 
off with a sterilized toothpick and put in the test tube. The culture was incubated at 37 °C with 
200 rpm overnight (Infors HT shaker). For better oxygen transfer, tubes were attached in an 
inclined way if possible. Glycerol stocks were prepared by mixing 700 µL preculture with 
400 µL 80% glycerol (aq) and stored at -80 °C. 
For precultures in 2.2 mL squared 96 dw-plates (VWR), 900 µL LB-kan50 medium were pro-
vided in a plate. Single colonies from a LB-agar plate or material from glycerol stocks were 
picked with toothpicks, the plates sealed with a gas-permeable foil, attached in the shaker in 
an inclined way and cells grown overnight at 37 °C and 200 rpm (Infors HT shaker, equipped 
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with angled plate holders). Glycerol stocks of plates were prepared by mixing 50 µL 80% glyc-
erol (aq) with 100 µL preculture in 96 dw-plates (Nunc). The plate was sealed with belonging 
plastic lid and stored at -80 °C. 
7.1.9 Heterologous Expression for Enzyme Production 
7.1.9.1 WelO15 in Baffled Flasks 
Halogenase production was performed in 2 L flasks with 0.5 L LB medium. For smaller scale 
the ratio of flask and volume was kept constant. 
Heterologous expression was performed by inoculation of 0.5 L LB-kan50 media containing 
50 µM FeCl3 (from a 0.05 M stock in H2O) in a 2 L baffled flask with 5 mL of preculture. The 
culture was incubated at 37 °C, 200 rpm (Infors HT shaker) until an OD600 of 0.4 was reached. 
Then the temperature was shifted to 22 °C and IPTG (0.1 M in H2O) was added to a final con-
centration of 0.02 mM. Cells were grown overnight, harvested by centrifugation (5000 rpm, 
15 min, 4 °C) and resuspended either in Tris A buffer (100 mM, pH=7.4) for purification or in 
HEPES 2 buffer for biotransformations. The cell suspension was transferred into 50 mL plastic 
tubes and stored at -20 °C until further use. 
7.1.9.2 WelO15 Variants in 2.2 mL Squared Deep Well Plates 
Heterologous expression was performed by adding 100 µL preculture to 700 µL LB-kan50 with 
20 µM IPTG and 50 µM FeCl3 in a 2.2 mL dw-plate. The culture was grown at 37 °C, 200 rpm 
for 2 h followed by temperature reduction to 22 °C and incubation for additional 16 h. The 
plates were centrifuged at 4000 rpm and 4°C (5810R Eppendorf centrifuge) for 10 min. The 
supernatant was discarded, the plates sealed with plastic lids and frozen at -80°C. For longer 
storage the plates were moved to a -20 °C freezer. 
7.1.9.3 Heterologous Expression of WelP1, HpiI1 and HpiI3 
Heterologous expression was performed by N. Braun in analogy to ene-reductase TsER. 
315 mL TB-medium, 35 mL 10x phosphate buffer and 50 μg/mL kanamycin were filled into a 
2 L baffled flask. After adding 3.5 mL preculture the flask was incubated at 37 °C and 200 rpm 
until OD600 of 0.4 - 0.6. Then 35 μL IPTG (0.1 M) were added and the culture incubated further 
incubated at 22 °C and 200 rpm overnight. Next, harvest of the cells was accomplished by cen-
trifugation at 4 °C and 5000 rpm for 15 min. The cell pellets were resuspended in 5 mL KPi 
buffer (0.1 M, pH 7.4). 
It must be noted that HpiI1 and Hpi3 are FeII dependent and probably the presence of high 
phosphate concentration is not suitable to produce these enzymes, if enzyme production 
should be repeated, LB medium should be tested in parallel. 
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7.1.9.4 Heterologous Expression of Wi-WelO11-14 
Different expression conditions were tested in 100 mL flasks with 25 mL LB or TB medium. 
250 µL preculture was used to inoculate the medium, containing 50 µM FeCl3 and 50 µg/mL 
kan. The culture was incubated at 37 °C, 200 rpm (Infors HT shaker) until an OD600 of 0.4 was 
reached. Then the temperature was shifted to 30 °C or 23 °C and IPTG (0.1 M in H2O) was 
added to a final concentration of 0.015, 0.05, 0.1 or 0.5 mM. Cells were grown overnight, and 
1 mL harvested by centrifugation (14 000 rpm, 1 min, Eppendorf, 5418) and either resuspended 
with 4x SDS-PAGE sample buffer or lysed with HEPES 2 buffer containing 1 mg/mL lysozyme. 
The samples with lysis buffer were incubated for 37 °C for 30 min followed by centrifugation 
for 2 min at 14000 rpm, Eppendorf 5418 and the supernatant mixed with 4x SDS-PAGE sample 
buffer. The samples were further processed as described in chapter 7.1.11.  
Wi-WelO11 should further be produced with 0.5 mM IPTG at 30 °C and LB medium. Wi-
WelO12 should further be produced with 0.05 mM IPTG at 30 °C and LB medium. The tests 
should be repeated for Wi-WelO13 and 14 to get clear results. 
7.1.9.5 Expression of WelO16-WelO18 
Different expression conditions were tested in 250 mL flasks with 100 mL LB or TB medium. 
1 mL preculture was used to inoculate the medium, containing 50 µM FeCl3 and 50 µg/mL 
kan. The culture was incubated at 37 °C, 200 rpm (Infors HT shaker) until an OD600 of 0.4-0.6 
was reached. Then the temperature was shifted to 25 °C and IPTG (0.1 M in H2O) was added 
to a final concentration of 0.025 or 0.25 mM. Cells were grown overnight, and 1 mL harvested 
by centrifugation (14 000 rpm, 1 min, Eppendorf, 5418) and either resuspended with 4x SDS-
PAGE sample buffer or lysed with HEPES 2 buffer containing 1 mg/mL lysozyme. The sam-
ples with lysis buffer were incubated for 37 °C for 30 min followed by centrifugation for 2 min 
at 14000 rpm, Eppendorf 5418 and the supernatant mixed with 4x SDS-PAGE sample buffer. 
The samples were further processed as described in chapter 7.1.11. 
WelO16 and 17 should further be produced in LB medium, for WelO18 both media should 
be tested again. Also, the IPTG concentrations have to be tested again since no clear results 
were reported. 
7.1.9.6 TsER C25D/I67T 
Heterologous expression was performed by inoculation of 0.5 L TB-amp100 in a 2 L baffled flask 
with 5 mL preculture. The culture was incubated at 37 °C, 200 rpm (Infors HT shaker) until an 
OD600 of 0.4 was reached. Then the temperature was shifted to 22 °C and IPTG (0.1 M in H2O) 
was added to a final concentration of 0.01 mM. Cells were grown overnight, harvested by cen-
trifugation (5000 rpm, 15 min, 4 °C), resuspended in 5 mL potassium phosphate buffer 
(100 mM, pH=7.4), transferred into 50 mL plastic tubes and stored at -20 °C until further use.  
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7.1.9.7 P450BM3 Variants in 2.2 mL Squared Deep Well Plates 
The protocol according to Kille was used.[414] 800 µL LB-kan50 were provided in a 2.2 mL 
squared dw-plate. The medium was inoculated with existing glycerol stocks of the working 
group or with colonies picked from an agar plate. The dw plate was incubated overnight at 
37 °C, 200 rpm (Infors HT shaker, attached in an inclined way). Expression was performed by 
providing 700 µL LB-kan50-IPTG (final concentration 0.1 mM) with addition of 10 mL/L power 
mix, 1 mM MgCl2, 1 mL/L transition metal mix and 0.5% glucose. After inoculation with 
100 µL preculture, the plates were incubated for 8 h at 30 °C, centrifuged for 10 min at 
4000 rpm, 4 °C (5810R Eppendorf centrifuge) and frozen at -80 °C. 
7.1.9.8 P450 Variants in Baffled Flasks 
A preculture was prepared, the day before by inoculation of 25 mL LB-kan50 in a 100 mL baf-
fled Erlenmeyer flask with E. coli cells from glycerol stock or from agar plates. The culture was 
grown overnight at 37 °C, 200 rpm (Infors HT shaker).  
For expression, 1 L TB-medium was prepared with 40 µg/mL kanamycin, 10 mL preculture 
and the following additives: 10 mL power mix, 1 mM MgCl2, 1 mL transition metal mix and 
0.5% glucose. The cells were grown at 37 °C, 200 rpm (Infors HT shaker) to an OD600 of 0.8-1 
and IPTG (0.1 M in H2O) was added to a final concentration of 0.1 mM. The temperature was 
reduced to 25 °C and the culture incubated for 15 h. The cells were harvested by centrifugation 
(5000 rpm, 15 min, 4 °C), resuspended in 5 mL potassium phosphate buffer (100 mM, pH=7.4), 
transferred into 50 mL plastic tubes and stored at -20 °C until further use.  
7.1.10 Purification of Enzymes and Determination of Concentration 
7.1.10.1  WelO15 
The frozen cell suspension was defrosted in cold water and cells were lysed by sonication for 
6 min with 30 s pulses and 30 s rest. Because during sonification heat is generated, the suspen-
sion is put on ice water. The suspension was pelleted (16 000 rpm, 4 °C, 45 min) and the su-
pernatant filtered by syringe filter (0.45 µM pores, polyether sulfone, VWR). 
Purification was performed at 4 °C, with a 6 mL column (1CV=6 mL) Ni-NTA agarose (ar-
ticle nr 30210) purchased from Qiagen. The cleared lysate was loaded on the column with a 
10 mL loop and 100% buffer Tris A with a flow rate of 1 mL/min for the complete purification 
process. The loop was emptied with 25 mL Tris A buffer. If necessary, the process was re-
peated. Followed by a washing step of 12 CV with Tris A buffer. Then the protein was eluted 
by a gradient (0% to 100% buffer Tris B in 12 CV, delay 15 CV) and a final washing step of the 
column with 10 CV, 100% buffer B. The purity of proteins was checked by SDS-PAGE. The 
selected fractions were concentrated using 10 kDa concentrators of Merck Millipore. The pro-
tein solution was filled into the concentrators and centrifuged at 4 000 rpm for 6 min repeat-
edly with gentle mixing in between.  
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The protein solution was concentrated to about 30 mL and dialyzed overnight at 4°C 
against 2 L HEPES 1 buffer to remove imidazole, high sodium chloride concentration from 
Tris buffer as well as Ni2+ and Fe-ions which might be bound in the active site of the enzymes. 
Another dialyzing step of 4-5 h at 4 °C was performed against HEPES 2 buffer to remove 
EDTA. After concentrating the solution to about 10 mL, it was either aliquoted into 200 µL 
aliquots, shock frozen in N2 (l) and stored at -80 °C or further purified by size exclusion chro-
matography.  
The protein solution was concentrated to 1 mL and after preequilibrating the column with 
HEPES 2 buffer, the sample was loaded on a Superdex 26/60 (GE Healthcare) column from a 
1 mL loop. The sample was loaded to the column with a flow rate of 1 mL/min, then the flow 
rate was increased to 1.5 mL/min. The WelO5 enzymes eluted at 227 mL which corresponds 
to a monomeric state in HEPES buffer. The fractions were analyzed again by SDS-PAGE. Se-
lected fractions were combined and concentrated. 
In the beginning, the enzyme concentration was measured by Nanodrop (Peqlab). Molec-
ular weightss and extinction coefficients were calculated by Protparam, Expasy (34.45 kDa and 
ε=30.37*103 for Wi-WelO15 and 34.37 kDa and ε=28.88*103 for Hw-WelO15). However, after 
comparing several defrosted enzymes via SDS-PAGE analysis, the band thickness was quite 
different, therefore later the concentration determination was made by Bradford assay.  
7.1.10.2  Bradford Assay 
The principle of concentration determination via Bradford assay is the interaction of Coo-
massie brilliant blue G-250 with basic amino acids of the protein. Because of this interaction 
the absorption maximum shifts from 465 nm to 595 nm.[438] 5x Bradford solution from Bio-Rad 
was diluted to 1x and 1 mL mixed with different amounts of protein solution (1-20 µL), 
the mixture was incubated at room temperature for 5 min. It is important to work in a diluted 
range of concentration because of the limits of the Lambert-Beer-law. First, a calibration line 
was determined with bovine serum albumin. The same diluted 1x solution was made used to 
determine the concentration of several halogenases. The received equation for concentration 
determination is shown in equation (1). 
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Figure 59. Calibration line of Bradford solution with BSA. 
A = 0.024 mL/mg c + 0.0586     (1) 
A=Absorption, c=concentration 
The concentration determination was made with a fresh calibration curve each time. For fur-
ther measurements, a calibration curve was made with Wi-WelO15 V6I/A82L/D284N. 
7.1.10.3  Ene-Reductase TsER C25D/I67T 
Cell pellets were thawed in cold water. Cells were lysed by sonication for 6 min with 30 s 
pulses and 30 s rest. After pelleting the suspension (16 000 rpm, 4 °C, 45 min), the cleared ly-
sate was heat purified. 
Since TsER is thermostable and does not have a His-tag, the enzyme was purified by incu-
bating the cleared lysate in a 50 mL plastic tube at 70 °C for 90 min in a drying oven. After-
wards the suspension was stored at room temperature for 10 min to cool down. Followed by 
a centrifugation step (16 000 rpm, 4 °C, 45 min). FMN (0.1 M, aq) was added to the enzyme to 
a final concentration of 100 µM and dialyzed overnight against 5 L, 0.1 M potassium phos-
phate buffer. Concentration determination was performed by measuring absorption of the co-
factor FMN in a wavelength region between 350-600 nm. The protein solution was shock fro-
zen in N2 (l) and stored at -80 °C. The measured absorption spectrum is shown in figure 60.  
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Figure 60. Absorption spectra of old yellow enzyme TsER C25D/I67T after heat purification. 
The concentration of active enzyme can be calculated with the absorption maximum at about 
450 nm, the extinction coefficient of ε=11600 and equation 2. 
 
c =
A
d·ɛ
=
0.75
1cm·11600M−1cm−1 
= 65 µM   (2) 
with 
A = absorption (measured), d = length of cuvette (1 cm),  
ɛ = extinction coefficient=11600 M-1cm-1[439] 
7.1.11 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
To separate proteins by their molecular weight, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis can be performed.[440] The sample preparation buffer con-
tains SDS and β-mercaptoethanol. By heating the sample up to 95 °C the tertiary and sec-
ondary structures are denatured, so that the proteins are linearized, the disulphide bridges 
are split and the intrinsic charge of the proteins covered. In this way the linearized proteins 
are separated only depending on their length. 
The preparation of the gel consists of a two-step procedure, first preparation of the separa-
tion gel followed by preparation of the stacking gel. The gels are prepared in a caster that can 
take up to 12 glass planes in which the gels are prepared. The gel is prepared by preparing an 
acrylamide containing buffer solution with radical starter (ammonium persulfate) and stabi-
lator (tetramethylethylenediamine). Separation and stacking gel have different polymerization 
grades and different pH values.  
12% acrylamide separation gel for proteins with a molecular weight of 30-40 kDa:  
24 mL 40% acrylamide, 34.75 mL H2O, 20 mL buffer (1.5 M Tris pH 8.8, 800 µL SDS (10% in 
H2O), 400 µL APS (10% in H2O), 40 µL TEMED  
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5% acrylamide stacking gel:  
4.4 mL 40% acrylamide, 21.26 mL H2O, 8.75 mL buffer (1.5 M Tris pH 6.8, 350 µL SDS (10% in 
H2O), 175 µL APS (10% in H2O), 35 µL TEMED  
The samples are prepared by mixing 3 volumes of sample with 1 volume of 4x sample 
buffer (100 mM tris/HCl, pH=6.8, 110 mM SDS, 2 mM β-mercaptoethanol, 40% (w/v) glycerol, 
1 % (w/v) bromophenol blue) and denatured at 95 °C for 5 min, followed by centrifugation 
(14000 rpm, Eppendorf centrifuge 5418, 10 min). 
The protein bands were stained with a staining solution of EtOH 50% (v/v), acetic acid 10% 
(v/v) and Coomassie brilliant blue G-250 250 mg/L. Excessive stain was removed by washing 
and boiling the SDS-PAGE gel three times for 5 min in water.  
For good visualization, 3.3 µg purified protein should be applied. For cell or lysate samples, 
pellets normalized to OD600=5.0 are resuspended in 100 µL water or lysis buffer. For lysis, the 
cells were suspended and incubated at 37 °C for 30 min. After centrifugation (14000 rpm, Ep-
pendorf centrifuge 5418, 10 min), 30 µL supernatant were mixed with 10 µL 4x sample buffer. 
Whole cell samples were prepared by mixing 30 µL cell suspension with 10 µL 4x sample 
buffer. 6 µl of the sample are applied to the gel. As standard 10 µL of protein marker (page 
ruler 26610 by thermo scientific) were applied as well.  
 
7.1.12 Determination of Intact Protein Mass (performed by Mass Department) 
To analyze if a self-modification (oxidation or hydroxylation) occurs, 20 µL of a 5-50 µM solu-
tion with purified Wi-WelO15 V6I/D284N and Hw-WelO15 were given to the mass department 
of the Philipps-University Marburg.  
Depending on their concentration and the expected protein masses, 1-10 µL of the buffered 
protein solutions were desalted online using a Waters ACQUITY H-Class HPLC-system 
equipped with a monolithic 50/1 ProSwift RP-4H column (ThermoScientific). Desalted 
proteins were eluted into the ESI source of a Synapt G2Si mass spectrometer (Waters) by the 
following gradient of buffer A (water/0.05% formic acid) and buffer B (acetonitrile/0.045% 
formic acid) at a column temperature of 40 °C and a flow rate of 0.1 mL/min: Isocratic elution 
with 5% A for two minutes, followed by a linear gradient to 95% B within 8 min and holding 
95% B for additional 4 min. Positive ions within the mass range of 500-5000 m/z were detected. 
Glu-Fibrinopeptide B was measured every 45 s for automatic mass drift correction. Averaged 
spectra were deconvoluted after baseline subtraction and eventually smoothing using Mass-
Lynx instrument software with MaxEnt1 extension.  
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7.1.13 Tryptic Digestion (performed by Mass department) 
To determine masses of peptides from SDS-PAGE analysis, gel-bands were cut out of the gel 
and given to the mass department of the Philipps-University Marburg. After-destaining, sam-
ples were digested "in-gel" by the addition of sequencing grade modified trypsin (Promega) 
and incubated at 37 °C overnight. 
The mass spectrometric analysis of the samples was performed using an Orbitrap Velos 
Pro mass spectrometer (ThermoScientific). An Ultimate nanoRSLC-HPLC system (Dionex), 
equipped with a custom 20 cm x 75 µm C18 RP column filled with 1.7 µm beads was connected 
online to the mass spectrometer through a Proxeon nanospray source. 1-15 µL of the tryptic 
digest (depending on sample concentration) were injected onto a C18 pre-concentration col-
umn. Automated trapping and desalting of the sample were performed at a flowrate of 
6 µL/min using water/0.05% formic acid as solvent. 
Separation of the tryptic peptides was achieved with the following gradient of water/0.05% 
formic acid (solvent A) and 80% acetonitrile/0.045% formic acid (solvent B) at a flow rate of 
300 nL/min: holding 4% B for 5 min, followed by a linear gradient to 45%B within 30 minutes 
and linear increase to 95% solvent B in additional 5 min. The column was connected to a stain-
less steel nanoemitter (Proxeon, Denmark)) and the eluent was sprayed directly towards the 
heated capillary of the mass spectrometer using a potential of 2300 V. A survey scan with a 
resolution of 60000 within the Orbitrap mass analyzer was combined with at least three data-
dependent MS/MS scans with dynamic exclusion for 30 s either using CID with the linear ion-
trap or using HCD combined with orbitrap detection at a resolution of 7500. 
Data analysis was performed using Proteome Discoverer (ThermoScientific) with SE-
QUEST and MASCOT (version 2.2; Matrix science) search engines using either SwissProt or 
NCBI databases. 
7.1.14 Crystallization 
The enzyme was purified as described in ch. 7.1.10 . The enzyme was not frozen before using 
it for crystallization. The purified enzyme was mixed with cofactors and 50 µL solution for 
each crystallization plate were given to the crystallization department MarXTal of the 
Philipps-University Marburg. Imaging was performed by automation in the beginning regu-
larly, later after query. For an anaerobic crystallization trial, enzyme solution and plates were 
brought into an anaerobic chamber. There the solution was also pipetted by robot. The plates 
had to be checked manually with a microscope. Several crystallization trials were attempted 
using available commercial screens with 300 nL drop volume of enzyme solution with a Hon-
eybee robot. The sitting drop vapor diffusion method was used for crystallization and crystals 
were obtained from 0.2 M KAc and 2.2 M AmSO4 after storing the plates at 18°C The crystal 
structure was solved from the crystals that grew from an enzyme solution of 32.5 mg/mL Wi-
WelO15 in 50 mM HEPES, 10 mM NaCl, 10% glycerol, 0.5 mM DTT, 2 mM KG and 1 mM 
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FeSO4. Crystals were flash-frozen after a pre-treatment soak of the crystal in a solution consist-
ing of the crystallization reservoir solution and a cryoprotectant, 20%(v/v) glycerol for data 
collection. 
Diffraction data were collected at the European Synchroton Radiation Facility (ESRF) mi-
crofocus beamline ID23-2. All data were processed using XDS[441] in space group C121. Data 
reduction and scaling was done using the CCP4 suite of programs.[442] Data collection and pro-
cessing statistics are given in table 28. The structure was determined by molecular replacement 
with PHASER[443] using the coordinates (PDB code: 5IQS) as a search model. After an initial 
rigid body refinement, the structure was further refined with rounds of simulated annealing, 
energy minimization, and individual B-factor refinement with a maximum likelihood target 
using Phenix.[444] Difference Fourier maps were calculated with Phenix and used to locate elec-
tron density corresponding to bound Fe and KG, and the structure was built using COOT.[445] 
Structure validation was done with Molprobity[446]. Final refinement statistics are given in table 
28. All structural figures were generated with Chimera version 1.11.2.[447] The coordinates and 
structure factors have been deposited in the Protein Data Bank (PDB 6GEM).  
Table 28. Final refinement statistics of crystal structure of Wi-WelO15 V6I/D284N. 
Wavelength (Å ) 0.8726 
Resolution range (Å ) 49.48  - 3.46 (3.58-3.46) 
Space group C 1 2 1 
Unit cell (Å, Å, Å ° , °, 
°) 
195.83   155.45   133.23  
90.00  126.91  90.00 
Total reflections 280951 
Unique reflections 41091 (3643) 
Multiplicity 6.8 (6.4) 
Completeness (%) 98.2 (84.2) 
Mean I/sigma (I) 8.0 (1.6) 
Rmerge 0.200 (1.284) 
Rfactor 0.1930 
Rfree 0.2418 
Number of atoms 8836 
Protein 8792 
Ligands 44 
RMS (bonds) 0.022 
RMS (angles) 1.679 
Ramachandran fa-
vored (%) 
88.58 
Ramachandran outliers 
(%) 
1.81 
 
In table 29 all crystallization projects are listed that were performed in cooperation with the 
MarXtal laboratory of the Philipps-University Marburg.  
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Table 29. List of all crystallization projects that were performed in cooperation with the MarXtal laboratory of the Philipps-Uni-
versity Marburg 
Enzyme, Date  
Qiagen Plates 
Drop1* Drop2* 
Wi-0 21.10.2015 
JCSG I,II,III,IV, PACT, AmSO4, Cryos, 
Classics, Morpheus, MBC II 
32.5 mg/mL Wi-0 
+ 2 mM KG 
32.5 mg/mL Wi-0  
+2mM KG  
+ 1mM FeSO4 
Hw-WelO15  
JCSG III, IV, AmSO4, 
32.5 mg/mL 
Hw-WelO15 +2mM 
KG 
20 mg/mL Hw-WelO15** 
+2 mM KG  
+ 1.5 mM hapalindole Q 
(8% EtOH) 
Wi-0 (aerobe) 
JCSG III, IV,  
Morpheus II, AmSO4, 
33.8 mg/mL Wi-0 
+2mM KG 
35.0 mg/mL Wi-0  
+2mM KG 
+1mM FeSO4 
Wi-0 (anaerobe) 
JCSG III, IV,  
Morpheus II, AmSO4, 
35 mg/mL Wi-0  
+2mM KG 
35 mg/mL Wi-0  
+2mM KG 
+1mM FeSO4 
*The enzyme was prepared in 50 mM HEPES, 10 mM NaCl, 10% glycerol, 0.5 mM DTT pH 7.4 **an enzyme solution of 
32.5 mg/mL was prepared, after addition of hapalindole Q in EtOH, precipitation was observable. After mixing, the solution was 
filtered, and the concentration was remeasured by Nanodrop to be only 20 mg/mL 
Pictures of the crystals can be found in chapter 8.3.4, table 37. In addition, refinements were 
pipetted by hand. Hanging drop vapor diffusion method was used with 500 µL reservoir so-
lution. Used conditions are shown in table 30. The final concentration of the well solution is 
given in row 1, pipetted volume in row 2 and enzyme to buffer ratio in row 3. One unit repre-
sents 1 µL, which means a ratio of 1 / 1 is 1 µL of each solution. After pipetting the drops on 
the cover slip, the wells were sealed with grease, so that no solution can evaporate. As salts, 
ammonium sulfate (AmSO4), potassium acetate (KAc) and sodium acetate (NaAc) in bigrade 
were used. The enzyme solution was concentrated to 42 mg/mL and used with the following 
conditions: 50 mM HEPES, 10 mM NaCl, 10% glycerol, 42 mg/mL enzyme. 
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Table 30. Refinements for crystallization which was pipetted by hand. As salts, ammonium sulfate (AmSO4), potassium acetate 
(KAc) and sodium acetate (NaAc) were used. Hanging drop vapor diffusion method was used with 500 µL reservoir solution. 
The final concentration of the well solution is given in row 1, pipetted volumes in row 2 and enzyme to buffer ratio in row 3. One 
unit represents 1 µL, which means a ratio of 1 / 1 is 1 µL of each solution. After pipetting the drops on the cover slip, the wells 
were sealed with grease, so that no solution can evaporate. 
Plate 1 
final conc. 
1.5 M 
AmSO4 
0.2 M KAc 
2 M 
AmSO4 
0.2 M KAc 
2.2 M 
AmSO4 
0.2 M KAc 
2.2 M 
AmSO4 
0.2 M KAc 
2.5 M 
AmSO4 
0.2 M KAc 
2.8 M 
AmSO4 
0.2 M KAc 
pipetted 
volume 
187.5 µL 
AmSO4 
20 µL KAc 
292.5 µL 
H2O 
250 µL 
AmSO4 
20 µL KAc 
230 µL H2O 
275 µL 
AmSO4 
20 µL KAc 
205 µL H2O 
275 µL 
AmSO4 
20 µL KAc 
230 µL H2O 
312.5 µL 
AmSO4 
20 µL KAc 
167.5 µL 
H2O 
350 µL 
AmSO4 
20 µL KAc 
130 µL H2O 
ratio en-
zyme/buffer 
1 / 1 1 / 1 1 / 1 2 / 1 1 / 1 1 / 1 
Plate 2 
final conc. 
1.5 M 
AmSO4 
0.2 M 
NaAc 
2 M 
AmSO4 
0.2 M 
NaAc 
2.2 M 
AmSO4 
0.2 M 
NaAc 
2.2 M 
AmSO4 
0.2 M 
NaAc 
2.5 M 
AmSO4 
0.2 M 
NaAc 
2.8 M 
AmSO4 
0.2 M 
NaAc 
pipetted 
volume 
187.5 µL 
AmSO4 
33.3 µL 
NaAc 
280 µL H2O 
250 µL 
AmSO4 
33.3 µL 
NaAc 
217.5 µL 
H2O 
275 µL 
AmSO4 
33.3 µL 
NaAc 
192.5 µL 
H2O 
275 µL 
AmSO4 
33.3 µL 
NaAc 
155 µL H2O 
312.5 µL 
AmSO4 
33.3 µL 
NaAc 
155 µL H2O 
350 µL 
AmSO4 
33.3 µL 
NaAc 
117.5 µL 
H2O 
ratio 
ezyme/buffer 
1 / 1 1 / 1 1 / 1 2 / 1 1 / 1 1 / 1 
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7.1.15 Circular Dichroism Spectroscopy 
Selected variants were analyzed with circular dichroism spectroscopy (CD). Since high salt 
concentrations interfere with the measurement, a buffer concentration of 5 mM HEPES and 
1 mM NaCl and an enzyme concentration of 25 µM was used. The enzyme was assumed to be 
in apo state after purification without further analysis. In comparison, the addition of 1 eq KG 
and the addition of 1 eq KG and 1 eq (NH4)2Fe(SO4)2 (holo state) were compared. For meas-
urements a Jasco J810 spectropolarimeter was used with a Jasco CDF 4265 Peltier element and 
Haake WKL26 water bath of Thermo. First a blank measurement with buffer was performed. 
Then the folding was analyzed by measuring the CD signal in the range of 190 nm-280 nm. 
The following settings were used: 20 °C, scanning mode continuous, 50 nm/s, 1 nm band-
width, sensitivity: standard, data pitch: 0.2 nm, accumulations: 3. 
Melting was analyzed in the range of 20-80 °C with conditions: λ=220 nm, data pitch 1 °C, 
a temperature slope of 2 °C/min, a response of 2 s and a bandwidth of 10 nm. The ellipticity 
(mdeg) was converted in molar ellipticity with equation (3) 
[𝜃](𝑑𝑒𝑔 𝑐𝑚2 𝑑𝑚𝑜𝑙−1) =
𝜃
𝑐∙𝑑∙10
     (3) 
[θ] = molar ellipticity, θ = ellipticity, c = enzyme concentration, d = length of cuvette (1 cm) 
The data was analyzed with Origin 8.0. The molar ellipticity was plotted against the wave-
length to show folding or the temperature to determine the melting temperature after fitting 
with the Boltzmann equation. The inflection point gives the melting temperature Tm. The 
melting curves are shown in figure 70-figure 75. An overview of all determined folding values 
is given in table 38. 
7.1.16 Docking 
7.1.16.1 Isonitrile and Isothiocyanate Molecules 
The docking experiments were performed by Henrik Müller with SwissDock[385] which is a 
web-based application that is able to predict molecular interactions between molecules and 
target proteins based on the EADock DSS docking software, whose algorithm consists of the 
following steps. First, many bindings modes of the molecule inside a predefined box are gen-
erated. At the same time, the CHARMM (Chemistry at Harvard Macromolecular Mechanics) 
energies of these are estimated. Based on that, the binding modes with the most favorable 
energies are in silico evaluated and clustered. These can be downloaded and manually evalu-
ated in Chimera by eye. For that purpose, the small molecules were created in Chem3D and 
saved as a mol2-file. The crystal structure of WelO5 with substrate and closed lid was chosen 
as the target (PDB 5IQT). The docking box was defined based on the point with the coordinates 
X: -0.072, Y: 0.766, Z: -0.108 (Chain A) which is the center point of the box with a side length of 
10 Å for each side. The apparently most favorable binding modes were chosen with due regard 
to the predicted energies. 
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7.1.16.2  Hapalindole-like Ketones 
Rigid body docking was performed with Yasara STRUCTURE[363] (Yet Another Scientific Arti-
ficial Reality Application) by Henrik Mueller. As ligand the crystal structure of 54 and as re-
ceptor, crystal structure chain D of Wi-0 (PDB 6GEM) was used. The docking procedure re-
quires a preparation of both structures. The preparation of the receptor was performed using 
the standard settings of Dock Prep tool from UCSF Chimera, Version 1.11.2. This program 
deletes the solvent, fixes incomplete side chains and adds hydrogens and charges to the pro-
tein and the bound ligands. In the prepared receptor-file, KG had a charge of -2 and the Fe-
ion a charge of +2. A generously proportioned simulation cell was generated around the bind-
ing pocket of the protein with YASARA to cut down the calculation time and increase the 
accuracy of the docking. The docking process was performed by running YASARAs 
‘dock_run’ macro. Here, the Amber99 force field was used. The results were visually analyzed 
using Chimeras ViewDock-tool. 
7.2 Biotransformation  
7.2.1 General Information 
Biotransformations were conducted with lysate or purified enzymes (optimized reaction con-
ditions are described in chapter 7.2.5). As buffer system 50 mM HEPES pH 7.4 was used, which 
was purged with N2 gas for at least 0.5 h. As cofactor -ketoglutarate was used as disodium 
salt. The salt was solved in buffer and frozen as 0.1 M stock solution at -20 °C. In lysate assays 
a final concentration of 2.5 mM was used since it was assumed that E. coli enzymes might re-
cycle succinate or consume high KG concentrations, while with purified enzymes 5 mM was 
used. It was found out that an increase of sodium chloride from originally 10 mM to later 
100 mM leads to an increase of activity. As iron source (NH4)2Fe(SO4)2 ∙ 6H2O was used and 
freshly prepared each time before the reaction. A reducing agent was added to the reactions 
to recycle oxidized iron back to FeII. In the beginning DTT was used but later it was found out 
that ascorbic acid works better. Also, the reducing agent was freshly prepared each time before 
the reaction. It could be observed mixing the assumed apo enzyme with KG and iron, the 
solution with Wi-WelO15 turned lilac while the reaction mixture with Hw-WelO15 stayed col-
orless. However, no further experiments were conducted to closer analyze if this behavior can 
be changed with different cofactor concentrations. 
In the beginning, no positive control for the activity of the enzyme was available, a variety 
of different reaction conditions were tested. In the screening, variants able to chlorinate 54 
were found. Variants Wi-1, Wi-5 and Wi-8 (ch. 8.2, p. 190) showed highest conversions and 
were further used to test different reaction conditions. 
Extraction of Reactions in Vials 
Reactions were stopped by extraction with 200 µL ethyl acetate. Phase separation was per-
formed by centrifugation. The organic phase was transferred in HPLC vials, placed at room 
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temperature in a clean fume-hood overnight, covered with a paper box, to evaporate all ethyl 
acetate but prevent dust to go in. Remaining dry samples were solved in 70 µL acetonitrile and 
analyzed via HPLC with detection at 280 nm. 
7.2.2 Biotransformation and Analysis of Substrate Scope - Hw-WelO15 and Wi-0 
The biotransformations were performed with Hw-WelO15 and Wi-WelO15 V6I/D284N (Wi-0) 
in various conditions. The following reactions were performed before any positive control was 
available. Conditions based on information from Hillwig et al.[155] were used. Since a low turn-
over number for non-native substrates was expected, a higher enzyme concentration was used.  
7.2.2.1  Assays with Isonitrile and Isothiocyanate Containing Molecules 
 
1) The reaction was performed in 1.5 mL reaction tubes and a total volume of 200 µL. The 
reaction was performed with 100 µM purified Hw-WelO15 or Wi-0, 2.5 mM KG, 2 mM 
(NH4)2Fe(SO4)2 and 0.5 mM DTT. Finally, 2 µL of the substrate (100 mM stock solution in ace-
tonitrile) was added. The reaction tubes were closed and incubated at 30 °C for 3 h. Then the 
reaction was extracted with 200 µL ethyl acetate and the organic layer analyzed by GC. 
2) This assay was performed in a 2.2 mL dw-plate and a total volume of 200 µL. All reac-
tions were performed in triplicates. Substrates 68-75 were tested in a combinatorial set-up, 
testing different reducing agents as well as the influence of indole as decoy molecule. A master 
mix of HEPES buffer (50 mM Hepes, 10 mM NaCl) containing 100 µM Hw-WelO15, 2 mM 
KG and 0.5 mM (NH4)2Fe(SO4)2 was prepared. 194 µL reaction solution was pipetted into the 
plate. Stock solutions were prepared: 100 mM DTT in HEPES buffer, 100 mM ascorbic acid in 
HPEPES buffer, 100 mM indole in acetonitrile, 100 mM 68-75 in acetonitrile. 2 µL of each of 
the needed additives was added by 8-channel pipette. The following 6 conditions were tested: 
DTT, DTT + indole, ascorbic acid, ascorbic acid + indole, no reducing agent, no reducing agent 
+ indole. Resulting final concentrations were 1 mM DTT, 1 mM ascorbic acid, 1 mM indole, 
1 mM substrate.  
All reactions were performed in duplicates three times and stopped, after 3 h, 7 h and 24 h 
by extraction with 400 µL ethyl acetate. Phase separation was performed by centrifugation. 
The organic phase was transferred in microtiter plates with a Tecan robot equipped with a 96-
tip head MCA (Multichannel Arm). The organic layer (ethyl acetate) was analyzed by GC.  
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7.2.2.2  Assays with Hapalindole-like Substrates 
 
1) The reaction was performed in 1.5 mL reaction tubes and a total volume of 200 µL. 1 mM 
KG, 10 mM NaCl and 0.5 mM (NH4)2Fe(SO4)2 were mixed with either 60 µM enzyme 
Hw-WelO15 or 60 µM Wi-0 and HEPES 2 or KPi buffer. Substrate 86 or 87 was added by pipet-
ting into the lid and it was mixed by inverting. After short centrifugation to collect the solution 
at the bottom of the tube, two holes were pricked into the lid of the reaction tube. The reaction 
was incubated at 1400 rpm, 30 °C in an Eppendorf Thermomixer. After 20 h the reaction was 
stopped by extraction with 200 µL ethyl acetate. Phase separation was performed by centrifu-
gation. The organic phase was handled as described above and analyzed by HPLC-UV/Vis. 
2) The reaction was performed in 1.5 mL reaction tubes and a total volume of 200 µL. Either 
20 or 50 mM HEPES were combined with 0.0625 mM; 0.25 mM or 0.5 mM DTT or 50 or 100 mM 
potassium phosphate buffer were combined with 0.0625 mM; 0.25 mM or 0.5 mM DTT and 
individually tested. In all reactions 2 mM KG, 10 mM NaCl and 0.5 mM (NH4)2Fe(SO4)2 and 
44 µM Hw-WelO15 were present. A master mix was prepared with a 10 mM NaCl solution N2 
purged. The master mix contained Fe, KG and enzyme. HEPES and phosphate salts as well 
as DTT were prepared as 10x concentrated stock and added directly to the vials. Substrate 87 
was added by pipetting 1 µL into the lid and inverting. After short centrifugation to collect the 
solution at the bottom of the tube, two holes were pricked into the lid of the reaction tube.  
3)No conversion could be detected, in the reaction described above, so the assay was re-
peated with purged buffers and overlaying the enzyme solution with N2 after mixing every-
thing. After 15 min the tubes were washed with pressed air by blowing to the top of the liquid. 
After 16 h the reaction was stopped by extraction with 200 µL ethyl acetate. The organic phase 
was handled as described above and analyzed by HPLC-UV/Vis. 
4) The reaction was performed in 2 mL reaction tubes and a total volume of 200 µl. In the 
reaction set-up, 50 µL Hw-WelO15 (250 µM) was mixed with N2 purged HEPES 2 (10 mM 
NaCl, 50 mM HEPES, 10 %glycerol) and cofactors, so that final concentrations of 62.5 µM en-
zyme, 5 mM KG (0.1 M in HEPES 2), 1 mM (NH4)2Fe(SO4)2, 1 mM DTT and a concentration 
of 2 mM substrate 54 (100 mM in EtOH) were present. After 16 h the reaction was stopped by 
extraction with 200 µL ethyl acetate. The organic phase was handled as described above and 
analyzed by HPLC-UV/Vis. 
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7.2.3 Screening of Libraries in Cell Lysate 
7.2.3.1  Pooling of Plates (Screening of Error Prone Variants) 
For activity assays, enzyme production was performed in 2.2 mL dw-plates. After harvesting, 
the plates were frozen at -80°C. For reactions, cell pellets were thawed at room temperature 
and resuspended by vortexing with 200 µL HEPES 2 buffer and combined via liquidator. The 
plates were centrifuged (Eppendorf 5810R, 10 min, 4 °C, 4000 rpm) and the supernatant dis-
carded. The pellets were resuspended by vortexing with 100 µL N2 purged HEPES 3 (50 mM 
HEPES, 10 mM NaCl, pH 7.4) buffer containing 1 mg/mL lysozyme. The plates were incubated 
at 37 °C for 30 min. For the reaction buffer, N2 purged HEPES 3 buffer was prepared and co-
factors added to a concentration of 5 mM KG, 1 mM (NH4)2Fe(SO4)2, 1 mM DTT in the 2x re-
action buffer. While KG was prepared as 0.1 mM stock solution, (NH4)2Fe(SO4)2 and DTT 
were weighed as solids and solved in 1 mL N2 purged buffer just before usage. 100 µL of the 
2x reaction buffer was added to the cell suspension. 2 µL of 0.1 M substrate solution in EtOH 
was added by 8-channel pipette*. The plate was closed with a plastic lid and incubated at 30°C, 
200 rpm (Infors HT shaker, attached in an inclined way). After 24 hours, the reaction was 
stopped by extraction with 400 µL ethyl acetate. Phase separation was performed by centrifu-
gation (Eppendorf 5810R, 10 min, 4 °C, 4000 rpm). The organic phase was transferred in mi-
crotiter plates with a Tecan robot equipped with a 96-tip head MCA (Multichannel Arm). 
Plates were placed at room temperature in a clean fume-hood overnight, covered with a paper 
box to evaporate all ethyl acetate but prevent dust to get in. Remaining dry samples were 
solved in 100 µL acetonitrile and analyzed via HPLC-UV/Vis. For measurement in HPLC, the 
glass plates were put in a metal frame and closed with a white plastic septum. 
*the addition with 8-channel pipette later was changed to Multipette since the solvent evapo-
rated too fast from the container, needed to take up the substrate stock. 
7.2.3.2  Screening of Libraries Generation 1-3 
For activity assays, enzyme production was performed in 2.2 mL dw-plates (ch. 7.1.9.2). After 
harvesting, the plates were frozen at -80°C. The cell pellets were thawed at room temperature. 
For the reaction, first cells were resuspended by vortexing with 100 µL HEPES 3 buffer (50 mM 
HEPES, 10 mM NaCl, pH 7.4) containing 1 mg/mL lysozyme. To lyse the cells, the plates were 
incubated at 37 °C for 30 min. In the meantime, 2xreaction buffer was prepared. For the reac-
tion buffer, N2 purged HEPES 3 buffer was used and mixed with freshly prepared reaction 
compounds so that a concentration of 5 mM KG, 1 mM DTT and 1 mM (NH4)2Fe(SO4)2 were 
present in the 2x buffer. Fresh prepared (NH4)2Fe(SO4)2 solution has a turquoise color, fresh 
prepared reaction buffer has a dark reddish to brown color. If DTT is not added fresh to the 
reaction mix, the color of the reaction buffer is colorless. 100 µL of the reaction buffer were 
added to the cell suspension. 2 µL of the substrate prepared as stock solution in EtOH was first 
added by 8-channel pipette, later on with the Multipette, so that a final concentration of 1 mM 
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(library 1) or 0.5 mM (library 2 and 3) was present. The plates were closed with a plastic lid 
and incubated at 30°C, 200 rpm (Infors HT shaker, attached in an inclined way). 
After 24 hours, the reaction was stopped by extraction with 400 µL ethyl acetate. Phase 
separation was performed by centrifugation (Eppendorf 5810R, 10 min, 4 °C, 4000 rpm). The 
organic phase was transferred in 96-well microtiter glass plates (Zinsser) with a Tecan robot 
equipped with a 96-tip head MCA. Plates were placed at room temperature in a clean fume-
hood overnight, covered with a paper box to evaporate all ethyl acetate but prevent dust to 
get in. Remaining dry samples were solved in 100 µL acetonitrile and analyzed via HPLC-
UV/Vis. For measurement in HPLC, the glass plates were put in a metal frame and closed with 
a white plastic septum. 
7.2.3.3  Screening of Library Generation 4 
The reaction was performed as described in chapter 7.2.3.2 above but using HEPES buffer with 
50 mM HEPES, 50 mM NaCl, pH 7.4 and final cofactor concentrations of 2.5 mM KG, 
1.25 mM ascorbic acid, 1 mM (NH4)2Fe(SO4)2 and 0.5 mM substrate. 
7.2.4 Analysis of Reaction Conditions with Wi-WelO15 Variants 
The following reactions were performed with substrate 54, after the first activity was shown. 
If not mentioned otherwise, generally the reactions were performed in duplicates in a 2 mL 
reaction tube or in 2.2 mL squared 96 dw plate.  
7.2.4.1  Concentration of Enzyme and Cofactors  
1) The reactions were performed in a 2.2 mL squared 96 dw plate with a total volume of 
300 µL and purified Wi-1. The reaction was performed in 50 mM HEPES, 10 mM NaCl which 
was purged with N2, before adding reaction components. 8 different master solutions with 
enzyme, (NH4)2Fe(SO4)2 and KG were prepared. 50 µM or 100 µM enzyme were combined 
with 0.25 mM or 0.1 mM (NH4)2Fe(SO4)2, and 1.25 or 2.5 mM KG. Different reducing agents 
were added to the plate directly with final concentrations of 0.5 mM DTT, 0.5 mM ascorbic 
acid or no reducing agent to see the influences on the reaction. Substrate 54 was used in a final 
concentration of 0.5 mM. The reaction was incubated for 4 h at 30 °C, 200 rpm (Infors HT 
shaker, attached in an inclined way) and stopped by extraction with 400 µL ethyl acetate. 
Phase separation was performed by centrifugation (Eppendorf 5810R, 10 min, 4 °C, 4000 rpm). 
The organic phase was transferred in microtiter plates with a Tecan robot equipped with a 96-
tip head MCA. The plates were placed at room temperature in a clean fume-hood overnight 
to evaporate all ethyl acetate. Remaining dry samples were solved in acetonitrile and analyzed 
via HPLC-UV/Vis. 
2) The above described reaction was repeated with 20, 50 and 100 µM enzyme in combina-
tion with 0.25 and 0.5 mM (NH4)2Fe(SO4)2 and again 1.25 and 2.5 mM KG. All reactions were 
performed with 0.5 mM DTT and 0.5 mM 54. The reaction was run for 24 h. 
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3) Different reducing agents in three different concentrations (0.25, 0.5 and 1 mM) were 
tested with cell lysate of Wi-1. The conversion in dependency to time was analyzed as well. A 
pellet from flask expression (0.5 L cell culture) was thawed in cold water and diluted to 
47.5 mL with HEPES 3 buffer. 0.5 mL of the suspension was pipetted in each well of a 2.2 mL 
96 dw plate. The cells were pelleted by centrifugation (4000 rpm, 4 °C, 5810R Eppendorf cen-
trifuge) for 10 min and the supernatant discarded. The pellets were suspended in HEPES 3 
buffer containing 1 mg/mL lysozyme and 100 µM FeCl3 (which was forgotten during the en-
zyme production). After vortexing and incubation for 30 min at 37 °C (Infors HT shaker), 
150 µL master mix consisting of N2 purged HEPES 3 buffer with 1 mM (NH4)2Fe(SO4)2 and 
5 mM KG was added to the wells. Finally, the reducing agents and 3 µL substrate 54 (100 mM 
in EtOH) was added to each well by Multipette. After 1, 2, 4, 6, and 22 h, samples were taken 
out of the plate and extracted in 2 mL reaction tubes. The organic phase was handled as de-
scribed above and analyzed by HPLC. 
4) The reaction was performed in 2 mL reaction tubes and a total volume of 200 µl. Purified 
enzymes Wi-5 and Wi-8 were examined. The enzymes were diluted with N2 purged HEPES 3 
(50 mM HEPES, 10 mM NaCl, pH 7.4) to 20 µM. 100 µL of the enzyme solution was filled into 
the reaction tube. A 2x concentrated reaction buffer consisting of 10 mM KG, 1 mM ascorbic 
acid, 1 mM (NH4)2Fe(SO4)2 was prepared and 100 µL added to the tube. Resulting in final con-
centrations of 10 µM enzyme, 5 mM KG, 0.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2. 2 µL 
of 54 (50 mM in EtOH) was added to a final concentration of 0.5 mM. The reaction tubes were 
closed, incubated at 30 °C, 700 rpm and stopped by extraction with 200 µL ethyl acetate. The 
organic phase was handled as described above and analyzed by HPLC-UV/Vis. 
7.2.4.2  Temperature Stability of Wi-WelO15 Variants 
The reaction was performed in 2 mL reaction tubes and a total volume of 200 µl. Variants Wi-5, 
Wi-5P3, Wi-8, Wi-11 and Wi-12 were analysed. The enzymes were diluted with N2 purged 
HEPES 4 (50 mM HEPES, 100 mM NaCl, pH 7.4) to 20 µM. 100 µL of the enzyme solution was 
filled into the reaction tubes. A 2x concentrated reaction buffer consisting of 10 mM KG, 
5 mM ascorbic acid, 1 mM (NH4)2Fe(SO4)2 was prepared and 100 µL added to the tube. Result-
ing in final concentration of 10 µM enzyme, 5 mM KG, 0.5 mM ascorbic acid, 0.5 mM 
(NH4)2Fe(SO4)2. 2 µL of 54 (50 mM in EtOH) was added to a final concentration of 0.5 mM. The 
reaction was incubated in an Eppendorf Thermomixer at 30 °C, 35 °C, 40 °C or 45 °C and 
700 rpm. After 5 h, the reaction was stopped by extraction with 200 µL ethyl acetate. The or-
ganic phase was handled as described above and analyzed by HPLC-UV/Vis. 
7.2.4.3  Solvent Stability of Wi-WelO15 Variants 
1) The reaction was performed in 2 mL reaction tubes and a total volume of 200 µl. Variants 
Wi-5 and Wi-8, were analyzed. The enzymes were diluted with N2 purged HEPES 3 (50 mM 
HEPES, 10 mM NaCl, pH 7.4) to 20 µM. The solvent (8 µL = 5% or 18 µL = 10%) was pipetted 
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into the vial together with 2 µL substrate 54 (50 mM in EtOH, ACN or acetone). N2 purged 
HEPES 3 buffer was added to a volume of 50 µL. A 4x concentrated reaction buffer consisting 
of 20 mM KG, 10 mM ascorbic acid, 2 mM (NH4)2Fe(SO4)2 was prepared and 50 µL added to 
the tube. 100 µL of the enzyme solution was filled into the reaction tube Resulting in final 
concentration of 10 µM enzyme, 5 mM KG, 0.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2 and 
0.5 mM 54. The reaction was incubated in Eppendorf Thermomixer at 30 °C, 700 rpm. After 
5 h, the reaction was stopped by extraction with 200 µL ethyl acetate. The organic phase was 
handled as described above and analyzed by HPLC-UV/Vis.  
2) The reaction was performed in 2 mL reaction tubes and a total volume of 200 µl. Variants 
Wi-5, Wi-5P3, Wi-8, Wi-11 and Wi-12 were analyzed. The enzymes were diluted with N2 
purged HEPES 4 (50 mM HEPES, 100 mM NaCl, pH 7.4) to 20 µM. EtOH or acetone (0 µL = 
1%; 8 µL = 5% or 18 µL = 10%) was pipetted into the vial together with 2 µL substrate 54 
(50 mM in EtOH, or acetone). N2 purged HEPES 4 was added to a volume of 50 µL (48 µL = 
1%; 40 µL =5 % or 30 µL = 20 %). A 4x concentrated reaction buffer consisting of 20 mM KG, 
10 mM ascorbic acid, 2 mM (NH4)2Fe(SO4)2 was prepared and 50 µL added to the tube. 100 µL 
of the enzyme solution was filled into the reaction tube, resulting in final concentration of 
10 µM enzyme, 5 mM KG, 0.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2 and 0.5 mM sub-
strate. The reaction was incubated in Eppendorf Thermomixer at 30 °C, 700 rpm. After 5 h, the 
reaction was stopped by extraction with 200 µL ethyl acetate. The organic phase was handled 
as described above and analyzed by HPLC-UV/Vis.  
7.2.4.4  Whole Cell Assay 
To test if the biotransformation can take place in whole cells, the reaction was performed in 
2.2 mL squared dw plates with 200 µL culture. 5 mL LB or TB medium containing 50 µg/mL 
kan, 20 µM IPTG and 50 µM FeCl3 was inoculated with either 1% preculture or other 10% 
preculture and distributed to the plate. The plate was incubated at 37 °C, 200 rpm for 2 h or 
4 h. Then substrate 54 (final conc. 0.5 mM) and KG (final conc. 2.5 mM) were added to the 
culture and let grown for 4 h or 16 h at 30 °C. After the according time, the samples were pi-
petted out of the plate and extracted in a 1.5 mL reaction tube with 200 µL ethyl acetate. The 
organic phase was handled as described above and analyzed by HPLC-UV/Vis. 
7.2.5 Analysis of Substrate Scope with Optimized Reaction Conditions 
7.2.5.1  Lysate-Based Biotransformation from Normalized Cell Mass 
Expression was performed in flasks as described in ch. 7.1.9.1. To obtain equal cell mass in 
each reaction, the OD600 was determined and a volume of culture corresponding to an optical 
density of 5.0 was filled in plates or 2 mL reaction tubes and pelleted. The supernatant was 
discarded and the pellets frozen and stored at -20 °C. The cell pellets were thawed at room 
temperature. For the reaction, cells were resuspended by vortexing with 100 µL HEPES 4 
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buffer (50 mM HEPES, 100 mM NaCl, pH 7.4) containing 1 mg/mL lysozyme. To lyse the cells, 
the plates were incubated at 37 °C for 30 min. In the meantime, 2x reaction buffer was pre-
pared. For the reaction buffer, N2 purged HEPES 4 buffer was used and mixed with freshly 
prepared reaction compounds so that a concentration of 5 mM KG, 5 mM ascorbic acid and 
1 mM (NH4)2Fe(SO4)2 were present in the 2x buffer. 100 µL of the reaction buffer were added 
to the cell suspension. 2 µL of the substrate prepared as stock solution in EtOH was added by 
Multipette, so that a final concentration of 0.5 mM was present. The plates were closed with a 
plastic lid and incubated at 30°C, 200 rpm (Infors HT shaker, attached in an inclined way). 
After 8 hours, the reaction was stopped by extraction with 400 µL ethyl acetate. Phase sep-
aration was performed by centrifugation. The organic phase was transferred in 96-well micro-
titer glass plates (Zinsser) with a Tecan robot equipped with a 96-tip head MCA. Plates were 
placed at room temperature in a clean fume-hood overnight, covered with a paper box to evap-
orate all ethyl acetate but prevent dust to get in. Remaining dry samples were solved in 100 µL 
acetonitrile and analyzed via HPLC-UV/Vis. For measurement in HPLC, the glass plates were 
put in a metal frame and closed with a white plastic septum. 
The expression levels were analyzed by SDS-PAGE analysis (see chapter 8.5.2): by resus-
pending the pellets in 100 µL lysis buffer (50 mM HEPES, 100 mM NaCl, pH 7.4, 1 mg/mL 
lysozyme). After incubation 37 °C for 30 min for cell lysis, the suspension was centrifuged for 
2 min at 14000 rpm. 15 µL of the supernatant was mixed with 5 µL 4x SDS-PAGE sample 
buffer and incubated at 95 °C for 10 min. The samples were centrifuged for 10 min at 
14000 rpm and 6 µL applied to the gel.  
7.2.5.2  Analysis of Substrate Scope with Purified Enzyme 
HEPES 4 buffer (50 mM HEPES, 100 mM NaCl, pH 7.4) was purged with N2 for at least 0.5 h 
to remove oxygen. All reaction components were prepared in this buffer. KG (as disodium 
-ketoglutarate) was stored as 100 mM stock at -20°C, ascorbic acid and (NH4)2Fe(SO4)2 solu-
tions were prepared each time fresh. The 2x reaction buffer consists of the N2 purged HEPES 
4 buffer containing 10 mM KG, 5 mM ascorbic acid and 1 mM (NH4)2Fe(SO4)2. The reaction 
was performed in total a volume of 200 µL. The purified enzymes were diluted with purged 
buffer to a concentration of 20 µM. 100 µL enzyme solution and 100 µL of the 2x buffer were 
added in each well. 2 µL (0.05 M in EtOH) substrate was added using a Multipette (Eppendorf) 
reaching a final concentration of 0.5 mM. After 8 hours incubation at 30°C and 200 rpm (Infors 
HT shaker), the reaction was stopped by extracting with 400 µL ethyl acetate. Phase separation 
was performed by centrifugation. The organic phase was transferred in microtiter plates with 
a Tecan robot equipped with a 96-tip head MCA. Plates were placed at room temperature in a 
clean fume-hood overnight to evaporate all ethyl acetate. Remaining dry samples were solved 
in 100 µL acetonitrile and analyzed via HPLC-UV/Vis.  
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7.2.6 Kinetic Analysis of Halogenase Variants 
For kinetic analysis, enzyme and KG were thawed on ice. HEPES 3 buffer (50 mM HEPES, 
10 mM NaCl, pH 7.4) was purged with N2 to remove oxygen. All reactions were made in du-
plicates or quadruplicates. Reaction buffer was prepared by mixing enzyme (final conc. 
10 µM), KG (final conc. 5 mM), (NH4)2Fe(SO4)2 (final conc. 0.5 mM), ascorbic acid (final conc. 
0.5 mM) in N2 purged HEPES 3 buffer. Iron and ascorbic acid were solved with nitrogen 
purged buffer and added latest. The reaction mix was aliquoted as 200 µL in 2 mL reaction 
tubes and incubated in an Eppendorf Thermomixer at 30 °C, 700 rpm at least for 2 min to reach 
the reaction temperature of 30 °C. The lid of all reaction tubes was left open during the reac-
tions to allow O2 diffusion into the reaction mixture. The reactions were stopped after different 
times to gain product formation versus time. For technical reasons, for short measurements (3, 
6, 10 s), the vial was taken out of the Thermomixer. The substrate was added to one vial which 
was shaken by hand in the meantime and finally extracted by adding ethyl acetate and vor-
texing. For longer incubation times (20, 40 and 60 s) the vials were left in the Eppendorf Ther-
moshaker while 2 µL substrate was added to the vials every 3 s. The tubes were taken out and 
the reaction stopped by adding ethyl acetate by Multipette (Eppendorf) and vortexing. Differ-
ent substrate concentrations, 1.5, 1.0, 0.5, 0.25, 0.125, 0.0625 and 0.031 mM were used for en-
zymes with Km>100 µM. Enzymes with lower Km were further analyzed with substrate con-
centrations of 0.0156, 0.0078 and 0.0039 mM. A 150 mM stock solution of 54, 77, 78 was pre-
pared in EtOH and diluted accordingly to create the lower concentrated stocks. However, 53 
and 76 were only soluble in EtOH up to 75 mM. Lower stock solutions were prepared by di-
luting 1-1 with solvent. Resulting in stock solutions with 100-fold concentration so that a vol-
ume of 2 µL was added to each reaction. The reaction was stopped by the addition of 200 µL 
ethyl acetate. After phase separation by centrifugation, 140 µL of the organic phase were trans-
ferred to an HPLC vial, ethyl acetate was evaporated, and remaining samples resuspended in 
70 µL acetonitrile. The samples were analyzed by HPLC and measured on a Shimadzu LC2030 
HPLC. The injection volume varied depending on concentration. Extraction of 54 is linear in a 
concentration range of 0.0625-2.5 mM comparing HPLC-UV signal areas (figure 61). After the 
reaction, the obtained areas did not fit to the calibration curve anymore. Therefore, the con-
version was calculated from relative areas. Based on the conversion, the product formation in 
µM was calculated from the used substrate concentration. Product formation was plotted 
against time and initial velocity was determined. Initial velocity was plotted against substrate 
concentration. Vmax and Km were determined using GraphPad Prism 7 Michaelis Menten model 
(equation 4). Wi-2 and Wi-5 with substrate 54 showed substrate inhibition. Equation 5 was 
used for fitting curves with substrate inhibition. 
[Y = Vmax*X/(Km + X)]       (4) 
[Y=Vmax*X/(Km + X*(1+X/Ki))]     (5) 
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Figure 61. Comparing HPLC areas in dependency to concentration 54 after extraction out of 50 mM HEPES, 10 mM NaCl.  
7.2.7 Screening of P450 Libraries 
The reactions were performed in 2.2 mL dw 96-well plates. Protein production was performed 
as described in ch. 7.1.9.7. The cell pellets were stored at -80 °C. To start the reaction, the pellets 
were thawed in cold water and 196 µL 1 mg/mL lysozyme in 0.1 M KPi buffer was added. The 
pellets were suspended by vortexing and the plate was incubated for 30 min at 200 rpm (Infors 
HT shaker). 2x reaction buffer was prepared, of which 200 µL were added after the lysis, so 
that a final concentration of 0.25 mM NADP+, 0.25 M Glucose, 5% glycerol, 5 mM EDTA, 1 U 
GDH was present. 4 µL of a 100 mM stock solution 54 in EtOH was added, so that a final 
concentration of 1 mM 54 was present in the reaction. The plates were incubated for 24 h at 
30 °C then, the reaction was stopped by extraction with 400 µL ethyl acetate. Phase separation 
was performed by centrifugation. The organic phase was transferred in microtiter plates with 
a Tecan robot equipped with a 96-tip head MCA. Plates were placed at room temperature in a 
clean fume-hood overnight to evaporate all ethyl acetate. Remaining dry samples were solved 
in acetonitrile and analyzed via HPLC-UV/Vis. 
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7.3 Preparative Scale Biotransformation 
7.3.1 Halogenase 
7.3.1.1  General Information  
Within the different reaction set-ups, the conditions were optimized. Individual reaction con-
ditions and analysis of products can be found below. Conditions that worked best and are 
recommended to use are: 20-30 µM enzyme*, 50 mM HEPES, 100 mM NaCl, pH 7.4, 10 mM 
KG, 5 mM ascorbic acid, 1 mM (NH4)2Fe(SO4)2 and a substrate concentration of 0.5-0.75 mM. 
As standard, later, the reaction was performed in 0.5 L flat bottom round flasks with 50 mL 
volume. The flask was closed with a gas permeable foil and incubated at 30 °C, 100 rpm in 
Infors Ecotron shaker. 
*The enzyme concentration in lysate cannot be determined except by SDS-PAGE analysis 
which includes a high error.[383] Therefore the chlorinase concentration was estimated to be 60-
80 mg/L cell culture, based on the fact that all variants reliably yield 60-65 mg/L after IMAC 
purification. 
7.3.1.2  Characterization of 53a 
 
The reaction was performed by L. Schmermund[317] in a total reaction volume of 34.2 mL with 
1.00% (v/v) ethanol. The purified Hw-WelO15 was diluted with nitrogen purged buffer 
(50 mM HEPES, 10 mM NaCl, pH 7.4) to a final concentration of 40 µM. Then 2x reaction 
buffer was added to the enzyme solution. For the reaction, reactants KG, DTT and 
(NH4)2Fe(SO4)2 were solved in nitrogen purged buffer and added to the enzyme solution, to a 
final concentration of 5 mM KG, 0.5 mM DTT, 0.5 mM (NH4)2Fe(SO4)2 and 20 µM 
Hw-WelO15. Then 15 mg (45.9 µmol, 1.0 eq, 1.35 mM) 53, solved in 340 µL ethanol, were 
added to the reaction. The reaction was incubated at 30 °C and 150 rpm for 24 h. After 24 h the 
reaction was extracted with EtOAc (5 x 10 mL), the phases were separated by centrifugation 
(4000 rpm, 15 min, 4 °C) and the solvent was removed under reduced pressure. The crude 
product was purified by preparative HPLC (isocratic ACN : water 60 : 40) and 8.0 mg 
(24.5 µmol, 48%) of 53a were obtained as colorless solid.  
 
1H-NMR (500 MHz, CDCl3), δ = 8.13 (s, 1H, NH), 7.45 (d, 1H, J = 7.85 Hz, H4), 7.39 (d, 1H, J = 
8.10 Hz, H7), 7.23-7.20 (m, 1H, H6), 7.39 (d, 1H, J = 2.30 Hz, H2), 7.16-7.12 (m, 1H, H5), 4.84 (s, 
1H, H17/cis), 4.72-4.71 (m, 1H, H17/trans), 4.30 (dd, 1H, J = 12.5, 4.70 Hz, H13), 3.81 (s, 1H, H11), 3.62-
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3.59 (m, 1H, H10), 3.20 (td, 1H, J= 12.3, 4.13 Hz, H15), 2.21-2.17 (m, 1H, H14), 2.13-2.05 (m, 1H, 
H14), 1.54 (s, 3H, H18), 1.35 (s, 3H, H19), 1.32 (s, 3H, H20) ppm; 13C-NMR (125 MHz, CDCl3), δ= 
158.5 (NC), 145.5 (C16), 135.8 (C8), 126.6 (C9), 123.6 (C2), 122.3 (C6), 119.8 (C5), 117.2 (C4), 113.5 
(C17), 112.5 (C3), 111.7 (C7), 68.1 (C11), 63.6 (C13), 44.4 (C15), 39.8 (C12), 38.8 (C14), 35.0 (C10), 26.9 
(C20), 19.3 (C19), 18.8 (C18) ppm; 
HRMS (ESI+): C20H23ClN2H+ [M+H]+, m/z found: 327.1618; calc.: 327.1623. 
7.3.1.3  Characterization of 54a 
 
The reaction was performed in a total reaction volume of 100 mL with 1.9% (v/v) ethanol. The 
reaction was performed with cleared lysate of Wi-1. A pellet of Wi-1 (0.8 L cell culture, ~48 mg 
enzyme) was suspended in 30 mL HEPES 3 buffer (50 mM HEPES, 10 mM NaCl, pH 7.4) and 
lysed by sonication. After centrifugation (45 min, 16 000 rpm, 4 °C), 25 mL cleared lysate were 
received. 75 mL of nitrogen purged HEPES 3 buffer was added and cofactors to a concentra-
tion of 7.5 mM KG, 1 mM DTT, 2.5 mM (NH4)2Fe(SO4)2, 56 mg 54 were solved in 1.9 mL EtOH 
and added to the reaction (2 mM final concentration), which was recovered from plate reac-
tions and therefore was impure with 54a. The mixture was filled into a 500 mL Erlenmeyer 
flask and incubated at 30 °C and 80 rpm in Infors Ecotron shaker. After 24 h the reaction was 
stopped by extraction with ethyl acetate. First for separation and later sickness reasons the 
reaction mixture was left at room temperature for 2 weeks. Phase separation was achieved by 
centrifugation in an Eppendorf centrifuge (Eppendorf 5810 R, rotor F-34-6-38), 4000 rpm for 
10 min and additional 5 min at 8000 rpm. The organic phase was concentrated in vacuo. Re-
maining samples were solved in 60 : 40 ACN : H2O and filtered by a 0.45 µm PTFE filter and 
purified via preparative HPLC. A total amount of 2.6 mL was injected via loop. An isocratic 
program with running time 60 min and 10 mL/min was used for purification. The product area 
increased to 15% in relative ratio to the educt, while the concentration of 54a in the educt was 
not known. After purification, 2 mg pure 54a (3.4%) were received. 1H, 13C NMRs were suc-
cessfully measured. The reaction was repeated by L. Schmermund to determine absolute ste-
reo conformation of the chloride by NOESY NMR.[317] 
 
1H-NMR (500 MHz, CDCl3), δ = 8.05 (s, 1H, NH), 7.33-7.31 (m, 1H, H7), 7.30-7.29 (m, 1H, H4), 
7.17-7.14 (m, 1H, H6), 7.08-7.05 (m, 1H, H5), 6.92 (d, 1H, J = 2.45 Hz, H2), 4.66 (s, 1H, H17/cis), 4.63-
4.62 (m, 1H, H17/trans), 4.23 (d, 1H, J = 12.8 Hz, H10), 4.12 (dd, 1H, J = 12.4, 4.49 Hz, H13), 2.82 (td, 
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1H, J = 12.7, 3.60 Hz, H15), 2.55-2.47 (m, 1H, H14), 2.34-2.30 (m, 1H, H14), 1.59-1.58 (m, 3H, H18), 
1.46 (s, 3H, H19), 1.30 (s, 3H, H20) ppm; 13C-NMR (125 MHz, CDCl3), δ= 209.5 (CO), 145.0 (C16), 
136.2 (C8), 127.4 (C9), 123.3 (C2), 122.0 (C6), 119.5 (C5), 119.6 (C4), 113.4 (C17), 111.5 (C7), 111.1 
(C3), 67.1 (C13), 52.0 (C12), 48.6 (C15), 47.0 (C10), 38.7 (C14), 23.0 (C20), 20.4 (C19), 18.5 (C18) ppm; 
HRMS (ESI+): C19H22ClNOH+ [M+H]+, m/z found: 316.1467; calc.: 316.1463.  
Optical rotation (in CHCl3, 22 °C, λ=589 nm, cuvette 50 mm, 0.48 g/100mL) 27.776.  
7.3.1.4  Characterization of 54b 
 
Protocol 1:  
The reaction was performed in a total reaction volume of 80 mL with 0.4% (v/v) ethanol. The 
reaction was performed with cleared lysate of Wi-4. Enzymes were produced as described in 
ch. 7.1.9.1. In total 1 L cell culture was cultivated and pelleted. The cell pellet was suspended 
with buffer (50 mM HEPES, 100 mM NaCl, pH 7.4) and frozen. The frozen cell suspension was 
thawed in cold water. Ascorbic acid was added to a final concentration of 1.5 mM and cells 
lysed by sonication (6 min with 30 s pulses and 30 s rest). During sonification the suspension 
is put on ice. Then the suspension was pelleted (16000 rpm, 4 °C, 45 min) and the supernatant 
used for the reaction. Reactants KG, ascorbic acid and (NH4)2Fe(SO4)2 were solved in N2 
purged buffer and added to the lysate, so that a final concentration of 10 mM KG, 5 mM 
ascorbic acid, 1 mM (NH4)2Fe(SO4)2 and roughly 20-30 µM Wi-5 (based on average yield from 
purification of enzyme) was obtained. Then 17 mg 54 were solved in 0.3 mL ethanol and added 
to the reaction to achieve a final concentration of 0.75 mM substrate. The reactions were incu-
bated at 30 °C, 100 rpm (Infors Ecotron shaker). After 24 h the reaction was stopped by extrac-
tion with ethyl acetate. 25 mL of the reaction solution were poured in a 50 mL falcon and ex-
tracted 2x with 25 mL ethyl acetate. Phase separation was achieved by centrifugation 
(9000 rpm, 45 min Eppendorf 5810 R, rotor F-34-6-38). The solvent was removed in vacuo. 
Conversion was analyzed by HPLC. A conversion of only 6.5% with 4.7% formation 54a and 
1.9% formation of 54b could be achieved. 
 
Protocol 2: 
The reaction was performed in a total reaction volume of 11x50 mL with 1% (v/v) ethanol. The 
reaction was performed with cleared lysate of Wi-4. Enzymes were produced by heterologous 
expression as described in ch. 7.1.9.1. In total 8.25 L cell culture were prepared and pelleted 
(0.75 L/50 mL reaction). The cell pellets were resuspended with buffer (50 mM HEPES, 
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100 mM NaCl, pH 7.4) and frozen. The frozen cell suspension was defrosted in cold water and 
cells lysed by sonication (6 min with 30 s pulses and 30 s rest). During sonification the suspen-
sion is put on ice and was pelleted (16000 rpm, 4 °C, 45 min). The supernatant was used for 
the reaction. Reactants KG, ascorbic acid and (NH4)2Fe(SO4)2 were solved in N2purged buffer 
and added to the lysate, so that a final concentration of 10 mM KG, 5 mM ascorbic acid, 1 mM 
(NH4)2Fe(SO4)2 and roughly 20-30 µM Wi-5 (based on average yield from purification of en-
zyme) was obtained. Then 77 mg 54 (7 mg/reaction, 0.5 mM final concentration) were solved 
in 3.5 mL ethanol, and 0.5 mL were added to the reaction to achieve a final concentration of 
0.5 mM substrate. The reactions were incubated at 30 °C, 100 rpm (Infors Ecotron shaker). Af-
ter 24 h the reaction was stopped by extraction with ethyl acetate. 25 mL of the reaction solu-
tion were poured in a 50 mL falcon and extracted 2x with 25 mL ethyl acetate. Phase separation 
was achieved by centrifugation (9000 rpm, 45 min, Eppendorf 5810 R, rotor F-34-6-38). The 
solvent was removed in vacuo. Conversion was analyzed by HPLC. A conversion of 35% with 
23% formation 54a and 12% formation of 54b could be achieved. 
Out of economical and time reasons, all samples from protocol 1 and 2 were combined 
before purification by preparative HPLC (ch. 7.5.4). In total 8 mg 54b could be isolated and 
used for analysis 
 
1H-NMR (500 MHz, DMSO), δ = 10.72 (s, 1H, NH), 7.27 (t, 2H, J = Hz), 7.00 (m, 2H), 6.88 (t, J =, 
1H), 5.07 (d, 1H, J =, OH), 4.58 (s, 1H, H17), 4.45 (s, 1H, H17), 4.14 (d, 1H, J = Hz, H10), 3.59 (dt, 
1H, J = Hz, H13), 2.79 (td, 1H, J = Hz, H15), 2.08 (q, 1H, H14), 1.82 (dt, 1H, H14), 1.54 (s, 3H, H18), 
1.22 (s, 3H, H19), 1.05 (s, 3H, H20) ppm; 13C-NMR (125 MHz, DMSO), δ= 211.74 (CO), 146.38, 
136.02, 127.34, 124.13, 120.29, 118.88, 117.86, 111.85, 111.17, 110.67, 73.89, 81.17, 46.04, 45.01, 
36.44, 22.01, 18.91, 18.01 ppm;  
HRMS (ESI+): C20H24ClNO2H+ [M+H]+, m/z found: 298.1804; calc.: 298.1802.  
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7.3.1.5  Characterization of 76a 
 
The reaction was performed in a total reaction volume of 120 mL with 1% (v/v) ethanol. Wi-5 
was produced as described in ch. 7.1.9.1. A pellet of 1.6 L cell culture was resuspended with 
buffer (50 mM HEPES, 100 mM NaCl, pH 7.4) and lysed by sonication. Solid components were 
removed by centrifugation (16000 rpm, 4 °C, 45 min). The supernatant was used for the reac-
tion. Reactants KG, ascorbic acid and (NH4)2Fe(SO4)2 were solved in N2 purged buffer and 
added to the lysate, so that a final concentration of 10 mM KG, 5 mM ascorbic acid, 1 mM 
(NH4)2Fe(SO4)2 and roughly 20-30 µM Wi-5 (based on average yield from purification of en-
zyme) was obtained. 32 mg 76 solved in 1.2 mL ethanol, were added to the reaction(0.11 mmol, 
0.92 mM). The reaction was incubated at 30 °C and 100 rpm (Infors Ecotron shaker). After 24 h, 
the reaction was extracted with 80 mL EtOAc, the phases were separated by centrifugation 
(9000 rpm, 45 min, 4 °C, Eppendorf 5810 R, rotor F-34-6-38) and the solvent was removed un-
der reduced pressure. The crude product was purified by preparative HPLC (isocratic 60 : 40 
ACN : water) and 8.1 mg (25.0 µmol, 25%) of product 76a were obtained as colorless solid.  
 
1H-NMR (500 MHz, CDCl3), δ = 7.93 (s, 1H, NH), 7.22 (d, 1H, J= 8.20 Hz, H7), 7.04 (d, 1H, J= 
0.66 Hz, H4), 7.00-6.96 (m, 1H, H6), 6.89 (d, 1H, J= 2.37 Hz, H2), 4.67 (s, 1H, H17/cis), 4.64-4.63 (m, 
1H, H17/trans), 4.20 (d, 1H, J= 12.8 Hz, H10), 4.13 (dd, 1H, J= 12.3, 4.55 Hz, H13), 2.82 (td, 1H, J= 
12.6, 3.89 Hz, H15), 2.57-2.2.45 (m, 1H, H14), 2.42 (s, 3H, H21) 2.35-2.28 (m, 1H, H14), 1.59 (s, 3H, 
H18), 1.46 (s, 3H, H19), 1.30 (s, 3H, H20) ppm; 13C-NMR (125 MHz, CDCl3), δ= 209.5 (CO), 145.1 
(C16), 134.6 (C8), 128.7 (C5), 127.6 (C9), 123.8 (C6), 123.4 (C2), 118.5 (C4), 113.4 (C17), 111.1 (C7), 
110.7 (C3), 67.1 (C13), 52.0 (C12), 48.4 (C15), 46.9 (C10), 38.7 (C14), 23.0 (C20), 21.8 (C21), 20.5 (C19), 
18.5 (C18) ppm  
HRMS (ESI+): C20H24ClNONa+ [M+Na]+, m/z found: 352.1434; calc.: 352.1439.  
Optical rotation (in CHCl3, 22 °C, λ=589 nm, cuvette 50 mm, 0.68 g/100mL) 7.814. 
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7.3.1.6  Characterization of 77a 
 
The reaction was performed by L. Schmermund[317] in a total reaction volume of 129 mL with 
1% (v/v) ethanol. Wi-5 was produced as described in ch. 7.1.9.1. A pellet of 0.8 L cell culture 
was resuspended with buffer (50 mM HEPES, 10 mM NaCl, pH 7.4) and lysed by sonication. 
Solid components were removed by centrifugation (16000 rpm, 4 °C, 45 min). The supernatant 
was used for the reaction. Reactants KG, DTT and (NH4)2Fe(SO4)2 were solved in N2 purged 
buffer and added to the lysate, so that a final concentration of 2.5 mM KG, 0.5 mM DTT, 
0.5 mM (NH4)2Fe(SO4)2 and roughly 20-30 µM Wi-5 (based on average yield from purification 
of enzyme) was obtained. 60 mg (0.19 mmol, 1.5 mM) ketone 77, solved in 1.29 mL ethanol and 
added to the reaction. The reaction was incubated at 30 °C and 150 rpm for 24 h. After 24 h the 
reaction was extracted with EtOAc (4 x 10 mL), the phases were separated by centrifugation 
(4000 rpm, 15 min, 4 °C) and the solvent was removed under reduced pressure. The crude 
product was purified by preparative HPLC (isocratic 60 : 40 ACN : water) and 4.5 mg 
(13.0 µmol, 7%) of chlorinated product 77a were obtained as colorless solid.  
 
HPLC: Retention time 6.23 min (isocratic ACN/H2O 71:29); 1H-NMR (500 MHz, CDCl3), δ = 
7.95 (s, 1H, NH), 7.22 (d, 1H, J = 8.75 Hz, H7), 6.90 (d, 1H, J = 2.45 Hz, H4), 6.82 (dd, J = 8.75, 2.40 
1H, H6), 6.72 (d, 1H, J = 2.41 Hz, H2), 4.67 (s, 1H, H17/cis), 4.64-4.63 (m, 1H, H17/trans), 4.20 (d, 1H, J 
= 12.8 Hz, H10), 4.11 (dd, 1H, J = 12.4, 4.53 Hz, H13), 3.83 (s, 3H, H21), 2.79 (td, 1H, J = 12.7, 3.65 
Hz, H15), 2.54-2.47 (m, 1H, H14), 2.34-2.29 (m, 1H, H14), 1.58-1.59 (m, 3H, H18), 1.45 (s, 3H, H19), 
1.29 (s, 3H, H20) ppm; 13C-NMR (125 MHz, CDCl3), δ= 209.5 (CO), 154.0 (C5), 144.9 (C16), 131.5 
(C8), 127.9 (C9), 124.2 (C4), 113.4 (C17), 112.0 (C7), 111.5 (C6), 110.7 (C3), 101.6 (C2), 67.1 (C13), 56.1 
(C21), 52.0 (C12), 48.4 (C15), 46.9 (C10), 38.6 (C14), 23.0 (C20), 20.4 (C19), 18.5 (C18) ppm;  
HRMS (ESI+): C20H24ClNO2H+ [M+H]+, m/z found: 346.1570; calc.: 346.1568.  
Optical rotation (in CHCl3, 22 °C, λ=589 nm, cuvette 50 mm, 0.65 g/100mL) 13.508. 
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7.3.1.7  Characterization of 78a 
 
The reaction was performed in a total reaction volume of 158 mL with 1% (v/v) ethanol. Wi-5 
was produced as described in ch. 7.1.9.1. A pellet originating from 1 L cell culture was resus-
pended with buffer (50 mM HEPES, 50 mM NaCl, pH 7.4) and lysed by sonication. Solid com-
ponents were removed by centrifugation (16000 rpm, 4 °C, 45 min). The supernatant was used 
for the reaction. Reactants KG, ascorbic acid and (NH4)2Fe(SO4)2 were solved in N2 purged 
buffer and added to the lysate, so that a final concentration of 2.5 mM KG, 1.25 mM ascorbic 
acid, 0.5 mM (NH4)2Fe(SO4)2 and roughly 20-30 µM Wi-5 (based on average yield from purifi-
cation of enzyme) was obtained. Then 70 mg (0.24 mmol, 1.5 mM) ketone 78, solved in 1.58 mL 
ethanol, were added to the reaction. The reaction was incubated at 30 °C, 100 rpm (Infors Eco-
tron shaker). The reaction was stopped by extraction after 24 h. The organic phase was dried 
in vacuo and purified via preparative HPLC. A conversion of 14% were achieved and after 
purification 7 mg pure 78a (10% yield) were obtained.  
 
1H-NMR (500 MHz, CDCl3), δ = 7.90 (s, 1H, NH), 7.10 (d, 1H, J = 8.1 Hz, H4), 7.12 (m, 1H, H7), 
6.90 (m, 1H, H5), 6.85 (d, 1H, J = 2.30 Hz, H2), 4.66 (m, 1H, H17/cis), 4.62 (m, 1H, H17/trans), 4.19 (d, 
1H, J = 12.8 Hz, H10), 4.12 (dd, 1H, J =12.4, 4.5 Hz), 2.80 (dt, 1H, J = 12.7, 3.7 Hz, H15), 2.54-2.46 
(m, 1H, H14), 2.43 (s, 3H, H21), 2.33-2.29 (dt, 1H, J=13.6, 4.1 H14), 1.58-1.57 (m, 3H, H18), 1.44 (s, 
3H, H19), 1.28 (s, 3H, H20) ppm; 13C-NMR (125 MHz, CDCl3), δ= 209.4 (CO), 142.0 (C16), 136.7 
(C8), 131.8 (C6), 125.2 (C9), 122.6 (C2), 121.4 (C5), 118.6 (C4), 113.4 (C17), 111.4 (C3.), 111.0 (C7), 67.1 
(C13), 52.0 (C12), 48.5 (C15), 47.0 (C10), 38.7 (C14), 23.0 (C20), 21.8 (C21), 20.4 (C19), 18.5 (C18) ppm; 
HRMS (ESI+): C20H24ClNO [M+H]+, m/z found: 330.1614; calculated 330.1619.  
Optical rotation (in CHCl3, 22 °C, λ=589 nm, cuvette 50 mm, 0.49 g/100mL) 5.039. 
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7.3.1.8  Product Identification from Biotransformation with 81 
 
The reaction was performed in a total reaction volume of 6x50 mL with 1% (v/v) ethanol. The 
reaction was performed with cleared lysate (50 mL Wi-5, 5x50 mL Wi-12) to compare conver-
sion. Wi-5 and Wi-12 were produced as described in ch. 7.1.9.1. The cell pellets of 0.75 L (Wi-5) 
and 3.75 L (Wi-12) cell culture were resuspended with buffer (50 mM HEPES, 100 mM NaCl, 
pH 7.4) and lysed by sonication. Solid components were removed by centrifugation 
(16000 rpm, 4 °C, 45 min). The supernatant was used for the reaction. Reactants KG, ascorbic 
acid and (NH4)2Fe(SO4)2 were solved in N2 purged buffer and added to the lysate, so that a 
final concentration of 10 mM KG, 5 mM ascorbic acid, 1 mM (NH4)2Fe(SO4)2 and roughly 20-
30 µM Wi-5 and Wi-12 (based on average yield from purification of enzyme) was obtained. 
Then 40 mg ketone 81 were solved in 2 mL ethanol (75 mM) and 13 mg 81 were solved in 1 mL 
ethanol (50 mM) so that 0.5 mL were added to the reaction to achieve a final concentration of 
0.75 mM or 0.5 mM substrate. The reactions were incubated at 30 °C, 100 rpm (Infors Ecotron 
shaker). The reaction was stopped by extraction after 24 h. After extraction, a sample was taken 
to compare conversion of each reaction. At least 6 products were produced within the reac-
tions. Total conversions of 11% (Wi-5 lysate), 28% (Wi-12 lysate, 0.75 mM 81) and 37% (Wi-12 
lysate, 0.5 mM 81) were obtained. The solvent was removed in vacuo and dry remaining sam-
ples solved again in acetonitrile. Out of economical and time reasons, the samples were com-
bined before purification by preparative HPLC. 
81a HPLC (71 : 29 ACN : H2O): 2.2 min LC-MS (ESI+) (M+H)+: 146.100 g/mol 
81b HPLC (71 : 29 ACN : H2O): 2.6 min LC-MS (ESI+) (M+H)+: 284.100 g/mol 
81c HPLC (71 : 29 ACN : H2O): 3.0 min LC-MS (ESI+) (M+H)+: 254.200 g/mol 
81d HPLC (71 : 29 ACN : H2O): 3.2 min LC-MS (ESI+) (M+H)+: 284.100 g/mol 
81e HPLC (71 : 29 ACN : H2O): 3.4 min LC-MS (ESI+) (M+H)+: 282.100 g/mol 
81f HPLC (71 : 29 ACN : H2O): 4.5 min LC-MS (ESI+) (M+H)+: 310.100 g/mol and 266 g/mol 
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7.3.1.9  Product Identification from Biotransformation with 82 
 
The reaction was performed in a total reaction volume of 6x50 mL with 1% (v/v) ethanol. The 
reaction was performed with purified enzyme (1x50 mL Wi-5) and cleared lysate (4x50 mL 
Wi-5, 1x50 mL Wi-12) to compare conversion. Wi-5 and Wi-12 were produced as described 
above. The cell pellets of 3 L Wi-5 and 0.75 L Wi-12 cell culture were resuspended with buffer 
(50 mM HEPES, 100 mM NaCl, pH 7.4) and lysed by sonication. Solid components were re-
moved by centrifugation (16 000 rpm, 4 °C, 45 min). The supernatant was used for the reaction. 
Reactants KG, ascorbic acid and (NH4)2Fe(SO4)2 were solved in N2 purged buffer and added 
to the lysate, so that a final concentration of 10 mM KG, 5 mM ascorbic acid, 1 mM 
(NH4)2Fe(SO4)2 and roughly 20-30 µM Wi-5 and Wi-12 (based on average yield from purifica-
tion of enzyme) was obtained. The reaction with purified enzyme was prepared with 30 µM 
Wi-5. Then 51 mg ketone 82 were solved in 3 mL ethanol, and 500 µL were added to the reac-
tion to achieve a final concentration of 0.75 mM substrate. The reactions were incubated at 
30 °C, 100 rpm (Infors Ecotron shaker). The reaction was stopped by extraction after 22 h. After 
extraction, a sample was taken to compare the conversion of each reaction. The solvent was 
removed in vacuo and dry remaining samples solved again in acetonitrile. Out of economical 
and time reasons, the samples were combined before purification by preparative HPLC. Two 
products were produced with all variants. Total conversions of 55% (Wi-5 lysate), 58% (Wi-5 
purified enzyme) and 55% (Wi-12 lysate) were achieved and after purification 5 mg 82a and 
5 mg 82b were obtained.  
82a HPLC (71-29 ACN/H2O): 2.0 min, HRMS (ESI+): C15H17NO3 [M+Na]+, m/z found: 282.1098; 
calculated 282.1101. NMR analysis revealed 82a to have an opened terpene ring and a carboxyl 
group, however no complete satisfying NMR analysis could be done since impurities were 
still remaining 
82b HPLC (71-29 ACN/H2O): 2.8 min LC-MS: 226.100 g/mol. NMR analysis revealed 82b to be 
a complex mix of at least two stereoisomers.  
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7.3.1.10  Product Identification from Biotransformation with 83 
 
The reaction was performed in a total reaction volume of 6x50 mL with 10% (v/v) ethanol. The 
reaction was performed with cleared lysate of Wi-12. Enzymes were produced by heterologous 
expression as described in ch.7.1.9.1. In total 4.5 L cell culture were prepared and pelleted 
(0.75 L/50 mL reaction). The cell pellets were resuspended with buffer (50 mM HEPES, 100 
mM NaCl, pH 7.4) and frozen. The frozen cell suspension was defrosted in cold water and 
cells lysed by sonication (6 min with 30 s pulses and 30 s rest). During sonification the suspen-
sion is put on ice and was pelleted (16 000 rpm, 4 °C, 45 min). The supernatant was used for 
the reaction. Reactants KG, ascorbic acid and (NH4)2Fe(SO4)2 were solved in nitrogen purged 
buffer and added to the lysate, so that a final concentration of 10 mM KG, 5 mM ascorbic 
acid, 1 mM (NH4)2Fe(SO4)2 and roughly 20-30 µM Wi-12 (based on average yield from purifi-
cation of enzyme) was obtained. Then 41 mg ketone 83 (6.8 mg/reaction) were solved in 3.0 mL 
ethanol, and 0.5 mL were added to the reaction to achieve a final concentration of 0.5 mM 
substrate. The reactions were incubated at 30 °C, 100 rpm (Infors Ecotron shaker). The reaction 
was stopped by extraction after 22 h. After extraction, a sample was taken to compare conver-
sion of each reaction. At least 5 products were produced within the reactions. The total con-
versions of 19% and 26% were obtained. The solvent was removed in vacuo and dry remaining 
samples solved again in acetonitrile. Out of economical and time reasons, the samples were 
combined before purification by preparative HPLC. Fractions were analyzed by LC-MS. Less 
than 1 mg of all products was obtained after purification process.  
83a HPLC (71-29 ACN/H2O): 2.2 min LC-MS (ESI+) (M+H)+: 146.100 g/mol 
83b HPLC (71-29 ACN/H2O): 2.4 min LC-MS (ESI+) (M+H)+: 282.100 g/mol 
83c HPLC (71-29 ACN/H2O): 3.0 min LC-MS (ESI+) (M+H)+: 266.200 g/mol 
83d HPLC (71-29 ACN/H2O): 3.6 min LC-MS (ESI+) (M+H)+: 266.100 g/mol 
83e HPLC (71-29 ACN/H2O): 4.3 min LC-MS (ESI+) (M+H)+: 282.100 g/mol 
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7.3.2 Oxygenase P450BM3 
 
Protocol 1: 
Cell pellets from protein production P450BM3 variants R47G/F87G (1 L culture) and F87G/ 
L181T (1 L culture) were thawed in cold water. The cell suspension was mixed with lysozyme 
to a final concentration of 2 mg/mL and 500 µL DNase I (concentration unknown) in a 50 mL 
reaction tube. The tube was incubated at 80 rpm, 37 °C in an Infors Ecotron shaker. After 
60 min, the probe was further lysed by sonication (6.5 min with 30 s pulses and 30 s pause). 
The cell suspension was cooled in a water/ice bath during sonication and subsequently pel-
leted (16000 rpm, 4 °C, 45 min). The supernatant was dark brown, indicating a high oxygenase 
concentration.  
The reactions were performed in two 500 mL flat bottom flasks with each 100 mL reaction 
volume. 10 mL glucose (from 1 M stock solution), 10 mL EDTA (from 50 mM stock solution), 
6.5 mL glycerol (80% in H2O) were mixed with 22.5 mL 100 mM potassium phosphate buffer, 
pH 7.4 buffer and 50 mL lysate. Finally, 900 µL substrate were added from a 0.115 M stock in 
acetonitrile to a final concentration of 1 mM. The flasks were incubated at 30 °C, 100 rpm in an 
Infors Ecotron incubator. The reactions were stopped by extraction after 21 h. 30 mL reaction 
volume were extracted with 2x20 mL ethyl acetate. The solvent was removed in vacuo. Variant 
F87G/L181T yielded a conversion of 23% with formation of two products (54e and 54f) and 
65% selectivity for 54e. Variant R47G/F87G yielded a conversion of 18% with formation of two 
products (54e and 54f) and 67% selectivity for 54f. 
Protocol 2: 
Cell pellets from protein production P450BM3 variants R47H/F87G/L181A (0.53 L culture), 
R47V/F87G/L181T/L188N (0.58 L culture) and R47E/F87G/L181V/M185S/L188G (0.56 L cul-
ture) were thawed in cold water. The cell suspension was mixed with lysozyme to a final con-
centration of 1 mg/mL and a spatula tip of DNase I (concentration unknown) in a 50 mL reac-
tion tube. The tube was incubated at 80 rpm, 37 °C in an Infors Ecotron shaker. After 20 min, 
the probe was further lysed by sonication (6.5 min with 30 s pulses and 30 s pause). The cell 
suspension was cooled in a water/ice bath during sonication and subsequently pelleted 
(16000 rpm, 4 °C, 45 min). The absorption of the supernatant was measured, and the concen-
tration determined by Lambert-Beer law and 417nm = 121 mM-1cm-1. 
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Figure 62. Absorption spectra of P450BM3 variants. 
The reaction was prepared by mixing 250 eq glucose (250 mM), 0.25 eq NADP+ (0.25 mM), 
2.2 U/ml glucose dehydrogenase, 5% glycerol and 5 µM enzyme in 100 mM potassium phos-
phate buffer pH 8.0. Finally, substrate was added from a 0.2 M stock in acetonitrile to a final 
concentration of 1 mM (1 eq). The flask was incubated at 30 °C, 80 rpm in an Infors Ecotron 
shaker. After 3.5 h the shaking speed was increased to 110 rpm and after 5 h, 6 mL lysate of 
each variant were added to the corresponding reactions. The reaction was stopped by extrac-
tion after 20 h. 30 mL reaction volume was extracted with 2x20 mL ethyl acetate. The solvent 
was removed in vacuo. Variant R47V/F87G/L181T/L188N yielded a conversion of 83%, 
R47E/F87G/L181V/M185S/L188G yielded a conversion of 65% and variant R47H/F87G/L181A 
60%. All variants formed four products 54c, 54d, 54e and 54f. Selectivities are given in table 
16, ch. 3.6.4.2.  
Protocol 3: 
Because only few 54e and 54f were produced in the above described reaction (protocol 2), the 
reaction was repeated with variants R47V/F87G/L181T/L188N and R47E/F87G/L181V 
/M185S/L188G. Lysate which was left over and frozen at -80 °C from protocol 2 was used. 
Reaction conditions were used as described in protocol 2 (without the second addition of ly-
sate). The reaction was stopped after 2.5 h by extraction with ethyl acetate as described above. 
Variant R47V/F87G/L181T/L188N yielded a conversion of 14% with formation of two prod-
ucts (54e and 54f) and 67% selectivity for 54e. Variant R47E/F87G/L181V/M185S/L188G 
yielded a conversion of 9% with formation of two products (54e and 54f) and 46% selectivity 
for 54e. 
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7.3.2.1 Characterization of 54c-54f 
All products were combined and purified via prep HPLC in 2 runs. Fractions were analyzed 
by HPLC-UV/vis and the solvent removed in vacuo, followed by NMR analysis of the prod-
ucts. All products were analyzed by 1H, 13C and HMQC NMR. 54e additionally by NOESY 
NMR. The spectra can be found in chapter 8.6. 
54c 
1H-NMR (500 MHz, DMSO-d6) δ 10.69 (s, 1H, NH), 7.28 (d, J = 8.8 Hz, 2H), 7.01 – 6.97 (m, 1H), 
6.93 (s, 1H), 6.89 – 6.85 (m, 1H), 5.01 (s, 1H, OH), 4.83 (s, 2H), 4.65 (t, J = 5.5 Hz, 1H), 4.19 (d, J 
= 12.3 Hz, 1H, H10), 3.83 – 3.79 (m, 1H, H14), 3.72 – 3.65 (m, 1H), 3.62 – 3.55 (m, 1H), 3.28 (dd, J 
= 12.4, 4.0 Hz, 1H, H15), 2.39 – 2.33 (m, 1H, H13), 2.07 (s, 2H, H18), 1.84 (dt, J = 14.0, 3.9 Hz, 1H, 
H13), 1.30 (s, 3H, H19), 1.03 (s, 3H, H20). 
13C-NMR (126 MHz, DMSO) δ 212.61 (CO), 174.27, 151.94, 136.17, 129.66, 127.20, 123.96, 120.31, 
119.42, 118.13, 117.74, 111.75, 111.20, 108.25, 76.06(C14), 62.43, 49.56(C12), 47.37(C10), 41.49(C15), 
35.68(C13), 24.87(C19), 21.86(C20), 1.19(C18). 
54d 
1H-NMR (300 MHz, DMSO-d6) δ 10.77 (s, 1H, NH), 7.33 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 7.8 Hz, 
1H), 7.15 (d, J = 2.4 Hz, 1H), 7.03 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 6.89 (ddd, J = 8.0, 7.0, 1.1 Hz, 
1H), 5.06 (d, J = 3.5 Hz, 1H, OH), 4.09 – 3.97 (m, 1H, H10), 3.90 (t, J = 3.1 Hz, 1H, H14), 2.35 (m, 
2H, H15, H13), 1.95 (d, J = 5.2 Hz, 1H, H17), 1.86 (m, 1H, H13), 1.57 (d, J = 5.2 Hz, 1H, H17), 1.28 (s, 
3H, H18), 1.23 (s, 3H, H19), 1.06 (s, 3H, H20) ppm. 
13C-NMR (75 MHz, DMSO-d6) δ 211.90 (CO), 136.40, 126.72, 124.13, 120.43, 119.54, 117.78, 
111.35, 110.99, 75.67(C14), 57.80(C17), 54.68(C16), 49.44(C12), 46.32(C10), 43.89(C15), 29.70(C13), 
24.88(C18), 21.76(C20), 15.50(C19) ppm.  
HRMS (ESI+): C19H23NO3 [M+H]+, m/z found: 314.1748; calculated 314.1751 
54e 
1H-NMR (300 MHz, DMSO-d6) δ 10.69 (s, 1H, NH), δ 7.28 (d, J = 8.2 Hz, 2H), 7.03 – 6.96 (m, 
2H), 6.92 – 6.83 (m, 1H), 5.03 (d, J = 3.4 Hz, 1H, OH), 4.50 (d, J = 2.4 Hz, 1H, H17), 4.46 – 4.41 (m, 
1H, H17), 4.12 (d, J = 12.4 Hz, 1H, H10), 3.84 (s, 1H, H14), 3.41 (td, J = 12.5, 4.1 Hz, 1H, H15), 2.36 
(s, 1H, H13), 1.75 (dt, J = 14.2, 4.0 Hz, 1H, H13), 1.57 (s, 3H, H18), 1.30 (s, 3H, H19), 1.04 (s, 3H, H20) 
ppm. 
13C-NMR (75 MHz, DMSO) δ 212.36(CO), 146.79(C16), 136.17, 127.10, 123.81, 120.23, 119.31, 
117.67, 111.52, 111.39, 111.14(C17), 76.03(C14), 49.45(C10), 46.69(C12), 45.25(C15), 34.22(C13), 24.87, 
21.76, 18.34(C18) ppm.  
HRMS (ESI+): C19H24NO2 [M+H]+, m/z found: 298.1799; calculated 298.1802 
54f 
1H-NMR (300 MHz, DMSO-d6) δ 10.82 (s, 1H, NH), 7.33 (d, J = 8.1 Hz, 1H), 7.25 (d, J = 7.6 Hz, 
1H), 7.17 (d, J = 2.4 Hz, 1H), 7.03 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 6.90 (ddd, J = 8.1, 7.0, 1.2 Hz, 
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1H), 4.11 – 4.05 (m, 1H, H10), 2.18 (t, J = 7.3 Hz, 1H), 1.94 (d, 1H, , J = 5.1 Hz,  H17), 1.91-1.68 (m, 
6H), 1.30 (s, 3H), 1.18 (s, 3H), 1.02 (s, 3H) ppm. 
13C-NMR (75 MHz, DMSO) δ 212.02, 136.24, 136.24, 126.99, 124.42, 120.43, 119.16, 117.94, 
111.37, 110.16, 58.67(C16), 55.45(C17), 50.96(C15), 47.39(C10), 44.97(C12), 38.69(C13/14), 26.30(C18) 
25.63(C20), 23.48 (C13/14) 15.99(C19) ppm.  
HRMS (ESI+): C19H23NO2 [M+H]+, m/z found: 298.1799; calculated 298.1802 
7.3.3 Reductase TsER 
To synthesize substrates which further should be tested within the substrate scope of the hal-
ogenase, several reductions had to be performed. Therefore the reductase TsER of Thermus 
scotoductus SA-01 was used as variant TsER C25D/I67T as described by Nett et al.[315,432] 
7.3.3.1 (2R,5S)-2-methyl-5-(prop-1-en-2-yl)cyclohexan-1-one (63) 
 
The reaction was performed in a total reaction volume of 500 mL with 20% (v/v) n-pentane in 
analogy to Nett et al.[315,432]. 9.91 g (50.0 mmol, 2.0 eq, 100 mM) glucose monohydrate, 1.25 mL 
of a 100 mM NADP+ disodium salt solution, 3 mL of a 222 U/mL BsGDH[448] solution 
(2.2 U/mL), 250 µL of a 100 mM CoCl2 (0.11 mM) and 14 mL of a 119 µM TsER C25DT/I67T 
solution were mixed with KPi-buffer (100 mM, pH 7.4) to a volume of 400 mL in a 500 mL 
Schott bottle. Then 5.4 mL (34.1 mmol, 67 mM) (S)-carvone 62 was solved in 100 mL n-pentane 
and added to the bottle. The reaction was incubated at 30 °C, 160 rpm for 24 h in an Infors HT 
Multitron shaker. Reaction progress was followed by GC. After 24 h no increase of conversion 
could be detected, and the reaction was extracted with diethyl ether (2 x 100 mL) with 98% 
conversion (%GC). The combined organic phases were washed with brine, dried over MgSO4 
and the solvent was removed under reduced pressure. 5.3 g (35.8 mmol) of product 63 was 
obtained as colorless oil. The diastereomeric ratio is 94:6 (cis/trans). 
Rf = 0.90 (pentane/EtOAc 5:1); 1H-NMR (500 MHz, CDCl3), δ = 4.83 (s, 1H, H9/cis), 4.69 (s, 1H, 
H9/trans), 2.62-2.52 (m, 2H), 2.43-2.37 (m, 2H), 1.90-1.82 (m, 3H, 1/2 H3, H4), 1.73 (s, 3H, H10), 1.65-
1.56 (m, 1H, 1/2 H3), 1.05 (d, 3H, J = 6.9 Hz, H7) ppm; 13C-NMR (125 MHz, CDCl3), δ = 214.0 
(CO), 147.0 (C8), 111.5 (C9), 44.6 (C6), 44.1 (C5), 44.0 (C2), 30.7 (C3), 26.4 (C4), 21.5 (C10), 15.6 (C7) 
ppm; 
HRMS (EI+): C10H16O1, m/z found: 152.12014, cal.: 152.12011. 
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7.3.3.1 2S,3S)-2-(1H-indol-3-yl)-6-methyl-3-(prop-1-en-2-yl)cyclohexan-1-one (81) 
 
The reaction was performed in a total reaction volume of 625 mL with 20% (v/v) acetone. Based 
on synthesis instructions of Nett et al.[315,432]. 11 g (55 mmol, 88 mM) glucose monohydrate, 
0.24 mM NADP+ disodium salt, 2.2 U/mL engineered BsGDH[448], 278 µL of 100 mM aq. 
CoCl2 (0.04 mM) and 16.0 µM TsER C25DT/I67T variant were mixed with 407 mL KPi-buffer 
(200 mM, pH 7.4) in a 1 L Schott bottle. Then 1.122 g (4.24 mmol, 1.0 eq, 6.78 mM) ke-
tone 84 was solved in 125 mL acetone and added to the reaction. The reaction was incubated 
at 30 °C, 160 rpm for 24 h in an Infors HT shaker. After 24 h the reaction was extracted with 
EtOAc. HPLC analysis showed 73% conversion. The solvent was removed in vacuo and the 
crude product was purified by flash column chromatography (pentane : EtOAc 4:1) to give 
635 mg (2.34 mmol, 55%) of product 81 as a brown solid. Further 240 mg product/educt mix 
(83% educt, 17% product) were collected as impure fractions after column chromatography.  
HPLC: Retention time 7.05 min (isocratic ACN/H2O 65:35); 1H-NMR (500 MHz, CDCl3), δ = 
8.09 (s, 1H, NH), 7.53 (d, 1H, J = 7.68 Hz, H7), 7.32 (d, 1H, J = 7.93, H4), 7.18-7.15 (m, 1H, H6), 
7.10-7.07 (m, 1H, H5), 7.01 (d, 1H, J = 1.68 Hz, H2), 4.75-4.74 (m, 2H, H17), 4.15 (dd, 1H, J = 8.05, 
0.50 Hz, H10), 3.08-3.04 (m, 1H, H15), 2.78-2.71 (m, 1H, H12), 2.05-2.00 (m, 3H, H13/14), 1.80-1.74 
(m, 1H, H13), 1.69 (s, 3H, H18), 1.20 (d, 3H, J = 6.90, H19)  ppm; 13C-NMR (125 MHz, CDCl3), δ= 
213.8 (CO), 146.8 (C16), 136.2 (C8), 127.2 (C9), 122.2 (C2), 122.2 (C6), 119.6 (C5), 119.6 (C4), 113.1 
(C3), 112.4 (C17), 111.3 (C7), 50.0 (C15), 49.7 (C10), 43.1 (C12), 31.3 (C13), 25.9 (C14), 20.7 (C18), 16.2 
(C19) ppm;  
HRMS (ESI+): C18H21NONa+ [M+Na]+, m/z found: 290.1511; calc.: 290.1515. 
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7.3.3.2  2-(1H-indol-3-yl)6-methylcyclohexan-a-one (82) 
 
The reaction was performed in a total reaction volume of 625 mL with 20% (v/v) acetone. Based 
on synthesis instructions of Nett et al.[315,432]. 11 g (55 mmol, 88 mM) glucose monohydrate, 
0.24 mM NADP+ disodium salt, 2.2 U/mL engineered BsGDH[448], 278 µL of 100 mM aq. 
CoCl2 (0.04 mM) and 16.2 µM TsER C25DT/I67T variant were mixed with 407 mL KPi-buffer 
(200 mM, pH 7.4) in a 1 L Schott bottle. Then 1.25 g (5.5 mmol, 1.0 eq, 8.88 mM) ketone 21 was 
solved in 125 mL acetone and added to the reaction. The reaction was incubated at 30 °C, 
160 rpm for 24 h in an Infors HT shaker. After 24 h the reaction was extracted with EtOAc. The 
solvent was removed in vacuo and the crude product was purified by flash column chroma-
tography (pentane : EtOAc 4:1) to give 424.4 mg (1.86 mmol, 34%) of product 82 as a brown 
solid. The diastereomeric ratio is 50:50 and was determined by HPLC-UV/Vis. The diastere-
omers were not separated. 
Rf = 0.42 (pentane : EtOAc 5:1); 1H-NMR (500 MHz, CDCl3), δ = 8.07 (s, 1H, NH), 7.45 (d, 1H, J 
= 7.95 Hz, H4), 7.38 (d, 1H, J = 8.75, H7), 7.23 (s, 1H, H2), 7.22-7.18 (m, 1H, H6), 7.14-7.09 (m, 1H, 
H5), 4.00-3.96 (m, 1H, H10), 2.73-2.68 (m, 1H, H12), 2.51-2.47 (m, 1H, H15), 2.29-2.24 (m, 1H, H15), 
2.02-1.98 (m, 2H, H14), 1.61-1.55 (m, 2H, H13), 1.13 (d, 3H, J = 6.56 Hz, H16) ppm; 13C-NMR (75 
MHz, CDCl3), δ= 199.5, 146.2, 136.5, 135.8, 127.4, 122.8, 119.6, 119.5, 113.2, 113.0, 111.5, 49.4, 
48.6, 31.1, 19.7, 16.5 ppm; 
HRMS (ESI+): C15H17NOH+ [M+H]+, m/z found: 228.1380; calc.: 228.1383. 
7.4 Chemical Synthesis 
7.4.1 General Information 
Commercially available chemicals were ordered in highest available purity and used without 
further purification. Analytical grade solvents for reactions and HPLC were purchased from 
VWR, if necessary dried using standard protocols.[449] Solvents for chromatography were used 
from the institute’s supply after distillation. Compressed air, liquid and gaseous nitrogen were 
used from the institutes supply without further purification. High-purity water was generated 
by further purifying the deionized water from the institute with a TKA Micropure purification 
system. 
Chemical syntheses were performed under inert nitrogen gas atmosphere unless otherwise 
specified, using Schlenk technique and flasks dried by repeated heating and flushing with in-
ert gas. Transfer of solvents and liquid compounds was achieved using syringes and septa. 
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For analysis by thin layer chromatography (TLC), commercially available silica gel sheets 
were used (TLC Silica 60 F254 from Merck). Detection of the substances was performed under 
UV light at wavelengths of 254 or by staining with a potassium permanganate dip. Purification 
by flash column chromatography was carried out using silica gel 60 (particle size of 40-60 µm, 
from Merck), and under increased pressure from the house air supply. 
Synthesis of 53, 67 and 77 were performed solely by L. Schmermund instructions can be found 
in his master thesis,[317] synthesis of substrates 76, 78, 82 and 83 were first made by L. 
Schmermund but later resynthesized within this thesis. Synthesis of 79 and 80 was made in 
the group of R. Viswanathan (unpublished results) and can be compared to a synthesis rout to 
hapalindole Q by Baran and Richter.[350] Analytical data to the latter compounds can be found 
in chapter 8.6. NMR spectra as well as HPLC chromatograms for all compounds can also be 
found in chapter 8.6. 
7.4.2  (S)-2,2-dimethyl-5-(prop-1-en-2-yl)cyclohexan-1-one (64) 
 
In analogy to instructions of Laplace et al.[450] under nitrogen atmosphere NaH (1.45 g, 
36.3 mmol, 1.0 eq) was suspended in abs. THF (111 mL). After adding (5S)-dihydrocarvone 
(63) (5.516 mg, 36.3 mmol, 1.0 eq), the suspension was heated to reflux (85°C) for 3 h. The re-
sulting orange solution was cooled down to –10°C (acetone/ice bath) and MeI (4.52 mL, 
72.6 mmol, 2.0 eq) was added dropwise within 10 min. The reaction was warmed up to rt 
(~22°C) and stirred for 18 h. Brine (100 mL) was added to the reaction mixture and it was 
stirred for 30 min. The suspension was extracted with Et2O (3 x 150 mL), the combined organic 
phases were dried over MgSO4 and the solvent was removed under reduced pressure. The 
crude product was purified by column chromatography (pentane : EtOAc 50:1) and 4.19 g 
(25.23 mmol, 70%) of 64 were obtained as colorless oil.  
Rf = 0.43 (pentane : EtOAc 25:1); 1H-NMR (500 MHz, CDCl3), δ = 4.77 (s, 1H, H10), 4.72 (s, 1H, 
H10), 2.57-2.47 (m, 1H, 1/2 H6), 2.37-2.34 (m, 1H, 1/2 H6), 2.33-2.30 (m, 1H, H5), 1.82-1.78 (m, 1H, 
1/2 H4), 1.77-1.76 (m, 2H, 1/2 H4, 1/2 H3), 1.73 (s, 3H, H11), 1.60-1.55 (m, 1H, 1/2 H3), 1.16 (s, 3H, 
H7), 1.07 (s, 3H, H8) ppm; 13C-NMR (125 MHz, CDCl3), δ= 215.7 (CO), 147.8 (C9), 110.0 (C10), 
46.5 (C5), 44.7 (C2), 43.2 (C6), 39.7 (C3), 26.6 (C4), 25.3 (C7), 25.3 (C8), 20.8 (C11) ppm;  
HRMS (EI+): C11H18O1, m/z found: 166.13497, cal.: 166.13576. 
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7.4.3 (5S,6S)-6-(1H-indol-3-yl)-2,2-dimethyl-5-(prop-1-en-2-yl)cyclohexan-1-one 
(54) 
 
In analogy to instructions of Maimone et al.[352] 1.65 g (8.3 mmol, 1.0 eq) 64 and 1.95 g 
(16.6 mmol, 2.0 eq) 92 were solved in 50 mL abs. THF under nitrogen atmosphere. The solution 
was cooled to -78 °C (acetone/dry ice) and 25.0 mL 1.0 M LiHMDS in THF (25.0 mmol, 3.0 eq) 
were added dropwise within 10 min. After stirring for 30 min, 4.35 g (12.45 mmol, 1.5 eq) cop-
per(II) 2-ethylhexanoate were added rapidly and stirring was continued for 15 h, while the dry 
ice/acetone bath was slowly warmed to room temperature. The solution was poured into 1 M 
HCl (100 mL) and EtOAc (90 mL). Subsequently the aqueous phase was extracted with EtOAc 
(3 x 90 mL). The combined organic phase was washed with 1 M HCl (100 mL), 1 M NaOH 
(100 mL), then brine (100 mL) and was dried over MgSO4. The solvent was removed under 
reduced pressure and the crude product was purified by flash column chromatography (pen-
tane : EtOAc gradient from 6:1 to 3:1) to give 730 mg (2.6 mmol, 31%) of the coupled product 
54 as a light brown solid.  
Rf = 0.35 (pentane : EtOAc 4:1); 1H-NMR (500 MHz, CDCl3), δ = 8.04 (s, 1H, NH), 7.34 (d, 1H, J 
= 7.90 Hz, H7), 7.28 (td, 1H, J = 8.08, 0.83 Hz, H4), 7.14-7.11 (m, 1H, H6), 7.06-7.03 (m, 1H, H5), 
6.87 (d, 1H, J = 2.25 Hz, H2), 4.62-4.61 (m, 1H, H17/cis), 4.56-4.55 (m, 1H, H17/trans), 4.20 (d, 1H, J= 
12.5 Hz, H10), 2.90 (dt, 1H, J = 12.2, 3.70 Hz, H15), 2.22-2.13 (m, 1H, H14), 1.95-1.90 (m, 1H, H13), 
1.85-1.78 (m, 2H, H13/14.), 1.58-1.57 (m, 3H, H18), 1.41 (s, 3H, H19), 1.14 (s, 3H, H20) ppm; 13C-NMR 
(125 MHz, CDCl3), δ= 213.7 (CO), 147.0 (C16), 136.2 (C8), 127.6 (C9), 123.3 (C2), 121.7 (C6), 119.3 
(C5), 119.1 (C7), 112.1 (C3), 112.0 (C17.), 111.3 (C4), 53.3 (C15), 47.8 (C10), 45.3 (C12), 40.3 (C13), 28.2 
(C14), 26.0 (C20), 25.5 (C19), 18.7 (C18) ppm;  
HRMS (ESI+): C19H23NOH+ [M+H]+, m/z found: 282.1852; calc.: 282.1854.  
Optical rotation (in CHCl3, 22 °C, λ=589 nm, cuvette 50 mm, 0.44 g/100 mL) -77.849 
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7.4.4 (5S,6S)-2,2-dimethyl-6-(5-methyl-1H-indol-3-yl)-5-(prop-1-en-2-yl)cyclo-
hexan-1-one (76) 
 
The synthesis was performed by M. Nikisch within the OC-FPR (practical training within the 
bachelor study). In analogy to instructions of Maimone et al.[352] 1.34 g (8.1 mmol, 1.0 eq) 64 and 
2.3 g (17.6 mmol, 2.5 eq) 93 were solved in 42 mL dry THF under nitrogen atmosphere. Then 
the solution was cooled to -78 °C and 25.0 mL 1.0 M LiHMDS in THF (25.0 mmol, 3.5 eq) were 
added dropwise within 10 min. After stirring for 30 min, 3.74 g (10.7 mmol, 1.5 eq) copper(II) 
2-ethylhexanoate were added rapidly and stirring was continued for 15 h at -78 °C. After-
wards the reaction was warmed to rt and was poured into 1 M HCl (120 mL) and EtOAc 
(120 mL). Subsequently the aqueous phase was extracted with EtOAc (3 x 120 mL). The com-
bined organic phase was washed with 1 M HCl (75 mL), 1 M NaOH (150 mL), then 
brine (75 mL) and was dried over MgSO4. The solvent was removed under reduced pressure 
and the crude product was purified by flash column chromatography (pentane : EtOAc gradi-
ent from 6:1 to 5:1) to give 290 mg (0.98 mmol, 12%) of the coupled product 76 as a brown 
solid.  
Rf = 0.29 (pentane : EtOAc 4:1); 1H-NMR (500 MHz, CDCl3), δ = 7.93 (s, 1H, NH), 7.18 (d, 1H, J 
= 8.25 Hz, H7), 7.09-7.08 (m, 1H, H4), 6.95 (dd, 1H, J = 8.25, 1.40 Hz, H6), 6.84 (d, 1H, J = 2.30 Hz, 
H2), 4.63-4.62 (m, 1H, H17/cis), 4.57-4.56 (m, 1H, H17/trans), 4.17 (d, 1H, J = 12.5 Hz, H10), 2.89 (dt, 
1H, J = 12.3, 3.70 Hz, H15), 2.42 (s, 3H, H21), 2.22-2.13 (m, 1H, H14), 1.94-1.90 (m, 1H, H13), 1.85-
1.78 (m, 2H, H13/14.), 1.59-1.58 (m, 3H, H18), 1.42 (s, 3H, H19), 1.15 (s, 3H, H20) ppm; 13C-NMR (125 
MHz, CDCl3), δ= 213.7 (CO), 147.1 (C16), 134.6 (C8), 128.4 (C5), 127.9 (C9), 123.4 (C6), 123.4 (C2), 
118.7 (C4), 112.0 (C17), 111.6 (C3.), 111.0 (C7), 53.1 (C15), 47.7 (C10), 45.3 (C12), 40.3 (C13), 28.3 (C14), 
26.0 (C20), 25.5 (C19), 21.8 (C21), 18.7 (C18) ppm;  
HRMS (ESI+): C20H25NONa+ [M+Na]+, m/z found: 318.1829; calc.: 318.1828.  
Optical rotation (in CHCl3, 22 °C, λ=589 nm, cuvette 50 mm, 0.58 g/100mL) -86.156. 
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7.4.5 (5S,6S)-6-(5-methoxy-1H-indol-3-yl)-2,2-dimethyl-5-(prop-1-en-2-yl)cyclo-
hexan-1-one (77) 
 
The synthesis was performed by L. Schmermund.[317] In analogy to instructions of Maimone et 
al.[352] 400 mg (2.41 mmol, 1.0 eq) 64 and 1.24 g (8.42 mmol, 3.5 eq) 94 were solved in 14 mL dry 
THF under nitrogen atmosphere. The solution was cooled to -78 °C and 8.18 mL 1.0 M 
LiHMDS in THF (8.18 mmol, 3.4 eq) were added dropwise within 5 min. After stirring for 
30 min, 1.26 g (3.61 mmol, 1.5 eq) copper(II) 2-ethylhexanoate were added rapidly and stirring 
was continued for 15 h at -78 °C. The reaction was warmed to rt and poured into 1 M HCl 
(40 mL) and EtOAc (20 mL). Subsequently the aqueous phase was extracted with EtOAc (3 x 
30 mL). The combined organic phase was washed with 1 M HCl (40 mL), 1 M NaOH (40 mL), 
then brine (30 mL) and was dried over MgSO4. The solvent was removed under reduced pres-
sure and the crude product was purified by flash column chromatography (pentane : EtOAc 
gradient from 7:1 to 3:1) to give 318 mg (1.02 mmol, 42%) of the coupled product 77 as a pale 
pink solid.  
Rf = 0.32 (pentane : EtOAc 4:1); 1H-NMR (500 MHz, CDCl3), δ = 7.93 (s, 1H, NH), 7.18 (dd, 1H, 
J = 8.70, 0.50 Hz, H7), 6.88 (d, 1H, H2), 6.80 (dd, 1H, J= 8.77, 2.52 Hz, H6), 6.77 (d, 1H, J = 2.35 Hz, 
H4), 4.63-4.62 (m, 1H, H17/cis), 4.57-4.56 (m, 1H, H17/trans), 4.14 (d, 1H, J = 12.4 Hz, H10), 3.83 (s, 3H, 
H21), 2.86 (dt, 1H, J = 12.4, 3.74 Hz, H15), 2.21-2.12 (m, 1H, H14), 1.94-1.90 (m, 1H, H13), 1.84-1.77 
(m, 2H, H13/14.), 1.59-1.58 (m, 3H, H18), 1.41 (s, 3H, H19), 1.14 (s, 3H, H20) ppm; 13C-NMR (125 
MHz, CDCl3), δ= 213.6 (CO), 153.9 (C5), 147.0 (C16), 131.6 (C8), 128.2 (C9), 124.2 (C2), 112.0 (C17), 
111.8 (C7), 111.8 (C3), 111.3 (C6), 101.9 (C4), 56.2 (C21), 53.2 (C15), 47.8 (C10), 45.3 (C12), 40.3 (C13), 
28.2 (C14), 26.0 (C20), 25.5 (C19), 18.7 (C18) ppm;  
HRMS (ESI+): C20H25NO2H+ [M+H]+, m/z found: 312.1958; calc.: 312.1958.  
Optical rotation (in CHCl3, 22 °C, λ=589 nm, cuvette 50 mm, 0.61 g/100mL) -55.674. 
  
Methods 
 
179 
7.4.6 (5S,6S)-2,2-dimethyl-6-(6-methyl-1H-indol-3-yl)-5-(prop-1-en-2-yl)cyclo-
hexan-1-one (78) 
 
The synthesis was performed by Tobias Itzenhäuser within the OC-FPR (practical training 
within the bachelor study). In analogy to instructions of Maimone et al.[352] 793 mg (4.78 mmol, 
1.0 eq) 64 and 2.2 g (16.8 mmol, 3.5 eq) 95 were solved in 37 mL dry THF under nitrogen at-
mosphere. The solution was cooled to -78 °C and 17.0 mL 1.0 M LiHMDS in THF (17.0 mmol, 
3.5 eq) were added dropwise within 5 min. After stirring for 30 min, 2.52 g (7.2 mmol, 1.5 eq) 
copper(II) 2-ethylhexanoate were added rapidly and stirring was continued for 15 h, while the 
dry ice/acetone bath was slowly warmed to room temperature. The solution was poured into 
1 M HCl (40 mL) and EtOAc (25 mL). Subsequently the aqueous phase was extracted with 
EtOAc (3 x 30 mL). The combined organic phase was washed with 1 M HCl (30 mL), 1 M 
NaOH (35 mL), then brine (30 mL) and was dried over MgSO4. The solvent was removed un-
der reduced pressure and the crude product was purified by flash column chromatography 
(pentane : EtOAc gradient from 6:1 to 3:1) to give 320 mg (1.08 mmol, 23%) of the coupled 
product 78 as a colorless solid.  
Rf = 0.36 (pentane : EtOAc 4:1); 1H-NMR (500 MHz, CDCl3), δ = 7.91 (s, 1H, NH), 7.21 (d, 1H, J 
= 8.05 Hz, H4), 7.07-7.06 (m, 1H, H7), 6.87 (dd, 1H, J = 8.10, 1.00 Hz, H5), 6.81 (d, 1H, J = 2.30 Hz, 
H2), 4.62-4.61 (m, 1H, H17/cis), 4.56-4.55 (m, 1H, H17/trans), 4.17 (d, 1H, J = 12.4 Hz, H10), 2.88 (dt, 
1H, J = 12.3, 3.74 Hz, H15), 2.42 (s, 3H, H21), 2.21-2.12 (m, 1H, H14), 1.94-1.89 (m, 1H, H13), 1.84-
1.77 (m, 2H, H13/14.), 1.58-1.57 (m, 3H, H18), 1.40 (s, 3H, H19), 1.14 (s, 3H, H20) ppm; 13C-NMR (125 
MHz, CDCl3), δ= 213.6 (CO), 147.0 (C16), 136.7 (C8), 131.4 (C6), 125.5 (C9), 122.6 (C2), 121.1 (C5), 
118.7 (C4), 112.0 (C3), 111.9 (C17.), 111.3 (C7), 53.2 (C15), 47.8 (C10), 45.3 (C12), 40.3 (C13), 28.2 (C14), 
26.0 (C20), 25.4 (C19), 21.8 (C21), 18.7 (C18) ppm;  
HRMS (ESI+): C20H25NONa+ [M+Na]+, m/z found: 318.1828; calc.: 318.1828.  
Optical rotation (in CHCl3, 22 °C, λ=589 nm, cuvette 50 mm, 0.48 g/100mL) -45.886. 
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7.4.7 (5S,6S)-6-(1H-indol-3-yl)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2e-n-1-one (84) 
 
The synthesis was performed in analogy to instructions of Maimone et al.[352] 
1.32 mL (8.3 mmol, 1.0 eq) (S)-carvone 62 and 1.95 g (16.6 mmol, 2.0 eq) indole 92 were solved 
in 50.0 mL THF. Then the solution was cooled to -78 °C and 25.0 mL 1.0 M LiHMDS in THF 
(25.0 mmol, 3.0 eq) were added dropwise within 5 min. After stirring for 30 min, 4.35 g 
(12.5 mmol, 1.5 eq) copper(II) 2-ethylhexanoate were added rapidly and stirring was contin-
ued for 16 h at -78 °C. Afterwards the reaction was warmed to rt and was poured into 1 M HCl 
(100 mL) and EtOAc (100 mL). Subsequently the aqueous phase was extracted with EtOAc (3 x 
100 mL). The combined organic phase was washed with 1 M HCl (100 mL), 1 M NaOH 
(100 mL), then brine (100 mL) and was dried over MgSO4. The solvent was removed under 
reduced pressure and the crude product was purified by flash column chromatography (pen-
tane : EtOAc gradient from 5:1 to 3:1) to give 1.12 g (3.96 mmol, 47.6%) of product 84 as a 
brown solid.  
Rf = 0.28 (pentane : EtOAc 4:1); 1H-NMR (500 MHz, CDCl3), δ = 8.01 (s, 1H, NH), 7.45 (d, 1H, J 
= 7.59 Hz, H7), 7.32 (d, 1H, J = 8.02, H4), 7.18-7.13 (m, 1H, H5), 7.09-7.04 (m, 1H, H6), 6.90 (d, 1H, 
J = 2.19 Hz, H2), 6.81-6.78 (m, 1H, H13), 4.68-4.66 (m, 1H, H17/cis), 4.65-4.64 (m, 1H, H17/trans), 3.92 
(d, 1H, J = 10.7 Hz, H10), 3.31-3.23 (m, 1H, H15), 2.63-2.41 (m, 2H, H14), 1.87-1.86 (m, 1H, H19), 
1.63 (s, 3H, H18) ppm; 13C-NMR (125 MHz, CDCl3), δ= 199.4 (CO), 146.1 (C16), 143.6 (C13), 136.4 
(C8), 135.7 (C12), 127.3 (C9), 122.7 (C2), 122.0 (C5), 119.5 (C6), 119.4 (C7), 113.1 (C3.), 112.9 (C17), 
111.4 (C4), 49.2 (C10), 48.5 (C15), 31.0 (C14), 19.6 (C18), 16.4 (C19) ppm;  
HRMS (ESI+): C18H19NONa+ [M+Na]+, m/z found: 288.1359; calc.: 288.1359. 
7.4.8 (S)-2-(1H-indol-3-yl)-3-methyl-6-(propan-2-ylidene)cyclohexan-1-one (8) 
 
In analogy to instructions of Maimone et al.[352] 1.28 g (8.4 mmol, 1.0 eq) (R)-pulegone 96 and 
1.95 g (16.6 mmol, 2.0 eq) indole 92 were dissolved in 45 mL THF. Then the solution was 
cooled to -78 °C (dry ice/acetone) and 25.0  mL 1.0 M LiHMDS in THF (25.0 mmol, 3.5 eq) were 
added dropwise within 5 min. After stirring for 30 min, 4.35 g (12.6 mmol, 1.5 eq) copper(II) 2-
ethylhexanoate were added rapidly and stirring was continued for 15 h, while the dry ice/ac-
etone bath was slowly warmed to room temperature. Afterwards the reaction was warmed to 
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rt and poured into 1 M HCl (100 mL) and EtOAc (60 mL). Subsequently the aqueous phase 
was extracted with EtOAc (3 x 35 mL). The combined organic phase was washed with 1 M HCl 
(100 mL), 1 M NaOH (100 mL), then brine (50 mL) and was dried over MgSO4. The solvent 
was removed under reduced pressure and the crude product was purified by flash column 
chromatography (pentane : EtOAc gradient from 6:1 to 4:1) to give 300 mg product 84 which 
was only 70% pure based on HPLC analysis. After a second flash column chromatography, 
110 mg (90% pure) product 84 could be obtained.  
Rf = 0.33 (pentane : EtOAc 5:1); 1H-NMR (500 MHz, CDCl3), δ = 8.11 (s, 1H, NH), 7.46 (d, 1H, J 
= 7.95 Hz, H4), 7.32 (d, 1H, J = 8.15, H7), 7.17-7.14 (m, 1H, H6), 7.07-7.04 (m, 1H, H5), 6.97 (d, 1H, 
J = 12.4 Hz, H2), 3.40 (d, 1H, J = 10.2 Hz, H10), 2.82-2.79 (m, 1H, H13), 2.59-2.52 (m, 1H, H13), 2.35-
2.27 (m, 1H, H15), 2.05-1.99 (m, 1H, H14), 1.88 (m, 3H, H19), 1.84 (s, 3H, H18), 1.58-1.50 (m, 1H, 
H14), 0.93 (d, 3H, J = 6.55 Hz, H16) ppm; 13C-NMR (125 MHz, CDCl3), δ= 204.7 (CO), 141.6 (C17), 
136.7 (C8), 132.7 (C12), 126.9 (C9), 123.0 (C2), 122.0 (C6), 119.7 (C4), 119.4 (C5), 114.2 (C3.), 111.4 
(C7), 57.4 (C10), 37.5 (C15), 32.3 (C14), 28.8 (C13), 22.9 (C19), 22.1 (C18), 21.4 (C16) ppm;  
HRMS (ESI+): C18H21NONa+ [M+Na]+, m/z found: 290.1516; calc.: 290.1515. 
7.4.9 6-(1H-indol-3-yl)-2-methylcyclohex-2-en-1-one (85) 
 
In analogy to instructions of Maimone et al.[352] 1.04 mL (9.14 mmol, 1.0 eq) 2-methylcyclohex-
2-en-1-one 97 and 2.69 g (24.2 mmol, 2.6 eq) indole 92 were solved in 50 mL dry THF under 
nitrogen atmosphere. The solution was cooled to -78 °C and 32.0 mL 1.0 M LiHMDS in THF 
(32.0 mmol, 3.5 eq) were added dropwise within 10 min. After stirring for 30 min, 5.58 g 
(16.0 mmol, 1.75 eq) copper(II) 2-ethylhexanoate were added rapidly and stirring was contin-
ued for 15 h at -78 °C. Afterwards the reaction was warmed to rt and poured into 1 M HCl 
(120 mL) and EtOAc (80 mL). Subsequently the aqueous phase was extracted with EtOAc (3 x 
90 mL). The combined organic phase was washed with 1 M HCl (90 mL), 1 M NaOH (90 mL), 
then brine (90 mL) and was dried over Na2SO4. The solvent was removed under reduced pres-
sure and the crude product was purified by flash column chromatography (pentane : EtOAc 
gradient from 6:1 to 3:1) to give 1.25 g (5.5 mmol, 60.1 %) of product 85 as brown solid.  
Rf = 0.38 (pentane : EtOAc 5:1); 1H-NMR (500 MHz, CDCl3), δ = 8.09 (s, 1H, NH), 7.53 (d, 1H, J 
= 8.05 Hz, H7), 7.33 (td, 1H, J = 8.11, 0.89 Hz, H4), 7.19-7.16 (m, 1H, H5), 7.12-7.08 (m, 1H, H6), 
6.94 (d, 1H, J = 2.35, 0.50 Hz, H2), 6.82-6.79 (m, 1H, H13), 3.97-3.94 (m, 1H, H10), 2.46-2.40 (m, 2H, 
H14), 2.40-2.33 (m, 2H, H15), 1.89-1.88 (m, 3H, H16) ppm; 13C-NMR (125 MHz, CDCl3), δ= 200.0 
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(CO), 145.1 (C13), 136.4 (C8), 135.9 (C12), 127.2 (C9), 122.1 (C5), 121.7 (C2), 119.5 (C6), 119.4 (C7), 
114.2 (C3.), 111.4 (C4), 45.1 (C10), 30.4 (C15), 25.3 (C14), 16.5 (C16) ppm;  
HRMS (ESI+): C15H15NONa+ [M+Na]+, m/z found: 248.1046; calc.: 248.1046. 
7.4.1 6-(1H-indol-3-yl)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one (86) 
 
In analogy to instructions of Baran et al.[350], 1.06 mL (6.6 mmol, 1.0 eq) (R)-carvone 98 and 
1.55 g (13.2 mmol, 2 eq) indole 92 were solved in 1.00 mL dry THF. The solution was cooled 
down to -78°C. 19.8 mL (19.8 mmol, 3 eq) 1 M LHMDS and 20 mL dry THF was added. After 
stirring for 30 min, 3.46 g (9.89 mmol, 1.5 eq) Cu(II)ethylhexanoate were added. The solution 
was stirred for 16 h at -78°C and then was warmed up to rt. The reaction was quenched with 
100 mL 1 M HCl. After extraction with 100 mL EA, the organic phase was washed with 100 mL 
1 M HCl, 1 M NaOH, 100 mL H2O and 100 mL brine. The organic phase was dried with MgSO4 
and concentrated in vacuo. The obtained product was purified via flash chromatography 
(n-hexane : EtOAc 5:1 gradient 2:1). 0.59 g (2.23 mmol, 33%) of the product was obtained as 
brown foam. 
1H-NMR (300Mhz, CDCl3) δ= 7.46-7.43 (m, 1H, indole-Harom), 7.32 (dt, 3J = 8.0 Hz,1H, indole-
Harom), 7.18-7.12 (m, 1H, indole-Harom), 7.09-7.04 (m, 1H, indole-Harom), 6.89 (d, 3J = 8.0 Hz, 1H, 
H6), 6.80 (sept, 1H, indole-Harom), 4.67 (quint,1H, H9), 4.64 (quint, 1H, H9), 3.91 (d, 3J = 10.7 Hz, 
1H, H5), 3.31-3.23 (m, 1H,H3), 2.63-2.47 (m, 2H, H4), 1.88-1.86 (m, 3H, H7), 1.66 (m, 3H, H10) 
ppm 13C-NMR: 75 MHz, CDCl3; d = 199.3, 146.1, 143.6, 135.7, 127.3, 122.6, 122.0, 119.5, 119.4, 
113.3, 112.9, 111.4, 49.3, 48.5, 31.1, 19.6, 16.4 ppm.  
HRMS (ESI+): C18H19NO (M+H)+ calculated: 266.1539, found: 266.1542. 
7.4.1 (1H-indol-3-yl)-6-methyl-3-(prop-1-en-2-yl)cyclohexan-1-one (87) 
 
0.28 mL (1.71 mmol, 1.0 eq) (5R)-dihydrocarvone 99 (mixture of isomers with 96% purity) and 
0.39 g (3.33 mmol, 2.0 eq) indole 92 were solved in 2.00 mL dry THF. The solution was cooled 
down to -78 °C. 5.00 mL (5.00 mmol, 3.0 eq) 1 M LHMDS and 20 mL THF were added. After 
stirring for 30 min, 0.87 g (2.49 mmol, 1.5 eq) Cu(II)ethylhexanoate was added. The solution 
was stirred for 14.5 h at -78 °C and then was warmed to rt. The reaction was quenched with 
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20 mL 1 M HCl solution. After extraction with 50 mL EtOAc, the organic phase was washed 
with 20 mL 1 M HCl solution, 20 mL 1 M NaOH solution, 20 mL H2O and 20 mL saturated 
brine. The organic phase was dried with MgSO4 and concentrated in vacuo. The obtained prod-
uct was purified via flash chromatography (n-hexane : EtOAc gradient 5:1 to 2:1). 80.2 mg (0.30 
mmol, 18%) of the product was obtained as brown colored oil. 
1H-NMR: 300 MHz, CDCl3; d = 7.53 (d, 3J = 8.0 Hz, 1H, indole-Harom), 7.47 (d, 3J = 7.8 Hz, 1H, 
indole-Harom), 7.40-7.03 (m, indole-Harom), 6.94 (d,3J = 2.4 Hz, 1H, indole-Harom), 4.88, 4.83 (m, 
2H, H10]) 4.60, 4.54 (m,2H, H10), 4.14 (d, 3J = 7.5 Hz, 1H, H2), 3.93 (d, 3J = 12.1 Hz, 1H, H2),3.09-
3.03 (m, 1H, H3), 2.90 (dt, 3J = 12.0 Hz, 4.0 Hz, 1H, H3), 2.78-2.66(m, 2H, H6), 2.53-2.46 (m, 1H, 
H5), 2.28-2.19 (m, 1H, H5), 2.03-1.93 (m,5H, H4), 1.80 (bs, 3H, 10]), 1.57 (m, 3H, H10), 1.20 (d, 
3J = 6.9 Hz, 3H,H7), 1.10 (d, 3J = 6.5 Hz, 3H, H7) ppm. 13C-NMR: 75 MHz, CDCl3; d = 146.8, 
123.2, 122.3, 122.2, 121.8, 119.7, 119.7,119.6, 119.4, 19.3, 112.4, 112.1, 111.3, 111.2, 54.1, 52.5, 50.0, 
49.8, 45.5,43.4, 43.0, 35.8, 32.4, 31.3, 25.9, 25.8, 20.7, 18.7, 16.1, 14.9 ppm.  
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7.5 Analytical Methods 
7.5.1 GC Measurements 
GC analysis was performed at different temperatures and gradients, using a Agilent GC7820A 
system with FID-detector (Heater 300 °C, H2-Flow 30 mL/min, Air-Flow 400 mL/min, Makeup 
Flow 25 mL/min; Date Rate/ Min Peak width 50 Hz/0.004 min) with a 30 m HP-5 column with 
0.25 μm inner diameter with a flow of 6.5 mL/min. 1 μL of a diluted sample was injected with 
a split of 40-1 with 250 mL/min. Heater was at 250 °C, 1 bar, gas saver 20 mL/min after 2 min. 
In table 31 all used GC programs are listed with retention time of compounds.  
Table 31: Temperature programs for GC runs. Measurements were performed on a HP-5 column. 
substrate program retention time 
adamanthanisonitril 68 
120°C to 132°C with 4°C/min, 
hold 3 min, 10°C/min to 200°C 
2.1 min 
tetramethylbutylisocyanide 69 
56°C to 66°C with 2°C/min hold 
3 min 10°C/min to 120°C 
2.3 min 
2-naphtylisocyanide 70 
120°C to 140°C with 4°C/min, 
hold 3 min, 10°C/min to 190°C 
2.5 min 
cyclohexylisonitril 71 
82°C to 96°C with 4°C/min, hold 
3 min, go to 160°C with 10°C/min 
1.0 min 
2(4-morpholinyl)ethylisocyanid 72 
120°C to 144°C with 4°C/min, 
hold 3 min, 10°C/min to 190°C 
3.0 min 
cyclohexylisothiocyanat 73 
102°C to 120°C with 4°C/min, 
hold 3 min, 10°C/min to 180°C 
2.1 min 
3-morpholinopropylisothiocyanat 74 
120°C to 144°C with 4°C/min, 
hold 3 min, 10°C/min to 190°C 
4.2 min 
phenethylisothiocyanat 75 
120°C to 140°C with 4°C/min, 
hold for 3 min 
3.0 min 
(S)-carvone 62 92°C, 4min 3.6  min 
(2S,5S)-dihydrocarvone 63 92°C, 4min 2.9  min 
2,2 dimethyl-(5S)-dihydrocarvone 64 92°C, 4min 3.3  min 
7.5.2 HPLC Measurements 
For HPLC measurements, either a Shimadzu LC2030 or a Shimadzu LC2010C HT category 
number 228-41501-38, serial number C2154103183LP was used. 
The samples were prepared in acetonitrile. The measurements were performed on a Shimadzu 
Prominence-i LC2030. As solvents, acetonitrile and water were used. The mixtures were ana-
lyzed with an Agilent Zorbax Eclipse C-18 (150 mmx4.6 mm, 5.4 µm particle size) or Durashell 
C-18 column (150 mmx4.6 mm, 5.4 µm particle size). An isocratic solvent mixture of 71:29 
ACN : H2O was used for a length of 9.0 min. The time was elongated for measurement of 
Methods 
 
185 
hapalindole Q to 30 min. The injection volume (1-10 µL) was adapted to absorption of sub-
strate, so that an average absorption of about 150 mV for the starting material was present. In 
table 32, the retention time and solvent composition of HPLC measurements is given. 
Table 32: Retention time of chemicals in Shimadzu HPLC 
system with Agela Durashell C-18 column. 1mL/min flow 
rate. 
substrate 
retention 
time 
(min) 
solvent 
53 
53a 
8.41 
9.18 
73 : 27 ACN/H2O 
54 
54a 
54b 
54c 
54d 
54e 
54f 
6.66 
7.48 
2.69 
2.09 
2.37 
2.99 
3.79 
71 : 29 ACN/H2O 
65 
6.07 
6.31 
30 : 70 to 80 : 20 
ACN : H2O+0.1%TFA 
in 20 min 
67 
67a 
9.37 
9.95 
68 : 31 ACN : H2O 
76 
76a 
7.77 
8.89 
71 : 29 ACN/H2O 
77 
77a 
5.48 
6.30 
78 
78a 
8.12 
9.35 
79 4.39 
60 : 40 ACN/H2O 
80 5.63 
 
 
 
 
 
81 
81a 
81b 
81c 
81d 
81e 
81f 
5.30 
2.16 
2.58 
3.0 
3.2 
3.4 
4.5 
 
71 : 29 
ACN : H2O 
 
82 
82a 
82b 
4.16 
2.01 
2.86 
83 
83a 
83b 
83c 
83d 
83e 
5.96 
2.16 
2.4 
3.0 
3.6 
4.3 
84 4.67 
85 5.5 60 : 40 
86 11 min 63 : 37 
87 
14.40 
15.14 
16.35 
55 : 45 
91 
91a 
91b 
91c 
7.81 
2.93 
3.22 
6.63 
80 : 20 ACN/H2O 
 
7.5.3 LC-MS  
LC-MS was performed at an Agilent 1260 Infinity II HPLC-System using a D2 lamp coupled to 
Mass Infinity Lab G6 125 B, equipped with a 1 cm precolumn and 150x4.6 mm, 5µm Agela 
DuraShell column.  
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7.5.4 Preparative HPLC Purification 
Preparative reverse-phase HPLC was performed at a Gilson HPLC equipped with Macherey-
Nagel Nucleodur C18 HTec 250/16, 5µm (762556-160). To analyze new occurring peaks during 
biocatalytic transformation, the reactions were scaled up and the extracted compounds puri-
fied via preparative HPLC.  
Remaining samples from dried organic phase were resolved in 60%-40% ACN-H2O and 
centrifuged for 5 min at 14000 rpm. The supernatant was filtered (0.45 µm PTFE-filter, VWR) 
and the flow through applied on the pre-equilibrated column by loop injection (loop volume 
4.5 mL). An isocratic eluent (60%-40% ACN-H2O) was used and run for 60 min. For reactions 
with substrate 54, the last peak eluted at about 38 min. Collected fractions were rechecked on 
analytical HPLC. Pure peaks were concentrated in vacuo and analyzed by mass and NMR. 
7.5.5 Mass Analysis 
Samples were given to the mass department of Philipps University Marburg.  
HR-ESI-spectra: HR-ESI mass spectra were acquired with a LTQ-FT Ultra mass spectrometer 
(Thermo Fischer Scientific). The resolution was set to 100.000. 
HR-EI-spectra: HR-EI mass spectra were acquired with a AccuTOF GCv 4G (JEOL) Time of 
Flight (TOF) mass spectrometer. An internal or external standard was used for drift time cor-
rection. 
Enzyme Characterization from SDS-PAGE Gel: Samples from SDS-PAGES were destained 
and were digested "in-gel" by the addition of Sequencing Grade Modified Trypsin (PROMEGA) 
and incubated at 37 °C overnight. 
The mass spectrometric analysis of the samples was performed using an Orbitrap Velos 
Pro mass spectrometer (Thermo Scientific). An Ultimate nanoRSLC-HPLC system (Dionex), 
equipped with a custom 20cm x 75µm C18 RP column filled with 1.7 µm beads was connected 
online to the mass spectrometer through a Proxeon nanospray source. 1-15 µL of the tryptic 
digest (depending on sample concentration) were injected onto a C18 pre-concentration col-
umn. Automated trapping and desalting of the sample was performed at a flowrate of 6 
µL/min using water/0.05% formic acid as solvent. 
Separation of the tryptic peptides was achieved with the following gradient of water/0.05% 
formic acid (solvent A) and 80% acetonitrile/0.045% formic acid (solvent B) at a flow rate of 
300 nL/min: holding 4% B for five minutes, followed by a linear gradient to 45%B within 30 
minutes and linear increase to 95% solvent B in additional 5 minutes. The column was con-
nected to a stainless steel nanoemitter (Proxeon, Denmark) and the eluent was sprayed di-
rectly towards the heated capillary of the mass spectrometer using a potential of 2300 V. A 
survey scan with a resolution of 60000 within the Orbitrap mass analyzer was combined with 
at least three data-dependent MS/MS scans with dynamic exclusion for 30 s either using CID 
with the linear ion-trap or using HCD combined with orbitrap detection at a resolution of 7500. 
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Data analysis was performed using Proteome Discoverer (Thermo Scientific) with Sequest and 
Mascot (version 2.2; Matrix science) search engines using either SwissProt or NCBI databases. 
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8. Appendix 
8.1 List of Abbreviations 
Abbreviations of proteinogenic amino acids are listed in table 33, general abbreviations are 
given in table 34. 
Table 33. Abbreviation of proteinogenic amino acids in one and three letter code. 
amino acid 3 letter code 1 letter code 
alanine Ala A 
arginine Arg R 
asparagine Asn N 
aspartic acid Asp D 
cysteine Cys C 
glutamine Gln Q 
glutamic acid Glu E 
glycine Gly G 
histidine His H 
isoleucine Ile I 
leucine Leu L 
lysine Lys K 
methionine Met M 
phenylalanine Phe F 
proline Pro P 
serine Ser S 
threonine Thr T 
tryptophan Trp W 
tyrosine Tyr Y 
valine Val V 
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General Abbreviations 
Table 34. General abbreviations used in this document. 
2OG 2-oxoglutarate 
aa amino acid 
ac acetate 
ACN acetonitrile 
ACP acyl carrier protein 
ad. (lat) bring to volume 
αKG α-ketoglutarate 
amp ampicillin 
amp100 100 µg/mL ampicillin 
AmSO4 (NH4)2SO4 – ammonium sulfate 
anh. anhydrous 
asc. acid ascorbic acid 
aq. aqueous 
β-ME beta-mercaptoethanol 
bp base pairs 
CD circular dirchroism 
ch. chapter 
CPO chloroperoxidase 
conc. concentration 
conv. conversion 
Da Dalton 
DCM dichlormethane 
ddH2O deionized water 
dep. dependent 
DTT dithioreithol 
dw deep-well 
EtOAc ethyl acetate 
EDTA ethylenediaminetetraacetic acid 
e.g. exempli gratia (for example) 
epPCR error prone PCR 
etc. et cetera 
EtOH ethanol 
eq equivalent 
FeCl350 50 µM FeCl3 
ff following 
fl. flavin 
FMN flavin mononucleotide 
form. formation 
gDNA genomic DNA 
HEPES 
4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid 
HPLC 
high performance liquid chroma-
tography 
IMAC 
immobilized metal-ion affinity 
chromatography 
IPTG 
Isopropyl β-D-1-thiogalactopyra-
noside 
kan kanamycin 
kan50 50 µg/mL kanamycin 
Km Michaelis Menten constant 
LB lysogeny broth 
MCA multi-channel arm 
ms milliseconds 
na not available 
nd not determined 
nc no conversion 
NHI non-heme iron 
PAGE polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
Pi phosphates 
PROSS Protein Repair One Stop Shop 
rf-cloning restriction free cloning 
rt room temperature 
SDS sodium dodecyl sulfate 
TB terrific broth 
tet tetracycline 
Tm melting temperature 
Tr retention time 
Tris 
2-amino-2-(hydroxymethyl)propan-
1,3-diol 
TOF turnover frequency 
TON turnover number 
UV ultra violet 
VCPO vanadium chloroperoxidase 
Vis visible 
Vmax maximal initial velocity 
wt wild type 
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8.2 Names of Enzyme Variants 
Table 35. Abbreviation of selected WelO15 variants. 
name WelO15 variant 
Wi-0 Wi-WelO15 V6I/D284N 
Wi-1 Wi-WelO15 V6I/A82L/D284N 
Wi-2 Wi-WelO15 V6I/N74R/D284N 
Wi-3 Wi-WelO15 V6I/V90P/D284N 
Wi-4 Wi-WelO15 V6I/A82V/I84H/D284N 
Wi-5 Wi-WelO15 V6I/A82L/V90P/D284N 
Wi-6 Wi-WelO15 V6I/A88V/V90P/D284N 
Wi-7 Wi-WelO15 V6I/V81T/A82M/A88V/V90P/D284N 
Wi-8 Wi-WelO15 V6I/N74R/V81T/A82M/A88V/V90P/D284N 
Wi-9 Wi-WelO15 V6I/M221L/M225I/D284N 
Wi-10 Wi-WelO15 V6I/A82L/V90P/M221L/M225I/D284N 
Wi-11 Wi-WelO15 V6I/N74R/V81T/A82M/A88V/V90P/ S93L/S103A/D284N 
Wi-12 Wi-WelO15 V6I/N74R/A82L/V90P/S93D/D284N 
Wi-13 Wi-WelO15 V6I/N74R/A82L/V90P/S93H/S103A/A175N/D284N 
Wi-P1 Wi-WelO15 V6I/S103A/D284N 
Wi-P2 Wi-WelO15 V6I/S103A/Q123R/S230K//D284N 
Wi-P3 Wi-WelO15 V6I/S103A/Q123R/S230K/Q236N/S239W/S268R/Q282D/D284N 
Wi-5P3 
Wi-WelO15  
V6I/A82L/V90P/ S103A/Q123R/S230K/Q236N/S239W/S268R/Q282D/D284N 
Hw-1 Hw-WelO15 A82L 
Hw-2 Hw-WelO15 A82L/V90P 
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8.3 Biological Part 
8.3.1 Cloning Information 
In figure 63, a part of the multiple cloning site of the pRSF-Duet vector is given. In the first and 
last row, the two primer (shown in purple) are given that overlap with the vector when re-
striction free cloning into this vector was used. In figure 64, a vector map of the pRSF-Duet 
vector carrying welO genes is given. All oxygenase genes were cloned at identical positions. 
 
Figure 63. DNA sequence of the multiple cloning site of the pRSF-Duet vector. In the first and the last row, the overlap with the 
vector is shown as primer which was used in restriction free cloning. The bases between the primers is exchanged by the restriction 
free cloning against the gene that should be inserted. The sequence is shown with SnapGene Viewer version 2.8.3. 
 
Figure 64. Vector map of pRSF-Duet vector carrying WelO genes. DNA sequences were modified and edited with Ape and 
SnapGene Viewer version 2.8.3. With green and cyan, the sequences are shown that are line the incorporated genes.  
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In table 36 an overview of all cloned genes is given. Furthermore, errors and silent mutations 
that were seen by sequencing after the cloning, are listed.  
Table 36. Overview of all genes that were cloned within this project. For some genes, errors or silent mutations in comparison to 
published sequences (NCBI databank, date of retrieving 08/2015) were seen and are listed here. 
enzyme aa* bp* 
MW 
(Da) 
errors and 
silent mutations 
Wi-WelO11 359 1077 40699 silent mutation in stop codon (taa instead of tga) 
Hw-WelO11 328 984 37179  
Wi-WelO12 357 1071 40652 
I5V (primer att instead of gtt position 13) 
silent mutation: act instead of acc (421-423) 
Hw-WelO12 357 1071 40682  
Wi-WelO13 362 1086 41202 
3 silent mutations: 217-219 cac instead of cat; 394-396 
tat instead of tac; 469-471 aac instead of aat 
Hw-WelO13 362 1086 41282  
Wi-WelO14 359 1077 40877  
Hw-WelO14 359 1077 40868  
Wi-WelO15 290 870 32450 
I6V (16-18 atc instead of gtc); D284N (aat instead of 
gat 850-852) 
Hw-WelO15 290 870 32406  
Wi-WelO16 382 1146 43660 
ttc instead of ttt position 4-6; aaa instead of aag posi-
tion 16-18 
Hw-WelO16 382 1146 43693 
ttc instead of ttt position 4-6; aaa instead of aag posi-
tion 16-18 
Wi-WelO17 518 1554 58110 
G515E (gga instead of gaa position 1543-1545) 
 
Hw-WelO17 518 1554 58137 
att instead of ttt (I436F, 1306-1308); 
Silent: agg instead of aga (silent, 1303-1305); att in-
stead of atc silent 1309-1311 
Wi-WelO18 482 1446 55682  
Wi-WelO19 358 1074 40673  
*without His6-tag 
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8.3.2  Genes 
The following genes are depicted as they were sequenced after cloning in pRSF-Duet vector if 
not noted otherwise. In the cloning process, a His6-tag with linker is incorporated within the 
open reading frame with the following sequence: 
atgggcagcagccatcaccatcatcaccacagccaggatccgaattcgagctcg 
 
welO11 KJ767018.1| Westiella intricata UH HT-29-1 wel gene cluster, partial sequence 
atggttagctatattgaaaagagcgtaaatctagtcaaagaaccagaaactcaaattaagcagtccatgaatctggcagcaagttggtatattgccatgcaatcggtgg
aactaggcaaaaaaccaatagcaattgagctatttggtcgcgccttagttgcatggcgagacaaagaccgcaaagcagtaattatggaacgtttctgttcacatgtcgg
tgcatctttagctataggtgaagtcgtagatggttgcattcaatgtccttttcatcactggcgctatgatagttctggtgtatgcgtgcatataccaaaagtggcaactcctc
acacagaccacattccatctacagcacgtcaaaaaacctatgtcactgaagaaagatatggttacatttgggtttggtatggtactgcaactcctttgtttgaattacctgg
gtttgatgcagcagaaagcaacaagcataaatatatgccttatcgcttctctttcttagtaaaaactagtgtgcgacgggtagtggaaaacgcatttgatcaccaccatttc
gttacagtacacaatgtgcctgtagctgattcaattgacctaactctagttaatcacaaggatacagaactgagcgaactaccgatcgcaaaagaagcctggtttggaa
ctgtaattgaggcccgaattaaaactttgactggtgttggtgctgcgatcgctaagtttttagggttaaatattgaaactcaaaagaaccgagtagatgcttggcctactg
gatacataaatatatttagctgcgacggacagcagaggggtaaagtactctttggtgttaccccaatctctaaaaacgaaacaagattgcaagttttaattatgttcaata
aaatgggcaacttattgttggatctgttttcctacattgtttttgtcaagcaattcaaagccaacggattgcttgataaaccaatattcgataccatgagtacagatacaacg
ggcggggcatttattaggtctgatcagccattgttgaaatttagacagttttatcaaagttgggttgctaaagcacagtga 
 
welO12 KJ767018.1| Westiella intricata UH HT-29-1 wel gene cluster, partial sequence 
atggttagctatgttgaaaagagcgcaaatctagtcaaagaaccagaaactcaaattaagcagtccatgaatctggcagcaagttggtatattgccatgcaatcagtgg
aactagacaaaaaaccaatagcaattgagctatttggtcgcgccttagttgcatggcgagacaaagaccgcaaagcagtgattatggaacgtttctgttcacatgtcgg
tgcatctttagctataggtgaagttgtagatggttgcattcaatgtccttttcatcactggcgctatgatagttctggtgtatgcgtgcatataccaaaagtggcaactcctc
acacagaccacattccatctacagcacgtcaaaaaacctatgtcaccgaagaaagatatggttacatttgggtttggtatggtactgcaacccctttgtttgaattacctgg
gtttgatgcagcagaaagcaacaagcataaatatatgccttatcgcttttctttccaaactgaaactagtgtgcgacgggcaattgaaaatggatttgaccaccatcatttt
gtttcagtacatggtttaccagtaattgatcaaattgaaatgaccttgctcgatgagaaagatgcagaatttagcgaactaatacttgcaaaagaagcctggattggaag
caaactcgatgctcgaattaaaaattttattggggtaggtgcgatcgctaagtttttaggattaaatgttgaaactatatcagcacgaatagatgcttggcctagtggagt
tttaagtacaatcaaatttaataaacagcaaaagatgaagctatttgttagtgttactccaatctctgaaaaccaaacaatattgcaatatttgatcatgataaacaaaactg
gtaacttatggctaaatctactttcctacattgtttttggttggcaaaacaaagctagtgcattggaggacacaaaaatcttcgacactatgagtgcagatacaggcaaag
catttatcaaatccgaccagccagtattgaaatttaggcaattttatcaaagttgggttaataaggcacagtaa 
 
welO13 KJ767018.1| Westiella intricata UH HT-29-1 wel gene cluster, partial sequence 
atggttagctatattgaaaacgacctacagccaaaactcacaaaatcagaagctcaaattgagagtaaggggataaatctggcagcgagttggtatattgccatggaa
tccaaagaattaggcaaaaagccactagcaattgagctatttggtcgcgccttagttgcatggcgagacaaagaccgcaaagcagtaattatggaacgtttctgttcac
atgtcggtgcatctttagctataggtgaagttgtagatggttgcattcaatgtccttttcatcactggcgctatgatagttctggtgtatgcgtgcatataccaaaagtggca
actcctcacacagaccacattccatctacagcacgtcaaaaaacctatgtcaccgaagaaagatacggttacatttgggtttggtatggtactgcaacccctttgtttgacc
taccgaaattcgatgccgcagaaagcaataagcataaatatatgccttatcgcttctccataatggttcaaacaaatgtacgacggatcattgaaaactcatgtgatcatc
atcatcttgtcacaatacatgatatgcaagtcaatgattcagtaaaattgacggtgcttgatgagaaggatgtcgaattgaataaactaccgatcgcgaaagaagcttg
gatgggattcatagtcgaagcccggattaagacttttcttggtgtacgcggaattactaaagctttagggttaaatgttgaaacaatgtcaacccgagcagatctttggcc
cagtggaatcctagccactacaaagcttgacggacaagaaagacttgtagtactggatactgtcactcccatctctgaaaaccagacaaattggcaagttttgatcatgg
ttaataaaactggtaacttgtttttagatctgctttcctacatagtttttggctggcaaggtcgagccaatggatttgccgataaattacttttcgataatatgagtgcggata
caggtcgagcatttattaaatgtgaccagccagtattgaaatttcggcaattttatcaaagttgggttaataaggcacagtcaaacaaataa 
 
welO14 KJ767018.1| Westiella intricata UH HT-29-1 wel gene cluster, partial sequence 
atggttagctatattgaaaacgacctacagccaaaactcacaaaatcagaagctcaaattgagagcaagggaataaatctggcagcgagttggtatattgccatggaa
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tccaaagaattaggcaaaaagccactagcaattgagctatttggtcgcgccttagttgcatggcgagacaaagaccgcaaagcagtaattatggaacgtttctgttcac
atgtcggtgcatctttagctataggtgaagttgtagatggttgcattcaatgtccttttcatcactggcgctatgatagttctggtgtatgcgtgcatataccaaaagtggca
actcctcacacagaccacattccatctacagcacgtcaaaaaacctatgtcaccgaagaaagatacggttacatttgggtttggtatggtactgcaactcctttgtttgacc
taccgaaattcgatgccgcagaaagcaataagcatcgctatataccctatcgttcttccttcacggctaatactagcgtgcgacgagttattgaaaatatatttgatcatcat
cacctcgttgctgtacatgatatgcaggtaaatgatttaattaacctcaccctgcttgatgagaaggatgtcgaattgagtgaactaccgatcacgaaagaagcttggttt
ggatgcaaaatagaagccaacatgaaagcctttcttggtgtacgtggaattgctaagtttttagggttaaatgtcgaagttctgtcggctcggatagatgcttggcctact
ggatacataaatacactcaagtttgacggaaaacagaagtttacaatactcattggtattactcctttctctgagaataaaacaagatggaacgttttgttcatgctgaata
aaactggtaacttgtggctggacatactttccttctttgcttttggcaagcaaggcgaagcttcttcggtggtagataaaatcattttcgatagcatgagtccagacacagg
caaggcatttgtcaagtctgaccaaccagtgctgaagtttagacagttttatcaaagttgggttaataaagcacagtaa 
 
welO15 KJ767018.1| Westiella intricata UH HT-29-1 wel gene cluster, partial sequence 
atgggcagcagccatcaccatcatcaccacagccaggatccgaattcgagctcgatgtccaataacaccatctctacaaagcctgctttgcattttttagatatcaatgca
acagaggtaaaaaaatatcccactgctattcaagacataattatcaaccgtagcttcgatgggatgatcattcgcggagtattccctcgcgatactatggagcaagtagc
ccgttgcttggaagagggaaatgacggtggtatgaaatcaattcttaataagaatgaagaatttggtaccaaagtggctcaaatatatggtcatgccattgtcggtcaat
cacccgatctcaaagactactttgcttcttcagcaatcttccggcaggcttgtcgtactatgtttcaaggaagtccggattttgaggaacaagtagagtcaatatttcactct
ctttctgaattgccagtagaaattcccacaggaccagaagggcaaacctataccccagctactatccggctattactcgagggtcgcgaaatcgcagtccatgttggca
atgatttcctgttaatgcctgcggctaaccatctgaaaactttgcttgatttatctgatcagcttagttacttcatcccccttactgttcctgaagctggtggtgagctggtagt
ctatagtttggaatggaatccacaagaagcaagcaaatatgctcaaatgcaggaatatatggatgatgtagagtccaagattaagtctaaccaatctcagagtgtagct
tatgcaccaggccctggagatatgctgctgttcaatggtggtcgatactaccatcgagttagtgaagtaattggtaattctccacggcgaaccattggtggatttttagcc
ttctctaaacagcgtaataagatttattactggagttaa 
 
welO16 KJ767018.1| Westiella intricata UH HT-29-1 wel gene cluster, partial sequence 
atgttttcacaattaaaacaaccagtaattgataatttagacgcctatcaagtcgattttgaacgaggttttttaccgaaagaagatccacttgaaagattaccagatcaatt
tgaaatcatagaaaatattgctacaaacttgtctgcacttttaattacaggtcaatacagacatgtaattgataaagtacaatttcctgatatttcccaattagaaactcaac
ggcaaatcaagcgtgcatttcttctcatgtcaatctttggtaatgcatatgtatggggtggagagatacctgcaacagtaattccacattcgctggccataccgttgtgtaa
gctcgcaaacatacttgatcgcccgccaatagttgcgttcagttcgatggtgttggataactggagaagaatcgataaaactcaaccaattgaattagataatattgctcc
actccagcttttccttggcggaattgatgaatattggttttacgcaacagcaatcgtaattgaagccaaaggagcgcctgctctgatatcgcttgtagaagcacaaaaatt
tgtcaacctcgataatactgcactagtgagtatgcatttgcaaaaaattgttgcggttattgctagaatgcaggcgatatttaaagaaattactaacaaatgtgacccatac
attttttatcatcgtgtgcgtccatttgttggcagctggcaagaaccgggtgtaatttatcagggagtcagcgatactccacaaatgtttgtaggaggaagtgcagcaca
aagttcgcttctccagtccttggatgcaggtttaggaatcaaacacgaccgagaaaaacacgaatcatatttgcggcagatacgtgtgtatatgcccgtagcgcatcgc
cgatttcttgaagcgttggagatgggaccatcaattcgagaatttgtactcaacaatcaagaaaattatccggtgttgcgtcaacattacaacgaatgtgtgcaggcgat
cgagcattttagaaagcagcatatggaaattgcggtccattacataaccaagcaggcaccccagcataaacaaggtacaggtagtacaaactttgcccatttcttaaga
aaagttaaacaacagacaaccgcacatttaatttcttga 
 
welO17 KJ767018.1| Westiella intricata UH HT-29-1 wel gene cluster, partial sequence 
atgactactgcacactacgatttaatcattattggtactggggcgggtggtggtacgctggcttataaacttgcttccactggtaagaaaattctgattttagaacgtggtt
cttttttacctcgtgagaaagctaactgggataccgtggaagtagtacagaaagaccgttatcataccaatgaagtttggtacgaccaaaaaggacaagctatttatccc
ggtacaggttactttgtgggtggtaacactaaagtttatggcggagcgctgtttcgttggcgagaacaagattttaatcaggtgattcacaaaggtggtatttcgcccga
atggcctttgaagtaccgcgattttgaaccttactacacccaagcagaaaaactgtacgaagttcatggtaaacggggtttagatccgactgaaccagttgcaactgaa
gattatccttatcctgcgattcgtcacgaaccacgtattcaagaaattcatgactctttattagacgaaggttatcatccgttttatctgcctcttgctatcaagttaaatgagg
tgaatcggcgtttgagtagttgtattcgttgtaatacttgtgatggttttccttgtctagtggatgcaaaagccgatgctgatgttaactgtgtgcgtccagccgagcaatat
gataatgttacgctgatgactgaagctaaggtaaaacggttacatactagtcatactgggcgagaagttactaatgtagaagtcgaaattgatagagaaattcattttttt
tctagtgatattgtagtggttgcttgtggggcaattaattcagctgctttattgttacgttctgctaatgagcagcatcctaatggattagccaatagttctgatctggtggg
acgaaacttaatgaagcatcaaaatggagcgatgattggggtaagtttgaaatccaatttgaccgcctttcaaaaaactttagcaatcaacgatttttactggggtgatg
cagattttgattatccaatgggtcatgtgcagttattgggtaaagtgaatgcagatatgattgctcaagagtctccatcggttttaggattatcatttaaggaaagaaatac
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ttttgaagcgatcgccactcactcagtagactggtggttgactgcggaagatttgccagaccccaataatcgcgtcactcttagaggtgattctatccaattgcattacact
gagaacaacaccgaagcctacaatcgtcttgtcaatcgctggacacaggtattgaaaaaaattggttgtggtgaaaggattattcccgcctctttctatttccgtaaaaaa
ctaccactgcaaggtgtggcgcatcagtgcggtacttgtcgctttggggaagattctaaaacgtctgtattggatatcaattgctgtactcatgacgttgataatttgtatgt
agtagatggtagtttcttccgttccagtgctgctgttaatccaaccctcacaattattgctaatgctttacgggtaggcgaacatttaattggacgtatggcttaa 
 
welO18 KJ767018.1| Westiella intricata UH HT-29-1 wel gene cluster, partial sequence 
atgcgtaagttctactattattcaacctattgtgaagacagctttgtcgtactaaatcaaatgcaacaacccaatccactaaaagctccctcgtttattcaatcacttcagttta
ttcttaatccagtaggatttttggaaaaagtgcatcagcagtatcctgatattttcactgctaaaatttttggttttacgggtatcccagttgtagttgtacagcatcctcaagc
aattcaagaaatattaaccaatgatagaaaaaagtttgtagttccaggtcatgtcaacaaaattttgcaacccttgttaggtaagcattcacttttaatggtatcaggagaa
cagcacaaacgtcagcgtcaacttgtgatgccctcgtttcataaagagcggatgcaatcctatgggcaacttattgttaatctgactgaaaaagtcatgagtcagttgtcg
cttaatcaagtattctcagcttgtagtgtcatgcaggaaatttccttacaagttattttacaggctgtgtttggcttatacgaagggcaaagatacgaaaaactaaagcattt
actaccattgatgttgggtctttttagatccccactgtacaatagtttcctattttttcctttcctacaaaaagattttggagcatggagtccttggggaagatttgtacgcattc
gccagcagatagatgaattgttatacgctgagattgctgaacgccgtgtacaacccaattcagatcgtattgatatcctctcattattgatggaagcaacagatgaagaa
ggtcaaccaatgacagataaggagttgcgcgatgagttgatgactatgttggttggtggatttgacagtacagcaatagcaatggcttgggaattatattggactcatc
atttaccagaagttggtgaaaaacttcgtcaagaactggataacttgggtaattcaaaaaatccaatggatatttttcggctgccttatttgagtgctgtttgtaatgaaact
ttgcgtatttatcctgtaggagtaatggcgaatgttagatttgtgcaagaacctgtcgaactactggggtatcacttagagcctggtacggcagtgattccttgtatctatct
gactcatcatcgtaaggatttatatcaaaagcccaagcagtttctgccagaacgctttgtacaacgtcaatatactccctacgaattcctgccgtttggtggtggtgtccgt
cgttgcattggcgatgctttagctatgtttgaaatgaagttagtcttggcaactatcctgtcacactataaactagcactggcagatcatcaaccagtaacacttcaacggc
aaattatgtttgttgggcctggaaatggaatcaagatggttatgacaggacgacgtacgccctttaagattccacagtctacaagtaaaacaacttag 
 
welO19 KJ767018.1| Westiella intricata UH HT-29-1 wel gene cluster, partial sequence  
atggttaatgttgaaaagagcgtagtagcaaaaataacaaaattagaaactcaatttgaaaataaagtaatggatctggcagctagttggtatattgccatgcaatcga
aggaactaggtaaaaagccacaagcaatccagttatttggtagacctttagttgcatggcgagacaaacttggcaaaccagtgattatggagcgtttctgctcacatat
gggtgcatctttagcaatcggtcagatcatagatggttgcattcaatgtccttttcatcactggcggtacgatagttccggtgtgtgtgtggatataccaaaggtagcaac
accgacaacagatgtaattccgtcaacagcgcatcaacatacttatgtgacccaagaaaaatatggttacatttgggtctggtatggttccgtaaaccctttgtttcccttg
cccaagtttgatcctgccgaaagcgacaagcataactatatgtcttaccgtttctttagcaaaactaaaactactgtgttacgggtacttgaaaattcatttgatcatcacca
tgttgttgcaacacataatctaccggtaattaatcaaattaaacagaccctccttaataaagaagatataaaaattagtgaactatcgattgcaaaagaagcctggtttgg
aacagtaatggaagctcagattaaaagttatgctggtgtaggtgcgatcgctaagtttttagggttaaatgttgaaacttggaagacccgactggatgcttggccgagt
ggcagcttaggcacaacgagctttaatggacaacagaaaataagagtactctctggcatcactccaatttctgaaaaccagacaacatggcacttgttgttcatgatcaa
aaaaactggtaacttgtggctggatctactttcctacattgtttttggctggcaaaacgaagttgctgtatcggcagatgtagtcatctgggataccatgagcgcaaaaac
agggcaagcatttatcaagcctgaccagccagtattaaaatttagacaattttatcaaaattgggttgataaggcacagtaa 
 
welO11 KJ767017.1 Hapalosiphon welwitschii UH IC-52-3 wel gene cluster,  
atgggcagcagccatcaccatcatcaccacagccaggatccgaattcgagctcgatggttagctatattgaaaagagcgtaaatctagtcaaagaaccagaaactcaa
attaagcagtccatgaatctagcagcaagttggtatattgccatgcaatcggtggaactaggcaaaaaaccaatagcaattgagctatttggtcgcgccttagttgcatg
gcgagacaaagaccgcaaagcagtgattatggaacgtttctgttcacacgtcggtgcatctttagctataggtgaagttgtagatggttgcattcaatgtccatttcatca
ctggcgctatgatagttctggtgtatgcgtgcatataccaaaagtggcaactcctcacacagaccacattccatctacagcacgtcaaaaaacctatgttaccgaagaaa
gatatggttacatctgggtttggtatggtactgcaactcctttgtttgaattacctgggtttgatgcagcagaaagcaacaacaagcataaatatatgccttatcgcttctctt
tcttagtaaaaactagtgtgcgacgggtagtggaaaacgcatttgatcaccaccatttcgttacagtacacaatgtacctgtagctgattcaattgacctaactctagttaa
tcaaaaggatacagaactgagcgaactaccgatcgcaaaagaagcttggtttggaactgtaattgaggcccgaattaaanctttgactggtgttggtgctgcgatcgct
aagtttttagggttaaatattgaaactcaaaagaaccgagtagatgcttggcctactggatacataaatatatttagctgcgacggacagcagaggggtaaagtactctt
tggtgttaccccaatctctaaaaacgaaacaagattgcaagttttaattatgttcaataaaatgggcaacttntnggtgggatcngtttncctacattgtttttgtcaagca
attcaaagccaacggattacttga 
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welO12 KJ767017.1 Hapalosiphon welwitschii UH IC-52-3 wel gene cluster,  
atggttagctatattgaaaagagcgcaaatctagtcaaagaaccagaaactcaaattaagcagtccatgaatctggcagcaagttggtatattgccatgcaatcggtgg
aactagacaaaaaaccaatagcaattgagctatttggtcgcgccttagttgcatggcgagacaaagaccgcaaagcagtgattatggaacgtttctgttcacatgtcgg
tgcatctttagctataggtgaagttgtagatggttgcattcaatgtccatttcatcactggcgctatgatagttctggtgtatgcgtgcatataccaaaagtggcaactcctc
acacagaccacattccatctacagcacgtcaaaaaacctatgttaccgaagaaagatatggttacatttgggtttggtatggtactgcaactcctttgtttgaattacctgg
gtttgatgcagcagaaagcaacaagcataaatatatgccttatcgcttttctttccaaactgaaactagtgtgcgacgggcaattgaaaatggatttgaccaccatcatttt
gtttcagtacatggtttaccagtaattgatcaaattgaaatgaccttgctcgatgagaaagatgcagaatttagcgaactaatacttgcaaaagaagcctggattggaag
caaactcgatgctcgaattaaaaattttattggggtaggtgcgatcactaagtttttaggattaaatgttgaaactatatcagcacgaatagatgcttggcctagtggagtt
ttaagtacaatcaaatttaataaacagcaaaagatgaagctatttgttagtgttactccaatctctgaaanccaaacaatattgcaatatttgatcatgataaacaaaactg
gtaacttatggctaaatctactttcctacattnttttnggttggcaaaanaaagctag 
 
welO13 KJ767017.1 Hapalosiphon welwitschii UH IC-52-3 wel gene cluster,  
atggttagctatattgaaaacgacctacagccaaaactcacaaaatcagaagttcaaattgagagtaagggaataaatctggcagcaagttggtatattgccatgcaat
cagtggaactagacaaaaaaccaatagcaattgagctatttggtcgcgccttagttgcatggcgagacaaagaccgcaaagcagtgattatggaacgtttctgttcaca
tgtcggtgcatctttagctataggtgaagtcgtagatggttgcattcaatgtccatttcatcactggcgctatgatcattctggtgtatgcgtgcatataccaaaagtggca
actcctcacacagaccacattccatctacagcacgtcaaaaaacctatgtcactgaagaaagatatggttacatttgggtttggtatggtactgcaactcctttgtttgacct
accgaaattcgatgccgcagaaagcaacaagcataaatatatgccttatcgcttctccataatggttcaaacaaatgtacgacggatcattgaaaactcatgtgatcatc
atcatcttgtcacaatacatgatatgcaagtgaatgattcagtaaaattgacggtgcttgatgagaaggatgtcgaattgagtgaactaccgatcgcgaaagaagcttg
gatgggattcatagtcgaagcccggattaagactttccttggtgtacgcgggattactaaagctttagggttaaatgttgaaacaatgtcaacccgagcagatctttggc
ccagtggaatcttagccaccacaaagcttgacggacaagaaagacttgtagtactggatactgtcactcccatctctgaaaaccagacaaattggcaagttttgatcatg
gttaataaaactggtaacttgtttctag 
 
welO14 KJ767017.1 Hapalosiphon welwitschii UH IC-52-3 wel gene cluster,  
atggttagctatattgaaaacgacctacagccaaaactcacaaaatcagaagttcaaattgagagtaagggaataaatctggcagcaagttggtatattgccatgcaat
cagtggaactagacaaaaaaccaatagcaattgagctatttggtcgcgccttagttgcatggcgagacaaagaccgcaaagcagtgattatggaacgtttctgttcaca
tgtcggtgcatctttagctataggtgaagtcgtagatggttgcattcaatgtccatttcatcactggcgctatgatcattctggtgtatgcgtgcatataccaaaagtggca
actcctcacacagaccacattccatctacagcacgtcaaaaaacctatgtcactgaagaaagatatggttacatttgggtttggtatggtactgcaactcctttgtttgacct
accgaaattcgatgccgcagaaagcaacaagcataaatatatgccttatcgcttctccataatggttcaaacaaatgtacgacggatcattgaaaactcatgtgatcatc
atcatcttgtcacaatacatgatatgcaagtgaatgattcagtaaaattgacggtgcttgatgagaaggatgtcgaattgagtgaactaccgatcgcgaaagaagcttg
gatgggattcatagtcgaagcccggattaagactttccttggtgtacgcgggattactaaagctttagggttaaatgttgaaacaatgtcaacccgagcagatctttggc
ccagtggaatcttagccaccacaaagcttgacggacaagaaagacttgtagtactggatactgtcactcccatctctgaaaaccagacaaattggcaagttttgatcatg
gttaataa 
 
welO15 >gi|669033326|gb|KJ767017.1| Hapalosiphon welwitschii UH IC-52-3 wel gene cluster, 
atgtccaataacaccatctctacaaagcctgctttgcantttttagatatcaatgcaacagaggtaaaaaaatatcccactgctattcaagacataattatcaaccgtagctt
cgatgggatgatcattcgcggagtattccctcgcgatactatggagcaagtggcccgttgcttggaagagggaaatgacggtggtatgaaatcaattcttaataagaa
tgaagaatttggtaccaaagtggctcaaatatatggtcatgccattgtcggtcaatcacccgatctcaaagactactttgcttcttcagcaatcttccggcaggcttgtcgta
ctatgtttcaaggaagtccggattttgaggaacaagtagagtcaatatttcactctctttctggattgccagtagaaattcccacaggaccagaagggcaaacctataccc
cagctactatccggctattactcgagggtcgcgaaatcgcagtccatgttggcaatgatttcctgttaatgcctgcggctaaccatctgaaaactttgcttgatttatctgat
cagcttagttacttcatcccccttactgttcctgaagctggtggtgagctggtagtctataatctcgaatggaaccctcaagaagtagacaaatctgctgatttacacaaat
acatagatgaggtcgagtctaagttcaagtctaaccaatctcagagtgtagcttatgcaccaggtcctggagatatgctgctgttcaatggtggtcgatactaccatcga
gttagtgaagtaattggtaattctccacggcgaaccattggtggatttttagccttctctaaagagcgtaataagatttattactggagttaa 
 
welO16 KJ767017.1 Hapalosiphon welwitschii UH IC-52-3 wel gene cluster,  
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atgttctcacaattaaagcaaccagtaattgataatttagaagcctatcaagtagattttgaacgaggttttttaccgaaagaagatccacttgaaagattaccagatcaat
ttgaaatcatagaaaatattgctacaaacttgtctgcacttttaattacaggtcaatacagacatgtaattgataaagtacaatttcctgatatttcccaattagacactgaac
ggcaaatcaagcgtgcatttcttctcatgtcaatctttggtaatgcatatgtatggggtggagagatacctgcaacagtaattccacattcgctggccataccgttgtgtaa
gctcgcaaacatacttgatcgcccgccaatagttgcgttcagttcgatggtgttggataactggagaagaatcgataaaactcaaccaattgaattagataatattgctcc
actccagcttttccttggcggaattgatgaatattggttttacgcaacagcaatcgtaattgaagccaaaggagcgcctgctctgatatcacttgtacaagcacaaaaattt
gtcaacctcgataatactgcactagtgagtatgcatttgcaaaaaattgttgcggttattgctagaatgcaggcgatatttaaagaaataactaacaaatgtgacccatac
attttttatcatcgtgtacgtccatttgttggcagctggcaagaaccgggtgtaatttatgagggagtcagcgatactccacaaatgtttgtaggaggaagtgcagcaca
angttcgcttctccagtccttggatgcaggtttaggaatcaaacacgaccgagaaaancacgaatcatatttgcggcagatacgtgtgtatatgcccgtagcgcatcgc
cgatttcttga 
 
welO17 KJ767017.1 Hapalosiphon welwitschii UH IC-52-3 wel gene cluster 
atgactactgcacactacgatttaatcattattggtactggggcgggtggtggtacgctggcttataaacttgcttccactggtaagaaaattctgattttagaacgtggtt
cttttttagctcgtgagaaagctaactgggataccgtggaagtagtacagaaagaccgttatcataccaatgaagtttggtacgaccaaaaaggacaagctattcatcc
cggtacaggttactttgtgggtggtaacactaaagtttatggcggagcgctgtttcgttggcgagaacaagattttaatcaggtgattcacaaaggtggtatttcgcccg
aatggcctttgaagtaccgcgattttgaaccttactacacccaagcagaaaaactgtacgaagttcatggtaaacggggtttagatccgactgaaccagttgcaactga
agattatccttatcctgcgattcgtcacgaaccacgtattcaagaaattcatgactctttattagacgaaggttatcatccgttttatctgcctcttgctatcaagttaaatgag
gtgaatcggcgtttgagtagttgtattcgttgtaatacttgtgatggttttccttgtctagtggatgcaaaagccgatgctgatgttaactgtgtgcgtccagccgagcaat
atgataatgttacgctgatgactgaagctaaggtaaaacggttacatactagtcatactgggcgagaagttactagtgtagaagtcgaaattgatagagaaattcatttt
ttttctagtgatattgtagtggttgcttgtggagcaattaattcagctgctttattgttacgttctgctaatgagcagcatcctaatggattagccaatagttctgatctggtgg
gacgaaacttaatgaagcatcagaatggagcgatgattggggtgagtttgaaatccaatttgacagcatttcaaaaaactttagcaatcaacgatttttactggggtgat
gcagattttga 
 
welP1 – Orf2-1-related aromatic prenyltransferase [Westiella intricata UH HT-29-1]  
Sequence ID: AIH14803.1 codon optimized[238] in pJ express vector 
atgaacgacgtcaaccgcattagaaccgacatcgtcaacgtagcaaccacctttggtgctgagtatagcgagaaggttctggatgaagtgttccaagtttttggtgaac
agtttgccgacaacagcttcatgatccgtaccagcaataaacaaccggataaactgggttgttacttccgctaccacgaggaagatgagagccatctgggtctggcgtg
ggatattgcgcgtaaaagcggtctgctgtccgatcaaggccgtccggtcgatcaactgattccggagatttgcgaaacctttccgatcatggccgatggcgtggacttt
gatgtgaaacacggcctggcgaagatctggcagtccatcaaaggcgtggttccggtccaagatgcgttcaagctgtccctgccaccgtctgtgaatgcccacgcggac
tttctgaagaatcatcacctggacgcgctgtatgcgttcggcgttgactatcaccacagcagcgtgaacctgtacttcgacacttaccacccgaagcatcatacgagcga
atactacgagaacctgctgcaagacctgcagtttcagccacctagcgatgaggtcctggagctgttggctaacaatggcgagatcgcgctgaccttcaacttcgcaagc
ccgcgtattgaacgtttgtgcttttatctgccgttcctgaatcgtgaggctgttccgcagaatttgttgacgccgctgctgaagaaatacattaatgaagcaccggccttgg
tggacaatccgggtttcatcttgggctggagctttggtccgcagggtggtaaaggtacgtataccaaagttgatgtggactaccacggtcgcacggttccgctgttcatt
aaggtccattctcagcctctgccgaaggcagcggacttcgcactggcgaagcttgggccccatcatcatcatcatcattga 
 
hpI1 tryptophan isonitrile synthase [Fischerella sp. ATCC 43239] Sequence ID: AIJ28525.1 
codon optimized[238]  
atgatcagcgagaaaatcctgcgccacattttccagtatcgtcgtctgctgtctgatacggagccgtgtgcgaaagaaccatgctccatttgcctggcccctcatctgccg
aagattcagagctttatcgaaaacaatgagccgatccacttcattttaccggcgtttccggcaaagagcccgaacccgcagaaagtactgggtccaatgccggatatgg
gcgaacgtgttgccttgcaatttctgcaaaacctgtgcaaccaaatctccgagatttacgctagcggtgcgaaaatcaccatttgttctgacggtcgcgtgtttactgatct
ggtcgcgatcacggacgagaatgtttccttgtatcgccagggcatccagcgcctgctgaacgaaatcaatgcggatgccattgataccttctgtctggagaacgtgttta
ccggtatgagcttcgaccagatgcgtaaaaccctggttaagcaatacgcacagccgattgaaagcattcaagagcgcgtgaatagcgaggataaacaccgtcagtttt
tcaagggcatttatcacctgttgttcgacgactacctggtcctgtacccggacaagagccgtgaacaaatcgaagtggagtgcaaccttcgtgcgtacgaagtgattca
gcgttcgaatgcttggaccacgctggttggtcagcatttcccgcagagcctccgtttgagcatccatcctcaagattatcacagcaacaaaatcggtatccacatgattaa
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gaccagcgaccagtggggcacgccgtggcacaatgcaccgatgttcaatggcaaagaatttctgctgatgaagcgtaaacatattgaggacattggtgcgagcctgg
tctggcataatgatcacccgagccactacatcctgagcgagcaagttagccaagcactggtcaccttcgacaacaagtcataa 
 
hpI3 tryptophan isonitrile synthase [Fischerella sp. ATCC 43239] Sequence ID: AIJ28523.1 
codon optimized[238]  
atgatggttagcacgagcgtagaacaaagcacccaatttagcgttaaatccttaactccgtttggcgcgctgttggaagcgaccgaggatcacagcgacatccagcag
ctgagcattgaacaactgtgccagttgacctgggaacaccgtctgattgtgctgcgcggtttctctctgctggagcgcgaggaactgagcatctattgccagcgttggg
gtgaattgctggtctggaatttcggtacggtcctggatctgattgttcaccagaacccggagaactacctctttaccaacggcaatgtgccgttccattgggacggtgcat
tcgccgaagcggttccgcgtttcctgttcttccaatgtctgaaggcaccggaagctggcagcggtggcgagtctctgttttgtgatacggtccgtaccctgcagaacgtc
agcccgcaacagcgtgagatctggcaaaagaccgagatctcgtacaaaaccgagaaagtggctcattatggtggcgagatcacgaagtccctggtgattaaacacc
cgatcaccggtctgagcacgctgcgttttgcagagccattgaacgatgcgagcgttcacctgaatccgctgtatgttgaggtgtgcaatctgccgaccgaagaacaga
atagcttcatcaatgaactgattgagaacctgtacttgccgcaaanctgttttgcgcatgagtggcaagagggcgacttcctgattgccgacaatcatgcgctgcttcac
ggtcgcaatccttttctgtccaacagccagcgccatctgcagcgtgtgcacattctgtaa 
 
tser AM902709.1| Thermus scotoductus chrR gene for chromate reductase, strain SA-01 
ttcaattgggtaacgcccgggttttcccagtcgcgacgctgcagaacgacggctaagctctcgaggatccatatccccgaagaggaggctttccacgtagcggaagg
cagccgccagatcggagccttgcccctgaccgaagccggggttcataagaccagtctatcccaaaaaagagcgcggggaaacccggcccccacgggactgtttcctt
acgctttccttcaagagccctccataatggaggcatggccttgctcttcacccccctggaactcggcggcctccggctgaaaaaccgcctggccatgtcccccatgtgcc
agtactccgccaccttggagggagaggtaaccgactggcacctcctccactaccccacgcgggcccttgggggcgtggggctcattctggtggaggccaccgccgtg
gaacctttgggccgtatcagcccctatgacctgggcatctggtcggaggatcaccttccgggcctgaaggagctcgcccggaggatccgggaagctggagcggtgc
cggggatccagctggcccacgccgggcgcaaggcggggaccgccaggccctgggaagggggaaagcccctgggctggcgggtggtggggccaagccccattc
cctttgacgagggctacccggtacccgaacccctggacgaagcagggatggagcgcatcctccaggccttcgtggaaggagccagacgtgcccttagggcaggctt
tcaggtgatcgagctccacatggcccatggctacctcctttcctccttcctctcccccctttccaaccagcgcaccgacgcctacgggggaagcctggaaaaccgcatgc
gctttcccctccaggtggcccaggcagtgcgggaggtggtgcccagggagcttccccttttcgtgcgggtctccgccacggactggggggaaggaggatggagcct
cgaggacaccctggccttcgcccggaggcttaaggagctgggggtggaccttttggactgctcctcgggcggggtggtgctcagggtgcggattcccctggccccg
ggctttcaggtgcccttcgccgacgccgtgcgcaagagggtgggcctgcgaacgggagccgtgggcctcatcaccacccccgagcaggcggaaaccctcctgcag
gcgggaagcgccgatctggtgcttctgggccgggttctcctcagggacccctacttccccttacgggctgccaaggccttgggcgtggccccggaggtacccccccag
taccaaagggggttttagcaccatcccaacctggcaggaaccaggttggagggcaccggccagttcctc 
 
P450BM3 
atggcaattaaagaaatgcctcagccaaaaacgtttggagagcttaaaaatttaccgttattaaacacagataaaccggttcaagctttgatgaaaattgcggatgaatt
aggagaaatctttaaattcgaggcgcctggtcgtgtaacgcgctacttatcaagtcagcgtctaattaaagaagcatgcgatgaatcacgctttgataaaaacttaagtc
aagcgcttaaatttgtacgtgattttgcaggagacgggttatttacaagctggacgcatgaaaaaaattggaaaaaagcgcataatatcttacttccaagcttcagtcag
caggcaatgaaaggctatcatgcgatgatggtcgatatcgccgtgcagcttgttcaaaagtgggagcgtctaaatgcagatgagcatattgaagtaccggaagacat
gacacgtttaacgcttgatacaattggtctttgcggctttaactatcgctttaacagcttttaccgagatcagcctcatccatttattacaagtatggtccgtgcactggatga
agcaatgaacaagctgcagcgagcaaatccagacgacccagcttatgatgaaaacaagcgccagtttcaagaagatatcaaggtgatgaacgacctagtagataaa
attattgcagatcgcaaagcaagcggtgaacaaagcgatgatttattaacgcatatgctaaacggaaaagatccagaaacgggtgagccgcttgatgacgagaacat
tcgctatcaaattattacattcttaattgcgggacacgaaacaacaagtggtcttttatcatttgcgctgtatttcttagtgaaaaatccacatgtattacaaaaagcagcag
aagaagcagcacgagttctagtagatcctgttccaagctacaaacaagtcaaacagcttaaatatgtcggcatggtcttaaacgaagcgctgcgcttatggccaactgc
tcctgcgttttccctatatgcaaaagaagatacggtgcttggaggagaatatcctttagaaaaaggcgacgaactaatggttctgattcctcagcttcaccgtgataaaac
aatttggggagacgatgtggaagagttccgtccagagcgttttgaaaatccaagtgcgattccgcagcatgcgtttaaaccgtttggaaacggtcagcgtgcgtgtatc
ggtcagcagttcgctcttcatgaagcaacgctggtacttggtatgatgctaaaacactttgactttgaagatcatacaaactacgagctggatattaaagaaactttaacg
ttaaaacctgaaggctttgtggtaaaagcaaaatcgaaaaaaattccgcttggcggtattccttcacctagcactgaacagtctgctaaaaaagtacgcaaaaaggcag
aaaacgctcataatacgccgctgcttgtgctatacggttcaaatatgggaacagctgaaggaacggcgcgtgatttagcagatattgcaatgagcaaaggatttgcac
cgcaggtcgcaacgcttgattcacacgccggaaatcttccgcgcgaaggagctgtattaattgtaacggcgtcttataacggtcatccgcctgataacgcaaagcaattt
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gtcgactggttagaccaagcgtctgctgatgaagtaaaaggcgttcgctactccgtatttggatgcggcgataaaaactgggctactacgtatcaaaaagtgcctgcttt
tatcgatgaaacgcttgccgctaaaggggcagaaaacatcgctgaccgcggtgaagcagatgcaagcgacgactttgaaggcacatatgaagaatggcgtgaacat
atgtggagtgacgtagcagcctactttaacctcgacattgaaaacagtgaagataataaatctactctttcacttcaatttgtcgacagcgccgcggatatgccgcttgcg
aaaatgcacggtgcgttttcaacgaacgtcgtagcaagcaaagaacttcaacagccaggcagtgcacgaagcacgcgacatcttgaaattgaacttccaaaagaagc
ttcttatcaagaaggagatcatttaggtgttattcctcgcaactatgaaggaatagtaaaccgtgtaacagcaaggttcggcctagatgcatcacagcaaatccgtctgg
aagcagaagaagaaaaattagctcatttgccactcgctaaaacagtatccgtagaagagcttctgcaatacgtggagcttcaagatcctgttacgcgcacgcagcttcg
cgcaatggctgctaaaacggtctgcccgccgcataaagtagagcttgaagccttgcttgaaaagcaagcctacaaagaacaagtgctggcaaaacgtttaacaatgct
tgaactgcttgaaaaatacccggcgtgtgaaatgaaattcagcgaatttatcgcccttctgccaagcatacgcccgcgctattactcgatttcttcatcacctcgtgtcgat
gaaaaacaagcaagcatcacggtcagcgttgtctcaggagaagcgtggagcggatatggagaatataaaggaattgcgtcgaactatcttgccgagctgcaagaa
ggagatacgattacgtgctttatttccacaccgcagtcagaatttacgctgccaaaagaccctgaaacgccgcttatcatggtcggaccgggaacaggcgtcgcgccgt
ttagaggctttgtgcaggcgcgcaaacagctaaaagaacaaggacagtcacttggagaagcacatttatacttcggctgccgttcacctcatgagactatctgtatcaa
gaagagcttgaaaacgcccaaagcgaaggcatcattacgcttcataccgctttttctcgcatgccaaatcagccgaaaacatacgttcagcacgtaatggaacaagac
ggcaagaaattgattgaacttcttgatcaaggagcgcacttctatatttgcggagacggaagccaaatggcacctgccgttgaagcaacgcttatgaaaagtatgctga
cgttcaccaagtgagtgaagcagacgctcgcttatggctgcagcagctagaagaaaaaggccgatacgcaaaagacgtgtgggctgggtaa 
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8.3.3 Fast Protein Liquid Chromatography 
 
Figure 65. Ni-NTA IMAC elution profile of Wi-WelO15 and Hw-WelO15 variants. Elution buffer (buffer B) is increased in a linear 
gradient from 20 mM imidazole (0% buffer B) to 250 mM imidazole (100% buffer B) in 12 CV. Tailing was also observed with 
steeper gradients (up to 0.5 M imidazole/12CV). 
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Figure 66. Ni-NTA IMAC elution profile of Wi-WelO15 and Hw-WelO15 variants. Elution buffer (buffer B) is increased in a linear 
gradient from 20 mM imidazole (0% buffer B) to 250 mM imidazole (100% buffer B) in 12 CV. Tailing was also observed with 
steeper gradients (up to 0.5 M imidazole/12CV). 
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Figure 67. Ni-NTA IMAC elution profile of Wi-5 in comparison with two different buffer systems.  
Calibration of Superdex 26/60 Column 
 
Figure 68. Calibration of size exclusion column by measuring different enzymes. Measured samples are bovine serum albumin 
(68 kDa, 183 mL elution volume), lysozyme (trimer 45 kDa, 205 mL elution volume), TsER (38 kDa, 215 mL elution volume), Wi-
WelO15 V6I/D284N (35 kDa, 227 mL elution volume). Linear regression : MW(kDa)=3.06-0.0007∙elution volume (mL). 
Mass spectrum of isolated, denatured Hw-WelO15  
 
Figure 69. Mass spectra of Hw-WelO15. The denatured enzymes were measured via HPLC by the mass department of Philipps-
University Marburg. The theoretical, with Expasy Protparam calculated, mass of Hw-WelO15 is 34394 Da.  
Appendix 
 
 
203 
8.3.4 Crystallization 
Table 37. Pictures of all crystals that were obtained from WelO15 enzymes. 
crystallization set up (Wi-0) 20.10.2015, pictures taken 27.10.2015 
 
AmSO4 plate well B10 drop2 
0.2 M KOAc, 2.2 M AmSO4 
 
JCSG IV plate well A12 drop1 
0.1 M Bicine pH9, 2.4 M AmSO4 
crystallization set up (Wi-0) 20.10.2015, pictures taken 15.01.2016 
 
AmSO4 plate well D6 drop1:  
0.2 M Na2HPO4, 2.2 M AmSO4 
 
AmSO4 F5 drop1: 
0.1 M Tris pH8, 0.8 M AmSO4 
 
AmSO4 plate well F6 drop1:  
0.1 M Bicine pH9, 0.8 M AmSO4 
 
JCSG III plate well B10 drop1: 
0.1 M Tris pH8.5, 2.4 M AmSO4 
 
JCSG IV plate well A12 drop1: 
0.1 M Bicine pH9, 2.4 M AmSO4  
 
 
Appendix 
 
 
204 
aerobic crystallization set up (Wi-0) 14.7.2016, pictures taken 16.03.2017 
 
AmSO4 plate well E12 drop1: 
0.1 M Bicine pH9, 1.6 M AmSO4 
AmSO4 plate well G10 drop1 
0.2 M NaCl, 0.1 M HEPES sodium salt 
pH 7.5, 1.6 M AmSO4 
 
AmSO4 plate well G12 drop1 
0.1 M MES sodium salt pH 6.5  
1.6 M AmSO4 in5%(w/v) PWG 400 
 
anaerobic crystallization set up (Wi-0) 14.7.2016, pictures taken 29.03.2017 
 
SG Core III E3 drop2: 
0.1 M MES pH 6.5, 1.6 M AmSO4 
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8.3.5 Circular Dichroism and Stability 
8.3.5.1 Folding 
Table 38: Folding properties of WelO15 variants in presence of 5 mM HEPES, 1 mM NaCl, pH 7.4 and given cofactors. 
  Wi-0 Hw-WelO15 Wi-5 Wi-8 Wi-2 Wi-9 
apo  
enzyme 
α-helices 30 16 18 23 19 21 
β-sheet 
 
24 36 32 32 33 13 
turn 
 
16 18 19 27 24 26 
random 24 30 31 19 24 41 
1eq 
KG 
 
α-helices 16 22 24 20 25 18 
β-sheet 
 
49 23 0 41 23 24 
turn 
 
25 23 34 19 32 25 
random 21 32 42 20 21 34 
1eq 
KG + 
1eq FeII 
 
α-helices 17 22 27 14 32[a] 17[b] 
β-sheet 
 
55 29 20 42 0[a] 35[b] 
turn 
 
10 18 30 16 38[a] 22[b] 
random 18 30 24 28 30[a] 27[b] 
[a] 5 mM KG+0.5 mM (NH4)2Fe(SO4)2 [b] 1 eq KG+1 eq NiCl2 
The error of measured melting temperature was determined by measuring 5 times the melting 
temperature of apo enzyme Wi-13 and calculate standard deviation which was 0.3°C. 
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8.3.5.2 Melting Curves 
 
Figure 70. Melting curve of Hw-WelO15 and Wi-WelO15 in combination with different cofactors. 
Appendix 
 
 
207 
 
Figure 71. Melting curves of Wi-5 and Wi-8 in combination with different cofactors. 
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Figure 72. Melting curves of Wi-11 and Wi-12 in combination with different cofactors. 
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Figure 73. Melting curves of Wi-2 and Wi-9 in combination with different cofactors. 
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Figure 74. Melting curves of Wi-9 and Wi-10 in combination with different cofactors. 
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Figure 75. Melting curves of Wi-P1, Wi-P2, Wi-P3 and Wi-5P3 in combination with different cofactors. 
8.3.5.3 SDS-PAGE Analysis of Stabilized Variants 
 
Figure 76. SDS-PAGE analysis of soluble fraction of Wi-0 after incubation at different temperatures. 
 
Figure 77. SDS-PAGE analysis of soluble fraction of Wi-P1 after incubation at different temperatures. 
 
Figure 78. SDS-PAGE analysis of soluble fraction of Wi-P2 after incubation at different temperatures. 
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Figure 79. SDS-PAGE analysis of soluble fraction of Wi-P3 after incubation at different temperatures.  
 
Figure 80. SDS-PAGE analysis of soluble fraction of Wi-5P3 after incubation at different temperatures. 
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8.3.6 Docking 
8.3.6.1 Isonitrile and Isothiocyanate Molecules 
 
Figure 81. On the left, the docking results of 12-epi-fischerindole U (light blue) is shown, overlaid with the soaked 12-epi-fischerin-
dole U (gray). On the right, the docking results of 12-epi-hapalindole C (light blue) is shown, overlaid with the soaked 12-epi-
fischerindole U (gray). 
8.3.6.2 Hapalindole-like ketones 
 
Figure 82. Docking poses after docking with YASARA docking tool. Shown are proposed poses 11, 16 and 22. 
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Figure 83. Crystal structures of 53 (left) and 54 (right). It can be seen that the isonitrile and ketone functionality points in opposite 
directions based on the indole ring. 
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8.4 Mutagenesis 
8.4.1 Mutations in Sequenced Clones after Error Prone PCR 
In table 39 all mutations, found in the sequenced clones after error prone are listed. 
Table 39: Mutations incorporated with error prone PCR. Out of 6 variants that were sequenced for each library, 3 variants without 
frameshift were identified. Two sequenced mutants were wild type and one mutant had a frameshift. m= mutations, silent = silent 
mutation, fs = frameshift, aa= amino acid 
 
number of  
mutations(m) 
mutations 
active site region 
2m +1silent Y190F, P244P, R256Q 
4m +1silent V196V, V228D, F232L, S262G 
5m + 1silent  A104A, T180A, T195P, D220V, F252I, F279V, 
3m + 1 silent + 1fs fs (additional A at 756), S234S, V264E, K285R 
2 sequenced genes still had the template sequence 
lid region 
7m M67K, S69T, I70V, L71I, K73M, E75V,K80I 
3m K73R, G78S, K80N 
2m M113V, Q123H 
1 variant with frameshift  
1 variant with stop codon after 52 aa 
1 sequenced gene still had the template sequence 
 
Figure 84. Amino acid sequence alignment of the Hw-WelO15 sequence, used to create the model and the sequence of WelO5. 
Red boxes indicate a low RMSD and highlight the amino acids that were used to calculate the RMSD from 74 pruned atom pairs. 
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8.4.2 Quick Quality Control after Semi-Rational Mutagenesis 
8.4.1.1 1st Generation 
 
Figure 85. Sequencing chromatogram: Height of the signal correlates with the concentration of the base. Every color represents 
one base (adenine=green, thymine=red, cytosine=blue, guanine=black). Degeneration of mutated positions from library genera-
tion 1. 
 
Figure 86. Sequencing chromatogram: Height of the signal correlates with the concentration of the base. Every color represents 
one base (adenine=green, thymine=red, cytosine=blue, guanine=black). Degeneration of mutated positions from two site libraries 
in generation 2.  
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8.4.1.2 2nd Generation 
 
Figure 87. Sequencing chromatogram: Height of the signal correlates with the concentration of the base. Every color represents 
one base (adenine=green, thymine=red, cytosine=blue, guanine=black). Degeneration of mutated positions from 5-site library in 
generation 2. The amino acid position is given with the wild-type codon (1st row) and selected DNA codons which should be 
introduced are shown. 
8.4.1.3 4th Generation Library 
 
Figure 88. Sequencing chromatogram: Height of the signal correlates with the concentration of the base. Every color represents 
one base (adenine=green, thymine=red, cytosine=blue, gunanine=black). Degeneration of mutated positions from library genera-
tion 4. The amino acid position is given with the wild-type codon (1st row) and selected DNA codons which should be introduced 
are shown. 
In table 40, all sequenced variants from the 4th generation library are shown. 
Table 40. Found variants in the 4th generation library, sorted by their template DNA. Given letters represent positions S93, S103 
and A175. Letters shown in grey are still the wild-type amino acid. 
V6I/N74Q/A82L/ 
V90P/D284N 
V6I/N74R/A82L/ 
V90P/D284N 
V6I/A82L/V90P/ 
D284N 
V6I/N74R/V81T/A82M/ 
A88V/V90P/D284N 
SAA DSA NSH DSA 
DAH DSN DSA NAS 
DSV AAN DSN NSS 
LAN ASV DSH VSL 
DSL LSN DSS DAA 
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HAS HSH HAS LAA 
ASA HAN LSN  
  HSH  
  SSN  
  SSS  
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Figure 89. Triplicate measurement of found hits from library generation 4. All variants are based on Wi-0. 
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8.5 Biotransformation 
8.5.1 SDS-PAGE Analysis of Whole Cells 
 
Figure 90. SDS-PAGE analysis of OD600 normalized E. coli BL21-Gold(DE3) cells induced with IPTG. The cell pellet was suspended 
in water and mixed with SDS-PAGE sample buffer. After heating for 10 min at 95 °C, insoluble components were removed by 
centrifugation and supernatant was applied to a gel (12% separation gel, 5% stacking gel). 1) pRSF-Duet 2) Hw-WelO15 3) Hw-1 
4) Hw-2 5) Wi-0 6) Wi-3 7) Wi-2 8) Wi-1 9) Wi-7 10) Wi-8 11) Wi-5 12) Wi-6 13) Wi-9 14) Wi-10 15) Wi-13 16) Wi-4 
8.5.2 SDS-PAGE Analysis of OD600 normalized Cell Lysate  
 
Figure 91. SDS-PAGE analysis of OD600 normalized E. coli BL21-Gold(DE3) cells induced with IPTG after lysis with lysozyme. 
After removing insoluble cell debris, the cleared lysate was with SDS-PAGE sample buffer. After heating for 10 min at 95 °C, the 
sample was centrifuged for 10 min at 14000 rpm and the supernatant applied to a gel (12% separation gel, 5% stacking gel). 1) 
pRSF-Duet 2) Hw-WelO15 3) Hw-1 4) Hw-2 5) Wi-0 6) Wi-3 7) Wi-2 8) Wi-1 9) Wi-7 10) Wi-8 11) Wi-5 12) Wi-6 13) Wi-9 14) Wi-10 
15) Wi-13 16) Wi-4 
SDS-PAGE analysis shows that in assays with lysate approximately the same amount of cata-
lyst is present as with purified enzymes. In both gels (figure 91 and figure 92), the thickness of 
the bands is comparable. The following calculation shows how the concentration was calcu-
lated. 
1) lysate: Cell pellet was suspended in 100 µL lysis buffer, lysed and centrifuged to re-
move insoluble cell debris. 50 µL of the supernatant was mixed with 17.5 µL 4x SDS-
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PAGE sample buffer. 6 µL of the mix was applied to the gel, resulting in 4.4% of the 
total enzyme amount within one reaction. 
2) Purified enzyme: 100 µL of 20 µM enzyme was prepared (total enzyme amount of as-
say, which is performed with 200 µL but 10 µM) and mixed with 33 µL 4x SDS-PAGE 
sample buffer. 6 µL of this solution was applied to the gel, resulting in 4.5% of the total 
enzyme amount. 
8.5.3 SDS-PAGE Analysis of Purified Enzymes 
 
Figure 92. The SDS-PAGE analysis shows purified halogenase variants. Enzyme stock solutions were diluted to 20 µM before 
starting assays. 3.1 µg enzyme was applied to the gel, which represents 4.5% of the enzyme present in the assay (gradient gel 4-
15% BioRad). M=Marker, 1) Wi-0 2) Wi-2 3) Wi-1 4) Wi-5 5) Wi-12 6) Wi-9 7) Wi-10 8) Wi-7 9) Wi-8 10) Wi-11 11) Wi-4 
12) Hw-WelO15.  
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8.5.4 HPLC Chromatograms of Biotransformation  
 
Figure 93. HPLC chromatograms of hapalindole-like ketones in 200 µL scale and purified enzymes. 
 
Figure 94. HPLC chromatograms of biotransformation with Wi-1 and 67 or 91 in 200 µL scale and purified enzymes. 
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Figure 95. HPLC chromatograms of biotransformation with cell lysate containing Wi-12 and 81 in 50 mL scale. 
 
Figure 96. HPLC chromatograms of biotransformation with cell lysate containing Wi-12 and 83 in 50 mL scale. 
TR (79a) = 2.5 min with [M+H]+ m/z = 328 TR (80a) = 2.8 min with [M+H]+ m/z = 266 
TR (79b) = 2.7 min with [M+H]+ m/z = 328 TR (80b) = 7.4 min with [M+H]+ m/z = 268 
TR (79c) = 3.1 min with [M+H]+ m/z = 266 TR (80c) = 7.9 min with [M+H]+ m/z = 346 
TR (79d) = 6.1 min with [M+H]+ m/z = 266  
TR (79e) = 7.4 min with [M+H]+ m/z = 310  
TR (79f) = 8.0 min with [M+H]+ m/z = 266  
Retention times and masses of products 81a-81d, 82a and 82b as well as 83a-83e are further 
described in chapter 7.3.1.8 - 7.3.1.10. 
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8.5.5 Selectivities of Hapalindole-like Ketones 
Table 41. Overview of selectivities and conversion of variants transforming 79 and 80. Final reaction conditions: 200 µL volume 
in 2.2 mL 96 dw-plates, 50 mM HEPES, 100 mM NaCl, 5 mM KG, 2.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM sub-
strate, 8 h reaction time, 30 °C, 200 rpm (Infors HT shaker). Area of starting material and new produced products (new peak in 
HPLC in comparison to control reaction without halogenase) were included. If relative conversion was below 5% no selectivity 
was determined.  
 79 80 
 
conv. 
(%HPLC) 
sel. 
79a 
sel. 
79b 
sel. 
79c 
sel. 
79d 
sel. 
79e 
sel. 
79f 
conv. 
(%HPLC) 
sel. 
80a 
sel. 
80b 
sel. 
80c 
Wi-0 3 nd nd nd nd nd nd 1 nd nd nd 
Wi-2 28 5 3 55 23 8 5 11 24 3 73 
Wi-1 50 3 74 2 17 4 0 9 34 4 62 
Wi-4 11 <1 24 66 5 2 2 2 nd nd nd 
Wi-5 45 3 2 83 9 2 1 8 41 4 55 
Wi-7 6 4 12 36 4 31 13 1 nd nd nd 
Wi-8 12 <1 7 45 10 36 2 1 nd nd nd 
Wi-11 10 <1 13 49 8 28 2 1 nd nd nd 
Wi-12 45 3 2 77 14 3 0 11 36 3 61 
Wi-9 6 1 18 38 27 14 1 1 nd nd nd 
Wi-10 31 4 4 77 10 3 2 2 nd nd nd 
Hw-WelO15 59 3 1 59 37 0 1 6 22 0 78 
 
Table 42. Overview of selectivities and conversion of variants transforming 81 and 82. Final reaction conditions: 200 µL volume 
in 2.2 mL 96 dw-plates, 50 mM HEPES, 100 mM NaCl, 5 mM KG, 2.5 mM ascorbic acid, 0.5 mM (NH4)2Fe(SO4)2, 0.5 mM sub-
strate, 8 h reaction time, 30 °C, 200 rpm (Infors HT shaker). Area of starting material and new produced products (new peak in 
HPLC in comparison to control reaction without halogenase) were included. If relative conversion was below 5% no selectivity 
was determined. 
 81 82 83 
 
conv. 
%HPLC 
sel. 
81a 
sel. 
81b 
sel. 
81c 
sel. 
81d 
conv. 
%HPLC 
sel.  
82a 
sel.  
82b 
conv. 
%HPLC 
sel.  
83a 
sel.  
83b 
sel.  
83c 
sel.  
83d 
sel.  
83e 
Wi-0 7 8 23 20 49 14 46 54 26 3 20 19 0 55 
Wi-2 2 nd nd nd nd 15 51 49 17 5 15 30 0 46 
Wi-1 3 nd nd nd nd 27 31 69 6 13 23 18 6 34 
Wi-4 <1 nd nd nd nd 3 nd nd 1 nd nd nd nd nd 
Wi-5 10 21 8 22 49 31 28 72 15 9 30 28 0 29 
Wi-12 31 19 7 29 46 40 29 71 38 14 32 11 10 28 
Wi-7 3 nd nd nd nd 12 23 77 11 5 31 35 0 24 
Wi-8 3 nd nd nd nd 15 21 79 26 12 39 27 0 20 
Wi-11 7 12 13 19 57 14 20 80 30 12 36 27 0 21 
Wi-9 3 nd nd nd nd 18 50 50 6 6 16 28 0 41 
Wi-10 4 nd nd nd nd 29 30 70 9 5 30 29 0 31 
Hw-
WelO15 
20 8 45 33 13 10 41 59 16 8 14 9 8 57 
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8.5.6 Hydroxylation with P450BM3 
 
Figure 97. HPLC chromatograms of P450BM3 with ketone 54. 
Quick Quality Control of P450BM3 Library 
 
Figure 98. Quick quality control of P450BM3 library. 
 
Figure 99. HPLC chromatogram of biotransformation with P450BM3 variant. New arising peaks are assigned to products which 
have to be characterized in the next steps. 
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8.5.7 Kinetics 
 
Figure 100. Kinetic assays of Wi-0 and 53 and Wi-WelO15 variants and 54. 
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Figure 101. Kinetic assays of Wi-5 and 76, 77, and 78. 
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8.6 Analytic of Compound Characterization 
8.6.1 NMR and HPLC/GC Chromatograms of Compounds 53-87 
8.6.1.1 Analytic of 53 and 67 
Synthesis was performed by L. Schmermund within his Master Thesis[317] 
53 Minor diastereomer: Rf = 0.73 (pentane:EtOAc 4:1); 1H-NMR (500 MHz, CDCl3), δ = 8.09 (s, 
1H, NH), 7.46 (d, 1H, J = 8.15 Hz, H4), 7.37 (td, 1H, J = 8.10, 0.85 Hz, H7), 7.21-7.18 (m, 2H, H6, 
H2), 7.14-7.11 (m, 1H, H5), 4.81-4.80 (m, 1H, H17/cis), 4.66-4.65 (m, 1H, H17/trans), 3.61-3.60 (m, 1H, 
H11), 3.54-3.50 (m, 1H, H10), 2.84 (dt, 1H, J = 11.9, 4.30 Hz, H15), 1.89-1.82 (m, 1H, H14), 1.80-1.72 
(m, 1H, H13), 1.71-1.66 (m, 2H, H13.), 1.53-1.52 (m, 3H, H18), 1.46-1.42 (m, 1H, H14), 1.28 (s, 3H, 
H19), 1.15 (s, 3H, H20) ppm; 13C-NMR (125 MHz, CDCl3), δ= 156.4 (NC), 147.7 (C16), 135.8 (C8), 
126.8 (C9), 123.7 (C2), 122.0 (C5), 119.5 (C6), 117.3 (C4), 114.0 (C3), 112.3 (C17), 111.6 (C7), 67.5 (C11), 
43.6 (C15), 35.4 (C10), 34.2 (C12), 32.8 (C14), 29.6 (C20), 28.6 (C13), 24.0 (C19), 19.0 (C18) ppm;  
HRMS (ESI+): C20H24N2Na+ [M+Na]+, m/z found: 315.1835; calc.: 315.1832.  
Optical rotation (in CHCl3, 22 °C, λ=589 nm, cuvette 50 mm, 0.43 g/100mL) 38.742 
67 Major diastereomer: Rf = 0.61 (pentane:EtOAc 4:1); 1H-NMR (500 MHz, CDCl3), δ = 8.12 (s, 
1H, NH), 7.50 (d, 1H, J = 8.16 Hz, H4), 7.40 (d, 1H, J = 8.10, H7), 7.24-7.21 (m, 2H, H6, H2), 7.17-
7.14 (m, 1H, H5), 4.84-4.83 (m, 1H, H17/cis), 4.69-4.68 (m, 1H, H17/trans), 3.63-3.63 (m, 1H, H11), 3.57-
3.55 (m, 1H, H10), 2.86 (dt, 1H, J = 11.9, 4.36 Hz, H15), 1.91-1.78 (m, 1H, H14), 1.77-1.70 (m, 2H, 
H13), 1.55-1.54 (m, 3H, H18), 1.49-1.45 (m, 1H, H14), 1.30 (s, 3H, H19), 1.17 (s, 3H, H20) ppm; 13C-
NMR (125 MHz, CDCl3), δ= 156.5 (NC), 147.8 (C16), 135.9 (C8), 126.9 (C9), 123.8 (C2), 122.2 (C5), 
119.6 (C6), 117.4 (C4), 114.2 (C3), 112.4 (C17), 111.7 (C7), 67.5 (C11), 43.7 (C15), 35.5 (C10), 34.4 (C12), 
32.9 (C14), 29.8 (C20), 28.7 (C13), 24.1 (C19), 19.1 (C18) ppm;  
HRMS (ESI+): C20H24N2Na+ [M+Na]+, m/z found: 315.1833; calc.: 315.1832.  
Optical rotation (in CHCl3, 22 °C, λ=589 nm, cuvette 50 mm, 0.46 g/100mL) 78.336. 
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.
 
Figure 102. 1H-NMR of 53 measured in CDCl3. 
 
Figure 103. 13C-NMR of 53 measured in CDCl3. 
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Figure 104. HPLC chromatogram of 53. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 73 : 27 ACN-H2O for 11 min. 
The retention time is 8.41 min. 
 
Figure 105. Crystal structure of isonitrile 53 with the (R)-configuration of the isonitrile group. The nitrogen atoms are shown in 
blue, the carbon atoms as large white spheres with black stripes and the hydrogen atoms as small white spheres. Crystals were 
obtained, storing a 50 mM solution of 53 in EtOH at -20°C. CCDC 1839577 
 
Figure 106. 1H-NMR of isonitrile 67 measured in CDCl3. 
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Figure 107. 13C-NMR of isonitrile 67 measured in CDCl3. 
 
Figure 108. HPLC chromatogram of 67. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 73 : 27 ACN-H2O for 11 min. 
The retention time is 7.29 min.  
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8.6.1.2 Analytic of 53a 
 
Figure 109. 1H-NMR of 53a measured in CDCl3. 
 
Figure 110. 13C-NMR of 53a measured in CDCl3. 
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Figure 111. HPLC chromatogram of 53a. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 73 : 27 ACN-H2O for 11 min. 
The retention time is 9.18 min. 
8.6.1.3 Analytic of 54 
 
Figure 112. 1H-NMR of 54 measured in CDCl3. 
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Figure 113. 13C-NMR of 54 measured in CDCl3. 
 
Figure 114. HPLC chromatogram of 54. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 9 min. 
The retention time is 6.66 min. 
 
Figure 115. Crystal structure of 54. The carbon atoms as large white spheres with black stripes and the hydrogen atoms as small 
white spheres. Crystals were obtained after storing a saturated solution of 54 in EtOH at -20 °C. CCDC 1839575. 
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8.6.1.4 Analytic of 54a 
 
Figure 116. 1H-NMR of 54a measured in CDCl3. 
 
Figure 117. 13C-NMR of 54a measured in CDCl3. 
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Figure 118. HPLC chromatogram of 54a. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 11 min. 
The retention time is 7.48 min. 
8.6.1.5 Analytic of 54b 
 
Figure 119. 1H-NMR of 54b measured in d6-DMSO. 
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Figure 120. 13C-NMR of 54b measured in d6-DMSO. 
 
Figure 121. NOESY-NMR of 54b measured in d6-DMSO. 
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Figure 122. HPLC chromatogram of 54b. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 11 min. 
The retention time is 2.69 min. 
8.6.1.6 Analytic of 54c 
 
Figure 123. 1H-NMR of 54c measured in d6-DMSO. Protons from carbon 16 and 17 cannot clearly be assigned. 
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Figure 124. 13C-NMR of 54c measured in d6-DMSO. Carbons 16 and 17 cannot clearly be assigned. 
 
Figure 125. HPLC chromatogram of 54c. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 11 min. 
The retention time is 2.08 min. 
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8.6.1.7 Analytic of 54d 
 
Figure 126. 1H-NMR of 54d measured in d6-DMSO.  
 
Figure 127. 13C-NMR of 54d measured in d6-DMSO. 
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8.6.1.8 Analytic of 54e 
 
Figure 128: 1H-NMR of 54e measured in d6-DMSO. In the area between 5.0 and 3.4 it can be seen that a second product is present 
in the sample because a double set of signals is present for peaks of C-H 14, 10 and 17 with an integral of 0.5. Also, the signals of 
C-H 13 have an integral of 1.5 instead of 1. From HPLC measurements it could be seen, that the peak is quite broad. These results 
indicate that a mix of two diastereomers is produced. 
 
Figure 129. 13C-NMR of 54e measured in d6-DMSO. 
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Figure 130. HPLC chromatogram of 54e. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 11 min. 
The retention time is 2.99 min. 
8.6.1.9 Analytic of 54f 
 
Figure 131. 1H-NMR of 54f measured in d6-DMSO. 
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Figure 132. HMQC NMR of 54f measured in d6-DMSO. 
 
Figure 133. 13C-NMR of 54f measured in d6-DMSO. 
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Figure 134. HPLC chromatogram of 54f. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 11 min. 
The retention time is 3.79 min. 
8.6.1.10 Analytic of 63 
 
Figure 135. 1H-NMR of 63 measured in CDCl3. 
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Figure 136. 13C-NMR of 63 measured in CDCl3. 
 
Figure 137. GC chromatogram of 63. Analysis was performed for 4 min at 92 °C, using a Agilent GC7820A system with FID-
detector (Heater 300 °C, H2-Flow 30 mL/min, Air-Flow 400 mL/min, Makeup Flow 25 mL/min; Date Rate/ Min Peak width 
50 Hz/0.004 min) with a 30 m HP-5 column with 0.25 μm inner diameter with a flow of 6.5 mL/min. 1 μL of a diluted sample was 
injected with a split of 40-1 with 250 mL/min. Heater was at 250 °C, 1 bar, gas saver 20 mL/min after 2 min.  
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8.6.1.11 Analytic of 64 
 
Figure 138. 1H-NMR of 64 measured in CDCl3. 
 
Figure 139. 13C-NMR of 64 measured in CDCl3. 
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Figure 140. GC chromatogram of 64. Analysis was performed for 4 min at 92 °C, using a Agilent GC7820A system with FID-
detector (Heater 300 °C, H2-Flow 30 mL/min, Air-Flow 400 mL/min, Makeup Flow 25 mL/min; Date Rate/ Min Peak width 
50 Hz/0.004 min) with a 30 m HP-5 column with 0.25 μm inner diameter with a flow of 6.5 mL/min. 1 μL sample was injected 
with a split of 40-1 with 250 mL/min. Heater was at 250 °C, 1 bar, gas saver 20 mL/min after 2 min.  
8.6.1.12 GC chromatograms of 68-75 
 
Figure 141. Adamanthanisonitril (68) was measured 120°C to 132°C with 4°C/min, hold 3 min, 10°C/min to 200°C 
 
Figure 142. Tetramethylbutylisocyanide (69) 56°C to 66°C with 2°C/min hold 3 min 10°C/min to 120°C. 
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Figure 143. 2-naphtylisocyanide (70) 120°C to 140°C with 4°C/min, hold 3 min, 10°C/min to 190°C. 
 
Figure 144. Cyclohexylisonitrile (71) 82°C to 96°C with 4°C/min, hold 3 min, go to 160°C with 10°C/min 
 
Figure 145. 2(4-morpholinyl)ethylisocyanid (72) 120°C to 144°C with 4°C/min, hold 3 min, 10°C/min to 190°C 
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Figure 146. Cyclohexylisothiocyanat (73) 102°C to 120°C with 4°C/min, hold 3 min, 10°C/min to 180°C 
 
Figure 147. 3-Morpholinopropylisothiocyanat(74) 120°C to 144°C with 4°C/min, hold 3 min, 10°C/min to 190°C 
 
Figure 148. Phenethylisothiocyanat (75) 120°C to 140°C with 4°C/min, hold for 3 min 
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8.6.1.13 Analytic of 76 
 
Figure 149. 1H-NMR of 76 measured in CDCl3. 
 
Figure 150. 13C-NMR of 76 measured in CDCl3. 
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Figure 151. HPLC chromatogram of 76. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 10 min. 
UV detection was set to 280 nm. The retention time is 7.77 min.  
 
Figure 152. Crystal structure of 76 with a methyl group at the C5 of the indole ring. The nitrogen atom is shown in blue, the 
oxygen atom in red, the carbon atoms as large white spheres with black stripes and the hydrogen atoms as small white spheres. 
CCDC 1839576 
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8.6.1.14 Analytic of 76a 
 
Figure 153. 1H-NMR of 76a. Measurement in CDCl3. 
 
Figure 154. 13C-NMR of 76a. Measurement in CDCl3. 
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Figure 155. HPLC chromatogram of 76a. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 11 min. 
The retention time is 8.89 min. 
8.6.1.15 Analytic of 77 
 
Figure 156. 1H-NMR of 77 measured in CDCl3. 
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Figure 157. 13C-NMR of 77 measured in CDCl3. 
 
Figure 158. HPLC chromatogram of 77. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 9 min. 
The retention time is 5.48 min. 
Appendix 
 
256 
8.6.1.16 Analytic of 77a 
 
Figure 159. 1H-NMR of 77a measured in CDCl3. 
 
Figure 160. 13C-NMR of 77a measured in CDCl3. 
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Figure 161. HPLC chromatogram of 77a. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 9 min. 
The retention time is 6.30 min. 
8.6.1.17 Analytic of 78 
 
Figure 162. 1H-NMR of 78 measured in CDCl3. 
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Figure 163. 13C-NMR of 78 measured in CDCl3. 
 
Figure 164. HPLC chromatogram of 78. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 10 min. 
The retention time is 8.12 min. 
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8.6.1.18 Analytic of 78a 
 
Figure 165. 1H-NMR of 78a measured in CDCl3. 
 
Figure 166. 13C-NMR of 78a measured in CDCl3. 
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Figure 167. HPLC chromatogram of 78a. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 11 min. 
The retention time is 9.35 min. 
8.6.1.19 Analytic of 79 and 80 
 
Figure 168. HPLC chromatogram of diastereomer mix of 79 (4.39 min) and 80 (5.63 min). Measurement was performed with Shi-
madzu LC2030 and C18 Durashell column by Agela and an isocratic flow of 60 : 40 ACN : H2O and 1 mL/min. Detection by 
UV/Vis at 280 nm. 
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Figure 169. 1H-NMR of 79 measured in CDCl3. 
 
Figure 170. 13C-NMR of 79 measured in CDCl3. 
Appendix 
 
262 
 
Figure 171. HPLC chromatogram of 79. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 60 : 40 ACN-H2O for 8 min. 
The retention time is 4.39 min. 
 
Figure 172. HPLC chromatogram of 80. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 60 : 40 ACN-H2O for 8 min. 
The retention time is 5.63 min. 
Appendix 
 
263 
8.6.1.20 Analytic of 81 
 
Figure 173. 1H-NMR of 81 measured in CDCl3. 
 
Figure 174. 13C-NMR of 81 measured in CDCl3. 
Appendix 
 
264 
 
Figure 175. HPLC chromatogram of 81. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 9 min. 
The retention time is 5.30 min. 
8.6.1.21 Analytic of 82 
 
Figure 176. 1H-NMR of 82 measured in CDCl3. 
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Figure 177. 13C-NMR of 82 measured in CDCl3. 
 
Figure 178. HPLC chromatogram of 82. The sample was measured on Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn). The analysis was performed with 1 mL/min and an isocratic flow 71 : 29 ACN-H2O for 9 min. 
The retention time is 4.16 min. 
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8.6.1.22 Analytic of 84 
 
Figure 179. 1H-NMR of 84 measured in CDCl3. 
 
Figure 180. 13C-NMR of 84 measured in CDCl3. 
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Figure 181. HPLC chromatogram of 84. The sample was measured with an Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn) with an isocratic program of 65 : 35 ACN/H2O and a flow rate of 1 mL/min. The retention time 
is 6.24 min. 
8.6.1.23 Analytic of 85 
 
Figure 182. 1H-NMR of 85 measured in CDCl3. 
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Figure 183. 13C-NMR of 85 measured in CDCl3. 
 
Figure 184. HPLC chromatogram of 85. The sample was measured with an Agela Durashell C-18 column (150 mm x 4.6 mm, 5 µm 
particle size + 10 mm precolumn) with an isocratic program of 60 : 40 ACN/H2O and a flow rate of 1 mL/min. The retention time 
is 5.5 min. 
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8.6.1.24 Analytic of 86 
 
Figure 185. HPLC chromatogram of 86. The sample was measured with Zorbax Eclipse C-18 column (150 mm x 4.6 mm, 5 µm 
particle size) with an isocratic program of 63 : 37 ACN/H2O and a flow rate of 1 mL/min. The retention time is 11 min. Detection 
was made at 254 nm. 
8.6.1.25 Analytic of 87 
 
Figure 186. HPLC chromatogram of 87. The sample was measured with Zorbax Eclipse C-18 column (150 mm x 4.6 mm, 5 µm 
particle size) with an isocratic program of 55 : 45 ACN/H2O and a flow rate of 1 mL/min. The retention time is 11 min. Detection 
was made at 254 nm. 
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